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Abstract 
Background: The Improving Outcomes Guidelines recommended treatment of teenage and 
young adult patients with cancer at designated principle treatment centres. Alongside age 
appropriate care, site specialist centres exist for several of the diagnostic groups commonly 
seen in these patients.  
Objectives: This project aimed to produce a definition of specialist care for teenage and young 
adult (TYA) patients, describe the variation in care pathways nationally in England and to 
determine what effect the level of specialist care received has on patient outcomes. 
Materials and methods: Patients aged between 15 and 24, diagnosed with cancer in England 
between 2001 and 2006 were identified and cancer registration and hospital episode statistics 
data were extracted for these cases. Patients were assigned a level of specialist care based on 
the proportion of their inpatient stay during treatment which was spent at a specialist centre. 
The variation in access to the specialist centres was assessed for each diagnostic group, as 
were the demographics of the patients receiving each level of specialist care. Outcomes were 
measured within the distinct diagnostic groups. Kaplan-Meier curves and Cox regression 
modelling were used to assess the impact of specialist care on survival. 
Results: Variation in access to specialist care centres was seen in all diagnostic groups. The 
proportion of patients in each group who received specialist care also varied, with some 
diagnostic groups receiving very little care at specialist centres. The level and type of specialist 
care received was shown to affect survival in all groups. More specialist care was associated 
with a survival benefit in the case of leukaemia, central nervous system tumours and 
lymphoma, significantly so in the case of lymphoma. 
Conclusions: The uptake of specialist care for teenage and young adult patients was variable 
across England and not all patients were seen to be receiving the care pattern associated with 
optimum outcomes. 
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Chapter 1 Introduction 
Cancer is a major public health problem in the UK. Over 320,000 cases are diagnosed annually; 
one in three people will develop cancer during their lifetime1. Over 120,000 die from cancer 
annually2 and it was the leading disease related cause of death in England in 20103. Cancer is 
often perceived to predominantly be a disease of the elderly, however, despite only 0.6% of 
the total number of diagnoses being in the 15 to 24 age group cancer is the leading cause of 
non-accidental death in this population2 4. In comparison to many other countries cancer 
survival in the UK is low and there is known variation in both the quality and type of care 
received across the National Health Service (NHS). Improving survival and patient outcomes 
and eliminating inequalities has become a priority. 
In an attempt to improve cancer outcomes and bring the UK in line with comparable countries 
the NHS and Department of Health (DoH) have implemented major service reforms. These 
were based upon a systematic review of the literature to form an evidence base and to 
determine what constitutes optimal care. This research indicated that implementing a model 
of specialist care would improve patient outcomes. As a result a sequence of policy 
documents, detailing the changes needed, were published. The Calman-Hine report5 
recommended a move from general care supported by specialists to care buy high volume, 
highly specialised teams. The NHS Cancer Plan6 and the subsequent Cancer Reform Strategy7 
both focused on service changes necessary to bring about improvement in survival and both 
supported the emphasis placed on specialist care by the Calman-Hine report. These reports, in 
association with the Improving Outcomes Guidance (IOG) published by the DoH described the 
need for the centralisation of NHS services and specialization in cancer care. In 2005 a strategy 
for improving the outcomes for children and young people with cancer was released by the 
National Institute of Health and Clinical Excellence (NICE)8 which recommended that specialist 
multi-disciplinary teams be involved throughout the care pathway, that cancer networks 
should strive to meet the needs of children and young people with cancer and that care should 
be co-ordinated across the NHS. Prior to this report there was little documentation relating 
specifically to this age group defining what the gold standard care pathway should be for this 
patient group. 
The service restructuring brought about by the release of this report is now underway. It is 
important, therefore, to now assess the impact of centralisation and specialisation on 
outcomes for this age group but also to establish what proportion of patients are receiving this 
preferred pathway.  
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This project aims to quantify specialist care for teenage and young adult cancer patients. In 
order to do this it is vital to quantify the inequalities and inequities in relation to uptake of 
specialist care alongside the influence of various pathways and patterns on patient outcomes.  
1.1 Study rationale 
Cancer is primarily a disease of older people with 75% of all cases being diagnosed in those 
aged over 60. In contrast malignancy in teenagers and young adults (TYA) is less common, 
accounting for less than 2% of cancer diagnoses each year9 10.  Whilst there were only 1,892 
diagnoses of cancer in patients aged between 15 and 24 in the UK in 20079 the disease remains 
2.7 times more common than in those aged less than 1510 and is also the leading natural cause 
of death in this age group11-13. The overall incidence of cancer is increasing14 15, a trend which is 
mirrored in the TYA population. However, whilst survival is improving in the cancer population 
as a whole16-19 TYA survival has not improved to the same extent4 20. This is cause for concern. 
Over the past two decades improving cancer outcomes has been a top priority for the NHS and 
remains as such today. Major organizational changes have been undertaken in an attempt to 
achieve this. The Department of Health (DoH) has issued evidence-based Improving Outcomes 
Guidelines (IOG) which detailed service structures and operational protocols to which cancer 
services ought to adhere in order to obtain optimal outcomes. This guidance focused in the 
most part on site-specific issues, such as lung21 and colorectal22 cancers. All guidelines 
emphasized the importance of the involvement of specialist multi-disciplinary teams and the 
guidance issued for TYA8 was no exception. However in a step away from the previous 
guidelines the Children and Young Peoples IOG, issued in 2005 referred to the importance of 
both site- and age-specific specialist care, stating that; 
“Care should be appropriate to a child’s or young person’s age and type of cancer”8 
To define ‘appropriate’ is very difficult, in part due to the wide spectrum of cancers which 
affect TYA23 24, also due to the acknowledged complexities of meeting the age related needs of 
this group25-28 meaning that ‘appropriate’ care for one is not necessarily the same as that for 
another patient. 
Little is understood about the effect of specialist care on outcomes for this group. As the 
evidence base is currently equivocal, it is not known whether it is age- or site-specific care or a 
combination of the two that leads to the best outcomes.  
The Teenage Cancer Trust (TCT)29 had eight units in place in England over the time period of 
this study and they aimed to fulfil the age-appropriate needs of the TYA group. These may not, 
however, fully encompass the site-specific needs of these patients and there is no evidence to 
quantify the impact of receiving one, both or neither types of specialist care. Producing a 
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model which can both determine what constitutes specialist care for TYA and, given the need 
to improve survival in this group, quantify its impact on outcomes is important and will form 
the main part of this project. In essence the study aims to determine whether care that is age- 
or site-specific in its entirety is truly ‘specialist’. 
As well as establishing the optimal care pathway for TYA patients it is also vital to understand 
the reasons for the variation in the proportion of patients receiving optimal care, including 
barriers to the uptake of this care, be they geographical or patient related. The effect of place 
of care on survival have been well studied for both older and younger patients and have been 
shown to influence survival, however there is a dearth of information with regards to this in 
TYA patients. This project will address this by quantifying the pathways and footprints of TYA 
patients with cancer in order to assess the national variation in the place of treatment and 
how this alters according to diagnosis. In an attempt to understand reasons for the variation in 
the proportion of patients receiving specialist care due to differing referral practices a survey 
of  medical professionals was undertaken in which they were asked to describe factors they 
thought were vital for specialist care and were also asked to score each factor, from high to 
low importance. 
A final aim is to address the paucity of information on the health service burden for TYA cancer 
in England. The study will examine how the level of specialist care received influences health 
service usage, including, number of admissions, length of stay and proportion of time spent as 
an inpatient. This will be an important benchmarking exercise to inform future service design. 
It is acknowledged that there are issues with data quality and completeness regarding the HES 
and cancer registry data, many steps were undertaken in this project to address these as far as 
possible. These issues and methods are discussed in detail and explored extensively in the 
following chapters. 
1.2 Summary of the aims and objectives 
 
This project has three key aims: 
I. To produce a definition of specialist care for TYA  
A definition of specialist care will be produced for each diagnostic group. Patients will be 
assigned a ‘level’ of specialist care according to the proportion of their treatment period which 
was spent at a ‘specialist’ centre as opposed to any secondary or tertiary care location. The 
results will be described in detail in order to demonstrate the proportion of TYA patients who 
receive specialist care in relation to various patient demographics and diagnostic criteria, such 
as age, gender and tumour biology.  
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II. To describe variation in care pathways nationally in England. 
The variation in access to such specialist care will then be quantified for each diagnostic group 
according to geography and patient demographics.  This will help to determine the barriers 
that prevent individuals having access to optimal care. Variations in care pathways across 
England will be examined in order to quantify the known variation in place of care and to 
attempt to explain this. This will be performed by cancer network and proximity to an age- or 
site-specialist unit.  
III. To determine the effect of the level of specialist care received on survival and health 
service usage, during treatment. 
The level of care received will be used to model variations in survival, treatment patterns and 
other outcomes, such as cost of admissions during treatment, alongside patient factors such as 
level of deprivation. This will be done as an attempt to describe and quantify inequalities and 
inequities in the treatment of TYA cancer patients in order to determine how much of an effect 
the optimal treatment pathway has on patient outcomes.  
The patient outcomes to be assessed will include survival, treatment and health service usage 
during the treatment period. These will be modelled alongside other patient and tumour 
characteristics such as age and diagnostic group. 
1.3 Main contribution of this work 
This work aims to address the current gap in the literature surrounding specialist care for 
teenage and young adult patients.  Whilst it is acknowledged that specialist care is associated 
with better outcomes for older adults and children30-35, little fix reference is known about the 
impact on outcomes for TYA patients. Previous studies have sought to qualify where TYA 
patients are treated36-38, to define specialist care for this group, including both age- and site-
specific specialist inpatient care37 39-41, and to quantify its influence on outcomes42 43. However 
none have examined all three together and few examine such a broad range of diagnostic 
groups. This will be the first to attempt to identify factors which influence outcomes in all the 
diagnostic groups most commonly seen in this age range and will also be the first to describe 
the factors which affect the likelihood of attendance at a pre-defined specialist centre. 
1.4 Report outline 
The evidence base for this study is discussed in Chapter Two, detailing what is already known 
about specialist care in teenage and young adult cancer patients and describing the paucity of 
information for certain areas. The methodologies used are detailed in Chapter Three and 
describe both the statistical and descriptive methods used. Chapter 4 describes the 
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characteristics of the study population. The details of a survey examining attitudes towards 
specialist care are described in Chapter 5, and Chapter 6 to Chapter 13 discuss the findings of 
the study. These results are then described in the context of current cancer policy and practice 
in Chapter 14 and Chapter 15. 
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Chapter 2 Literature review and evidence base 
2.1 Introduction 
The majority of cancers occur in patients over the age of 60, fewer than 2% of all cancers are 
diagnosed in patients between the ages of 15 and 249. Despite the rarity of cancer among 15- 
24 year olds, when compared to older age ranges cancer is the leading natural cause of death 
in the aforementioned group 44-46. 
Cancers in TYA occur at different frequencies to those of older adults and children, additionally 
survival for this group has not shown the same degree of improvement as others. This, along 
with the proportion of deaths in TYA caused by cancer and the unique characteristics and 
needs of this group means that they have different requirements and so do not fit easily in 
with any other group. This has been a relatively recent realisation and so there are gaps in the 
evidence base regarding the treatment, outcomes and needs of this patient group. Before 
attempting to address the aims identified in the previous chapter it is firstly vital to assess the 
current evidence base regarding specialist care for teenage and young adult patients and to 
identify areas where little or no research has been undertaken and any remaining unanswered 
questions. 
2.2 Why are teenage and young adult patients a distinct group?    
The definition of adolescence or teenage in the terms of cancer differs from the legal and 
social definition 47. The current definition of TYA in the UK varies slightly between study groups 
however the most commonly used is that of patients aged between 15 and 24 years. The 
National Cancer Action Team and the Improving Outcomes for Children and Young People with 
Cancer guidelines both refer to TYAs as being between ages 16 and 24, but both state this can 
be expanded to include patients as young as 13 48. The National Cancer Research Institute 
(NCRI) also defines TYA as being aged 13 to 24 years 49. In contrast the National Cancer 
Institute in America defines their equivalent of TYAs, AYAs (adolescents and young adults), as 
being aged 15 to 39 years 50. The World Health Organisation defines youth as being between 
the ages of 15 and 24 and this definition of teenagers and young adults therefore falls in the 
middle of the definition used by US and Australian cancer study groups and mirrors that 
commonly used in the UK. The National Registry of Childhood Tumours (NCRT) collects data on 
patients up to their 15th birthday, this means that 15 acts as an ideal lower age range for TYA’s 
in England as patients aged above 15 are not covered by the childhood research groups. The 
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upper age limit of 24 also prevents overlapping research as patients aged greater than this 
tend to be included in adult studies. The age ranges may vary from study to study depending 
on the type of malignancy being examined and the country of origin. However the age range of 
15 – 24 years appears to define TYAs without overlapping with paediatric or adult studies. This 
age group has also seen the poorest improvement in both the long and short term when 
compared to other ages; this also makes this age range appropriate when defining a cohort 
with the greatest need 44 51-63.  
Teenagers and young adults fall into a gap between paediatric oncology and adult oncology; 
this causes problems with consistency of treatment as they may be treated in either unit.  
There are several factors which have been stated that make TYAs a distinct treatment group.  
Those which are commonly mentioned are the differing psychosocial needs of this age group, 
the delays in diagnosis and the long term effects of both the cancer and the treatment 
provided 50 64. The host and disease biology of cancer in teenagers and young adults differs 
from that seen in both children and adults 64-67.  Teenagers often undergo growth spurts; these 
have been associated with more virulent disease than that seen in adults.  
The spectrum of cancers which affect teenagers and young adults varies greatly from those 
seen in other age groups.  Common cancers of teenagers and young adults include; Hodgkin’s 
lymphoma, germ cell tumours, acute leukaemia, CNS tumours, soft tissue sarcomas, non-
Hodgkin’s lymphoma, thyroid carcinoma, malignant melanoma and bone sarcomas 64 68.  
Common tumours of childhood such as embryonal malignancies are rarely seen in teenagers 
and young adults, carcinomas commonly seen in later adulthood are rarely seen in TYA 
patients.  
The widely varying spectrum of cancers affecting this age group and their unusual position in 
terms of age focused services means that specialist care, encompassing all aspects of care, age 
and cancer site specific, does not exist for these patients in the same way that it does for both 
older and younger patients. As such specialist care is difficult to define for TYA cancer patients. 
The unique set of characteristics of TYA cancer patients often means that they exist in a gap in 
cancer services, with diagnostic and treatment decisions varying from patient to patient. This 
project aims to address the national variation in referrals and treatment and assess the 
influence of specialist care on patient outcomes in this age group.  
This combination of factors means that cancer in TYA patients poses a unique problem for 
policy makers and those involved in their treatment. They cannot easily fit into services 
designed for use by others and it is thought that attempts to do so result in suboptimal 
outcomes11 12 39 69. 
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2.3 The epidemiology of cancer in teenagers and young adults 
Common cancers of TYA include; Hodgkin’s lymphoma, germ cell tumours, acute leukaemia, 
CNS tumours, soft tissue sarcomas, non-Hodgkin’s lymphoma, thyroid carcinoma, malignant 
melanoma and bone sarcomas 44-46 50 70-77. Some of the most common malignancies in subjects 
aged 15 to 19 years are leukaemia and bone tumours, in comparison to patients aged 20 to 24 
years where the most common are carcinomas, central nervous system tumours and 
melanoma 77. Common tumours of childhood such as embryonal malignancies are rarely seen 
in teenagers and young adults 78.   
Cancers diagnosed in TYA but also seen in other age groups often present with different 
tumour characteristics in TYA than in children and older adults. For example gastric and 
colorectal cancers are infrequently seen in TYA; when they do occur the tumours are often of a 
different morphological type than those seen in older patients and are often more aggressive 
79 80. These differences will also have implications for the treatment of malignancies in patients 
aged 15 to 24 years. 
2.4 Classification of cancer in teenagers and young adults 
There are several schemes to classify childhood, young adult and adolescent cancers. These 
are different from the classification schemes used to describe cancers of adulthood as there is 
a greater morphological variation in younger patients which is not fully described by the ICD-
10 coding system which refers mainly to the topography of a tumour. The International 
Classification of Childhood Cancer scheme (ICCC), published in 1996, is based on histological 
characteristics and was developed specifically for childhood cancers 81. However within this 
classification scheme a high percentage of teenage and young adult cancers fall within the 
other and unspecified carcinoma category, 5.6% of 15-19 year olds and 13.6% of 20-24 year 
olds were shown to fall into the other and unspecified carcinoma group in one study76. 
Another classification scheme is the Histological Groups for Comparative Studies which was 
developed by the International Agency for Research on Cancer (IARC) in 1998. This scheme has 
15 main groups 76. The classification scheme by Jill Birch et al 77   (see Appendix 1) is specifically 
designed for use in the classification of teenagers and young adults. It consists of ten main 
groups and several subgroups and allows malignancies to be classified more accurately by 
morphological type and topography where relevant 77. The advantage of this scheme is the 
detailed groupings of malignancies and the division by morphological type rather than cancer 
site as the morphological type of a cancer in TYA’s has greater influence than in adults. 
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There is some disagreement as to whether benign tumours ought to be included in the analysis 
of TYA malignancies. In the Birch classification scheme benign central nervous system tumours 
are included due to their symptomology and associated mortality.  
2.5 Incidence of cancer in teenagers and young adults 
The spectrum of cancers in TYA patients are different from those seen in younger and older 
patients (Figure 1 & Figure 2). The most common cancers differ between male and female TYA 
patients and in both cases these differ from those seen in other age groups. Common 
diagnoses include leukaemia, lymphomas, and brain and bone tumours82, far fewer epithelial 
malignancies are seen in this age group compared to older adults. 
 
It is important to understand that it is not only the incidence by diagnostic group which varies 
by age but also the morphology within these groups77. Differing morphologies have differing 
prognoses and treatment pathways meaning that this is an important factor to quantify. This is 
particularly marked in haematological malignancies, the incidence of acute lymphoid 
leukaemia (ALL) decreases with age whereas chronic myeloid leukaemia (CML) increases. The 
two diseases have very different treatment profiles and outcomes9.  
 
 
 
 
Figure 1: The 5 most commonly diagnosed 
cancers in males, by age, UK, 2008-2010
9
 
 
Figure 2: The 5 most commonly diagnosed 
cancers in females, by age, UK, 2008-2010
9
 
 
Source: Cancer Research UK (CRUK): http://www.cancerresearchuk.org/cancerinfo/cancerstats/incidence/age/ 
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2.5.1 Incidence by diagnostic group 
2.5.1.1 Leukaemia 
Figure 3: Leukaemia (C91-95), average number of new cases per year and age-specific incidence rates, 
UK, 2006-2008
83
 
 
Source: Cancer Research UK (CRUK), 2012 
 
Leukaemia is amongst the five most common cancers diagnosed in both male and female 
patients aged between 15 and 24 (Figure 1 & Figure 2). Despite this the peak of incidence for 
leukaemia occurs at 70 to 74 years of age for males and 85 years plus for female patients. 
Teenagers and young adults fall into a group with the lowest incidence rate, males have a 
greater incidence than females. The incidence of leukaemia in patients aged less than 5 years 
is double that of patients aged between 15 and 24 years (Figure 3). However this data does not 
take into account the variation in incidence of different morphological types of leukaemia 
which have a high incidence in younger patients. The low overall incidence of leukaemia in 
teenagers and young adults compared to older and younger patients does not account for the 
relatively high incidence of leukaemia compared to other malignancies within the age group. 
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2.5.1.2 Lymphoma 
Figure 4: Non-Hodgkin’s Lymphoma (C82-C85 and 
C96), average number of new cases per year 
and age-specific incidence rates, UK, 2007-
2009
84
 
 
Figure 5: Hodgkin’s Lymphoma (C81), average 
number of new cases per year and age-
specific incidence rates, UK, 2008
85
 
 
Source: Cancer Research UK (CRUK), 2012 
Non-Hodgkin’s lymphoma is one of the five most common malignancies diagnosed in male TYA 
patients (Figure 1), Hodgkin’s lymphoma is one of the most common for both male and female 
TYA patients (Figure 1 & Figure 2). Hodgkin’s lymphoma is unusual in that it has a bimodal peak 
of incidence, one of which occurs in early adulthood (Figure 5). Incidence of Hodgkin’s 
lymphoma is higher in female patients aged 20 to 24 than male patients of the same age, this 
is the opposite of the trend for the remaining age groups, both older and younger. For both 
genders there is a peak in incidence of Hodgkin’s lymphoma at approximately 25 years of age.  
The greatest number of cases of Hodgkin’s lymphoma are diagnosed within the TYA age group 
(Figure 5), for non-Hodgkin’s lymphoma this occurs in patients aged between 70 and 74 (Figure 
4). 
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2.5.1.3 Brain and central nervous system tumours 
Figure 6: Malignant brain and other CNS tumours (C70-C72), average Number of New Cases per Year 
and Age-Specific Incidence Rates per 100,000 Population, UK, 2006-2008
86
 
 
Source: Cancer Research UK (CRUK), 2012 
Brain and central nervous system tumours have a peak in incidence later in life for both sexes, 
once again incidence is higher in males than females with the exception of a slightly higher 
incidence in females aged over 85 years. The number of new cases in male patients between 
15 and 24 years is very similar (approximately 40 cases in 2005), however the number of cases 
in female patients almost doubles between patients aged 15 to 19 years and those aged 20 to 
24 years. Although the incidence of brain and CNS tumours in teenagers and young adults is 
lower than any other age group the incidence of brain and central nervous system tumours is 
high when compared to other malignancies within the 15-24 age group (Figure 6). 
Brain tumours are unusual in that the morphological types have very different outcomes. The 
most common morphological types in TYA are astrocytoma, gliomas and medulloblastoma and 
other  primary neurorectodermal tumours (PNET) tumours10 75 82 87.  A study by Barr found a 
common increase in gliomas with age and a decrease in medulloblastoma and other PNET with 
increasing age88. 
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2.5.1.4 Osseous and chondromatous neoplasms 
Figure 7: Bone and connective tissue cancer (C40-41, C47 and C49), Average Number of New Cases per 
Year and Age-Specific Incidence Rates per 100,000 Population, UK, 2006-2008
89
 
 
Source: Cancer Research UK (CRUK), 2012 
The incidence of bone and connective tissue cancers does not show the same age related 
pattern as for other cancers. There is a higher average incidence in male patients than female 
patients, and in other diagnostic groups young adults do not have the lowest incidence (Figure 
7). The number of new cases between 2006 and 2008 in patients aged 15 to 24 years was 
twice that of patients less than 15 years of age.  
Bone tumours account for approximately 3% of the cancers of childhood and 4% of 
malignancies in teenagers and young adults90-93. The similarity between the incidence of bone 
tumours in children, teenagers and young adults does not take into account the differing 
morphologies between the age groups.  
 
2.5.1.5 Soft tissue sarcoma 
In the population as a whole soft tissue sarcomas are rare, accounting for approximately 1% of 
all cancer diagnoses annually94. Despite this soft tissue sarcomas are amongst the most 
common malignancies diagnosed in TYA patients75 82 95. Different morphological types occur at 
different rates within the population (Figure 8) and occur at different sites within the body94. 
Each requires different treatment and is associated with different outcomes. This combination 
of rarity and wide range of morphologies and cancer sites means that few centres treat large 
numbers of STS patients, even fewer treat significant volumes of TYA STS patients. 
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Figure 8: Percentage of sarcomas and selected morphologies by age, England, 1990-2007
94
 
 
 
2.5.1.6 Germ cell and trophoblastic neoplasms 
Germ cell and trophoblastic tumours are most commonly found in the gonads of both male 
and female patients. Over 95% of all testicular tumours are germ cell tumours96, in contrast 
fewer than 10% of ovarian tumours are of germ cell origin. However the majority of ovarian 
tumours diagnosed in pre-menopausal women are germ cell tumours97. 
Most germ cell tumours are found in the male gonads (testes), a smaller proportion are found 
in the ovaries and a smaller proportion still are found elsewhere in the body. The most 
common site for these is the central nervous system98. 
The incidence of both gonadal and non-gonadal germ cell tumours increases with age. Germ 
cell and trophoblastic neoplasms of the gonads have the second highest incidence of the 
malignancies commonly found in patients aged between 20 and 24 years, surpassed only by 
Hodgkin’s lymphoma. 
Figure 9 and Figure 10 demonstrate the age-incidence peaks for all ovarian and germ cell 
tumours, both epithelial and non-epithelial. The vast majority of tumours diagnosed in the age 
range of interest will be of germ cell origin, therefore these figures are representative of the 
incidence of germ cell tumours in TYA. 
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Figure 9: Ovarian Cancer (C56-C57), Average 
Number of New Cases per Year and Age-
Specific Incidence Rates, UK, 2006-2008
97
 
 
Figure 10: Testicular Cancer (C62), Average 
Number of New Cases per Year and Age-
Specific Incidence Rates, UK, 2006-2008
96
 
 
Source: Cancer Research UK (CRUK), 2012 
 
2.5.1.7 Melanoma and skin carcinoma 
Figure 11: Malignant Melanoma (C43), Average Number of New Cases per Year and Age-Specific 
Incidence Rates, UK, 2008-2010
99
 
 
Source: Cancer Research UK (CRUK), 2012 
The incidence of melanoma peaks in later life (Figure 11) but is one of the most common 
malignancies diagnosed in females between the ages of 15 and 24 (Figure 2).  Non-melanoma 
skin cancer occurs more frequently than malignant melanoma but the quality of registration is 
known to be variable100. 
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2.5.1.8 Carcinomas 
Thyroid cancer has the highest incidence of all carcinomas in patients aged between 15 and 
1910 77 100. Carcinoma of the genito-urinary tract (GU tract) has the highest incidence in patients 
aged between 20 and 24 years77. 
The incidence of carcinoma increases rapidly with increasing age. Carcinomas account for 56% 
of malignancies diagnosed in patients aged over 24 year in comparison to 34% and 12% in 
teenagers and young adults and children respectively1.  
Carcinomas of the genitourinary tract are the most commonly diagnosed in TYA (excluding skin 
carcinoma), one study showed them as accounting for 6.4% of all diagnoses in this age group77. 
The second most commonly diagnosed carcinoma was that of the thyroid (3.2%), followed by 
carcinoma of the gastrointestinal tract (2.7%)77. Carcinomas are predominantly found in older 
adults and those diagnosed in younger patients tend to have poorer outcomes than their older 
counterparts101 102. The wide range of carcinomas diagnosed in small numbers of TYA patients 
result in few centres seeing many TYA carcinoma patients meaning that few truly specialist 
centres exist for this group. 
2.5.2 Temporal changes in incidence 
As with all cancers there has been a change in incidence over time of the malignancies which 
commonly occur in teenagers and young adults. This change is not limited to a single country 
or geographical region but is seen globally. The incidence of invasive cancer in both the United 
States and the United Kingdom in 15 to 19 year olds increased by approximately 0.9% per year 
103. Within this the incidence of non-Hodgkin’s lymphoma and testicular carcinoma had the 
greatest increase, at almost 2% per year 103. Data from the Southern Netherlands showed an 
increase of 3% per year between 1973 and 1999 for haematological malignancies in patients 
aged up to 24 years of age 104. A study from data collected in the North Netherlands showed an 
annual percentage increase of 2.15% 105. 
2.5.3 Geographical variation in incidence 
Studies into geographical variation in incidence have shown marked differences at local, 
national and international level. Data from England showed rates of leukaemia to be highest in 
London and the south east, Hodgkin’s and non-Hodgkin’s lymphoma to be highest in the south 
and bone and soft tissue sarcomas to have the highest incidence in the London and the lowest 
in the North West23 74.  Germ cell tumours also had the highest incidence in the south west.  
A study describing the incidence of cancer in TYA throughout Europe showed the overall 
incidence between 1988 and 1997 to be 139 per million. This varied between countries from 
116 per million to 173 per million 56. Some of this variation can be attributed to environmental 
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influences.  The incidence also varied greatly by region, from 169 per million in the East of 
Europe to 210 per million in the North of Europe for patients aged 15 to 19 years of age 106.  
The incidence of specific cancer type; also varies greatly by geographical region, an example is 
the incidence of lymphoid leukaemia which was shown to have the highest incidence in the UK 
and the South of Europe, whilst the lowest incidence was seen in Eastern Europe.  Variation 
was also seen in bone tumours, NHL, CNS and germ cell tumours71 106. 
2.5.4 Gender and incidence 
Rates of cancers are typically higher in males than females for all ages. On average males are 
10%- 25% more likely to be diagnosed with cancer than females in their teenage years, there is 
a transition to a female predominance in adult years 44.  
Rates for ALL and non-Hodgkin’s lymphoma are significantly higher in males than females but 
rates of Hodgkin’s lymphoma are similar for both sexes 77 82. Central nervous system tumours 
have been shown to have higher incidence rates in male patients aged 20 to 24 years than 
those aged 15 to 19 years, but not for females 77 103.  
The incidence of germ cell tumours in males increases with age and is most frequently seen in 
patients aged between 20 and 24 years. The most common subtype is non-seminomatous 
testicular cancer 107.  
2.5.5 Ethnicity and incidence 
The majority of studies focusing on ethnicity and the incidence of cancer in teenagers and 
young adults have been performed using American data due to the improved level of reporting 
of ethnicity in the United States compared to that of the UK and other countries. 
In the United States the highest reported incidences of cancer in people aged 15 to 35 years of 
age are found in the white, non-Hispanic population, this is approximately double that of the 
American Indians and Native Alaskans 73. It has also been shown that the incidence of common 
TYA malignancies is higher in Caucasian than in black persons of the same age 103.  
Hodgkin’s lymphoma has been shown to be more common amongst white, non-Hispanics in 
the United States, as this tends to be a more affluent group, there is also a potential link with 
deprivation and the incidence of Hodgkin’s lymphoma 108. Testicular cancers have also been 
shown to have an increased incidence in whites compared to blacks in the United States, as 
have tumours of the bone and joints108. Nasopharyngeal carcinoma is very common in 
teenagers and young adults in the Far East, however this has been linked to environmental and 
behavioural factors, such as smoking, nitrosamines and the Epstein-Barr virus, rather than 
ethnicity per se 108.  
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Studies have been performed using data from the UK to determine what, if any, effect 
ethnicity has on cancer incidence. In the UK, children of South Asian origin have an increased 
incidence of lymphoma and a lower incidence of Wilm’s tumour and soft tissue sarcoma when 
compared to white children.  
2.5.6 Deprivation and incidence 
In studies into common cancers of adulthood deprivation has been shown to have a significant 
effect not only on the outcome but also on the incidence of cancer. The relationship of higher 
incidence rates seen in the most deprived areas, has also been shown to apply to some 
teenage and young adult cancers. Several studies have shown chronic myeloid leukaemia to 
have a higher incidence in the most deprived areas74, however this trend does not apply to all 
leukaemia, there has been shown to be little association between level of deprivation and 
incidence of acute lymphoblastic leukaemia or acute myeloid leukaemia 74. The level of 
deprivation can be ascertained using several methods, two of the most common being the 
Indices of Multiple Deprivation (IMD)109 and the Townsend Material Deprivation Score110.  
The Oxford Indices of Multiple Deprivation is calculated using several components combined. 
The seven components used are; income, employment, health and disability, education, skills 
and training, barriers to housing and social services, living environment and crime. Each 
geographical area is then given a score which is weighted to produce an index value. In 
contrast the Townsend score is derived solely from census data. 
Hodgkin’s lymphoma does not follow the generally accepted rule of adult cancers that 
increasing deprivation leads to increased incidence, in fact Hodgkin’s lymphoma has shown a 
marked decrease in incidence with increasing deprivation 74. The incidence of central nervous 
system tumours (CNS), germ cell tumours and melanoma also follow the same pattern as 
Hodgkin’s lymphoma 74. There has been shown to be no link between deprivation and 
incidence in bone tumours and STS 74. 
2.6 What is specialist care for teenage and young adult cancer patients and how 
does it influence outcomes? 
The Calman Hine report identified a need for specialist units in every regional centre to provide 
access to a teenage unit for every patient between 13 and 25 years of age 5 111.  The need for 
change in order to improve outcomes for teenage and young adult cancer patients was 
recognised and led to the introduction of the Improving Outcomes Guidelines for Children and 
Young People. This report built on areas of concern which had been identified in previous 
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research. Through the review of the literature a need for increased specialisation and service 
reform was identified8. 
There is a compelling amount of research to suggest that teenagers and young adults have a 
significantly better outcome when treated using age appropriate protocols, either paediatric or 
TYA46 112 113. Those treated on a paediatric protocol are also more likely to be enrolled onto a 
clinical trial than those treated using an adult protocol 46 113. There are many possible reasons 
for this difference in outcome. One is the differing morphology of malignancies seen in 
patients aged between 15 and 24; an example is the increasing incidence of factors associated 
with poor outcomes in ALL. Children tend to have prognostically favourable subtypes of ALL, 
whereas TYA exhibit greater occurrence of pseudodiploidy and the Philadelphia 
chromosome65, both are linked to poor prognosis. The MLL gene rearrangement is more 
common in adults than children; it is associated with hyperleucocytosis and CD 10 negative B- 
precursor phenotype and a poor prognosis 65. 
As well as the differing clinical needs, their psychological and social requirements also need to 
be taken into account25 39 114. The effect of transition into adulthood is important in terms of 
the loss of recently gained independence and the impact of a life threatening illness25. TYA 
therefore not only need specialist medical treatment but also specialist support to facilitate 
their re-integration into society.  
Specialist care is defined for adult cancers as treatment received in a cancer centre, provided 
by a consultant specialising in the cancer in question, with surgery performed at a high volume 
centre by a surgeon who performs a large number of the same operation annually115-119. The 
impact of hospital volume on operative mortality for cancer surgery showed that hospitals 
which treated a low number of cases requiring complex surgery had a higher mortality than 
those treating a larger number of cases115. Several studies, which used patient volume to 
represent specialisation, suggested that specialist cancer care significantly improved 
outcomes115 117 119. Another defining factor of specialist care for adults is treatment by a 
multidisciplinary team (MDT). Studies have directly linked increasing workload of an MDT to 
improved quality of clinical care and greatly improved patient outcomes116 118. 
In the treatment of childhood cancer specialist care is defined more by age appropriate care 
than by cancer site 120. The care of teenagers and young adults often falls between the younger 
children and older adults and should include aspects of both populations.  
One of the major areas discussed in the IOG was the introduction of principal treatment 
centres (PTC) which would act as tertiary treatment centres for TYA cancer patients. The 
implementation of these guidelines began in 2006, towards the end of the time period that 
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this study covers. These guidelines recommended the involvement of MDTs in all aspects of 
care, and referral to a high volume treatment centre. As previously described both of these 
have been associated with improved patient outcomes for older adults. The IOG for Children 
and Young People with cancer produced by NICE 121 made several recommendations for the 
treatment of TYA with cancer. The recommendations focus on the provision of the best quality 
care as close to the patients home as possible, treatment by a TYA MDT; treatment based on 
agreed protocols, care appropriate to both the patient’s age and type of cancer and the 
opportunity to participate in clinical trials. 
NICE state in their Improving Outcomes in Children and Young People with Cancer guidelines 
that:  
    “ there is a need for all young people with cancer to benefit from the expertise of both site-
specific multidisciplinary teams (MDTs) and the new Teenage/Young Adult MDTs and have 
unhindered access to an age-appropriate care environment and psychosocial support is an 
essential aspect of the NICE Improving Outcomes for Children and Young People with Cancer 
Guidance” 8   
 This describes the need to incorporate aspects of specialisation from both adult and paediatric 
oncology treatment guidelines. Several factors which could influence the definition of 
specialization in teenagers and young adults are listed below; 
 Consultant/ hospital volume. 
 Age appropriate care. 
 Treatment by a consultant with a cancer specific interest (e.g. STS)  
 Age appropriate psychological and social support. 
 Access to clinical trials. 
The difficulty in defining specialization is in establishing the importance attached to each of 
these factors in terms of their effect on clinical outcomes.        
Principle treatment centres for TYA patients consist for the most part of Teenage Cancer Trust 
(TCT) units. The Teenage Cancer Trust (TCT) was founded in order to provide care specifically 
tailored to meet the needs of TYA with cancer. By the end of 2012 in the UK there were 20 TCT 
units offering inpatient beds and outpatient facilities 122. The current lack of units nationally 
means that two 16 year old patients referred to the same cancer centre with the same disease 
may be seen by different teams altogether, one by a paediatric team and one by an adult 
team.  This reduces the consistency of care and may lead to suboptimal treatment and 
unfavourable outcomes 46 114.    
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There is currently a programme of expansion underway in the UK with the aim of providing 
enough beds for all patients between 13 and 25 with cancer.  A study using data from the 
Thames cancer registry  revealed that the majority of 10- 14 year old patients were referred to 
a specialist unit away from their cancer network of residence 36.  However patients aged 15-24 
were much more likely to remain in their network of residence and not be referred to a 
specialist unit. Overall 23% of patients aged 15-19 were seen in a teenage cancer unit 36. There 
are 20 designated Children’s Cancer Study Group Centres in the UK, in contrast there are 
currently 8 TCT units in the UK.  It has been shown in the Southeast of England that there is an 
absence of a referral pattern despite there being a teenage cancer unit in the area 36 . This 
means that teenagers and young adults are much less likely to receive treatment in an age 
appropriate centre than any other age group. 
Teenagers and young adults fall between paediatric and adult oncology and so their care 
needs to encompass aspects of specialisation from each. The National Institute for Clinical 
Excellence (NICE) states that teenagers and young adults should be treated in an age 
appropriate but also a site-specific environment 36.   
The Calman-Hine report emphasised the need for specialisation in the treatment of cancer5. 
Site specific guidelines for the treatment of several of the cancers commonly seen in TYA 
patients have been introduced by NICE. All of the site specific guidelines describe the service 
requirements for the treatment of each cancer and the minimum numbers of patients to be 
treated by each unit. Due to the rarity of sarcoma, both bone and soft tissue, and brain and 
CNS tumours services are centralised throughout the UK with a small number of units treating 
all patients in order to meet the minimum number of patients required123.  
It will be possible to use this study to produce a baseline against which the changes in service 
delivery post implementation can be measured. Specialist treatment centres existed before 
the implementation of the IOG and the effect of treatment at a specialist unit can still be 
measured. 
2.7 Where are teenage and young adults patients treated? 
2.7.1 Cancer units 
A cancer unit is defined in the Calman-Hine report as a district hospital able to provide a full 
range of supportive services and to see a sufficient volume of the more common cancers to be 
able to provide surgical sub-specialisation for the treatment of these sites (breast, colorectal 
etc.)5. Each unit ought to have a lead clinician heading and co-ordinating the entire cancer 
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service, inclusive of chemotherapy. Radiotherapy is usually provided solely at cancer centres, 
as is complex chemotherapy and bone marrow transplantation. 
These units are often local and as such are attractive to patients not wanting to travel 
significant distances from home, a factor which is often important in the decision making 
process for TYA patients. 
2.7.2 Cancer centres 
A cancer centre provides both secondary and tertiary care to cancer patients and will treat 
both common and less common cancers. The additional services (radiotherapy, specialised 
surgery and complex chemotherapy) provided by a cancer centre are in place to support 
cancer units. Due to the large number of cases treated cancer centres provide a high level of 
sub-specialisation. 
For the majority of patients their local hospital is a cancer unit rather than a cancer centre, 
meaning that travel times to cancer centres are often greater than to the closest unit. 
However the high level of specialisation and availability of a wide range of treatments may 
encourage more patients to attend cancer centres.  
Many patients attend more than one hospital during the course of their treatment with 
complex procedures, such as radiotherapy or specialist surgery being performed at a centre 
and other treatments being administered at a unit. This is an important care pathway to 
understand as this may influence patient outcomes in a different way to receiving all care in 
one location. 
2.7.2.1 Cancer site specialist centres 
Cancer site specialist centres are based within cancer centres and often act as a tertiary or 
extra regional centre for the treatment of some of the rarer cancer types, or those requiring 
highly specialised treatment. Specialist centres exist for the treatment of bone tumours, STS 
and brain tumours amongst others123 124. 
2.7.3 Teenage and young adult cancer centres  
All teenage and young adult cancer units in England are located within a cancer centre, thus 
providing access to a high level of cancer site sub-specialisation and age appropriate 
treatment. However not all cancer centres have a teenage and young adult unit. This means 
that, as with cancer centres, teenage cancer units are often extra-regional29. 
There are currently 20 teenage cancer trust units in the UK, during the time period of this 
study there were between 4 and 7 fully functioning units29. 
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One of the major areas discussed in the IOG was the introduction of principal treatment 
centres (PTC) which would act as tertiary treatment centres for TYA cancer patients. The 
implementation of these guidelines began in 2006, towards the end of the time period that 
this study covers. This study will be used to produce a baseline against which the extent of the 
implementation of the guidelines and the impact of these changes can be measured. Specialist 
treatment centres existed before the implementation of the IOG and the effect of treatment at 
a specialist unit can still be measured. 
The Teenage Cancer Trust (TCT) was founded in order to provide care specifically tailored to 
meet the needs of teenagers and young adults with a malignant disease. There are currently 
eight TCT units in the UK, as of 2008, with the ninth under construction.  The Calman Hine 
report identified a need for specialist units in every regional centre to provide access to a 
teenage unit for every patient between 13 and 25 years of age 111.  Countries such as Australia, 
Canada and France have begun work on establishing specialist units.  There is currently a 
programme of expansion underway in the UK with the aim of providing enough beds for all 
patients between 13 and 25 with cancer.  
As teenagers and young adults fall between paediatric and adult oncology their care needs to 
encompass aspects of specialisation from each. The National Institute for Clinical Excellence 
(NICE) states that teenagers and young adults should be treated in an age appropriate but also 
a site-specific environment 36.   
2.8 Factors affecting access to and use of specialist care 
2.8.1 Travel times and access to specialist centres 
A study using data from the Thames Cancer Registry  revealed that the majority of 10- 14 year 
old patients were referred to a specialist unit from their cancer network of residence 36.  
However patients aged 15-24 were much more likely to remain in their network of residence 
and not be referred to a specialist unit, 23% of patients aged 15-19 were seen in a teenage 
cancer unit 36. In the USA 90% of children under 15 years of age are seen in units sponsored by 
the Children’s Oncology Group, in contrast only 24% of 15- 19 year olds are seen in specialist 
age appropriate units 125.There are 20 designated Children’s Cancer Study Group Centres in the 
UK, in contrast there are currently 8 TCT units in the UK.  It has been shown in the Southeast of 
England that there is an absence of a referral pattern despite there being a teenage cancer 
unit in the area 36 . This means that teenagers and young adults are much less likely to receive 
treatment in an age appropriate centre than any other age group. 
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Following the Improving Outcomes Guidelines and the Calman-Hine report cancer care in the 
UK has been reorganised into a small number of specialist centres, with a focus on a 
centralisation of specialist expertise. For less common cancers, such as those diagnosed in 
teenagers and young adults this resulted in a widespread distribution of relatively few TYA 
focused units. TCT units are located at cancer centres rather than cancer units (found at 
general hospitals) and due to the centralisation of tertiary care, patients often have to travel 
outside their local area for treatment. A study by CLIC Sargent discovered that 77% of 
childhood cancer patients (aged 0-18 at diagnosis) did not live in a city with a PTC leading to 
the average travel time for treatment being 55 minutes each way (average distance of 60 
miles) 126. There is a slight overlap in age groups between the CLIC Sargent study group and 
that of this study, suggesting that the results may mirror each other.  
Patients aged under 16 at diagnosis are automatically referred to a hospital with a TCT unit, 
patients aged 16 and above are given the choice as to whether to travel to the nearest TCT 
unit or visit their local hospital8.  
Alongside the centralisation of TYA services certain diagnoses which are more common in this 
age group require treatment at site specialist centres, such as bone tumours. There are 
currently five bone tumour specialist centres in the UK, all of which are located in England123. 
The dispersal of TYA units alongside that of the tertiary care centres for specific diagnoses 
means that TYA patients who choose to be treated at a cancer centre may travel significant 
distances to receive their cancer care.  
Centralisation of services leads to increased provider volume and specialisation at specified 
centres, high volume centres have been shown to have improved post-operative mortality 
when compared to low and medium volume centres for complex surgical cases 127. Patients 
seen at high volume centres have been shown to be more likely to undergo a surgical tumour 
resection for specified tumour sites 128, this was also associated with increased travel time for 
the same subset of patients.  There is some disagreement about whether it is the provider 
volume or the degree of specialisation of the centre which influences patient outcomes in 
cancer care but the two are closely correlated 119.  It ought to follow that patients who travel 
beyond their closest hospital would be travelling to a cancer centre and so would be receiving 
care from a high volume, specialised team and due to this patient outcomes were closely 
assessed alongside travel times. 
2.8.2 Patient choice 
Patient perceptions of treatment are known to influence the decision making process with 
regards to choice of place of treatment, however it is not known to what extent this influences 
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patients’ preference as to place of care. Overall self-reported patient satisfaction was higher 
for patients treated at a TCT centre129 130 but little research exists as to whether patients chose 
to access specialist care, were referred as standard or attended as it was simply the closest 
centre to their residence.  
2.8.3 Referral practice 
Little is known about the influence of referral practice on the uptake of specialist care. Whilst it 
has been shown that referral patterns vary across the UK36 it is not understood to what degree 
this influences the use of specialist care services compared to that of patient choice. 
2.9 Delivery of care 
2.9.1 Referral guidelines 
The National Institute for Health and Clinical Excellence (NICE) have a guideline for the referral 
of suspected cancers to secondary and tertiary care entitled “Referral for Suspected 
Cancer”131.  This was most recently updated in 2005 and provides a detailed outline of the 
cases where urgent referral is vital, symptoms which require immediate referral to a 
consultant and tests needed 132.  The two-week wait rule was introduced in 1998 in an attempt 
to improve outcomes for patients with cancer. For all suspected cancers this is set at a two 
week maximum wait and it is expected that a referral for suspected cancer should reach the 
NHS Trust within 24 hours of the patient’s appointment with their general practitioner 133.   
Referral guidelines vary from region to region across the UK and many are focused on a cancer 
site specific pathway, with the exception of paediatric referrals. It is important to quantify this 
variability and to attempt to understand the influence it has on both treatment and outcomes. 
2.9.2 Treatment guidelines 
The Department of Health have set guidelines as to the acceptable period for children and 
young adults to wait between a general practitioner’s referral and the commencement of 
treatment.  This is currently set at 62 days and applies to any diagnosis of cancer 133.  The DoH 
also states that treatment should begin no longer than 31 days after the patient has 
consented.  During the first quarter of 2008 England had an 85.7% compliance rate to the one-
month rule for children’s cancers 133.  These rules again apply to both adult and children’s 
cancers and so all teenagers and young adults ought to be seen within 62 days regardless of 
the type of malignancy.  The Joint Council for Clinical Oncology (JCCO) guidelines state that 
patients, regardless of age, sex or cancer type should commence treatment within 21 days of a 
referral by a general practitioner 134. The differing morphological and topological 
characteristics of cancer in teenagers and young adults mean that their treatment is also 
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varied. Chemotherapy, radiotherapy and surgery remain the mainstays of treatment in this age 
group, however there are few standard protocols used across the UK 125. 
The Peer Review Cancer measures published by the Department of Health in 2004 state that 
systemic cancer therapy can be provided at any hospital providing they can obtain and 
administer the drugs in accordance with their guidelines.  This means that there are few 
restrictions as to which hospitals can treat teenagers and young adults, providing the potential 
for greater variation in treatment practice nationally. 
With regards to surgery the relatively low likelihood of a patient having co-morbidity means 
that teenagers and young adults tend to tolerate procedures well 125.  Teenagers and young 
adults tend to be less susceptible to the negative effects of radiotherapy and chemotherapy 
than younger or older patients 125.  However younger teenagers are still growing and 
radiotherapy to sites still undergoing development (such as the breasts and gonads) can cause 
serious late effects 125.  The greatest problem with chemotherapy in this age group is 
adherence to the regime, which can detract from its effectiveness 125.  Teenagers and young 
adults are known to be suitable to undergo more intensive treatments than older patients due 
to a better organ function 125.  The greatest problem with assessing the effectiveness of various 
treatments for the different morphological and topological types of cancer in teenagers and 
young adults is the wide range of different treatment regimes used and the essential lack of 
standardised treatment protocols specifically targeted at this age group.  Teenagers and young 
adults are often treated using either paediatric or adult protocols, however the benefits and 
drawbacks of some of the more commonly used treatments may be examined. 
There is known to be a variation in treatment by geographical region, age group, diagnostic 
group and treating centre. This variation should be quantified, and it is important to determine 
what effect this is having on patient outcomes. 
Best practice guidelines for use in cancer care are evidence based and many draw from the 
outcome of clinical trials. In order to determine what level of care patients are receiving it is 
important not only to understand the gold standard of cancer care for each cancer type but 
also to be able to distinguish treatments with a curative intent from those which are best 
supportive care. Many curative treatments comprise of several treatment modalities, without 
one of which the treatment becomes less likely to be curative.  
2.9.3 Leukaemia 
Leukaemia is not surgically treated. For the most part it is treated using induction and 
consolidation chemotherapy, and in some cases, stem cell transplantation (SCT). Induction 
chemotherapy is used to induce remission, consolidation therapy is used during remission to 
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reduce the risk of relapse. The exact protocol used and the likelihood of SCT varies by 
morphology, karyotype, patient age and comorbidities. Chemotherapy in leukaemia usually 
requires an inpatient episode135. 
Stem cell transplantation requires high dose treatment prior to the actual transplantation. This 
involves high doses of chemotherapy and in some cases total body irradiation (TBI). Patients 
tend to remain as inpatients during high dose treatment and after transplantation, until blood 
counts have recovered. 
Acute myeloid leukaemia (AML) is treated using induction and consolidation chemotherapy. 
Several standard regimens require continuous infusion of a chemotherapeutic substance over 
several days, often resulting in inpatient stays. SCT is often used in high risk patients during 
their first remission, or in patients who have had multiple relapses 136 137.  
The only curative treatment for CML is stem cell transplantation, requiring a protracted stay in 
hospital 138. 
2.9.4 Lymphoma 
2.9.4.1 Non-Hodgkin’s lymphoma (NHL) 
The treatment for Non-Hodgkin’s lymphoma depends on the histological type and stage of 
disease. Patients with diffuse large B-cell non-Hodgkin lymphoma should be treated with 6-8 
cycles of chemotherapy combined with rituximab 139. Follicular lymphoma patients with stage 
I-II disease can be treated with radiotherapy alone. Patients with later stage disease are often 
treated only when symptoms appear. Rituximab is used in conjunction with chemotherapy for 
the majority of these cases 140. 
2.9.4.2 Hodgkin’s lymphoma (HL) 
The treatment of Hodgkin’s lymphoma depends on the stage of the disease. Increasing 
numbers of cycles of chemo-radiotherapy are used with increasing stage. In young adults 
chemotherapy only regimens may be used due to the slightly lower long-term sequelae of 
treatment 141. Relapsed patients may be treated using multiagent chemotherapy, high dose 
chemotherapy and autologous stem cell transplantation. Further relapse can be treated using 
reduced intensity conditioning allogeneic stem cell transplantation (RIC-allo) 141.  
2.9.5 Central nervous system and other intracranial and intraspinal 
neoplasms (CNS) 
Curative treatment for CNS tumours consists mainly of resection of the primary tumour, 
followed in most cases by radiotherapy or radiosurgery, especially when the surgical resection 
is considered to be incomplete. The treatment may vary dependent on the site of the tumour, 
with some being located in inoperable locations and therefore being treated primarily with 
radiotherapy or radiosurgery142-150.  
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Ependymomas are commonly treated using surgery and radiotherapy, in certain cases 
chemotherapy may also be used146. As with ependymomas, oligodendrogliomas are also 
chemosensitive and so a chemotherapeutic agent may be included in the treatment plan147. 
Medulloblastoma and PNET tumours are treated using surgery, chemotherapy and/or 
radiotherapy149. 
2.9.6 Osseous and chondromatous neoplasms, Ewing’s tumour and other 
neoplasms of bone 
2.9.6.1 Osteosarcoma 
Best practice guidelines for osteosarcoma vary depending on the grade of the tumour. Low 
grade tumours can be treated with a wide surgical excision alone 151. For high grade 
osteosarcomas treatment with a curative intent consists of surgery and chemotherapy (pre 
and/or post-operative), with the majority of patients being suitable for limb salvage surgery152. 
Most chemotherapy takes place for between 6 and 12 months pre-operatively.  
Radiotherapy is not employed as a curative treatment but can be used in palliative cases 152. 
2.9.6.2 Chondrosarcoma 
Grade 1 (low-grade) central and peripheral chondrosarcomas are managed by excision or 
curettage of the primary tumour. High grade chondrosarcomas and those of the pelvis and 
axial skeleton  are treated using a wide excision. Very few chondrosarcomas are 
chemosensitive, with the exception of mesenchymal chondrosarcoma. This means that where 
a wide resection margin cannot be achieved amputation is often employed over adjuvant 
chemotherapy 153. 
2.9.6.3 Ewing’s sarcoma 
Curative treatment for a Ewing’s sarcoma of the bone should involve neoadjuvant 
chemotherapy, local treatment (surgery and/or radiotherapy) followed by adjuvant 
chemotherapy, with the full treatment cycle lasting between 8 and 12 months on average 154 
155.  
Surgery is the preferred local treatment, as Ewing’s sarcoma is radiosensitive radiotherapy can 
be used for patients where a clear resection margin was not achieved at surgery as well as for 
inoperable cases 153-155.  
2.9.7 Soft tissue sarcomas (STS) 
Surgery (with or without radiotherapy) is the mainstay of curative treatment for all adult STS, 
paediatric STS are also surgically treated if the intent is curative. Paediatric type tumours tend 
to be more chemosensitive than adult tumours so in these cases chemotherapy may be 
employed alongside radiotherapy and surgery in these cases 156 157.   
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For STS located in an extremity and considered to be resectable, surgery is the mainstay of 
curative treatment. Adjuvant radiotherapy, and in some cases chemotherapy, may be utilised 
to ensure a clear surgical margin (R0 resection).  Neoadjuvant radiotherapy may be used in 
high-grade tumours, low-grade tumours over a certain size and resections which were not 
considered to result in a clear margin (R1 or R2 resections) 156 157. 
Soft tissue sarcomas located in an extremity which are not considered to be immediately 
resectable may be treated with radiotherapy in an attempt to render the tumour resectable. If 
successful a major resection is undertaken. In cases involving chemosensitive tumours 
combination chemoradiotherapy may be used to the same end 156. 
Retroperitoneal and abdominal STS are treated using surgical resection with clear margins. 
Adjuvant radiotherapy is less frequently used in these cases due to restrictions in dose related 
to the proximity of radiosensitive organs 156. 
2.9.8 Germ cell and trophoblastic neoplasms 
2.9.8.1 Gonadal germ cell and trophoblastic neoplasms 
Testicular germ cell tumours are treated by orchidectomy, either partial or total. Depending on 
the risk of relapse some cases are treated using adjuvant chemotherapy158-160.  Seminomatous 
gonadal germ cell patients are commonly treated with adjuvant radiotherapy to reduce 
relapse rates 158 161.  As with testicular germ cells ovarian germ cell tumours are commonly 
surgically treated with postoperative chemotherapy/radiotherapy use depending on the 
tumour stage and the risk of relapse 158. 
2.9.8.2 Non-gonadal germ cell tumours 
Pineal germ cell tumours are often treated with chemotherapy prior to surgery143. For CNS 
germ cell tumours the therapy depends on the tumour site. Chemo-radiotherapy and/or 
surgical resection are the most commonly used curative treatments 162. Mediastinal tumours 
are usually surgically resected after neoadjuvant chemotherapy 163. 
2.9.9 Melanoma and skin carcinoma 
2.9.9.1 Melanoma 
The treatment of melanoma varies slightly depending on the stage of disease. The mainstay of 
curative treatment for all cases is a wide excision of the primary tumour with clear excision 
margins (R0 resection) 164 165, however there is a debate as to what is a suitable clear margin 
166. In cases where regional lymph nodes are affected these may also be removed during 
surgery 164. 
Adjuvant therapy may be used in high risk cases (high grade), however there is no standard 
practice in these cases 164, immunotherapy has been trialled, but optimal timing has not been 
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determined 165. Systemic therapy may be used in palliative cases, radiotherapy is often used to 
treat patients with symptomatic metastases 164.  
2.9.9.2 Skin carcinoma 
The majority of skin carcinomas can be classified as either basal cell or squamous cell, these 
are called non-melanoma skin carcinoma (NMSC). The most commonly used treatments for 
NMSC are surgical resection resulting in clear margins and radiotherapy 167 168. Surgical 
approaches used may include Mohs micrographic surgery (MMS), cryosurgery, 
electrodessication and curettage, and standard surgical resection 168. Radiation therapy may be 
utilised as first line or adjuvant therapy.  
Photodynamic therapy, as with radiation therapy, can be used as first line treatment in cases 
of in situ squamous cell and basal cell carcinomas. Deeper carcinomas often require surgical 
resection 167-169. This also applies for the use of topical chemotherapy, applied directly to the 
lesion, often by the patient 168. 
2.9.10 Carcinomas 
2.9.10.1 Thyroid 
Differentiated thyroid cancers (DTC) consist of follicular and papillary cancers. The primary 
curative treatment for DTC is surgery, be it a total or partial thyroidectomy or a lobectomy. In 
the majority of cases this is then followed by radioiodine ablation, with the exception of low 
stage (T1) tumours, with no metastases 170 171. 
Medullary thyroid cancers (MTC) are less common than DTC but the initial treatment is similar 
with the majority of non-metastatic patients undergoing a thyroidectomy, extended to include 
a central lymph node dissection in a large proportion of cases 171. 
2.9.10.2 Head and neck 
2.9.10.2.1 Nasopharyngeal carcinoma 
Nasopharyngeal carcinoma is unusual within the solid tumours in that the mainstay of 
potential curative treatment is radiotherapy. Radiotherapy is targeted at the primary tumour 
and also at local regions considered to be at risk of spread. Later stage disease may be treated 
with chemo-radiotherapy rather than radiotherapy alone 172. 
Recurrent cases tend to be treated using a combination of surgery and radiotherapy, with or 
without chemotherapy, whilst metastatic cases are often treated using chemotherapy alone172.  
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2.9.10.2.2 Other sites in head and neck 
Curative treatment depends on the site of the primary tumour. Early stage tumours are often 
treated using surgery or radiotherapy. Later stage disease is treated using surgery and 
neoadjuvant radiotherapy or chemo-radiotherapy. For some anatomical sites neoadjuvant 
chemotherapy may be utilised 173. 
2.9.10.3 Trachea, bronchus, lung and pleura 
Lung cancer can be broadly grouped into small-cell and non-small-cell tumours. Limited (a 
tumour which can be covered by a single radiation port) small-cell lung cancer is treated using 
chemotherapy and thoracic radiotherapy. Very localised cases (T1-T2, N0) can also be offered 
a radical resection. More extensive disease is treated using chemotherapy alone 174. In all cases 
prophylactic cranial irradiation may be used to reduce the risk of brain relapse 174. 
The treatment of non-small-cell lung cancer depends mainly on the stage of the tumour. 
Surgical resection is a curative option for surgically fit patients. Adjuvant therapy is used in 
later stage cases. Neoadjuvant therapy can be utilised in patients with positive nodes. 
Adjuvant radiotherapy is utilised when surgical margins are not considered to be clear 175. 
Stage IV disease is treated with chemotherapy as first-line treatment 175. 
2.9.10.4 Breast 
Patients with a susceptibility to breast cancer, normally a BRCA mutation, may be offered 
prophylactic treatment. This ranges from chemoprevention to bilateral mastectomy 176.  
Non-invasive breast carcinoma can be treated with breast conserving surgery (BCS), only if 
clear margins can be achieved. If this is not possible then mastectomy may be used. Patients 
with ER+ve tumours may be offered tamoxifen 177. 
Invasive carcinomas are also surgically treated, either using BCS or mastectomy depending on 
the prognostic factors. If BCS is used or there are multiple positive local nodes then 
radiotherapy is often used post operatively. Advanced cancers are treated using neoadjuvant 
chemotherapy. If the patient is deemed at high risk of recurrence then adjuvant treatment is 
also used. The hormone status of the tumour determines the use of endocrine treatment such 
as Herceptin 177. 
2.9.10.5 Genito-urinary tract 
2.9.10.5.1 Kidney 
Encapsulated kidney cancer is treated surgically by a partial or total nephrectomy. Metastatic 
kidney cancer is also treated surgically but this may be followed by systemic multi-agent 
chemotherapy 178. 
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2.9.10.5.2 Bladder 
The majority of bladder cancers are removed by transurethral resection (TUR). The follow up 
treatment varies by risk factor. For low risk tumours TUR is followed by a single course of 
chemotherapy, medium risk tumours with multiple courses of chemotherapeutic agents and 
high risk with bacille Calmette-Guerin (BCG) 179. Tumours which invade the muscle are treated 
with radical cystectomy and lymphadenectomy, if the patient is not fit for this operation 
external beam radiotherapy may be used. In palliative cases multi-agent platinum based 
chemotherapy may be utilised 179. 
2.9.10.5.3 Ovary 
The treatment for ovarian carcinoma, as with many other sites, depends on the age of the 
patient, stage of disease and prognostic factors. Early stage disease (FIGO stage I and IIa) are 
surgically treated, usually involving a total hysterectomy, bilateral salpingo-oophorectomy, 
omentectomy and pelvic node dissection. In patients wishing to maintain fertility a unilateral 
salpingo-oophorectomy may be performed. Low grade tumours with poor prognostic factors, 
such as poor differentiation and large size may also be treated with chemotherapy post 
surgery 180.  More advanced cases are also surgically treated with adjuvant chemotherapy, 
usually given once every three weeks for 6 cycles 180. In highly specialised centres 
intraperitoneal chemotherapy may be given. 
Patients with advanced disease (FIGO stage IV) are often de-bulked surgically followed by 
chemotherapy 180. 
2.9.10.5.4 Cervix 
Curative treatment for cervical cancer is dependent on the patients age, co-morbidities and 
prognostic factors of the tumour, including stage. Early stage tumours (FIGO stage IA1 and IA2) 
are commonly treated surgically, with conisation or hysterectomy. For patients with clear 
margins the only follow up needed is surgical, for patients with involved or threatened 
margins, involved nodes or a large tumour postoperative pelvic radiotherapy or chemo-
radiotherapy may be used 181. 
Later stage tumours (FIGO stage IB1) are treated using one or a combination of the following; 
surgery, brachytherapy, radio-surgery or external radiotherapy 181. Stages IB2- IVA are often 
treated using chemoradiotherapy, stage IVB tumours often receive combination 
chemotherapy alone. Palliative cases are treated using chemotherapy, or radiotherapy if it has 
not been used before. In some cases a pelvic exenteration is undertaken 181.  
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2.9.10.6 Gastrointestinal tract 
2.9.10.6.1 Colon and rectum 
As with breast cancer, colorectal cancer in young patients is often associated with an increased 
familial cancer risk. Syndromes such as Lynch syndrome, familial adenomatous polyposis (FAP) 
and  MUTYH-associated polyposis (MAP) are associated with an increased risk of colorectal 
cancer. Patients may be referred for screening and surveillance if a number of first degree 
relatives develop colorectal cancer. This may lead to prophylactic surgery in some cases and 
higher than average levels of endoscopic polypectomy 182. 
The primary treatment for colorectal cancer is surgical removal of the primary tumour, with or 
without an extended removal of a larger section of the bowel to ensure clear margins. 
Adjuvant therapy may be given where the margins were not clear or the tumour was 
considered to be high risk 183. Studies have shown that neoadjuvant radiotherapy may offer a 
survival benefit and a reduced risk of recurrence in patients with operable rectal tumours 184. 
2.9.10.6.2 Stomach 
Carcinoma of the stomach can only be cured using surgery. The type of surgery, ranging from 
endoscopic mucosal resection (EMR) to radical gastrectomy, depends on the depth of invasion 
and extent of disease. Surgical resection may also include the exenteration of other local 
organs if direct invasion is seen. Neoadjuvant chemo-radiotherapy has been shown to improve 
survival in some cases 185. Palliative cases are treated using multiagent chemotherapy 185. 
2.9.10.6.3 Liver and intrahepatic bile ducts 
Cholangiocarcinoma is one of a group of primary liver cancers, the only curative treatment for 
this treatment is complete surgical resection, including lymphadenectomy and an en bloc 
hepatic resection 186.   
The treatment of choice for hepatocellular carcinoma which is considered to be resectable is a 
surgical resection without adjuvant therapy. Total removal of the liver and liver transplantation 
may be employed when the tumour is multifocal, not considered to be locally resectable or 
where the patient is found to have a cirrhosis 187. Trans-arterial chemoembolization (TACE) and 
radiofrequency ablation may be used in certain multifocal cases. 
2.9.10.6.4 Pancreas 
Extensive surgery is the only curative treatment for pancreatic cancer, however this is only 
suitable for early stage cancers and the majority of pancreatic cancers are diagnosed at a late 
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stage.  The type of resection depends on the location of the tumour within the pancreas. In 
some cases adjuvant chemotherapy may be utilised 188. 
Chemo-radiotherapy may be used in later stage cases. Endoscopic stents are used to ease 
jaundice in palliative cases188. 
2.9.10.6.5 Oesophagus 
Oesophageal cancer is again treated using  surgery as the mainstay of curative treatment, 
however this can only be applied when the tumour is localised. Patients unfit for a resection 
may be treated using chemo-radiotherapy. More advanced tumours are treated using 
neoadjuvant chemo-radiotherapy before a radical resection 189. 
2.9.11 Clinical trials 
2.9.11.1 Benefits of clinical trials 
Teenagers and young adults have different treatment needs and incidence patterns than 
either paediatric, adult or geriatric cancer patients. This means that they tend not to fit into 
the criteria specified for clinical trials 49 51 190. Fern et al in 2008 discovered that there were few 
trials which were open to patients aged 15-24 years49, in all only 16.6% of TYA patients were 
enrolled on a trial. However they also found that in several cases where the age eligibility 
criteria allowed the inclusion of TYAs few patients over the age of 16 were included. In the 
case of four brain cancer trials with upper age limits of between 18 and 21 only patients aged 
less than 15 were included 49. This demonstrates that it is not merely the entry criteria which 
are causing the low uptake in this age group. There is a large amount of evidence to show that 
adult and paediatric patients who partake in a clinical trial have a better outcome 44 49 191 . 
Teenagers and young adults who are treated in clinical trials have been shown to have greatly 
improved survival rates, however the majority of trials which they are enrolled into are not 
targeted to their age group and they tend to be involved in paediatric or adult trials. In France, 
the USA and the Netherlands a study into the recurrence rates and survival of 16 to 21 year old 
patients with acute lymphoblastic leukaemia showed that those treated in paediatric trials did 
significantly better than patients in the same age range on adult trials 44. This shows the 
benefits of clinical trials for the treatment of cancer in teenagers and young adults but also 
demonstrates a need for more age specific trials. 
2.9.11.2 Accrual of teenage and young adult patients to clinical trials 
Accrual of teenagers and young adults to clinical trials is disappointingly low when compared 
to that of adults and children, below 14. Approximately 70% of children in the developed world 
with cancer enter clinical trials 192 . Multiple reports have demonstrated the decline in study 
participation for teenagers and young adults. In England, Scotland and Wales 56% of cancer 
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patients aged 5-14 are involved in trials, compared to only 20% of 15-24 year olds 192. A more 
recent study has shown a similar pattern with accrual rates of 43.2% in patients aged between 
10 and 14 years, 25.2% in those aged between 15 and 19 and a further decrease to 13.1% in 
those aged 20-24 years 49. 80% of cancer patients aged 0- 14 in Italy are enrolled in clinical 
trials, in contrast only 25%-30% of patients between 15 and 24 years of age participate 192. This 
has also been demonstrated by several studies in the USA. Between 1997 and 2003 
involvement of 15- 19 year olds was between 10% and 15 % 105 193 . For patients between 20 
and 30 years of age this rate decreased to 2% of all patients 105 193 194. This is less than 5% of the 
number of children who were involved in trials in the same time period and approximately half 
the number of adult 194. Accrual rates for TYAs were found to vary between cancer types, with 
the accrual for TYAs with leukaemia, CNS tumours and osteosarcoma between 2005 and 2007 
lower than that of children 49. An exception to this rule was male germ cell tumours where only 
patients above the age of 14 were found to have been entered onto trials49. 
There is a large amount of speculation as to why the accrual rate of teenagers and young 
adults to clinical trials is so low when compared to children and adults. One factor is a lack of 
trials available for teenagers and young adults. Adult and paediatric cancer centres may not 
have appropriate protocols for the treatment of teenagers and young adults. Some patients 
may be excluded from trials on the basis of their age, many paediatric trials have an upper age 
limit of 16- 18 whilst many adult clinical trials have a set lower age limit 195 196. Trial age entry 
criteria can often divide the age incidence spectrum of teenage and young adult cancers which 
can result in different treatment approaches being used 192. As the spectrum of cancers which 
tend to occur in patients between 15 and 24 years differs greatly from both common adult and 
childhood cancers neither paediatric oncologists nor adult oncologists tend to run trials on 
these cancers 197.  
2.10  Morbidity and survival 
2.10.1 Morbidity 
Survival is not the only measurable outcome from cancer in TYA patients. Many of the 
treatments used in this group are associated with high levels of morbidity, occurring 
throughout treatment and for a significant time after the completion of treatment198-200. 
Second malignant neoplasms and recurrences also affect the quality of life of TYA patients post 
treatment201 202. These early and late effects affect the health service usage of these patients 
for the remainder of their lives.  
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2.10.1.1 Effects of treatment 
Treatment effects for TYA patients can be broadly grouped into two subgroups, early effects 
and late effects. Immediate effects of treatment include unplanned return to surgery, 
infections and prolonged stay in hospital. These can be used to assess the level of 
specialisation of care a patient is receiving and also determine the effect on the patient’s life. 
The impact of cancer on teenagers and young adults extends beyond the primary and on-going 
treatment for the malignancy. Treatment for cancer is highly toxic and often has long term 
effects. Long-term survivors of cancer have been shown to be at a greater risk of developing 
second and subsequent malignant neoplasms (SMNs), this is often considered to be late 
sequelae of their original treatment 203.  Treatment related complications, loss of or reduction 
in fertility and recurrences of the primary neoplasm are also common late effects within the 
TYA group 200. 
Hospital usage (inpatient and outpatient) can be used as a measure of long lasting effects on 
TYA patients.  
2.10.1.2 Loss of fertility 
Many studies into the concerns which affect teenagers and young adults undergoing cancer 
treatment have cited loss of fertility as a major issue. Even low doses of radiation can result in 
permanent ovarian failure and increase the rates of miscarriage, intrauterine growth 
retardation and premature delivery 204. Higher miscarriage rates are seen in women whose 
ovaries were within the radiation field 205.Infertility rates have been shown to be higher in 
males than females, however in this case fertility preservation is more successful 200 204 206. Both 
chemotherapy and radiotherapy have been shown to have an effect on ovarian function204 207. 
2.10.1.3 Recurrence of the primary cancer and occurrence of second and 
subsequent malignancies 
Studies have shown that the majority of late mortality can be linked to recurrence of the 
primary malignancy 200. It is the most common cause of late death in long-term survivors of 
childhood and teenage cancers 200. 
There have been several studies examining the risk of developing a second cancer after 
radiotherapy for a first cancer. The Late Effects Study Group (LESG) demonstrated that 
approximately 12% of children and adolescent (<20 years of age) survivors from a first cancer 
developed a second cancer after 25 years from diagnosis 208-211. The risk of developing thyroid 
cancer, osteosarcoma, and soft tissue sarcoma, melanoma and brain tumours increased with 
an increased radiation dose212 213. Bone, thyroid, CNS and breast cancers have been shown by a 
study using the Childhood Cancer Survivor Study (CCSS) to be the most commonly occurring 
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second malignancies 203 206 214. Although these are reported for survivors of childhood cancer it 
is important to consider the implications for TYA patients. An original diagnosis of soft tissue 
sarcoma, acute lymphoblastic leukaemia and Hodgkin’s lymphoma was associated with an 
increased risk of developing a second malignancy 206 210 215 216. Hodgkin’s lymphoma carries the 
greatest risk of developing an SMN, as does treatment with anthracyclines and 
epipodophyllotoxins 217.  One established association is between treatment for Hodgkin’s 
lymphoma and radiation induced breast cancer, the risk is again proportional to the dose of 
radiation 218 219.  
One possible explanation for the increased risk of developing SMNs associated with certain 
malignancies is the delivery of radiation to particularly sensitive tissues (thyroid) or treatment 
to tissues which are proliferating rapidly due to growth. This phenomenon is seen in children, 
teenagers and young adults who are still growing and so have a large amount of proliferating 
tissue. Another potential causative factor is the treatment regimes used to treat teenagers and 
young adults. As mentioned previously anthracyclines and epipodophyllotoxins are associated 
with  a greater risk of developing SMNs, as are alkylating agents. These have been shown to 
have a link with increased risk of developing bone cancers and soft tissue sarcomas 217. 
Therapy related acute leukaemia as a SMN is associated with the use of alkylating agents, 
topoisomerase II inhibitors, anthracyclines and platinum compounds 217. 
2.10.1.4 Other effects of treatment 
The highly toxic nature of the majority of treatments for cancer often result in damage to 
organ systems, myelosuppression and cardiac damage and is the second most common cause 
of late mortality in survivors of TYA and childhood cancers, surpassed only by recurrences of 
the primary neoplasm 200. There is an increased risk of non-neoplastic fatal complications 
amongst survivors of ALL, Hodgkin’s disease and CNS tumours when compared to other 
malignancies seen amongst the TYA group 200. Congestive heart failure is associated with the 
use of anthracyclines therapy and Mediastinal radiation 200. Pulmonary fibrosis, acute 
pulmonary toxicity and restrictive lung disease are also associated with chemotherapy and 
radiotherapy 200. Late toxicity effects have also been seen in the hepatic, renal and 
gastrointestinal systems 200.   
2.10.1.5 Other quality of life issues  
Several of the commonly studied treatment plans for TYA cancers have been linked to 
decreasing bone density and increasing osteoporosis. The most commonly studied are the 
treatment and clinical factors associated with acute lymphoblastic leukaemia (ALL) 220 221.   
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Alongside the physiological issues there are other psychological quality of life issues for 
teenagers and young adults. The most commonly studied of these are; 
 Abnormal perceptions of their body and increased level of hypochondria. 
 Increased levels of risk taking behaviour. 
 Persistent anxiety about a relapse or other health related issues 125. 
2.10.2 Survival 
2.10.2.1 Age and survival 
Several studies have shown that younger patients have a better survival rate from leukaemia 
and CNS tumours, whereas they have worse survival from germ cell tumours 103 222. Survival 
from lymphomas, bone tumours, soft tissue sarcomas, melanomas and carcinomas does not 
appear to be associated with age 103. The survival of patients from breast and colorectal cancer 
and Ewing’s sarcoma has been shown to be inversely proportional to age 222. In the case of 
breast and colorectal cancer, survival for individuals under 50 years of age is particularly poor 
independent of stage of disease at presentation 222. This is interesting as poor survival from 
cancer is commonly related to later stage at diagnosis, more aggressive tumours and other co-
morbidities. As teenagers are less likely than their adult counterparts to be suffering from 
multiple co-morbidities the other two factors must have greater influence. Cancers commonly 
believed to be those of childhood often have poorer survival rates in teenagers and young 
adults when compared to children. For example Wilm’s tumour, retinoblastoma and 
rhabdomyosarcoma have all been shown to have lower survival rates in teenagers and young 
adults 222. With the exception of non-Hodgkin’s lymphoma survival rates are found to be 
significantly worse for teenagers and young adults with leukaemia than children with the same 
disease 55. 
2.10.2.2 Temporal changes in survival 
There has been a temporal improvement in survival from all cancers. In teenagers and young 
adults the improvement varies by morphological and topological type as well as age group, 
gender, ethnicity and deprivation. A study using Canadian data showed survival rates in 
children to have increased by 40% between 1975 and 1998 compared to only 25% for 
adolescents in the same time period 113.The  Surveillance Epidemiology and End Results (SEER) 
group showed there to be an average annual improvement in survival in children under 15 
years and adults over 50 of approximately 1.5%, however in patients aged 15 to 24 years this 
improvement decreased to 0.5% annually 45 193.A study of French data showed the five year 
survival rates for teenagers and young adults with cancer to be 74.5% between 1988 and 1997 
with an 8% increase during the study period 223. This is supported by another study which 
showed relative survival to increase from 63% at the beginning of the study (1979) to 77% at 
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the end of the study 51. There was no improvement shown in this study for patients suffering 
from soft tissue sarcomas 51 .   Germ cell tumours had consistently high survival rates across all 
age ranges, genders and time period 51. As with teenagers and young adults the survival rate of 
children with cancer has increased drastically in recent decades. However the improvement in 
survival of children has been greater than that of teenagers and young adults.  For both age 
groups the improvement in survival has been greater in Western Europe than Eastern Europe 
55. It has been shown by A. Bleyer that in 1975 5 year survival for patients aged 15 to 19 years 
was 64%; however in children it was 55%. By 1990, five year survival of the older patients had 
increased to 76% and to 75% in the younger patients 44 103. This demonstrates the greater 
improvement in the younger age group. 
2.10.2.3 Geographical variation in survival 
Geographically there is a wide variation in survival to five years after diagnosis of cancer in 
teenagers and young adults. Survival in European countries is a good example of this, several 
eastern European countries; Czech Republic, Poland and Slovakia have survival to five years 
which is lower than the European average (75% in males and 78% in females). Estonia has 
particularly low survival to five years (approximately 40%) 55. The more recent data from 
EUROCARE-4 shows that there was a reduction in the geographical difference in survival 
between 1995 and 200256. This could be a result of the more recent data used in the 
EUROCARE-4 study. The survival of patients to five years also varies geographically by topology 
and morphology. Ewing’s sarcoma, bone cancers, astrocytoma, CNS cancers and testicular 
germ cell tumours vary widely across Europe 55. When survival in Central and Southern Europe, 
UK, Eastern Europe and Northern Europe was examined Northern Europe was shown by one 
study to have the highest survival rates for Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, 
ALL, germ cell tumours, melanoma, CNS tumours, soft tissue sarcomas, cervical, colon and 
breast cancers 55. Eastern Europe had the worst survival for all the afore mentioned 
malignancies with the exception of breast cancer 55. The UK had the best survival for ALL, and 
good survival for non-Hodgkin’s lymphoma and gonadal germ cell tumours when compared to 
the rest of Europe.  The greatest geographical variation by morphological type was seen in the 
five year survival for neuroblastoma and hepatic tumours in Europe, both more frequently 
seen in younger patients. CNS tumours, germ cell tumours, leukaemia and lymphomas showed 
much smaller geographical variation 91. 
A study comparing EUROCARE-3 data and SEER data for the survival of patients with Hodgkin’s 
disease found that survival in EUROCARE UK and EUROCARE East were similar to each other 
but significantly below that of the SEER data, however when the data was adjusted to allow for 
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morphological type the survival of SEER and EUROCARE UK were the same suggesting that 
there is a significant international geographical difference in morphological type 68. 
There is a clear link between geographical location and survival, however there are some flaws 
with several of the geographical studies. Completeness of follow up information varies by 
country, region and cancer registry and so may affect analysis. Within country variation needs 
to be taken into account when looking at an entire country. Results may also be affected by 
other factors, such as screening programs, classification schemes and completeness of follow 
up.  
This study seeks to examine the geographical variation in referral pathways, treatment and the 
associated effect this is having on survival. 
2.10.2.4 Gender and survival 
Gender also appears to influence the outcome for malignancies in teenagers and young adults. 
With the exception of germ cell tumours female patients tend to have better survival than 
male patients 51 53 55 56 64 88 125.  Gender differences in survival are not only seen in TYA patients 
but also in younger children and older adults and have been widely studied in the context of 
colorectal, lung and bladder malignancies 224-229 . 
2.10.2.5 Deprivation and survival 
Socioeconomic deprivation is known to be a factor, which affects both survival and outcome in 
older and younger patients125 230-232.  However its effect on TYAs with cancer has not been as 
widely studied.  Several of the more common malignancies of the TYA age group are known to 
be associated with increasing incidence in the more affluent groups, such as non-Hodgkin’s 
lymphoma.  This would imply an association between level of deprivation and survival in this 
group, which could be assessed alongside its connection with other factors, such as referral 
pathways and treatment. 
Deprivation is commonly associated with poorer survival from cancers of adulthood, such as 
colorectal cancers 233. This is in certain cases due to late presentation or lower uptake of 
screening programmes 233. However this relationship is not as widely studied in reference to 
cancers of the teenage years and young adulthood.  A study examining this relationship in 
Yorkshire has shown that unlike cancers of adulthood, the effect of deprivation on survival in 
TYAs varies depending on the cancer type.  For example CNS tumours were shown to have 
poorer survival in areas of medium affluence234.  A nationwide study found there to be no 
association between deprivation and survival, however it also found that this may have been 
affected by the variation in incidence of some malignancies nationwide 235.  
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2.10.2.6 Tumour biology and survival 
Malignant melanoma is considered to be one of the most common cancers of teenagers and 
young adults but has one of the best overall cure rates of all the cancers diagnosed in this age 
group.  The overall cure rate often exceeds 90%, however for patients suffering from 
metastatic disease the five year survival rate is considered to be less than 15% 1.  The survival 
rate from many cancers of the teenage and young adult years varies depending on the 
morphological type, this emphasises the importance of using a coding method which involved 
morphology alongside topology.  Examples of this are testicular and ovarian cancer, the cure 
rate for testicular seminomas and ovarian dysgerminomas exceed 90% but there is a greatly 
reduced cure rate for other morphological types 1.   
In patients aged 13 to 29 years of age in England and Wales the malignancies with the highest 
mortality rates between 1981 and 2005 were as follows; 
 Central nervous system tumours  
 Myeloid and monocytic leukaemia 
 Lymphoid leukaemia 
 Bone tumours 
 Non-Hodgkin’s lymphoma 
These five groups accounted for 50% of deaths in this study 235. 
A study using EUROCARE-3 data examining the effect of morphology on the survival from non-
Hodgkin’s lymphoma showed that morphological type had an effect.  Lymphoblastic, diffuse B, 
other T cell, Burkitt’s and mantle cell/ centrocytic lymphoma had worse outcomes than other 
types of NHL 236.  The effect of different morphological types on survival from Hodgkin’s 
lymphoma and leukaemia have also been studied and there has been shown to  be an 
association 236. Data from EUROCARE-4 shows Hodgkin’s lymphoma to have the highest 
survival in teenagers and young adults between 1995 and 2002 (93% to five years). 
Cancers which are considered rare in teenagers and young adults often have a worse prognosis 
than in older patients. Breast and gastric cancers are a good example of this. Breast cancer in 
patients under 30 years of age is often more aggressive and the tumours are more likely to be 
triple negative for hormone receptors (oestrogen, progesterone and HER2) 237. 
During the early 1970’s teenagers and young adults had better survival rates than younger 
patients. However, a slower rate of progress has meant that survival rates for patients aged 
less than 15 years now exceeds that of older patients 44. 
In the USA cancer is the leading non accidental cause of mortality amongst teenagers and 
young adults (Figure 14), exceeded only by accidental injuries, suicide and murder 46 64 135 and is 
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the leading cause of disease related death in England and Canada 51 74. In the UK it is the most 
common non-accidental cause of death in people aged between 15 and 24 and accounted for 
8% of deaths in male TYA between 2007 and 2009 (Figure 12) and 14% of deaths in female TYA 
(Figure 13) in the same time period. A large majority of the cancer mortality burden for TYA 
consists of sarcomas, leukaemia, lymphoma, CNS tumours and germ cell tumours 103 238 .  
Figure 12: The 4 most common causes of death in 
males by age, UK, 2007-2009 
 
Figure 13: The 4 most common causes of death 
in females by age, UK, 2007-2009 
 
Source: Cancer Research UK (CRUK), 2012 
Figure 14: Common causes of death amongst AYA's in the United States 
239
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Chapter 3 Methods 
This chapter explains the methods used to achieve the key aims of the study. Firstly the 
rationale behind the choice of study period, area and population are described.  This is 
followed by a detailed description of the data the study is based upon and the steps taken to 
‘clean’ and quality assure the raw data and produce a robust analytical study dataset. It then 
continues to detail the descriptive and statistical methods used to achieve each of the three 
key study objectives described below; 
I. To produce a definition of specialist care for TYA and investigate the proportion of care 
spent in a specialist environment by different demographic groups. 
II. To describe variation in pathways nationally in England by investigating the 
relationship between travel time and attendance at specialist centres. 
III. To determine the effect of the level of specialist care received on patient outcomes 
including health service resource use, cost and survival. 
3.1 Study design 
Due to the nature of the available data and the questions to be answered this was a 
retrospective observational study using population-based routine healthcare data. 
3.2 Study period 
The study period chosen spanned from 2001 to 2006 and all TYA patients diagnosed between 
these dates were eligible for inclusion.  Hospital admissions for all the individuals in this cohort 
were available up until 2009.  This study period was chosen for multiple reasons. Firstly, the 
Improving Outcomes Guidelines (IOG) for children and young people were released in 2005 
and so this period encompassed diagnoses and treatment both pre- and post- their issue. This 
study period enabled, therefore, the influence of these guidelines on practice to be assessed.  
Also, limiting the cohort to patients diagnosed up to 2006 ensured there was a minimum of 
three years follow up for each patient so allowing three-year survival analyses to be 
undertaken. 
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3.3 Study area 
The study area of England was chosen.  This was primarily because high quality population-
data were available for this area.  The health and cancer geography of England can be divided 
in multiple different ways, but for this study analyses were undertaken at cancer network level 
Map 1.  
Cancer networks were suggested in the Calman-Hine report5 and implemented as part of the 
NHS Cancer Plan in 20006. Cancer networks are clinical networks which are responsible for co-
ordinating, commissioning and organising care through from primary to tertiary settings and 
involve Primary Care Trusts (PCTs) and NHS Trusts. The principle aim of these was to improve 
cancer outcomes and patient experiences and so each cancer network has a series of multi-
disciplinary teams (MDT) with overarching responsibility for the treatment of patients within 
the network, within which there are trust level MDTs. Additionally cancer networks are named 
as the body responsible for ensuring access to clinical trials and availability of specialist centres 
alongside coordination of referral processes and treatment pathways. Cancer networks cover a 
larger area than a single NHS trust and organise access to specialist centres making them the 
ideal geography for use in this study. Over the time period of this study there were 28 cancer 
networks managing cancer service in England.  Their geographical coverage is detailed in Map 
1. 
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Map 1: The study area 
 
3.4 Data sources 
3.4.1 National Cancer Data Repository (NCDR) 
This study was based on data held in the 2008 iteration of the National Cancer Data Repository 
(NCDR)240. This resource was created by the National Cancer Intelligence Network (NCIN)241 
and is formed of multiple routine NHS cancer datasets linked at a patient level. This means 
that it provides detailed information on all persons diagnosed with cancer in England. The two 
46 | P a g e  
 
main components of the dataset are cancer registration data242 and Hospital Episode statistics 
(HES)243. 
The cancer registration dataset is comprised of data supplied from each of the eight English 
cancer registries pooled into a single national dataset. It includes basic demographic, 
diagnostic, treatment and death information for every cancer diagnosed in England.  
Unfortunately, however, it contains little information on treatment and management of these 
cancers and so these data are linked at a patient level to HES data. 
HES data is episode based and includes information on all in-patient and day case admissions 
to NHS hospitals since 1997. It also includes data on private sector patients treated at NHS 
hospitals or funded by the NHS. The HES data records a wide range of information including 
diagnostic and treatment information relating to every inpatient episode. Demographic, 
hospital and physician information are also included. Linkage of the two datasets enables the 
management and outcome of all cancer patients in England treated in NHS hospitals to be 
tracked, providing the information required to investigate the influence of specialist care for 
TYA patients. 
But, both cancer registry and HES data are routine datasets which are not designed for 
epidemiological research. As a result the raw dataset required ‘cleaning’ to remove duplicates 
and to clarify some of the diagnostic coding. 
3.4.1.1 Data quality 
There are acknowledged problems with the data, including duplicate registrations, incorrect 
coding and missing data. Where possible, methods were utilised which sought to avoid bias 
from this. These methods are described in this chapter. 
One significant, and unavoidable, problem affected the linkage of HES data to cancer registry 
data. HES data were only available for patients who had been admitted to hospital, and who 
had a diagnosis of cancer recorded during an admission. Patients who received treatment as 
an outpatient only, mostly melanoma and skin carcinoma patients, were excluded as there was 
no treatment information available. An additional group of patients were excluded as, despite 
having been admitted to hospital there was no HES data available in the dataset provided as 
they had no cancer diagnosis recorded in the data at any point.  It was not possible to 
determine whether there was a linkage failure due to either of the two reasons described 
above or whether it was caused by a mismatch of linkage information (date of birth, NHS 
number etc.) and so all patients who failed to link were excluded. This may have biased the 
results of the study in that a particular subset of patients may have been more likely to be 
excluded than others, however the study population analysis (Chapter 4) suggests that this 
was not a significant problem. 
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Another acknowledged problem with the linked dataset is that it is not possible to determine 
whether information, such as diagnostic codes, were missing or truly ought to have been left 
blank. This meant it was not possible to assess the completeness of treatment and diagnostic 
data, or to draw any conclusions from the missingness of data in certain fields. 
Treatment information is a key part of any analysis of cancer outcomes, however there is 
known to be variation in the quality and completeness of the treatment information available 
in HES and cancer registry data. As previously stated it is not possible to determine when a 
field is blank due to missing information or whether it is blank as the patient did not have that 
intervention/treatment/diagnosis. An audit of patients from the Leeds area (Table 5) showed 
that major surgical resections were relatively consistently recorded whilst additional therapy 
was reported with varying accuracy. This only covered a small group of patients but reflects 
what is thought to happen in England as a whole. It was not possible to do anything to address 
this in the course of this project. 
It was important to identify duplicated patients prior to analysis as this could have biased the 
results due to duplication of patient outcomes. Duplicates may have arisen for many reasons. 
TYA are a highly mobile population and may travel substantial distances for treatment. This 
may mean that they cross cancer registry boundaries and as a result may be registered in 
multiple locations. The national cancer registration dataset on which this study is based on 
pooled data from eight registries and so multiple registries may have recorded the same 
cancer leading to duplicate registrations.  Likewise it is possible that tumours may have been 
mistakenly recorded multiple times by the same registry. Identifying and resolving these data 
problems was vital prior to analysis and required several stages depending on the reason for 
the duplication. Due to these problems a bespoke set of de-duplication guidelines were 
created for this project. 
3.5 Data cleaning 
3.5.1 Cancer registration data 
Firstly, each tumour was allocated to a diagnostic category based on the Birch classification 
scheme (Table 2). This classification scheme assigns tumours to groups based on their 
morphology and the anatomical site of the tumour. All those in groups 1-10 were retained in 
the dataset. As this project focuses on malignant cancers those registrations determined to be 
benign were excluded (Table 1). Hydatidiform moles (International Statistical Classification of 
Diseases and Related Health Problems (ICD) code O01.9) were also excluded due to 
inconsistent registration nationally. Likewise neurofibromatosis (an umbrella name for a 
number of genetic conditions which cause multiple (often benign) tumours in the central 
nervous system) was also excluded.  
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Table 1: Benign and in situ diagnoses included regardless of behaviour code. 
Code Description Code Description
D32.0 Cerebral meninges
D32.1 Spinal meninges
D32.9 Meninges, unspecified
D33.0 Brain, supratentorial
D33.1 Brain, infratentorial
D33.2 Brain, unspecified
D33.3 Cranial nerves
D33.4 Spinal cord
D33.7 Other specified parts of central nervous system
D33.9 Central nervous system, unspecified
D35.2 Pituitary gland
D35.3 Craniopharyngeal duct
D35.4 Pineal gland
D42.0 Cerebral meninges
D42.1 Spinal meninges
D42.9 Meninges, unspecified
D43.0 Brain, supratentorial
D43.1 Brain, infratentorial
D43.2 Brain, unspecified
D43.3 Cranial nerves
D43.4 Spinal cord
D43.7 Other parts of central nervous system
D43.9 Central nervous system, unspecified
D44.3 Pituitary gland
D44.4 Craniopharyngeal duct
D44.5 Pineal gland
D44
Neoplasm of uncertain or 
unknown behaviour of 
endocrine glands
D42
Neoplasm of uncertain or 
unknown behaviour of 
meninges
D43
Neoplasm of uncertain or 
unknown behaviour of 
brain and central nervous 
system
D33
Benign neoplasm of brain 
and other parts of central 
nervous system
D35
Benign neoplasm of other 
and unspecified endocrine 
glands
ICD10 group ICD10 subgroup
D32
Benign neoplasm of 
meninges
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Table 2: Birch/Alston tumour groups 
Group 1 Leukaemia’s
Group 2 Lymphomas
Group 3 Central Nervous system and other intracranial and intraspinal neoplasms
Group 4 Osseous and chondromatous neoplasms, Ewing sarcoma and other neoplasms of bone.
Group 5 Soft tissue sarcomas
Group 6 Germ cell and trophoblastic neoplasms
Group 7 Melanoma and skin carcinoma
Group 8 Carcinomas
Group 9 Miscellaneous neoplasms NEC
Group 10 Unspecified malignant neoplasms NEC
9998 Benign and in situ diagnoses
 
During the reclassification process a group of tumours were identified for which the site code 
and morphology code were incompatible. These were also excluded, alongside these tumours 
which fell into either group 9 or 10 were excluded. This was due to the wide range of tumour 
biology encompassed by the two groups and the small number of patients, making meaningful 
analysis impossible for the purpose of this project. 
The following steps were then taken to ‘clean’ the remaining data. A schematic of this is shown 
in Figure 15. 
Figure 15: Cancer registration data cleaning process 
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3.5.1.1 Stage one - duplicate records 
Exact duplicates, those which matched on all fields, were identified and all but one record was 
excluded from the dataset.  
3.5.1.2 Stage two - duplicate tumours 
Duplicate records were identified. Firstly, guidelines from the International Agency for 
Research on Cancer (IARC) and International Association of Cancer Registries (IACR) for 
multiple primaries were applied to the data in order to exclude duplicate diagnoses244. These 
guidelines recognise a primary cancer as one which is not an extension, recurrence or 
metastasis of another. ICD codes are used to assess the likelihood of a tumour being a primary 
or incorrect registration. Multifocal or multiple tumours arising in paired organs are recorded 
as a single diagnosis. Multicentric cancers, such as leukaemia, should only be recorded once in 
each individual. Multiple tumours in the same organ with different morphologies are 
considered to be separate primary diagnoses. 
Secondly, records which were a match on patient characteristics, diagnosis information and 
geographical details, but not additional information such as treatment details (surgery Y/N, 
chemotherapy Y/N and radiotherapy Y/N) were identified and, after manual review, all but one 
of the records were excluded from the dataset. 
Tumours with a site code which could be bilateral (i.e. occurring in both of a paired set of 
organs such as the kidneys or testes) were assessed separately. The tumour site codes 
determined to potentially be bilateral are listed in Table 3. The laterality and diagnosis dates 
were checked in all cases and all records which appeared to be recurrences or multiple 
primaries were excluded.  
Patient numbers are assigned by cancer registries to uniquely identify a single patient within 
that registry. Tumour numbers, also assigned by the cancer registries, identify tumours 
uniquely. One patient may have multiple tumour numbers associated with them depending on 
the number of diagnoses. Multiple tumours diagnosed close together with the same patient 
number but different tumour numbers suggests genuine multiple diagnoses, however multiple 
diagnoses with different patient numbers are suggestive of duplication and were checked. 
3.5.1.3 Stage three – within register duplicates 
Patients with multiple diagnoses within one register were then identified using patient 
identifiers (NHS number, date of birth, sex, cancer registry patient number). Records which 
were suspected to be duplicates rather than multiple primaries were manually double 
checked. For records differing on the last digit of the site code the most specific was kept, e.g. 
C40.1 versus C40.9 use C40.1. This rule only applies to diagnoses which could not be bilateral. 
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If the site was potentially bilateral the tumours were checked as with cross register duplicates. 
As recorded in the IACR/IARC guidelines for tumour registration, tumours at the same site with 
different morphology should be recorded as separate tumours. However if the tumour number 
is the same for both records the most specific morphology code was kept.  
3.5.1.4 Stage four – cross register duplicates 
Patients with a diagnosis in two or more registers were then identified using patient identifiers 
(NHS number, date of birth, sex). Where the diagnoses were deemed to be duplicated (close 
diagnosis date, similar site code) the record from the registry of residence was kept. This 
register was identified using the patient’s postcode at diagnosis. If the site code or diagnosis 
date differed significantly the tumours were re-assessed in a later stage (Stage 6). Tumours 
with a site code which could be bilateral were also assessed separately. 
3.5.1.5 Stage five – queries returned to register 
Any suspected duplicates which could not be cross checked using the rules above were 
returned to the registry in question along with the alternative diagnosis 
site/morphology/diagnosis date. The records were then cross checked against the additional 
information held by the registers and a decision was made as to which record, if any, should be 
dropped from the final dataset. If there was disagreement between the registers as to which 
record was correct the reasoning behind the decisions was examined and a decision was made 
based on the information available. Codes for secondary tumours, systemic disease and 
multiple primaries (Table 4) were excluded from the deduplication process. 
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Table 3: Bilateral tumour sites 
Code Description Code Description
C07 Parotid gland
C09.0 Tonsillar fossa
C90.1 Tonsillar pillar
C09.8 Overlapping lesion of tonsil
C09.9 Tonsil, unspecified
C30 Nasal cavity and middle ear C30.1 Middle ear
C31.0 Maxillary sinus
C31.1 Ethmoidal sinus
C31.3 Sphenoidal sinus
C31.8 Overlapping lesion of accessory sinuses
C31.9 Accessory sinus, unspecified
C34.0 Main bronchus
C34.1 Upper lobe, bronchus or lung
C34.2 Middle lobe, bronchus or lung
C34.3 Lower lobe, bronchus or lung
C34.8 Overlapping lesion of bronchus and lung
C34.9 Bronchus or lung, unspecified
C40.0 Scapula and long bones of upper limb
C40.1 Short bones of upper limb
C40.2 Long bones of lower limb
C40.3 Short bones of lower limb
C40.8 Overlapping lesion of bone and articular cartilage of limbs
C40.9 Bone and articular cartilage of limb, unspecified
C43.1 Eyelid, including canthus
C43.2 Ear and external auricular canal
C43.6 Upper limb, including shoulder
C43.7 Lower limb, including hip
C47.1 Peripheral nerves of upper limb, including shoulder
C47.2 Peripheral nerves of lower limb, including hip
C49.1 Connective and soft tissue of upper limb, including shoulder
C49.2 Connective and soft tissue of lower limb, including hip
C50 Breast
C51.0 Labium majus
C51.1 Labium minus
C56 Ovary
C57.1 Fallopian tube
C57.8 Overlapping lesion of female genital organs
C62.0 Undescended testis
C62.1 Descended testis
C62.9 Testis, unspecified
C63.0 Epididymis
C63.1 Spermatic cord
C63.7 Seminal vesicles
C63.9 Male genital organ, unspecified
C64 Kidney, except renal pelvis
C65 Renal pelvis
C66 Ureter
C69.0 Conjunctiva
C69.1 Cornea
C69.2 Retina
C69.3 Choroid
C69.4 Ciliary body
C69.5 Lacrimal gland and duct
C69.6 Orbit
C69.8 Overlapping lesion of eye and adnexa
C69.9 Eye, unspecified
C72.2 Olfactory nerve
C72.3 Optic nerve
C72.4 Acoustic nerve
C74.0 Cortex of adrenal gland
C74.1 Medulla of adrenal gland
C74.9 Adrenal gland, unspecified
C76.4 Upper limb
C76.5 Lower limb
C74 Adrenal gland
C76 Other and ill-defined sites
C69 Eye and adnexa
C72
Spinal cord, cranial nerves and 
other parts of central nervous 
system
C62 Testis
C63
Other and unspecified male 
genital organs
C51 Vulva
C57
Other and unspecified female 
genital organs
C47
Peripheral nerves and 
autonomic nervous system
C49
Other connective tissue and 
soft tissue
C40
Bone and articular cartilage of 
limbs
C43 Melanoma of skin
C31 Accessory sinuses
C34 Bronchus and lung
ICD10 group ICD10 subgroup
C09 Tonsil
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Table 4: Secondary tumours and metastatic spread 
Code Description Code Description
C77.0 Lymph nodes of head, face and neck
C77.1 Intrathoracic lymph nodes
C77.2 intra-abdominal lymph nodes
C77.3 Axillary and upper limb lymph nodes
C77.4 Inguinal and lower limb lymph nodes
C77.5 Intrapelvic lymph nodes
C77.8 Lymph nodes of multiple regions
C77.8 Lymph node, unspecified
C78.0 Lung
C78.1 Mediastinum
C78.2 Pleura
C78.3 Other and unspecified respiratory organd
C78.4 Small intestine
C78.5 Large intestine and rectum
C78.6 Retroperitoneum and peritoneum
C78.7 Liver
C78.8 Other and unspecified digestive organs
C78.0 Kidney and renal pelvis
C79.1 Bladder and other and unspecified urinary organs
C79.2 Skin
C79.3 Brain and cerebral meninges
C79.4 Other and unspecified parts of nervous system
C79.5 Bone and bone marrow
C79.6 Ovary
C79.7 Adrenal gland
C79.8 Other specified sites
C79
Secondary malignant 
neoplasm of other sites
C77
Secondray and unspecified 
malignant neoplasm of 
lymphnodes
ICD10 group ICD10 subgroup
C78
Secondary malignant 
neoplasm of respiratory 
and digestive organs
 
 
3.5.2 Hospital episode statistics data 
Similarly to cancer registry data, duplicates existed in the HES dataset with several copies of 
the same admission being recorded in some cases. These were identified by ascertaining 
whether more than one admission began on the same date for a single patient and then cross 
checking this against admission reasons, procedure codes and treating physician code. 
Episodes of care (a period under the care of a single consultant) are grouped into spells or 
admissions. A spell can have multiple episodes contained within it. These spells were re-
calculated for each patient due to known coding issues in the HES data. This resulted in a new 
identifier for each admission and cross checked admission and discharge dates. 
3.5.2.1 Coding of treatment in hospital episode statistics data 
One caveat of the HES data is the known variability of the coding of treatment. HES data is 
used as part of the Payment by Results (PbR) process and so it is likely that the missing 
treatment data is skewed towards those treatments associated with a lower cost. In order to 
check the extent of the problem for this project a small audit of treatment data was 
undertaken for patients residing in the Northern and Yorkshire Cancer Registry and 
Information Service (NYCRIS) region. In total 1326 patients were identified, access to hospital 
records and additional clinical information was possible for 522 of these patients (Table 5). 
Overall, major surgical resection of a malignancy was only marginally under reported in HES 
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when compared directly to medical records. Chemotherapy was slightly under reported in HES 
for those with a haematological malignancy and those with germ cell neoplasms, however 
there was a relatively small difference in the number of cases identified using the two 
methods. The greatest difference was seen in the reporting of radiotherapy, with an additional 
35 cases being identified using medical records. These differences were not unexpected and 
support the need for caution when interpreting results relating to treatment, they do however 
demonstrate the relative accuracy of HES data when used to identify major surgery. 
Table 5: Assessment of completeness of treatment information for patients in the NYCRIS 
region, comparing HES data to hospital records 
Diagnostic group
Total
Not 
checked*
Checked
**
n % n % n % n % n % n %
Leukaemia 134 61 73 0 0.0 0 0 63 86.3 64 87.7 20 27.4 26 35.6
Lymphoma 252 87 165 0 0.0 0 0 150 90.9 155 93.9 43 26.1 80 48.5
Central nervous system and other intracranial and 
intraspinal neoplasms
138 108 30 26 86.7 27 90.0 26 86.7 10 33.3 13 43.3 16 53.3
Osseous and chondromatous neoplasms, Ewing's 
sarcoma and other neoplasms of bone
83 51 32 23 71.9 24 75.0 28 87.5 24 75.0 14 43.8 12 37.5
Soft tissue sarcoma 64 42 22 18 81.8 19 86.4 15 68.2 11 50.0 13 59.1 6 27.3
Germ cell and trophoblastic neoplasms 198 108 90 81 90.0 83 92.2 79 87.8 80 88.9 21 23.3 22 24.4
Melanoma and skin carcinoma 226 191 35 34 97.1 34 97.1 2 5.7 3 8.6 0 0.0 2 5.7
Carcinomas 231 156 75 70 93.3 71 94.7 27 36.0 27 36.0 43 57.3 38 50.7
Overall 1326 804 522 252 48.3 258 49.4 390 74.7 374 71.6 167 32.0 202 38.7
Treatment recorded
Patients in the NYCRIS region
* Records were not available for checking due to lack of access to records at the treating centre **Treatment information cross checked using clinical notes and pathology reports
Surgery Chemotherapy Radiotherapy
HES Medical records HES Medical records HES Medical records
 
3.6 Exclusions from the analysis dataset 
Patients for whom no HES linkage was possible were excluded from the analysis as it was not 
possible to say whether these patients had failed to link due to a lack of admissions or whether 
there were differences in the identifiers used to link the datasets. This meant that it was not 
possible to draw any conclusions about the level of specialist inpatient care received by this 
group. 
Patients who had previously been diagnosed with a malignancy, pre-2001, were also excluded 
from the analysis as the treatment for a second malignancy may differ from that of a primary 
diagnosis due to dose restrictions for chemotherapy and radiotherapy. 
Information for admissions during the treatment period were analysed for this study as the 
aim was to assess the impact of specialist care, which occurs during the active treatment 
phase. For solid tumours the treatment period was defined as being a month before diagnosis 
to 18 months post diagnosis. This was to encompass diagnoses occurring during an admission 
to hospital and also to include the vast majority of admissions which were treatment related. 
The treatment period for haematological malignancies was defined as beginning a month 
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before diagnosis and ending three years post diagnosis, in order to include all treatment-
related admissions. Admissions outside these time frames were not included in the analysis. 
3.7 Attitudes towards specialist care 
In an attempt to understand the reasons behind the variation in place of treatment for TYA 
patients the variation in attitudes towards specialist care amongst medical professionals caring 
for this group was assessed.  
Medical professionals from NHS Trusts across the UK involved in the treatment of TYA patients 
were identified using NHS websites. An online survey was distributed via email to over 600 
professionals.  
A list of statements encompassing both age appropriate and site specific aspects of care were 
compiled from areas of interest identified in the literature and listed in Table 6. Respondents 
were asked to rate the 17 statements from 1 to 5 depending on the level of importance 
assigned to them (1 – low importance to 5- high importance). Questions regarding the age 
range that respondents deemed appropriate for TYA patients, speciality and affiliation with a 
teenage cancer trust (TCT) unit were also included. 
Analysis of the responses was performed using Latent Gold 4.5245, a statistical package 
designed for latent class modelling, a method used to establish underlying characteristics and 
relationships used to group the data into natural/latent classes. This was utilised to establish 
underlying relationships or patterns which grouped the respondents into distinct classes. 
Questions which did not define the groups were excluded from the analysis. 
This preliminary work demonstrated the difficulty in defining specialist care for this age group, 
with different groups of health care providers rating certain aspects differently to each other. 
In order to fully define specialist care, data from other sources such as patient opinions and 
survival, and treatment results from different providers, need to be used to help refine the 
results of the web survey.   
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Table 6: Statements used in the survey of professionals 
Specialist type
1 Treatment by a site specific surgical or medical team
2 Diagnostics and staging by a site specialist team (radiology, pathology, etc.)
3 Access to site specific clinical trials
4 Inpatient treatment on a site specific ward (e.g. Breast)
5 Contact with a site specific clinical nurse specialist or Macmillan nurse
6 Regular follow up by a site specific MDT
7 Psychosocial and psychological support from those specialising in the care of persons with cancer
8 Access to site specific palliative care if needed
9 Access to site specific end of treatment care and support and information on late effects
10 Treatment by a medical or surgical team who specialise in the treatment and care of TYA
11 Diagnostics and staging by clinical teams specialising in the care of TYA
12 Access to age appropriate clinical trials
13 Treatment in an age appropriate environment
14 Contact with a nurse specialising in the care of TYA
15 Regular follow up by and age specific MDT
16 Psychosocial and psychological support from those specialising in TYA
17 Access to age appropriate palliative care if needed
18 Access to age appropriate end of treatment care and support and information on late effects
19 Treatment at a high volume cancer centre
20 Treatment at a hospital in close proximity to a patients home address
21 Contact with peers who have undergone or are undergoing similar treatments or have a similar diagnosis
22 Outpatient appointments in an age appropriate environment
23 Educational and employment support during and after treatment
24 Support for family, friends and partners of the patient
25 Treatment by the same team throughout
26 Access to fertility specialists and advice on reproductive issues
27 Ability to stay in contact with peers when in hospital, facebook, email, etc.
Question
Site
Age
General
 
3.8 Location of specialist care centres  
Over the time period of this study a number of ‘specialist’ TYA centres existed in England.  As 
this study aimed to investigate who in the TYA cancer population accessed these centres and 
their influence on care, information was required on their location and remit. 
Between 2001 and 2009 a number of Teenage Cancer Trust (TCT) centres were open to TYA 
patients.  These were identified using the TCT website (http://www.teenagecancertrust.org/) 
where information on their opening date was also sourced before being cross checked with 
the NHS Trust in question. The location of each centre was mapped using the coordinates of 
the hospital in which it was located (Map 2). Specialist centres existed for the treatment of 
bone and brain tumours and soft tissue sarcomas. 
Brain and central nervous system (CNS) centres were identified with assistance from the Brain 
Tumour Charity246 and the NHS trusts in question. At the time of this study there were 24 CNS 
centres in England acting as tertiary centres for the treatment of brain and CNS tumours.  Their 
location is shown in Map 3. 
The Bone Cancer Research Trust, Sarcoma UK and the websites of NHS trusts aided in the 
identification of the 16 soft tissue sarcoma (STS) specialist centres in England that operated 
during the period of study (Map 5). These centres provided specialist surgery or 
chemo/radiotherapy for patients diagnosed with a soft tissue sarcoma.  
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For bone tumour patients the specialist centres were identified using the National Specialist 
Services group. There were five centres operating as bone tumour specialist centres over the 
time period of this study (Map 4) and policy recommended that only these centres perform 
surgical resection of the tumours124. These guidelines were released in 2006 meaning that the 
place of care was a key analysis for this group. Additional therapy could be provided 
elsewhere, but only with the input of the team from the specialist centre at which the patient 
was receiving surgical treatment. 
 
Some centres, such as Southampton, opened part way through the study period. Others had 
an upper age limit which prevented some of the patients in the study cohort from being 
admitted there. These restrictions were taken into account when modelling the access to 
specialist centres and patients were assigned to the closest centre for which they met the 
criteria (Table 7).
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Map 2: Location of TCT centres in the UK (2001-2009) 
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Map 3: Location of CNS specialist centres in England (2001-2009) 
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Map 4: Location of bone tumour specialist centres in England (2001-2009) 
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Map 5: Location of STS specialist centres in England (2001-2009) 
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3.9 Definition of specialist care 
In order to assess the influence of specialist care on outcomes it was first vital to determine 
what specialist care is for this age group. A measure of specialist care was, therefore, produced 
for each of the diagnostic groups.  Defining what constitutes specialist care for this group is, 
however, difficult and the metric produced needed to encompass age- and site- specialist 
factors.  Age-appropriate specialist care is intrinsically linked with site-specific specialist care in 
a majority of cases. In addition, as the level of exposure to specialist care was deemed 
potentially important factors such as length of stay were also incorporated into the metric. 
The metric required to assign each patient to a level of specialist care needed to include 
several measures that encompassed both age-and site-specialist care. Age-appropriate and 
site-specific measures were included alongside more general measures of the quality of care 
such as length of inpatient stay. 
3.9.1 Levels of specialist care 
In order to address the varying number of admissions and length of stay between diagnostic 
and patient groups it was decided to examine the proportion of the total inpatient stay spent 
in a specialist centre rather than to use a binary variable (yes/no) or a count of the number of 
admissions. 
The proportion of total inpatient time during treatment spent at a specialist centre was 
compared to the time spent at any other type of hospital for leukaemia, lymphoma, germ cell 
tumours, melanoma and carcinoma.  
For diagnostic groups with centralised services (CNS and bone tumours and STS) the time 
spent in a TCT unit was compared to the time spent in a site specific specialist centre in order 
to encompass both age- and site- specific care. The results seen during this comparison are 
presented at the beginning of the results chapters. 
Patients in each diagnostic group were assigned to one of three ‘levels’ of specialist care 
depending on the proportion of the total time spent as an inpatient in one of the specialist 
centres described previously. The distribution of the data led to the following ‘levels’; 
Limited specialist input – less than 30% of the total inpatient period spent in a specialist 
centre. 
Some specialist input – between 30% and 60% of the total inpatient period spent in a 
specialist centre. 
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Mostly specialist care – greater than 60% of the total inpatient period spent in a specialist 
centre. 
In cases where patients could have both age- and site-specific specialist care the proportion of 
overall care that was determined to be specialist, regardless of type of care, was calculated. 
The type of specialist care was assessed separately. 
3.10 Variation in care pathways 
 Analysis of access to healthcare and geographical variation in care pathways was key to this 
project in order to examine how pathways alter nationally and to determine whether this was 
affected by access to specialist care. Variation in the levels of care received by patient and 
tumour demographics were assessed before geographical variation in access was investigated. 
Firstly the proportion of patients within each cancer network (determined from the postcode 
of residence at diagnosis) who received the various levels of specialist care was assessed. 
Access to specialist care was then analysed using a network analysis and the catchment areas 
of known specialist centres were determined in an attempt to further understand the 
variation. 
3.10.1 Patient demographics 
The level and type of care received was assessed by age at diagnosis, gender and 
socioeconomic score for each diagnostic group individually. The proportion of patients within 
each group was compared for each demographic. 
3.10.2 Diagnostic group 
Differences in the level and type of specialist care received were analysed for the diagnostic 
subgroups of each Birch group (based on the morphology recorded at diagnosis). The 
proportion of patients receiving each level or type was compared for each subgroup within a 
Birch group.  
3.10.3 Year of diagnosis 
Variation in level and type of specialist care was compared for each year of diagnosis (2001-
2006) by diagnostic group. The proportion of patients receiving each level or type was 
compared over time. 
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3.11 Geographical variation in specialist care 
Several of the units were not open to accept patients throughout the entire time period 
covered by this study. Additionally the age ranges accepted by each unit also varied. In order 
to address this the unit closest to each patient was determined to be not only the closest 
centre geographically but the closest centre which was accepting patients at the time of 
admission and which had a suitable age range, in line with the restrictions described in Table 7.  
3.11.1 Access to specialist centres 
In order to assess access to healthcare and how the journey of patients was affected by the 
centralisation of cancer services it was necessary to know not only the Euclidean (crow-fly) 
distance from residence to hospital but also the road travel distance and time. Alongside this it 
is also important to establish whether the patient was travelling beyond the closest hospital 
with the potential to treat them to a multi-regional (tertiary) centre. 
The postcodes of the address at the time of admission and all acute hospital sites in England 
were converted into national grid eastings and northings using GeoConvert. GeoConvert is 
undertaken at the Census Dissemination Unit at the University of Manchester and can be used 
to derive postcode metadata from the National Statistics Postcode Directory (NSPD) (Mimas, 
2011). Eastings and northings form a 2D Cartesian system and are used to locate a position in 
reference to a map.  This does not take into account the curvature of the earth but this will 
have a limited effect over relatively short distances.  
GeoConvert does not convert into latitude and longitude which does allow for the spheroid 
shape of the globe but this conversion is not as readily available and is not linked to the NSPD. 
For this reason latitude and longitude were used only where eastings and northings were not 
available (i.e. the Channel Isles and the Isle of Man which are outside the Ordnance Survey of 
Great Britain (OSGB) grid and are instead on the World Geodetic System (WGS)84 grid.)  
In order to address the geographical barriers affecting access to healthcare in more rural and 
remote areas it was decided to assess the road travel time and distance alongside the 
Euclidean distance from point to point. The ArcGIS road network analyst service was used to 
calculate the road travel time and distance between the address at admission and the hospital 
to which each patient was admitted. 
The specialist centre each patient was admitted to was compared to the closest centre in 
terms of travel distance and the closest in terms of travel time. For those patients seen in a 
different trust the difference in travel distance and time between the hospital attended and 
the closest hospital was examined. 
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3.12 Geographical distribution of patients 
The mapping of the catchment area of a hospital is complex, due to the small number of 
patients in some of the diagnostic groups in this study and the relatively small number of 
specialist centres it was decided to display the theoretical and actual catchment areas of each 
specialist centre using concentric circles representing travel distance. 
For each cancer site the travel distance (km) from home to the nearest specialist centre was 
calculated for each patient. As previously described, the closest centre was the closest centre 
which was accepting patients of the age of the patient at the time of admission, rather than 
just the centre which was closest geographically. The specialist centre was used as the centre 
and a buffer zone containing 25%, 50% and 75% of patients was drawn according to the 
distance from home to the centre for each patient. 
This was repeated to demonstrate actual travel distances using the same methodologies. This 
process meant it was possible to visually describe the catchment of each centre, both in theory 
and in practice. 
3.12.1 Travel distance 
Logistic regression modelling was used to calculate the effect of proximity to a specialist centre 
on the odds of admission to that specialist centre. Distance from registered home address to 
the closest centre, gender, age at diagnosis, deprivation score and diagnostic group were all 
modelled. 
3.13 Patient outcomes 
3.13.1 Treatment received 
Information on surgery is well reported in the HES data, however both chemotherapy and 
radiotherapy data are known to be less accurate. In an attempt to address this, information 
held by the cancer registries on treatment was combined with that found in the HES data to 
produce an overall treatment variable. Major surgical resection was identified in the HES data 
using procedure codes (OPCS) which classified potential curative procedures for each cancer 
site. The codes were identified using a combination of those used in the NCIN major surgical 
resections report247 and input from clinicians. Those used are listed in Appendix B – 
Classification of procedures. 
The treatment received was compared across all levels of care for each diagnostic group. A 
variable which contained the following options was produced; 
Surgery alone 
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Surgery and chemo/radiotherapy 
Chemo/radiotherapy 
No treatment recorded 
3.13.2 Survival 
Two different survival functions were calculated for each patient. Survival to the completion of 
the previously defined treatment period was calculated for each patient, each patient was 
either recorded as dead or alive at the end of the treatment period. Additional to this the 
survival to the end of the follow-up period was also calculated. Time between diagnosis and 
death was censored at three years from diagnosis to allow for the same follow up period for 
each patient. 
3.13.2.1 Kaplan Meier  
A Kaplan-Meier survival analysis was performed on the data to produce a nonparametric 
estimation of the survivor function. Three-year survival was assessed by level of specialist 
input, type of specialist input, diagnostic group and, where applicable, stage.   
3.13.2.2 Cox modelling 
Cox’s proportional hazards model allows multivariate testing of explanatory variables to 
establish which, if any, affect the hazard risk (in this case, death) for the patient groups248-250. It 
was selected for use here as the outcome being assessed in this case was survival. Multi-level 
modelling was fit for purpose due to the small numbers which would reduce the power of any 
analysis. 
This model was used to examine the effect of variables including those analysed in the Kaplan-
Meier analysis, allowing for other important aspects of care and patient characteristics. It was 
also used to evaluate the effect of specialist treatment and the effect of travelling for 
treatment, as opposed to treatment near to home. 
3.13.2.2.1 Model selection 
Model selection was based upon clinical significance and all models were tested to ensure that 
the proportional hazards assumptions were met250 251. This was tested using the proportional 
hazards test250 252 and Schoenfeld residuals253 254 in Stata255. The results of these tests were 
non-significant except in the case of lymphoma. When survival was modelled for Hodgkin’s 
and non-Hodgkin’s separately the proportional hazards assumption held and so separate 
models were included.  
The variability in the quality of chemo/radiotherapy data meant that this was tested in detail 
prior to inclusion in the final models. In each case the inclusion of a treatment variable meant 
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that the proportional hazards assumption was not met and it was felt that this was due to data 
quality issues rather than a true effect. There was also the suggestion of a significant 
interaction between diagnostic group and treatment received and lack of power meant it was 
not possible to model each diagnostic subgroup separately. Due to this, treatment was not 
included in the final Cox regression models. 
Interactions were tested and no significant interactions were discovered other than in the case 
of central nervous systems, where diagnostic group was found to be strongly correlated with 
tumour grade251 256. In this case the model was re-run including the two variables separately 
and the goodness of fit was tested by plotting the cumulative hazard against the Cox Snell 
Residuals257. It was found that model fit was improved by the exclusion of diagnostic group and 
the inclusion of tumour grade. 
Table 8: Summary of variables included in Cox regression models 
Variable Type
Age
Year of diagnosis
0 Male Reference category
1 Female
1 Most deprived Reference category
2
3
4
5 Least deprived
Diagnostic group Categorical
1 Limited Reference category
2 Some
3 Mostly
Variable Type
1 Limited Reference category
2 Site specialist
3 Age specialist
4 Age and site specialist
1 I Reference category
2 II
3 III
4 IV
5 Unknown
Variables included in all analyses
Description
Additional variables
Continuous
Continuous
See table detailing diagnostic information
Description
Sex
Deprivation score
Level of 
specialist care
Type of specialist 
care
Tumour grade
Categorical
Categorical
Categorical
Categorical
Categorical
 
3.13.2.2.2 Variables included in all models 
A summary of the variables included in each model is presented in Chapter 4 and includes the 
proportion of patients seen in each group. 
3.13.2.2.2.1 Age 
The distribution of diagnostic subgroups within each Birch group is known to vary by age at 
diagnosis; the same can be said for admission to a specialist centre. Due to this, age at 
diagnosis was included as a continuous variable in the models for each diagnostic group. 
The mean age at diagnosis varied between the diagnostic groups (Table 9), but, as expected 
was seen to fall around the middle of the age range. 
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Table 9: Mean age at diagnosis for each diagnostic group 
Diagnostic group Mean age at diagnosis
Leukaemia 19.3
Lymphoma 20.0
Central nervous system and other intracranial and intraspinal neoplasms 19.9
Osseous and chondromatous neoplasms, Ewing's sarcoma and other neoplasms of bone 19.1
Soft tissue sarcoma 20.0
Germ cell and trophoblastic neoplasms 21.0
Melanoma and skin carcinoma 21.1
Carcinomas 21.2
Overall 20.4  
3.13.2.2.2.2 Sex 
The gender of patients was modelled as a categorical variable (0- male, 1- female) and was 
included in the Cox model for each diagnostic group. 
3.13.2.2.2.3 Year of diagnosis 
Numerous guidelines for TYA cancers were released over the study period and this may have 
affected the ‘gold standard’ of care in place at the time. Consequently the year of diagnosis 
was included in each model, and was modelled as a continuous variable. 
3.13.2.2.2.4 Deprivation score 
There are known inequalities in the treatment of and survival from cancer between the most 
affluent and most deprived patients. In order to address these, the Index of Multiple 
Deprivation (IMD) score for each patient was included in the model. 
The IMD score used for this project ranks lower super output areas (LSOA) according to 
household income. Scores were assigned to patients according to their LSOA of residence at 
the time of diagnosis according to postcodes. 
3.13.2.2.2.5 Diagnostic group 
Within each diagnostic group there are multiple subgroups. These are important as the 
subgroups may have differing prognosis and treatments. Consequently the subgroups of each 
Birch group were included in each model. In the majority of diagnostic groups the first 
subgroup was used as the reference category (Table 10), however in the case of soft tissue 
sarcoma and carcinomas too few deaths were observed in this group to fit the model. In order 
to address this an alternative group, with a higher number of events was chosen and the fit of 
the new model was tested in each case by assessing the Schoenfeld residuals and a 
proportional hazards test. 
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Table 10: Summary of diagnostic grouping variables included in Cox regression models 
Diagnostic group
1 Acute lymphoid leukaemia (ALL) Reference category
2 Acute myeloid leukaemia (AML)
3 Chronic myeloid leukaemia (CML)
1 Non-Hodgkin lymphoma (NHL)
2 Hodgkin lymphoma (HL)
1 Astrocytoma
2 Other gliomas
3 Ependymomas
4 Medulloblastoma and other PNET
5 Other specified intracranial and intraspinal neoplasms
6 Unspecified intracranial and intraspinal neoplasms
1 Osteosarcoma Reference category
2 Ewing's sarcoma
3 Other
1 Fibrosarcoma
2 Rhabdomyosarcoma
3 Other specified STS Reference category
4 Unspecified STS
1 Germ cell and trophoblastic neoplasms Reference category
2 Germ cell and trophoblastic neoplasms of non-gonadal sites
1 Melanoma Reference category
2 Skin carcinoma
1 Thyroid
2 Head and neck
3 Trachea, bronchus, lung and pleura
4 Breast
5 Genito-urinary tract Reference category
6 Gastro-intestinal tract
7 Other
Soft tissue sarcoma
Germ cell and trophoblastic 
neoplasms
Melanoma and skin carcinoma
Carcinomas
Excluded as tumour 
grade was included and 
found to be strongly 
corellated with 
diagnostic group
Description
Modelled seperately
Leukaemia
Lymphoma
Central nervous system and other 
intracranial and intraspinal 
neoplasms
Osseous and chondromatous 
neoplasms, Ewing's sarcoma and 
other neoplasms of bone
 
3.13.2.2.2.6 ‘Level’ of specialist care 
The level of specialist care received by each patient was determined by the proportion of their 
time as an inpatient which they spent at a specialist centre. Cox models were run using the 
proportion as a continuous variable and compared to models using the groups described 
previously (limited specialist input, some specialist input and mostly specialist care). In all 
cases the models were shown to have the best fit when including specialist input as a 
categorical variable. 
3.13.2.2.3 Additional variables 
3.13.2.2.3.1 Type of specialist care 
The type of specialist care was only relevant for CNS and bone tumours and STS, where there 
were tumour specific specialist centres. Patients were grouped according to whether they had 
received; 
Limited specialist input – less than 30% of care in a specialist centre 
Site specific input – greater than 30% of care at a tumour specific centre, but less than 30% of 
time at a TCT centre 
Age specific input – greater than 30% of care at a TCT centre, but less than 30% of time at a 
tumour specific centre 
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Age and site specific input – greater than 30% of care at a tumour specific centre and greater 
than 30% of care at a TCT centre. 
This was included in the models for CNS and bone tumours and STS as a four-level categorical 
variable alongside the ‘level’ of care received. 
3.13.2.2.3.2 Tumour grade 
Stage is often used as a key prognostic factor; however it is poorly recorded for the majority of 
TYA tumour sites in cancer registration data. It was not possible to impute stage as it was 
missing in 99.93% of all cases.  For brain and CNS tumours it was possible to calculate grade (I-
IV or low to high) according to the World Health Organisation (WHO) classification of 
tumours258 259, based on the morphology of the primary tumour. For brain and CNS tumours 
grade was entered into the model as a categorical variable, unfortunately this was not possible 
for any other tumour site. 
3.13.3 Health service usage 
Hospital service usage during treatment was compared across all groups of specialist 
attendees. The median number of admissions per patient was calculated for each group of 
specialist attendees. The median was used rather than the mean as the data were skewed and 
the median went some way to addressing this. 
The proportion of the treatment period that each patient spent in hospital was calculated, 
censoring the follow up time at 18 months post diagnosis, unless a patient had died prior to 
this, in which case the date of death was used as the censor date. The length of hospital stay 
was divided by the length of follow up in order to determine the proportion spent as an 
inpatient. 
Unplanned readmission to hospital has been used in several studies as a marker of the quality 
of care received and can, in some cases, be implicated in variation in outcomes260-263. Others 
have suggested that the variation in emergency readmission rates may be due to case mix and 
treatment variation264. Once the case mix between centres had been assessed it was possible 
to assess the variation in unplanned readmission between centre types, allowing for patient 
variation. The median proportion of all admissions occurring during the treatment period 
which were unplanned was compared across all groups of specialist attendee. The source of 
each admission was extracted from the HES data and any which was either not elective or 
maternity related was marked as an unplanned. 
3.13.4 Health service costs 
Health service costs were compared between groups of specialist attendees. These costs were 
calculated from the HES data using Healthcare Resource Groups (HRG’s)265. HRG’s are used to 
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classify data in order for costings for payment by results (PbR)266 to be calculated. In this 
classification groups are assigned a cost for treatment which factors in length of stay, 
treatments received and certain patient demographic details. This process forms the basis of 
the NHS payment system, calculating the amount paid by commissioners to healthcare 
providers for each patient seen. 
Information about each spell was grouped using the HRG “Local Grouper” which produced a 
code for each admission which was linked to a cost (which varied by year). Particularly complex 
or expensive admissions were further broken down and a code was provided for each episode 
within a spell, in these cases the cost for the entire admission was used. 
In this study the HRG group for each admission occurring within the treatment period was 
calculated and a cost assigned to each. The total cost per patient was then calculated and 
median costs compared between types of specialist attendees. It is important to acknowledge 
that these costs are for all admissions during the treatment period, regardless of the reason 
for admission, and so may not be cancer related. It also does not include the cost of outpatient 
care, and as such is not a ‘complete’ cost but is representative of the cost of inpatient care. 
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Chapter 4 Study population  
This chapter details the results of the cleaning process and the demographics of both the 
patients in the cleaned dataset and those excluded due to non-linkage with the HES data. The 
demographics of the two subpopulations are compared in the following tables. 
In total 24,846 tumours were excluded during the cleaning process, leaving 10,005 tumours. 
The number of cases removed at each stage of the data cleaning are presented in Figure 16.  
Figure 16: Results of the deduplication process 
 
Of the remaining 10,005 tumours 979 were either unclassified when using the Birch 
classification scheme or fell into groups nine and ten, miscellaneous or unspecified neoplasms. 
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Due to the wide range of disease types in these groups and the small number of patients in 
each these tumours were excluded from further study. This left a study population of 9,026 
tumours. 
Patients did not link to a HES record if they had no inpatient stay and therefore no hospital 
record, this was more likely in patients diagnosed with a melanoma or skin carcinoma than 
other diagnostic groups. Patients receiving supportive care only may also have been less likely 
to be admitted than their peers. Patients only appear in the extract of HES data if a diagnostic 
code for cancer was included in an admission, if this was not the case data would not have 
been received. Additionally patients may have failed to link to HES if the identifiers differed 
between the cancer registration and HES data.  
The number of patients excluded due to a failure to link to HES data varied across England. In 
total 23.1% of those from the Oxford region were excluded compared to 11.4% from the 
Northern and Yorkshire region (Table 11). This reflects the geographical limitations of the data 
in that the registration of cancers is known to be variable with significant differences between 
regions. Whilst it was not possible to address this in this piece of work the variation was taken 
into consideration when analysing all results, in particular the access to healthcare work where 
the excluded cases may have biased the outcomes.  
Table 11: Number of patients by cancer registry of residence 
n % n %
Northern and Yorkshire Cancer Registry NYCRIS 1,326 88.6 171 11.4 1,497
West Midlands Cancer Intelligence Unit WMCIU 807 86.6 125 13.4 932
South West Cancer Intelligence Service SWCIS 1,173 87.0 175 13.0 1,348
North West Cancer Intelligence Service NWCIS 1,087 84.4 201 15.6 1,288
Trent Cancer Registry TRENT 712 83.3 143 16.7 855
Eastern Cancer Registration and Information Centre ECRIC 721 87.9 99 12.1 820
Thames Cancer Registry TCR 1,491 84.8 267 15.2 1,758
Oxford Cancer Intelligence Unit OCIU 406 76.9 122 23.1 528
7723 85.6 1303 14.4 9,026
Total
Included Excluded
Registry name
Total
Number of patients
 
In total 1,303 tumours were excluded from the study due to a lack of linkage to a HES record. 
This distribution of these exclusions over the eight diagnostic groups included in the study is 
shown in Figure 17 and Table 12. There is significant variation between the groups with 
approximately 5% of all leukaemia being excluded and over 30% of melanoma and skin 
carcinoma cases not linking to a HES record. This is representative of the variation in treatment 
modalities between the groups. Many melanoma and skin carcinoma patients are diagnosed 
after a biopsy and clear surgical resection margins on the biopsy would mean that further 
treatment was not necessary in the majority of cases. As a result there would be no inpatient 
stay, no HES record and consequently, no linkage.   
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Table 12: Number of patients in each diagnostic group 
Original 
dataset
n n % n %
Leukaemias 777 737 94.9 40 5.1
Lymphomas 1892 1716 90.7 176 9.3
Central Nervous system and other intracranial and intraspinal neoplasms 932 833 89.4 99 10.6
Osseous and chondromatous neoplasms, Ewing sarcoma and other neoplasms of bone 489 441 90.2 48 9.8
Soft tissue sarcomas 375 354 94.4 21 5.6
Germ cell and trophoblastic neoplasms 1331 1206 90.6 125 9.4
Melanoma and skin carcinoma 1635 1119 68.4 516 31.6
Carcinomas 1595 1317 82.6 278 17.4
Total 9026 7723 85.6 1303 14.4
Included Excluded 
Number of patients
 
Figure 17: Proportion of the population included and excluded from the study 
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In order to further examine the variation between those who were included and those who 
were excluded for each diagnostic group the patient demographic information for each group 
was compared. The results of this analysis are displayed in the following tables. 
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4.1 Leukaemia 
777 TYA patients were diagnosed with leukaemia during the study period, of these 40 did not 
link to the HES data, meaning that there was no information on admission for these patients. 
The characteristics of the leukaemia population are shown in Table 13. Although few patients 
were excluded from the analysis it was possible to see that the age distribution varied 
between those included and those excluded. More of those excluded were from the older age 
group (aged 20-24 at diagnosis) than those who were included. The gender distribution also 
differed, with all but one (2.5%) of those excluded being male, in contrast 38% of those 
included were female. A higher proportion of those excluded were diagnosed with CML than 
was seen in those included, the distribution between the other diagnostic groups was similar. 
Additionally more of those who were excluded were from the most affluent quintile than was 
seen in those included in the study.  
Table 13: The leukaemia population 
n % n % n %
53 7.2 4 10.0 57 7.3
97 13.2 4 10.0 101 13.0
90 12.2 3 7.5 93 12.0
81 11.0 1 2.5 82 10.6
81 11.0 4 10.0 85 10.9
80 10.9 5 12.5 85 10.9
62 8.4 6 15.0 68 8.8
64 8.7 2 5.0 66 8.5
68 9.2 6 15.0 74 9.5
61 8.3 5 12.5 66 8.5
457 62.0 39 97.5 496 63.8
280 38.0 1 2.5 281 36.2
118 16.0 9 22.5 127 16.3
126 17.1 5 12.5 131 16.9
120 16.3 7 17.5 127 16.3
116 15.7 7 17.5 123 15.8
144 19.5 7 17.5 151 19.4
113 15.3 5 12.5 118 15.2
366 49.7 18 45.0 384 49.4
244 33.1 11 27.5 255 32.8
93 12.6 9 22.5 102 13.1
34 4.6 2 5.0 36 4.6
129 17.5 13 32.5 142 18.3
125 17.0 6 15.0 131 16.9
141 19.1 5 12.5 146 18.8
151 20.5 8 20.0 159 20.5
181 24.6 6 15.0 187 24.1
10 1.4 2 5.0 12 1.5
737 40 777Total (number of patients)
2006
2005
Unknown
1 (Most deprived)
2
3
Total
2004
2003
21
20
17
16
24
2002
2001
23
19
Deprivation 
quintile
One or more admissions
Female
Male
4
5 (Most affluent)
Other
Acute Lymphoid Leukaemia (ALL)
No HES record
Diagnosis
22
Age at 
diagnosis
Gender
Year of 
diagnosis
15
18
Acute Myeloid Leukaemia (AML)
Chronic Myeloid Leukaemia (CML)
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4.2 Lymphoma 
1,892 TYA patients were diagnosed with lymphoma during the study period, of these 176 did 
not link to the HES data. The characteristics of the lymphoma population are shown in Table 
14. As with the leukaemia population there was variation in distribution of patients across the 
demographic groups. Although there was variation seen in the age at diagnosis, gender and 
year of diagnosis the main differences were seen in the diagnostic groups and deprivation 
quintile. The most common diagnostic group in those included in the study was Hodgkin’s 
lymphoma, accounting for 69% of all diagnoses. In contrast the most common diagnostic group 
in those excluded from the study was non-Hodgkin’s lymphoma, which accounted for over half 
(51.1%) of all diagnoses in this group. This is disproportionately large and suggests that an 
additional factor is leading to this group not being admitted, such as a higher rate of 
outpatient treatment. The majority of those who were included in the study were from the 
most deprived quintile, whereas the majority of those excluded were from more affluent 
groups. 
Table 14: The lymphoma population 
 
n % n % n %
68 4.0 4 2.3 73 3.9
164 9.6 7 4.0 171 9.0
155 9.0 21 11.9 176 9.3
150 8.7 14 8.0 164 8.7
175 10.2 15 8.5 190 10.0
194 11.3 23 13.1 217 11.5
209 12.2 22 12.5 231 12.2
205 11.9 21 11.9 226 11.9
214 12.5 29 16.5 243 12.8
182 10.6 20 11.4 202 10.7
939 54.7 109 61.9 1,048 55.4
777 45.3 67 38.1 844 44.6
279 16.3 33 18.8 312 16.5
262 15.3 37 21.0 299 15.8
289 16.8 23 13.1 312 16.5
297 17.3 33 18.8 330 17.4
276 16.1 29 16.5 305 16.1
313 18.2 21 11.9 334 17.7
532 31.0 90 51.1 622 32.9
1,184 69.0 86 48.9 1,270 67.1
332 19.3 42 23.9 374 19.8
322 18.8 38 21.6 360 19.0
321 18.7 29 16.5 350 18.5
341 19.9 29 16.5 370 19.6
383 22.3 34 19.3 417 22.0
17 1.0 4 2.3 21 1.1
1,716 176 1,892
No HES record
Diagnosis
22
Age at 
diagnosis
Gender
Year of 
diagnosis
15
18
Hodgkin lymphoma (HL)
23
19
Deprivation 
quintile
One or more admissions
Female
Male
4
5 (Most affluent)
Non-Hodgkin lymphoma (NHL)
Total
2004
2003
21
20
17
16
24
2002
2001
Total (number of patients)
2006
2005
Unknown
1 (Most deprived)
2
3
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4.3 Central nervous system and other intracranial and intraspinal neoplasms 
932 TYA patients were diagnosed with a brain or CNS tumour during the study period, of these 
99 did not link to the HES data. The characteristics of the brain and CNS tumour population are 
shown in Table 15. In contrast to both leukaemia and lymphoma very little variation was seen 
in the characteristics of those included and those excluded. There is a slight tendency towards 
those with unknown tumour grades being excluded and there was a peak in patients excluded 
in those diagnosed in 2002 and 2003. This lack of variation is suggestive that there was no 
single external factor affecting the likelihood of patients linking to a HES record.  
Table 15: The CNS population 
n % n % n %
15 43 5.2 2 2.0 45 4.8
16 100 12.0 13 13.1 113 12.1
17 74 8.9 6 6.1 80 8.6
18 67 8.0 14 14.1 81 8.7
19 84 10.1 9 9.1 93 10.0
20 83 10.0 13 13.1 96 10.3
21 78 9.4 10 10.1 88 9.4
22 93 11.2 8 8.1 101 10.8
23 96 11.5 11 11.1 107 11.5
24 115 13.8 13 13.1 128 13.7
Male 444 53.3 55 55.6 499 53.5
Female 389 46.7 44 44.4 433 46.5
2001 110 13.2 16 16.2 126 13.5
2002 141 16.9 20 20.2 161 17.3
2003 138 16.6 23 23.2 161 17.3
2004 135 16.2 14 14.1 149 16.0
2005 168 20.2 12 12.1 180 19.3
2006 141 16.9 14 14.1 155 16.6
Astrocytoma 315 37.8 37 37.4 352 37.8
Other gliomas 103 12.4 18 18.2 121 13.0
Ependymoma 40 4.8 3 3.0 43 4.6
Medulloblastoma and other PNET 56 6.7 7 7.1 63 6.8
Other specified intracranial and intraspinal neoplasms 283 34.0 28 28.3 311 33.4
Unspecified intracranial and intraspinal neoplasms 36 4.3 6 6.1 42 4.5
I 200 24.0 27 27.3 227 24.4
II 256 30.7 35 35.4 291 31.2
III 60 7.2 3 3.0 63 6.8
IV 127 15.2 9 9.1 136 14.6
Unknown 190 22.8 25 25.3 215 23.1
5 (Most affluent) 152 18.2 17 17.2 169 18.1
4 174 20.9 16 16.2 190 20.4
3 158 19.0 13 13.1 171 18.3
2 160 19.2 21 21.2 181 19.4
1 (Most deprived) 181 21.7 26 26.3 207 22.2
Unknown 8 1.0 6 6.1 14 1.5
1 823 98.8 99 100.0 922 98.9
2 10 1.2 0 0.0 10 1.1
>2 0 0.0 0 0.0 0 0.0
833 99 932
WHO grade 
of tumour
Total
Age at 
diagnosis
Gender
Year of 
diagnosis
Total (number of patients)
Deprivation 
quintile
One or more admissions No HES record
Diagnosis
Number of 
primary 
tumours
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4.4 Osseous and chondromatous neoplasms, Ewing’s sarcoma and other 
neoplasms of bone 
489 TYA patients were diagnosed with a bone tumour during the study period, of these 48 did 
not link to the HES data. The characteristics of the bone tumour population are shown in Table 
16. A greater proportion of those patients who were excluded from the study were diagnosed 
in 2002 and 2003 than those who were included. Whereas osteosarcoma was predominant in 
those who were included and Ewing’s sarcoma was the second most common diagnostic group 
the opposite was true of those who were excluded. More of the patients who were excluded 
were from the most affluent groups, contrasting with what was seen in those patients who 
linked to a HES record. The age incidence patterns in both groups were erratic and showed 
little variation between those included and those excluded. As with other tumour groups there 
does not appear to be one single factor which defines those that did not have a HES record. 
Table 16: The bone tumour population 
n % n % n %
15 38 8.6 2 4.2 40 8.2
16 60 13.6 3 6.3 63 12.9
17 59 13.4 5 10.4 64 13.1
18 59 13.4 9 18.8 68 13.9
19 35 7.9 2 4.2 37 7.6
20 38 8.6 6 12.5 44 9.0
21 49 11.1 4 8.3 53 10.8
22 41 9.3 5 10.4 46 9.4
23 35 7.9 8 16.7 43 8.8
24 27 6.1 4 8.3 31 6.3
Male 272 61.7 32 66.7 304 62.2
Female 169 38.3 16 33.3 185 37.8
2001 78 17.7 8 16.7 86 17.6
2002 70 15.9 9 18.8 79 16.2
2003 59 13.4 11 22.9 70 14.3
2004 86 19.5 8 16.7 94 19.2
2005 75 17.0 7 14.6 82 16.8
2006 73 16.6 5 10.4 78 16.0
Osteosarcoma 209 47.4 16 33.3 225 46.0
Ewing's sarcoma 168 38.1 20 41.7 188 38.4
Other 64 14.5 12 25.0 76 15.5
5 (Most affluent) 81 18.4 10 20.8 91 18.6
4 72 16.3 10 20.8 82 16.8
3 73 16.6 7 14.6 80 16.4
2 77 17.5 8 16.7 85 17.4
1 (Most deprived) 116 26.3 11 22.9 127 26.0
Unknown 22 5.0 2 4.2 24 4.9
1 434 98.4 47 97.9 481 98.4
2 7 1.6 1 2.1 8 1.6
>2 0 0.0 0 0.0 0 0.0
441 48 489
Total
Age at 
diagnosis
Gender
Year of 
diagnosis
Total (number of patients)
Deprivation 
quintile
One or more admissions No HES record
Diagnosis
Number of 
primary 
tumours
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4.5 Soft tissue sarcoma 
375 TYA patients were diagnosed with a soft tissue sarcoma during the study period, of these 
11 did not link to the HES data. The characteristics of the STS population are shown in Table 
17. Very few STS patients failed to link to a HES record making the interpretation of differences 
between the groups difficult. The main difference was seen in the gender distribution between 
those included and those excluded from the study, with more of those included being male 
(53.8%). In the group that was excluded from the study only 36.4% were male. 
Table 17: The soft tissue sarcoma population 
 
n % n % n %
15 16 4.4 1 9.1 17 4.5
16 38 10.4 1 9.1 39 10.4
17 39 10.7 2 18.2 41 10.9
18 32 8.8 1 9.1 33 8.8
19 37 10.2 1 9.1 38 10.1
20 29 8.0 0 0.0 29 7.7
21 41 11.3 2 18.2 43 11.5
22 41 11.3 0 0.0 41 10.9
23 43 11.8 3 27.3 46 12.3
24 48 13.2 0 0.0 48 12.8
Male 196 53.8 4 36.4 200 53.3
Female 168 46.2 7 63.6 175 46.7
2001 60 16.5 1 9.1 61 16.3
2002 56 15.4 1 9.1 57 15.2
2003 61 16.8 2 18.2 63 16.8
2004 64 17.6 4 36.4 68 18.1
2005 63 17.3 1 9.1 64 17.1
2006 60 16.5 2 18.2 62 16.5
Fibrosarcoma 68 18.7 3 27.3 71 18.9
Rhabdomyosarcoma 81 22.3 1 9.1 82 21.9
Other specified STS 153 42.0 5 45.5 158 42.1
Unspecified 62 17.0 2 18.2 64 17.1
5 (Most affluent) 50 13.7 0 0.0 50 13.3
4 68 18.7 0 0.0 68 18.1
3 74 20.3 0 0.0 74 19.7
2 77 21.2 0 0.0 77 20.5
1 (Most deprived) 87 23.9 0 0.0 87 23.2
Unknown 8 2.2 11 100.0 19 5.1
1 358 98.4 11 100.0 369 98.4
2 6 1.6 0 0.0 6 1.6
>2 0 0.0 0 0.0 0 0.0
364 11 375
Total
Age at 
diagnosis
Gender
Year of 
diagnosis
Total (number of patients)
Deprivation 
quintile
One or more admissions No HES record
Diagnosis
Number of 
primary 
tumours
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4.6 Germ cell and trophoblastic neoplasms 
1,331 TYA patients were diagnosed with a germ cell or trophoblastic neoplasm during the 
study period, of these 125 did not link to the HES data. The characteristics of the germ cell 
tumour population are shown in Table 18. The age distribution was broadly similar between 
those included and those excluded. In both groups the vast majority of patients were male, 
however there was a higher proportion of female patients in the excluded group than the 
included patients, this is reflected in the proportion of patients diagnosed with ovarian 
tumours in each group. The distribution of patients by both deprivation and year of diagnosis 
was very similar between the two groups. Again this suggests that no one single factor, such as 
increasing outpatient treatment, is influencing the proportion of patients linking to a HES 
record.   
Table 18: The germ cell population 
 
n % n % n %
15 20 1.7 3 2.4 23 1.7
16 44 3.6 4 3.2 48 3.6
17 70 5.8 6 4.8 76 5.7
18 91 7.5 5 4.0 96 7.2
19 110 9.1 12 9.6 122 9.2
20 135 11.2 13 10.4 148 11.1
21 156 12.9 15 12.0 171 12.8
22 159 13.2 21 16.8 180 13.5
23 205 17.0 17 13.6 222 16.7
24 216 17.9 19 15.2 245 18.4
Male 1,092 90.5 104 83.2 1,196 89.9
Female 114 9.5 21 16.8 135 10.1
2001 183 15.2 31 24.8 214 16.1
2002 185 15.3 19 15.2 204 15.3
2003 202 16.7 22 17.6 224 16.8
2004 202 16.7 23 18.4 225 16.9
2005 229 19.0 16 12.8 245 18.4
2006 205 17.0 14 11.2 219 16.5
Gonadal germ cell & trophoblastic neoplasms 1,114 92.4 115 92.0 1,229 92.3
Ovary 100 9.0 17 14.8 117 9.5
Testis 1,014 91.0 98 85.2 1,112 90.5
Germ cell & trophoblastic neoplasms of non-gonadal sites 92 7.6 10 8.0 102 7.7
5 (Most affluent) 254 21.1 38 30.4 292 21.9
4 234 19.4 26 20.8 260 19.5
3 222 18.4 21 16.8 243 18.3
2 247 20.5 21 16.8 268 20.1
1 (Most deprived) 244 20.2 18 14.4 262 19.7
Unknown 5 0.4 1 0.8 6 0.5
1,206 125 1,331
Total
Age at 
diagnosis
Gender
Year of 
diagnosis
Total (number of patients)
Deprivation 
quintile
One or more admissions No HES record
Diagnosis
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4.7 Melanoma and skin carcinoma 
1,635 TYA patients were diagnosed with melanoma or skin carcinoma during the study period, 
of these 516 did not link to the HES data. The characteristics of the melanoma and skin 
carcinoma population are shown in Table 19. The distribution of patients according to age at 
diagnosis, gender, year of diagnosis and deprivation was very similar between those excluded 
and those included. The major difference in this group is seen according to the diagnostic 
group. Patients with a HES record (and therefore one or more admission to hospital) had 
mostly been diagnosed with malignant melanoma (79.3%). In contrast only 54.5% of those 
without a HES record had been diagnosed with a malignant melanoma. Since the number of 
patients excluded in this group is so much larger than any other diagnostic group and more of 
the group who were excluded from the study had been diagnosed with a skin carcinoma, it can 
be suggested that this group are being treated out of the inpatient environment.  
Table 19: The melanoma population 
 
n % n % n %
15 23 2.1 6 1.2 29 1.8
16 46 4.1 10 1.9 56 3.4
17 53 4.7 24 4.7 77 4.7
18 69 6.2 28 5.4 97 5.9
19 87 7.8 40 7.8 127 7.8
20 119 10.6 45 8.7 164 10.0
21 147 13.1 72 14.0 219 13.4
22 171 15.3 86 16.7 257 15.7
23 187 16.7 87 16.9 274 16.8
24 217 19.4 118 22.9 335 20.5
Male 390 34.9 188 36.4 578 35.4
Female 729 65.1 328 63.6 1,057 64.6
2001 188 16.8 68 13.2 256 15.7
2002 190 17.0 77 14.9 267 16.3
2003 175 15.6 71 13.8 246 15.0
2004 171 15.3 101 19.6 272 16.6
2005 215 19.2 97 18.8 312 19.1
2006 180 16.1 102 19.8 282 17.2
Melanoma 887 79.3 281 54.5 1,168 71.4
Skin carcinoma 232 20.7 235 45.5 467 28.6
5 (Most affluent) 231 20.6 136 26.4 367 22.4
4 231 20.6 113 21.9 344 21.0
3 218 19.5 91 17.6 309 18.9
2 231 20.6 89 17.2 350 21.4
1 (Most deprived) 198 17.7 76 14.7 274 16.8
Unknown 10 0.9 11 2.1 21 1.3
1,119 516 1,635
Total
Age at 
diagnosis
Gender
Year of 
diagnosis
Total (number of patients)
Deprivation 
quintile
One or more admissions No HES record
Diagnosis
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4.8 Carcinomas 
1,595 TYA patients were diagnosed with a carcinoma during the study period, of these 278 did 
not link to the HES data. The characteristics of the carcinoma population are shown in Table 
20. The distribution of patients according to age, gender, year of diagnosis and deprivation was 
similar in those who were included in the study and those excluded. However the number of 
patients in each diagnostic group varied hugely. The second most common carcinoma in 
patients who were included in the study was carcinoma of the thyroid (26% of all cases), in 
contrast thyroid carcinoma accounted for only 12.9% of those excluded. The most common 
tumour site in both groups was the genitor-urinary (GU) tract, however the proportion that 
this accounts for differs between the groups (26.3% of those included versus 40.3% of those 
excluded). There was variation seen in all other diagnostic groups but it was not as significant 
as that seen in thyroid and GU carcinomas. 
Table 20: The carcinoma population 
 
n % n % n %
14 1.1 0 0.0 14 0.9
62 4.7 19 6.8 81 5.1
86 6.5 11 4.0 97 6.1
76 5.8 10 3.6 86 5.4
102 7.7 17 6.1 119 7.5
120 9.1 29 10.4 149 9.3
142 10.8 28 10.1 170 10.7
185 14.0 38 13.7 223 14.0
225 17.1 57 20.5 282 17.7
305 23.2 69 24.8 374 23.4
354 26.9 57 20.5 411 25.8
963 73.1 221 79.5 1,184 74.2
183 13.9 29 10.4 212 13.3
208 15.8 48 17.3 256 16.1
223 16.9 55 19.8 278 17.4
221 16.8 43 15.5 264 16.6
239 18.1 52 18.7 291 18.2
243 18.5 51 18.3 294 18.4
343 26.0 36 12.9 379 23.8
139 10.6 21 7.6 160 10.0
41 3.1 4 1.4 45 2.8
74 5.6 3 1.1 77 4.8
346 26.3 112 40.3 458 28.7
287 21.8 60 21.6 347 21.8
87 6.6 42 15.1 129 8.1
215 16.3 52 18.7 627 39.3
232 17.6 46 16.5 678 42.5
234 17.8 59 21.2 693 43.4
298 22.6 48 17.3 346 21.7
332 25.2 63 22.7 395 24.8
6 0.5 10 3.6 16 1.0
1,317 278 1,595
No HES record
Diagnosis
22
Age at 
diagnosis
Gender
Year of 
diagnosis
15
18
Head and neck
Trachea, bronchus, lung & pleura
23
19
Deprivation 
quintile
One or more admissions
Female
Male
4
5 (Most affluent)
Other
Thyroid
Total
2004
2003
21
20
17
16
24
2002
2001
Total (number of patients)
2006
2005
Unknown
1 (Most deprived)
2
3
Gastrointestinal tract
Genito-urinary tract
Breast
 
 
4.9 Final study population 
After all exclusions had been made the final number of patients to be included in the study 
was 7,733. The total number of patients by diagnostic group is shown in Table 21. 
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The proportion of patients excluded differed substantially between the eight diagnostic 
groups, being relatively low in leukaemia, lymphoma, CNS and bone tumours, STS and 
carcinoma. In contrast a much larger proportion of the germ cell, melanoma and skin 
carcinoma population was excluded due to non-linkage with HES data. The nature of the 
treatment pathways for both of these tumour groups means that these patients may be more 
likely to be treated as outpatients and less likely to require admission to hospital for either 
treatment or treatment related complications. 
Table 21: The study population 
Number of 
patients
Group 1 Leukaemias 737
Group 2 Lymphomas 1,716
Group 3 Central Nervous system and other intracranial and intraspinal neoplasms 833
Group 4 Osseous and chondromatous neoplasms, Ewing sarcoma and other neoplasms of bone 441
Group 5 Soft tissue sarcomas 364
Group 6 Germ cell and trophoblastic neoplasms 1,206
Group 7 Melanoma and skin carcinoma 1,119
Group 8 Carcinomas 1,317
7,733
Diagnostic group
Total  
The following chapters present the results of the analyses undertaken as part of this study. The 
results of the attitudes to specialist care are presented first (Chapter 5), followed by the 
analyses for each of the different TYA cancers by diagnostic group: 
Chapter 6- Leukaemia 
Chapter 7- Lymphoma 
Chapter 8- Central nervous system and other intracranial and intraspinal neoplasms 
Chapter 9- Osseous and chondromatous neoplasms, Ewing’s sarcoma and other neoplasms of 
bone 
Chapter 10– Soft tissue sarcoma 
Chapter 11 – Germ cell and trophoblastic neoplasms 
Chapter 12 – Melanoma and skin carcinoma 
Chapter 13 - Carcinomas 
Within each chapter there are three key sections examining access to specialist care, variation 
in patient characteristics by the level of specialist care received and patient outcomes.  
One factor thought to influence the uptake of specialist care is access to a centre and so this 
was examined using the proximity to a specialist centre from a patient’s address at diagnosis. 
The access to specialist care was further assessed by analysing the proportion of patients in 
each cancer network receiving each level of care (limited, some or mostly specialist care). High 
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volume centres were identified for each cancer site, both in terms of number of patients and 
number of admissions. The results are presented in the first subchapter for each diagnostic 
group. 
The characteristics of the tumour population were assessed according to the level of care 
received and the differences between the levels of care received both overall and for each 
diagnostic group individually.  The results are presented in the second subchapter for each 
diagnostic group. 
Multiple patient outcomes were assessed according to the level of care received for each 
diagnostic group. The results are detailed in the third subchapter for each diagnostic group. 
Treatment received, survival, health service usage and health service costs were all analysed in 
order to determine whether each outcome was affected by the level of specialist care 
received.
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Chapter 5 Survey of attitudes to specialist care 
In order to establish the degree to which attitudes towards specialist care varied between 
professionals involved in the diagnosis and treatment of TYA patients a survey of medical 
professionals was undertaken. This was used to assess to what extent opinions differed and 
whether there was a significant variation which could influence referral to and uptake of 
specialist services. 
In total 691 healthcare professionals from 98 NHS Trusts were asked to complete the 
questionnaire and were approached using email. Of these 338 (51.9%) responded. The 
responses to the questions asked were analysed and all statements were ranked in order of 
the proportion ranked four or higher. The results of the ranking process are presented in Table 
22.  
When the questions were ranked in order of importance the three questions ranked most 
highly were:  
o Contact with a nurse specialising in the care of TYA (94.6% marked as a 4 or 
higher)  
o Psychological and psychosocial support from those specialising in the care of 
TYA (94.3% marked as a 4 or higher) 
o Access to fertility specialists and advice on reproductive issues (93.7% marked 
as a 4 or higher) 
 The three statements ranked the lowest were:  
o Diagnostics and staging by clinical teams specialising in the care of TYA 
(radiology, pathology etc.) (58.6% marked as a 4 or higher) 
o Treatment at a hospital in close proximity to a patient’s home address. (39.0% 
marked as a 4 or higher) 
o Inpatient treatment on a site specific ward (e.g. breast) (34.3% marked as a 4 
or higher) 
The three statements which ranked the lowest also had the greatest number of indifferent 
responses (scored 3 on the Likert scale). These results did not follow what was expected when 
assessing them alongside the protocols in place at the time of the survey, such as access to 
clinical trials, both age- and site- specific and treatment at a high volume centre. All three of 
these statements ranked around the middle of the table of ordered responses. Certain aspects 
of care which have been recorded as being important by patients130, such as treatment close to 
home, ranked much lower on the scale than expected.  
In order to establish whether there were unseen factors influencing the responses to the 
survey and to group respondents according to the similarity of their responses a latent cluster 
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analysis was performed. This was used to cluster the respondents according to the responses 
given and hence determine any underlying relationships which define the groups. The 
goodness-of-fit test (Bayesian Information Criterion (BIC) scores) was used as a measure for 
model selection and was used to prevent ‘over-fitting’ by preferring a smaller number of 
parameters. For these data a three class model was selected. The patterns of responses are 
demonstrated in Figure 18. The three clusters had very different response patterns with 
cluster one rating age-appropriate treatment very highly in comparison to site-specific 
treatment. Cluster two rated most points high on the scale and didn’t show a preference 
towards either age- or site-specialist care. In contrast cluster three rated site- specific care 
higher than age-appropriate care, but did not rate any points as highly as the other two 
clusters.  
Overall it appeared that clusters should be grouped as follows; 
Cluster 1 – Age-specific preference 
Cluster 2 – Combined age- and site-specific preference 
Cluster 3 – Cancer site-specific preference 
Figure 18: Cluster analysis of the responses to the attitudes survey 
 
The characteristics of the respondents are detailed in Table 23 and are compared across the 
three clusters which were identified during the cluster analysis. Overall 190 (56.2%) reported 
that they were affiliated with a teenage cancer unit and 208 (61.5%) were linked to a 
Children’s Cancer and Leukaemia Group CCLG unit. The majority of respondents belonged to a 
medical rather than a surgical specialism (271 versus 67 respectively). Many respondents 
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additionally recorded that the patient range should not be restricted by age but by 
socioeconomic group and emotional maturity of the patient.  
On further examination of the self-reported interests of the respondents (Table 23), the 
distribution of those affiliated with a TCT or CCLG unit was found to be even across the three 
clusters. Overall 99 of the doctors who responded (42.3%) fell into cluster one. Over half of all 
nurses (56.3%) were in cluster two. 
The majority, 40.1%, of those specialising in oncology were in cluster one (57 respondents). 
Those specialising in haematology and paediatrics were seen more frequently in cluster one 
(60.0% and 55.6% of respondents), gynaecology and palliative care were seen mostly in cluster 
two (55.6% and 66.7% respectively). 
A greater proportion of those reporting a site-specific interest, 201 persons in total, were 
identified as being in cluster one than any other cluster (39.3%). Those reporting an interest in 
both age- and site-specific care were mainly seen in cluster two, while the majority of those 
with an age-specific interest, 49 respondents in total, were in cluster three (51.0%).  
Of those who reported an affiliation with a TCT centre the majority, 43.7%, were identified as 
being in cluster two. The majority of those recording no affiliation were found to belong in 
cluster one. 
The majority of individuals with a low annual TYA workload (<11 cases or <10% of the annual 
caseload) were identified in cluster one. Those with a high workload (>15 cases or >30% of the 
annual caseload) were seen in cluster two.  
These characteristics reflect what would be expected when comparing them to the clustered 
responses to the survey. Cluster two, who demonstrated both an age- and site-specific 
interest, had the highest TYA workload and the greater proportion of those affiliated to a TCT 
unit. Cluster one, who ranked age-appropriate care above site-specific, had the lowest TYA 
workload and had the lowest proportion of those reporting affiliation to a TCT centre. Despite 
their low involvement with TYA in comparison to other clusters they had the highest 
proportion of paediatric specialists, suggesting that their age-specific interest was related to 
age groups other than TYA patients. Cluster three, who reported a preference for site-
specialist care contained a large proportion of those with a surgical speciality (35.8%) and 
therefore may have had a tendency to focus on the importance of site specific care.
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Table 23: Characteristics of respondents to the attitudes survey 
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Chapter 6 Leukaemia 
6.1 Specialist care 
The proportion of total inpatient time during treatment spent at a specialist centre was 
compared to the time spent at any other type of hospital for leukaemia patients (Figure 19). 
Due to the form that leukaemia services take and the nature of the treatments for leukaemia, 
patients can be treated at many different centres and services are not centralised in the same 
way as those for some of the other diagnostic groups. This means that for leukaemia patients 
the proportion of treatment received at a TCT centre was compared to treatment at any other 
NHS facility. 
Figure 19: Assignment of leukaemia patients to a “level” of specialist care using the proportion of 
inpatient time spent in a specialist centre 
 
6.2 Access to specialist care 
6.2.1 Hospital catchment areas 
For each TCT centre the distance within which 25%, 50% and 75% of patients were found was 
mapped using concentric circles representing the distance from the patient’s home address to 
both their closest centre (Map 7) and the centre to which they were admitted (Map 6). These 
maps display the real ‘catchment area’ for each centre alongside the actual geographical 
distribution of patients in relation to their closest specialist centre. As previously stated, the 
specialist centres for leukaemia were determined to be TCT centres and the location of all 
relevant centres are mapped in the methods. 
The maps demonstrating the theoretical catchment areas of the TCT units treating leukaemia 
patients (Map 7) and the map demonstrating the actual catchment (Map 6) show a much 
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smaller catchment area and dispersion of patients admitted to Southampton, University 
College London Hospitals (UCL), Sheffield and Alder Hey. In contrast, Newcastle, Leeds, 
Birmingham and the Christie were attracting patients from outside their catchment area, as 
defined by proximity to the treating centre.  
Alder Hey, UCL and Southampton also had the greatest proportion of patients, for whom they 
were the closest centre, who didn’t attend any TCT unit during their treatment period. 
Newcastle and Leeds had, in reality, an increased catchment area compared to their 
theoretical coverage and they also had the smallest proportion of patients receiving no TCT 
input (11% and 22% respectively). Overall, for this diagnostic group, very few patients were 
admitted to a hospital other than their closest centre (Table 24). But the range of patients who 
were not admitted to a TCT unit during the treatment period varied widely across the country. 
For example, 83% of patients living closest to UCL had no admission to a TCT centre but, in 
contrast, only 11% of patients closest to Newcastle had no admission to a TCT centre. The 
number of patients closest to each centre also varied, reflecting the variation in population 
densities across England. 
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 Table 24: Numbers of leukaemia patients closest to each TCT centre, and the centre actually attended 
n % n % n % n % n % n % n % n % n %
Alder Hey Children's NHS Foundation 
Trust 4 13 0 0 0 0 0 0 2 6.5 0 0 0 0 0 0 25 81 31
Leeds Teaching Hospitals NHS Trust
0 0 56 76 0 0 0 0 1 1.4 1 1.4 0 1.8 0 0 16 22 74
Sheffield Teaching Hospitals NHS 
Foundation Trust 0 0 2 4.7 15 35 0 0 0 0 0 0 0 0 0 0 26 60 43
University Hospital Southampton NHS 
Foundation Trust 0 0 2 1.5 2 1.5 32 24 0 0 1 0.7 3 0.5 2 1.5 94 69 136
The Christie NHS Foundation Trust
0 0 1 1.2 0 0 0 0 26 32 0 0 0 0 6 7.4 48 59 81
The Newcastle upon Tyne Hospitals 
NHS Foundation Trust 0 0 0 0 0 0 0 0 0 0 32 89 0 247 0 0 4 11 36
University College London Hospitals 
NHS Foundation Trust 0 0 1 0.4 1 0.4 0 0 0 0 1 0.4 39 12 2 0.8 211 83 255
University Hospitals Birmingham NHS 
Foundation Trust 0 0 0 0 0 0 0 0 0 0 0 0 0 0 25 31 56 69 81
Total 737
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Increasing road distance from a TCT centre decreased the odds of being admitted to a TCT 
centre during treatment for leukaemia patients (Odds Ratio (OR) 0.93 95% Confidence 
Intervals (CI) 0.91-0.96). For every 5km increase in distance between the patient’s home 
address and the closest TCT centre there was a 7% decrease in the likelihood of admission to 
the centre. 
A diagnosis of “other” leukaemia and  CML (OR 0.48 and 0.67 respectively) and increasing age 
at diagnosis (OR 0.94) decreased the likelihood of admission to the closest TCT centre and 
were associated with a 52%, 33% and 6% decrease in the odds of admission to a TCT centre 
although these results did not reach statistical significance. In contrast a diagnosis of acute 
myeloid leukaemia increased the odds of admission to a TCT centre (OR 0.93) when compared 
to patients with ALL, these findings were not statistically significant (Table 25). 
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Table 25: Likelihood of admission to a TCT centre for leukaemia patients 
Odds 
ratio
p value
Lower 
95%
Upper 
95%
Male 1.00
Female 1.02 0.92 0.71 1.47
0.94 0.08 0.89 1.01
Acute lymphoid leukaemia 1.00
Acute myeloid leukaemia 1.31 0.18 0.89 1.94
Chronic myeloid leukaemia 0.67 0.20 0.37 1.22
Other 0.48 0.15 0.18 1.31
Most deprived 1.00
2 0.49 0.01 0.29 0.83
3 0.95 0.86 0.57 1.60
4 0.76 0.31 0.44 1.29
Most affluent 0.65 0.11 0.39 1.10
0.93 <0.01 0.91 0.96
Age at diagnosis
Distance to nearest TCT centres (increase of 5km)
Gender 
Diagnostic group
Deprivation
 
 
6.2.2 Geographical distribution of patients 
With the exception of patients resident in Lancashire and South Cumbria, Yorkshire, North 
Trent and North London, the majority of patients in all the English cancer networks received 
only limited care as an inpatient at a TCT centre (Table 26). This cannot be explained simply by 
the presence or absence of a TCT principal treatment centre within the network as only 
Yorkshire and North Trent had centres during the study period. 
Table 26: Cancer network of residence at diagnosis and level of specialist inpatient care for leukaemia 
patients (highlighted sections represent the highest proportion of patients for each cancer network) 
n % n % n %
Lancashire & South Cumbria 11 47.8 0 0.0 12 52.2 23
Greater Manchester & Cheshire 43 75.4 1 1.8 13 22.8 57
Merseyside & Cheshire 22 88.0 0 0.0 3 12.0 25
Yorkshire 23 35.9 5 7.8 36 56.3 64
Humber & Yorkshire Coast 14 73.7 3 15.8 2 10.5 19
North Trent 8 34.8 0 0.0 15 65.2 23
Pan Birmingham 15 65.2 3 13.0 5 21.7 23
Arden 18 81.8 3 13.6 1 4.5 22
Mid Trent 12 100.0 0 0.0 0 0.0 12
Derby/ Burton 7 87.5 0 0.0 1 12.5 8
Leicestershire, Northants & Rutland 13 100.0 0 0.0 0 0.0 13
Mount Vernon 9 52.9 1 5.9 7 41.2 17
West London 11 73.3 1 6.7 3 20.0 15
North London 8 44.4 0 0.0 10 55.6 18
North East London 15 71.4 0 0.0 6 28.6 21
South East London 18 100.0 0 0.0 0 0.0 18
South West London 25 92.6 0 0.0 2 7.4 27
Peninsula 25 100.0 0 0.0 0 0.0 25
Dorset 13 92.9 0 0.0 1 7.1 14
Avon, Somerset & Wiltshire 37 100.0 0 0.0 0 0.0 37
3 Counties 5 71.4 2 28.6 0 0.0 7
Thames Valley 25 92.6 1 3.7 1 3.7 27
Central South Coast 28 100.0 0 0.0 0 0.0 28
Surrey, West Sussex & Hampshire 12 100.0 0 0.0 0 0.0 12
Sussex 17 94.4 1 5.6 0 0.0 18
Kent & Medway 33 97.1 1 2.9 0 0.0 34
Greater Midlands 17 70.8 3 12.5 4 16.7 24
North of England 37 100.0 0 0.0 0 0.0 37
Anglia 39 90.7 1 2.3 3 7.0 43
Essex 13 81.3 0 0.0 3 18.8 16
Wales 3 100.0 0 0.0 0 0.0 3
Unknown 5 71.4 0 0.0 2 28.6 7
Total 581 26 130 737
Limited Some TCT Mostly TCT Number of 
patients
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6.2.3 High volume centres 
The greatest number of leukaemia patients were admitted to the centre at Leeds(Table 27) the 
majority of admissions (1,966 admissions, 6.9% of all admissions) took place at the University 
Hospitals Bristol NHS Foundation Trust (Table 28). Of the 15 highest ranking NHS trusts, in 
terms of numbers of leukaemia patients, six were TCT centres and 10 were not (Table 27). Of 
the 15 highest ranking NHS trusts, in terms of admissions for leukaemia patients, five were TCT 
centres and 10 were not (Table 28). University Hospital Birmingham saw 4.9% of all TYA 
leukaemia patients but accounted for fewer than 2.1% of all admissions. 
Table 27: Number of leukaemia patients admitted to each NHS trust during the treatment period (top 15 
only) 
Rank NHS Trust n %
1 Leeds Teaching Hospitals NHS Trust 61 8.3
2 Central Manchester University Hospital NHS Trust 52 7.1
3 University Hospitals Bristol NHS Foundation Trust 48 6.5
4 Cambridge University Hospitals NHS Foundation Trust 43 5.8
5 King's College Hospital NHS Foundation Trust 42 5.7
5 The Royal Marsden NHS Foundation Trust 42 5.7
5 University College London Hospitals NHS Trust 42 5.7
8 The Newcastle upon Tyne Hospitals NHS Trust 38 5.2
9 University Hospitals Birmingham NHS Foundation Trust 36 4.9
10 University Hospital of Southampton NHS Trust 32 4.3
11 Guy's & St Thomas's NHS Foundation Trust 29 3.9
11 The Christie NHS Foundation Trust 29 3.9
12 Barts and the London NHS Trust 27 3.7
12 Oxford Radcliffe Hospitals NHS Trust 27 3.7
14 Imperial College Healthcare NHS Trust 25 3.4
14 Nottingham University Hospitals NHS Trust 25 3.4 TCT centre
737
Number of patients
Total number of patients
 
 
Table 28: Number of admissions to each NHS trust during the treatment period, leukaemia patients 
Rank NHS Trust n %
1 University Hospitals Bristol NHS Foundation Trust 1,966 6.9
2 Central Manchester University Hospital NHS Trust 1,481 5.2
3 Cambridge University Hospitals NHS Foundation Trust 1,200 4.2
4 Leeds Teaching Hospitals NHS Trust 1,146 4.0
5 The Royal Marsden NHS Foundation Trust 1,122 3.9
6 The Christie NHS Foundation Trust 1,107 3.9
7 The Newcastle upon Tyne Hospitals NHS Trust 1,062 3.7
8 Oxford Radcliffe Hospitals NHS Trust 924 3.2
9 Barts and the London NHS Trust 892 3.1
10 University Hospital of Southampton NHS Trust 882 3.1
11 Royal Devon & Exeter NHS Foundation Trust 877 3.1
12 University College London Hospitals NHS Trust 781 2.7
13 Nottingham University Hospitals NHS Trust 774 2.7
14 University Hospitals Coventry & Warwickshire NHS Trust 688 2.4
15 King's College Hospital NHS Trust 597 2.1 TCT centre
28,447
Number of admissions
Total number of admissions
 
6.3 Variation in the uptake of specialist care 
The patient characteristics of the leukaemia patients vary by the amount of specialist care 
received as an inpatient (Table 29). The age distribution was roughly equal between those 
receiving some specialist input and those receiving mostly specialist care, with a greater 
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proportion of patients being in the younger age group (aged 15-19 at diagnosis). In contrast 
the patients with limited specialist input were mostly from the older age group (aged 20-24 at 
diagnosis). The gender distribution, deprivation score and proportion of patients alive at the 
completion of treatment were equal across all three groups. In all groups the majority of 
patients had a diagnosis of ALL; this group formed a larger proportion of the total group 
receiving some specialist input than in the other two groups. A significant variation in 
treatment received was seen across the three groups (p=<0.01). The majority of patients with 
limited specialist input were reported as having had chemotherapy alone (69.7%); the same 
was seen for patients for whom the majority of inpatient care was specialist, although this was 
a greater proportion (82.3%). For patients with some specialist input the most common 
treatment grouping was chemoradiotherapy (53.8%). 
Table 29: Leukaemia patient details by amount of specialist inpatient care 
n % n % n % p value
15-19 241 41.5 14 53.8 66 50.8 321
20-24 340 58.5 12 46.2 64 49.2 416 0.06
Male 358 61.6 16 61.5 83 63.8 457
Female 223 38.4 10 38.5 47 36.2 280 0.97
Acute Lymphoid Leukaemia (ALL) 288 49.6 17 65.4 61 46.9 366
Acute Myeloid Leukaemia (AML) 188 32.4 7 26.9 49 37.7 244
Chronic Myeloid Leukaemia (CML) 76 13.1 2 7.7 15 11.5 93
Other 29 5.0 0 0.0 5 3.8 34 0.94
Most affluent 100 17.2 4 15.4 25 19.2 129
4 102 17.6 3 11.5 20 15.4 125
3 112 19.3 10 38.5 19 14.6 141
2 127 21.9 3 11.5 21 16.2 151
Most deprived 132 22.7 6 23.1 43 33.1 181
Unknown 8 1.4 0 0.0 2 1.5 10 0.05
Yes 376 64.7 16 61.5 90 69.2 482
No 205 35.3 10 38.5 40 30.8 255 0.52
Chemotherapy 405 69.7 11 42.3 107 82.3 523
Radiotherapy 4 0.7 0 0.0 0 0.0 4
Chemoradiotherapy 116 20.0 14 53.8 16 12.3 156
None 56 9.6 1 3.8 7 5.4 64 <0.01
581 26 130 737
Type of specialist admissions
Limited Some TCT Mostly TCT
Total
Age at diagnosis
Gender
Diagnostic group
Total (number of patients)
Deprivation
Alive at end of 
treatment period
Treatment 
received
 
6.4 Patient outcomes 
6.4.1 Treatment received 
Outcomes for patients with leukaemia varied across the specialist care groups. Very few 
patients who received limited specialist input underwent radiotherapy, a small proportion 
underwent chemoradiotherapy but the majority received chemotherapy alone (Figure 20). For 
patients with some specialist inpatient input the dominant procedure was chemoradiotherapy 
(14 patients) with a slightly smaller group undergoing chemotherapy alone (11 patients). A 
different pattern was seen again in those with mostly specialist care, 82.3% of patients had 
chemotherapy alone. Across all groups the proportion of patients with no treatment recorded 
was low, with those having only limited specialist input  having the highest proportion with no 
recorded treatment (>10%). The median time from diagnosis to both first admission and first 
chemotherapy (for eligible patients) was equal across all groups (Table 30). 
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Figure 20: Treatment received, by specialist group 
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Table 30: Time from diagnosis to first admission and first treatment, by specialist group 
Median Median
Limited specialist input 0 -4 - 61 0 -4 - 149
Some specialist input 0 -2 - 0 0 -2 - 74
Mostly specialist care 0 -4 - 104 0 -4 - 119
* A negative value represents an event occuring before diagnosis
Range* Range*
Weeks from diagnosis to 
first admission
Weeks fro diagnosis to first 
chemotherapy
 
 
6.4.2 Survival 
The three-year survival for leukaemia patients was assessed by both diagnostic group and 
amount of specialist care received using Kaplan-Meier curves (Figure 21 & Figure 22). Overall 
those diagnosed with chronic myeloid leukaemia and those receiving mostly specialist care had 
the best survival with those diagnosed with acute myeloid leukaemia and “other” leukaemia 
and those with some specialist inpatient care having the poorest survival. Survival for those 
with limited specialist input fell in the middle of the three groups, supporting the suggestion 
that some of the patients in this group may have less aggressive disease than their 
counterparts in the other specialist care groups. 
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Figure 21: Survival to three years from diagnosis, by diagnostic subtype of leukaemia 
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Figure 22: Survival to three years by amount to specialist care received, leukaemia patients 
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Proportional hazards were tested to determine whether the chosen Cox regression model 
could be applied. The results from this analysis are displayed in Table 31. The global test was 
non-significant (p=0.94) meaning that the proportional hazards assumption held and the Cox 
regression model could be used. There was no evidence that including age as a categorical 
variable improved fit and so it was included as a continuous variable in the model (p=0.20). 
Table 31: Results of the proportional hazards test (stphtest) 
rho χ2 prob> χ2
0.08 1.66 0.20
Male 1.00
Female -0.02 0.06 0.80
-0.03 0.17 0.68
1 (Most deprived) 1.00
2 0.05 0.54 0.46
3 0.04 0.34 0.56
4 -0.01 0.04 0.85
5 (Most affluent) 0.02 0.09 0.77
ALL 1.00
AML -0.02 0.10 0.75
CML 0.02 0.15 0.70
Other -0.08 1.57 0.21
Limited 1.00
Some 0.04 0.32 0.57
Mostly 0.03 0.28 0.60
5.57 0.94Global test
Deprivation
Diagnostic 
group
Amount of 
specialist 
inpatient care
Age at diagnosis
Gender
Year of diagnosis
 
In the Cox regression model (Table 32) only the diagnostic group had a statistically significant 
effect on survival, with those diagnosed with CML being 47% less likely to die than those 
diagnosed with ALL (Hazard Ratio (HR) 0.53 95%CI 0.33-0.85). Those receiving mostly specialist 
care were 17% more likely to survive than those with limited specialist input. Those with some 
specialist input were 16% more likely to die than those with limited specialist input but the 
trend was not statistically significant. Trends in relation to age at diagnosis, gender, 
deprivation group and year of diagnosis were also not statistically significant. 
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Table 32: Cox regression model for leukaemia 
Haz. Ratio p value Lower 95% Upper 95%
1.02 0.30 0.98 1.07
Male 1.00
Female 1.11 0.41 0.86 1.44
0.94 0.11 0.88 1.01
Most deprived 1.00
2 0.87 0.45 0.60 1.25
3 0.80 0.25 0.54 1.17
4 0.83 0.37 0.56 1.24
Most affluent 1.09 0.65 0.76 1.56
ALL 1.00
AML 1.14 0.35 0.87 1.50
CML 0.53 0.01 0.33 0.85
Other 1.37 0.25 0.80 2.35
Limited 1.00
Some 1.16 0.65 0.61 2.21
Mostly 0.83 0.28 0.58 1.17
Diagnostic 
group
Deprivation
Gender
Confidence intervals
Age at diagnosis
Year of diagnosis
Amount of 
specialist 
inpatient care
 
6.4.3 Health service usage 
As demonstrated in Figure 23 the peak in admissions for leukaemia patients occurred at the 
same time from diagnosis in all three specialist care groups. This is more pronounced in the 
group receiving limited specialist input as it contained the largest number of patients in total. 
Patients receiving some specialist inpatient care had the highest median number of admissions 
during treatment (Figure 24), the greatest proportion of unplanned admissions (Figure 25) and 
spent the largest percentage of the treatment period as inpatients (Figure 26). Those with 
limited specialist input and those receiving mostly specialist care had similar levels of 
admission during treatment and proportion of unplanned admissions (Figure 24 & Figure 25). 
Those receiving limited specialist input spent the least amount of the treatment period as an 
inpatient (Figure 26). 
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Figure 23: Number of admissions per week, by time from diagnosis and specialist group 
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Figure 24: Median number of admissions per patient during treatment, by specialist group 
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Figure 25: Median proportion of admissions, per patient, during treatment which were unplanned 
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Figure 26: Median proportion of the treatment period spent as an inpatient, per patient 
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6.4.4 Health service costs 
Overall patients with some specialist input had the highest median total cost of admissions 
during treatment (Figure 27), this will be influenced by the fact that they had the highest 
median number of admissions per patient, the greatest number of unplanned admissions and 
spent the largest proportion of the treatment period as an inpatient of any of the three 
specialist care groups. The median cost per admission for the specialist care groups was 
calculated to counteract this and there was no variation seen between groups in the median 
cost. 
Figure 27: Median total cost of admissions during treatment, per patient 
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Chapter 7 Lymphoma 
7.1 Specialist care 
The proportion of total inpatient time during treatment spent at a specialist centre was 
compared to the time spent at any other type of hospital for lymphoma patients (Figure 28). 
As with leukaemia, the majority of lymphoma services (with the exception of bone-marrow 
transplantation) are not centralised in the same way as those for some of the other diagnostic 
groups.  For lymphoma patients the proportion of treatment received at a TCT centre was, 
therefore, compared to treatment at any other NHS facility. 
Figure 28: Assignment of lymphoma patients to a “level” of specialist care using the proportion of 
inpatient time spent in a specialist 
centre
 
7.2 Access to specialist care 
7.2.1 Hospital catchment areas 
Due to the type of treatments used in lymphoma and the centralisation of services there were 
no high volume lymphoma centres in the same way that there were centres for other 
diagnostic groups (e.g. bone and CNS tumours). This lead to TCT centres being treated as the 
sole specialist centre for this group. With the exception of the Christie, Newcastle and Alder 
Hey all TCT centres showed a smaller dispersion of patients (Map 8) than theoretical 
catchment area (Map 9) suggesting that patients are admitted to hospitals other than their 
closest TCT centre. These three centres were shown to be attracting patients from outside 
their theoretical catchment areas, based on proximity to a specialist centre. As was seen with 
leukaemia patients, Alder Hey, Southampton and UCL had the greatest proportion of patients, 
for whom they were the closest centre, who didn’t attend any TCT unit during their treatment 
period. In the case of lymphoma these three centres were joined by Birmingham, where 76.0% 
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of patients who lived closest to this centre had no inpatient stays at a TCT centre during 
treatment. Newcastle and the Christie both had larger catchment areas in actuality than that 
which was predicted, and had some of the lowest levels of patients with no TCT admission 
during treatment (27.0% and 38.0% respectively). Leeds also had very few patients with no TCT 
admissions during treatment (34.0%).  As with leukaemia, very few patients were admitted to 
a centre other than their closest one. With the exception of the Christie, who admitted 10 
patients for whom Alder Hey was the closest unit (Table 33). 
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Table 33: Numbers of lymphoma patients closest to each TCT centre, and the centre actually attended 
n % n % n % n % n % n % n % n % n %
Alder Hey Children's NHS Foundation 
Trust 6 6.3 0 0 0 0 0 0 10 11 0 0 0 0 1 1.1 78 82 95
Leeds Teaching Hospitals NHS Trust
0 0 68 56 1 0.8 0 0 3 2.5 1 0.8 0 0.7 0 0 49 40 122
Sheffield Teaching Hospitals NHS 
Foundation Trust 0 0 2 1.6 34 27 0 0 0 0 0 0 0 0 0 0 91 72 127
University Hospital Southampton NHS 
Foundation Trust 1 0.4 0 0 1 0.4 37 13 0 0 1 0.4 7 0.1 2 0.7 227 82 276
The Christie NHS Foundation Trust
1 0.8 0 0 0 0 0 0 63 53 0 0 0 0 1 0.8 53 45 118
The Newcastle upon Tyne Hospitals 
NHS Foundation Trust 0 0 0 0 1 1.3 0 0 0 0 50 64 0 82 0 0 27 35 78
University College London Hospitals 
NHS Foundation Trust 0 0 0 0 2 0.3 1 0.2 2 0.3 2 0.3 78 12 1 0.2 567 87 653
University Hospitals Birmingham NHS 
Foundation Trust 0 0 0 0 2 0.8 0 0 0 0 0 0 2 0 39 16 204 83 247
Total 1716
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As with leukaemia patients, increasing distance from the nearest TCT centre reduced the odds 
of admission to a TCT centre during treatment (Table 34). This trend was statistically significant 
and every 5km increase in distance between home and the closest TCT centre was associated 
with a 3% decrease in admission to the centre (OR 0.97 95%CI 0.96-0.98). Increasing 
deprivation, female gender and increasing age at diagnosis also decreased the odds of 
admission to a TCT centre but these were not statistically significant findings. 
 
Table 34: Likelihood of admission to a TCT centre for lymphoma patients 
Odds 
ratio p value
Lower 
95%
Upper 
95%
Male 1.00
Female 0.84 0.07 0.70 1.02
0.98 0.35 0.95 1.02
Non Hodgkins lymphoma 1.00
Hodgkins lymphoma 1.07 0.49 0.88 1.31
Most deprived 1.00
2 0.79 0.11 0.59 1.05
3 0.96 0.79 0.72 1.29
4 1.05 0.73 0.79 1.41
Most affluent 1.18 0.26 0.89 1.57
0.97 <0.01 0.96 0.98
Age at diagnosis
Distance to nearest TCT centres (increase of 5km)
Diagnostic group
Deprivation
Gender 
 
 
7.2.2 Geographical distribution of patients 
In seven of the 31 cancer networks the majority of patients received mostly specialist TCT 
inpatient care (greater than 60% of their total inpatient stay during treatment) (Table 35).  This 
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again cannot be explained purely by the location of TCT centres and must instead be 
influenced by referral processes. 
Table 35: Cancer network of residence at diagnosis and level of specialist inpatient care for lymphoma 
patients (the highlighted sections represent the most frequent level of care for each cancer network) 
n % n % n %
Lancashire & South Cumbria 14 28.6 0 0.0 35 71.4 49
Greater Manchester & Cheshire 35 38.0 6 6.5 51 55.4 92
Merseyside & Cheshire 44 62.9 0 0.0 26 37.1 70
Yorkshire 36 35.0 4 3.9 63 61.2 103
Humber & Yorkshire Coast 19 65.5 2 6.9 8 27.6 29
North Trent 19 33.9 1 1.8 36 64.3 56
Pan Birmingham 35 48.6 1 1.4 36 50.0 72
Arden 26 78.8 1 3.0 6 18.2 33
Mid Trent 42 72.4 0 0.0 16 27.6 58
Derby/ Burton 17 63.0 0 0.0 10 37.0 27
Leicestershire, Northants & Rutland 43 72.9 0 0.0 16 27.1 59
Mount Vernon 18 52.9 0 0.0 16 47.1 34
West London 32 57.1 3 5.4 21 37.5 56
North London 19 39.6 5 10.4 24 50.0 48
North East London 26 52.0 0 0.0 24 48.0 50
South East London 27 64.3 1 2.4 14 33.3 42
South West London 39 67.2 0 0.0 19 32.8 58
Peninsula 49 72.1 0 0.0 19 27.9 68
Dorset 14 77.8 0 0.0 4 22.2 18
Avon, Somerset & Wiltshire 50 64.1 0 0.0 28 35.9 78
3 Counties 21 65.6 0 0.0 11 34.4 32
Thames Valley 66 71.0 0 0.0 27 29.0 93
Central South Coast 45 68.2 0 0.0 21 31.8 66
Surrey, West Sussex & Hampshire 19 50.0 0 0.0 19 50.0 38
Sussex 18 58.1 2 6.5 11 35.5 31
Kent & Medway 32 62.7 1 2.0 18 35.3 51
Greater Midlands 34 68.0 2 4.0 14 28.0 50
North of England 66 67.3 0 0.0 32 32.7 98
Anglia 66 61.1 1 0.9 41 38.0 108
Essex 14 43.8 1 3.1 17 53.1 32
Wales 2 100.0 0 0.0 0 0.0 2
Unknown 0 0.0 0 0.0 2 100.0 2
Total 1,000 31 685 1,716
Limited Some TCT Mostly TCT Number of 
patients
 
7.2.3 High volume centres 
The greatest number of lymphoma patients were admitted to UCL (Table 36). The majority of 
admissions (1,632 admissions, 4.1% of all admissions) again took place at the University 
Hospitals Bristol NHS Foundation Trust (Table 28). Of the 15 highest ranking NHS trusts, in 
terms of numbers of lymphoma patients, six were TCT centres and 10 were not (Table 36). Of 
the 15 highest ranking NHS trusts, in terms of admissions for leukaemia patients, five were TCT 
centres and 10 were not (Table 37). University Hospital of Southampton NHS Trust saw 2.3% of 
all TYA lymphoma patients (40 patients) but accounted for less than 1.7% of all admissions. 
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Table 36: Number of lymphoma patients admitted to each NHS trust during the treatment period (top 15 
only) 
Rank NHS Trust n %
1 University College London Hospitals NHS Trust 83 4.8
2 The Christie NHS Foundation Trust 79 4.6
3 The Royal Marsden NHS Foundation Trust 75 4.4
4 Leeds Teaching Hospitals NHS Trust 69 4.0
5 University Hospitals Bristol NHS Foundation Trust 64 3.7
6 Nottigham University Hospitals NHS Trust 60 3.5
7 The Newcastle upon Tyne Hospitals NHS Trust 55 3.2
8 Cambridge University Hospitals NHS Foundation Trust 53 3.1
9 Oxford Radcliffe Hospitals NHS Trust 52 3.0
10 University Hospitals Birmingham NHS Foundation Trust 43 2.5
10 University Hospitals Leicester NHS Trust 43 2.5
12 Heart of England NHS Foundation Trust 40 2.3
12 University Hospital of Southampton NHS Trust 40 2.3
14 Sheffield Teaching Hospitals NHS Foundation Trust 39 2.3
14 St George's Healthcare NHS Trust 39 2.3
15 Barts and the London NHS Trust 37 2.2 TCT centre
1,716
Number of patients
Total number of patients
 
 
Table 37: Number of admissions to each NHS trust during the treatment period, lymphoma patients 
Rank NHS Trust n %
1 University Hospitals Bristol NHS Foundation Trust 1,632 4.1
2 The Christie NHS Foundation Trust 1,380 3.5
3 University College London Hospitals NHS Trust 1,360 3.4
4 Leeds Teaching Hospitals NHS Trust 1,327 3.3
5 The Royal Marsden NHS Foundation Trust 1,209 3.0
6 Sheffield Teaching Hospitals NHS Foundation Trust 1,067 2.7
7 Nottigham University Hospitals NHS Trust 1,049 2.6
8 Oxford Radcliffe Hospitals NHS Trust 949 2.4
9 The Newcastle upon Tyne Hospitals NHS Trust 939 2.3
10 Cambridge University Hospitals NHS Foundation Trust 923 2.3
11 Barts and the London NHS Trust 850 2.1
12 Royal Devon & Exeter NHS Foundation Trust 824 2.1
12 University Hospitals Leicester NHS Trust 760 1.9
14 Heart of England NHS Foundation Trust 677 1.7
15 Royal Cornwall Hospitals NHS Trust 671 1.7 TCT centre
39,986
Number of admissions
Total number of admissions
 
7.3 Variation in the uptake of specialist care 
The characteristics of the lymphoma patients vary slightly between the specialist care groups 
(Table 38). The age distribution of patients receiving mostly specialist care mirrored that of the 
patients with limited specialist input. In contrast the patients receiving some specialist input 
were mostly from the younger age group (aged 15-19 at diagnosis). This group also consisted 
of more female than male patients, whilst the opposite was seen for the other two groups. In 
all cases the majority of patients survived to the end of treatment, however in the patients 
with mostly specialist care this proportion was higher than the other groups (93%).  In all cases 
the most common treatment was chemotherapy alone, with chemoradiotherapy being 
recorded in between 16.1% and 18.9% of cases. 
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Table 38: Lymphoma patient details by amount of specialist inpatient care 
n % n % n % p value
15-19 404 40.4 18 58.1 290 42.3 712
20-24 596 59.6 13 41.9 395 57.7 1,004 0.14
Male 534 53.4 15 48.4 390 56.9 939
Female 466 46.6 16 51.6 295 43.1 777 0.11
Non-Hodgkin lymphoma (NHL) 334 33.4 11 35.5 187 27.3 532
Hodgkin lymphoma (HL) 666 66.6 20 64.5 498 72.7 1,184 0.81
Most affluent 180 18.0 4 12.9 148 21.6 332
4 187 18.7 4 12.9 131 19.1 322
3 192 19.2 8 25.8 121 17.7 321
2 218 21.8 3 9.7 120 17.5 341
Most deprived 208 20.8 12 38.7 163 23.8 383
Unknown 15 1.5 0 0.0 2 0.3 17 0.02
Yes 866 86.6 27 87.1 637 93.0 1,530
No 134 13.4 4 12.9 48 7.0 186 <0.01
Chemotherapy 727 72.7 25 80.6 484 70.7 1,236
Radiotherapy 14 1.4 0 0.0 22 3.2 36
Chemoradiotherapy 189 18.9 5 16.1 116 16.9 310
None 70 7.0 1 3.2 63 9.2 134 <0.01
1,000 31 685 1,716
Total
Age at diagnosis
Gender
Diagnostic group
Type of specialist admissions
Limited Some TCT Mostly TCT
Total (number of patients)
Deprivation
Alive at end of 
treatment period
Treatment 
received
 
7.4 Patient outcomes 
7.4.1 Treatment received 
Treatment for patients with lymphoma varied across the specialist care groups (Figure 29). The 
majority of patients in all specialist care groups underwent chemotherapy; very few were 
reported as having had chemoradiotherapy. In all groups the proportion receiving no 
treatment was low, it accounted for the smallest proportion in patients with some specialist 
care (<10%) and accounted for more than 10% in those with limited and mostly specialist care. 
The median time from diagnosis to first admission was equal across all three groups, the time 
from diagnosis to first chemotherapy for eligible patients varied slightly, ranging from three to 
four weeks post diagnosis (Table 39).  
 
Figure 29: Treatment received, by specialist group 
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Table 39: Time from diagnosis to first admission and first treatment, by specialist group 
Median Median
Limited specialist input 0 -4 - 61 3 -4 - 105
Some specialist input 0 -4 - 29 3 -2 - 98
Mostly specialist care 0 -4 - 144 4 -4 - 109
* A negative value represents an event before the date of diagnosis
Range* Range*
Weeks from diagnosis to 
first admission
Weeks from diagnosis 
to first chemotherapy
 
7.4.2 Survival 
Survival to three years was over 75% for all diagnostic and specialist care subgroups of the 
lymphoma population. Patients diagnosed with non-Hodgkin’s lymphoma had poorer survival 
than those diagnosed with Hodgkin’s lymphoma (Figure 30). NHL patients who received some 
or mostly specialist care had improved survival compared to those with limited specialist care 
(Figure 31). In contrast HL patients who received mostly specialist input had better survival 
than those with limited specialist care (Figure 32).  
Figure 30: Survival to three years from diagnosis, by diagnostic subtype of lymphoma 
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Figure 31: Three year survival by specialist care received for Non-Hodgkin's lymphoma patients 
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Figure 32: Three year survival by specialist care received for Hodgkin's lymphoma patients 
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In order to assess which other factors influenced survival for patients diagnosed with a 
lymphoma, Cox regression modelling was performed. The proportional hazards assumption did 
not hold when including both Hodgkin’s and non-Hodgkin’s lymphoma in a single model. When 
the two diagnostic groups were modelled separately, however, the assumptions held and so 
two models are presented for lymphoma (Table 41 & Table 42). Each variable was non-
statistically significant, as was the global test. There was no evidence found that including age 
as a categorical, rather than continuous, variable improved fit (p=0.75) and so age was 
modelled continuously in both cases. 
Table 40: Results of the proportional hazards test (stphtest) 
rho χ2 Prob> χ2 rho χ2 Prob> χ2
-0.03 0.23 0.63 -0.05 0.18 0.67
Male
Female 0.03 0.13 0.72 -0.04 0.09 0.76
0.00 0.00 1.00 0.18 2.04 0.15
Most deprived
2 0.10 1.90 0.17 0.23 3.56 0.06
3 0.01 0.02 0.90 -0.06 0.23 0.63
4 0.07 0.99 0.32 0.16 1.59 0.21
Most affluent 0.09 1.59 0.21 0.24 3.76 0.05
Limited
Some 0.09 1.56 0.21 0.06 0.23 0.63
Mostly 0.03 0.23 0.63 0.06 0.25 0.62
Hodgkin's lymphoma
Non-Hodgkin's lymphoma 0.44 34.68 <0.01
40.19 <0.01 10.32 0.32
Including diagnostic group
Separate models for 
diagnostic group
Amount of 
specialist care
Global test 
Age at diagnosis
Gender
Year of diagnosis
Deprivation
Diagnostic 
group
 
7.4.2.1.1 Non-Hodgkin’s lymphoma  
For patients diagnosed with non-Hodgkin’s lymphoma increasing age had a statistically 
significant detrimental effect on survival, each single year increase in age was associated with 
an 8% increased risk of death (HR 1.08 95%CI 1.01-1.15). Those who received mostly specialist 
care were 62% less likely to die than those who received limited specialist care (HR 0.38 95%CI 
0.25-0.57). Gender, year of diagnosis and deprivation had a non-statistically significant effect 
(Table 41). 
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 Table 41: Cox regression model for non-Hodgkin's  
Haz. Ratio p value Lower 95%Upper 95%
1.08 0.04 1.01 1.15
Male 1.00
Female 0.77 0.18 0.52 1.13
0.90 0.06 0.81 1.00
Most deprived 1.00
2 0.71 0.22 0.41 1.22
3 0.55 0.05 0.30 0.99
4 0.76 0.31 0.44 1.29
Most affluent 0.73 0.24 0.44 1.23
Limited 1.00
Some 0.28 0.21 0.04 2.03
Mostly 0.38 0.00 0.25 0.57
Age at diagnosis
Year of diagnosis
Amount of 
specialist care
Deprivation
Gender
 
7.4.2.1.2 Hodgkin’s lymphoma 
In contrast to the results seen for non-Hodgkin’s lymphoma, age at diagnosis had no effect on 
survival in Hodgkin’s lymphoma. All deprivation groups had improved survival when compared 
to the most deprived section of the population, although this was only statistically significant 
for the middle group. The amount of specialist care received was again a key factor influencing 
outcomes. Patients with mostly specialist care were 44% less likely to die than those with only 
limited specialist input (HR 0.56 95%CI 0.33-0.95). Patients receiving some specialist input 
were two fold more likely to die than those with limited input, although this was not 
statistically significant (Table 42). 
Table 42: Cox regression model for Hodgkin’s lymphoma 
Haz. Ratio p value Lower 95% Upper 95%
1.00 0.96 0.91 1.09
Male 1.00
Female 0.94 0.81 0.58 1.53
0.98 0.80 0.85 1.13
Most deprived 1.00
2 0.83 0.59 0.43 1.62
3 0.39 0.03 0.16 0.92
4 0.79 0.50 0.39 1.58
Most affluent 0.56 0.14 0.26 1.21
Limited 1.00
Some 2.38 0.15 0.73 7.79
Mostly 0.56 0.03 0.33 0.95
Amount of 
specialist 
care
Age at diagnosis
Gender
Year of diagnosis
Deprivation
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7.4.3 Health service usage 
The peak in admissions occurred during the same time period for all the specialist care groups 
(Figure 33). Patients receiving some specialist input had the highest median number of 
admissions during treatment (Figure 34), the greatest proportion of unplanned admissions 
(Figure 35) and spent the greatest proportion of the treatment period as an inpatient (Figure 
36). 
 
Figure 33: Number of admissions per week, by time from diagnosis and specialist group 
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Figure 34: Median number of admissions per patient during treatment, by specialist group 
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Figure 35: Median proportion of admissions, per patient, during treatment which were unplanned 
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Figure 36: Median proportion of the treatment period spent as an inpatient, per patient 
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7.4.4 Health service costs 
The median total cost of admissions during the treatment period was highest for patients with 
some specialist input and lowest for those with mostly specialist care (Figure 37). This is 
reflective of the fact that patients receiving some specialist care also have the highest number 
of admissions and spend the greatest proportion of the treatment period as inpatients. In an 
attempt to address this the median cost per admission was calculated for each group (Figure 
38), this showed that patients receiving mostly specialist care had the higher cost admissions, 
whilst patients with limited specialist input remained the lowest. 
 
Figure 37: Median total cost of admissions during treatment, per patient 
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Figure 38: Median cost per admission 
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Chapter 8 Central nervous system and other intracranial and 
intraspinal neoplasms 
8.1 Specialist care  
 Due to the rarity of brain and CNS tumours and the complex nature of their treatment, 
specialist centres exist for their management. In parallel, patients may also receive treatment 
at TCT centres and, as such, both types of specialist centre were included in the analysis of this 
diagnostic group. 
 
Figure 39: Assignment of CNS patients to a “level” of specialist care using the proportion of inpatient 
time spent in a specialist centre 
 
8.2 Access to specialist care 
8.2.1 Hospital catchment areas 
As previously mentioned two types of specialist care centres were in place for the treatment of 
CNS tumours during the study period and, as a result, both access to TCT centres and CNS 
specialist centres was assessed. 
All TCT centres, except for Sheffield, showed a smaller actual catchment area (Map 10) than 
theoretical catchment area (Map 11). Other centres were shown to be admitting patients from 
a smaller area than was suggested when mapping patients according to their proximity to their 
closest centre. 
Again Alder Hey, Southampton, Birmingham and UCL had the greatest proportion of patients, 
for whom they were the closest centre, who didn’t attend any TCT unit during their treatment 
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period (Table 43). Leeds and Newcastle had some of the lowest levels of patients with no TCT 
admission during treatment (31.0% and 26.0% respectively). As with both leukaemia and 
lymphoma very few patients were admitted to a centre other than their closest one. With the 
exception of the Christie, who admitted 11 patients for whom Alder Hey was the closest unit 
(Table 43). 
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Table 43: Numbers of CNS patients closest to each TCT centre, and the centre actually attended 
n % n % n % n % n % n % n % n % n %
Alder Hey Children's NHS Foundation 
Trust 4 6.7 0 0 1 1.7 0 0 11 18 2 3.3 0 5.6 0 0 42 70 60
Leeds Teaching Hospitals NHS Trust
0 0 33 61 2 3.7 1 1.9 1 1.9 0 0 0 0 0 0 17 31 54
Sheffield Teaching Hospitals NHS 
Foundation Trust 0 0 0 0 15 31 0 0 0 0 0 0 0 0 0 0 34 69 49
University Hospital Southampton NHS 
Foundation Trust 0 0 0 0 1 0.6 56 31 2 1.1 3 1.7 2 0.9 0 0 114 64 178
The Christie NHS Foundation Trust
0 0 1 1.2 0 0 0 0 32 37 1 1.2 0 1.4 1 1.2 51 59 86
The Newcastle upon Tyne Hospitals 
NHS Foundation Trust 0 0 0 0 0 0 0 0 0 0 45 74 0 121 0 0 16 26 61
University College London Hospitals 
NHS Foundation Trust 0 0 0 0 0 0 1 0.4 0 0 0 0 38 0 0 0 189 83 228
University Hospitals Birmingham NHS 
Foundation Trust 0 0 0 0 0 0 0 0 0 0 0 0 0 0 33 28 84 72 117
Total 833
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Increasing distance from the patient’s residence to the TCT centre was, again, associated with  
decreased odds of admission to a TCT centre during the treatment period (Table 44). Every 
5km increase in distance between a patient’s home address and their closest TCT centre was 
significantly associated with an 11% decrease in the likelihood of admission (OR 0.89 95%CI 
0.85-0.92). A diagnosis of medulloblastoma or other PNET tumours was associated with a two-
fold increase in the odds of admission to a TCT centre when compared to astrocytoma (OR 
2.58 95%CI 1.34-4.96). A similar effect was seen for female gender and belonging to groups of 
middle affluence, however neither of these effects were statistically significant.  
Table 44: Likelihood of admission to a TCT centre for CNS patients 
Odds 
ratio p value
Lower 
95%
Upper 
95%
Male 1.00
Female 1.32 0.13 0.92 1.90
1.03 0.37 0.97 1.10
Astrocytoma 1.00
Other gliomas 0.82 0.54 0.45 1.52
Ependymoma 1.28 0.58 0.54 3.01
Medulloblastoma & other PNET 2.58 0.00 1.34 4.96
Other specified intracranial and intraspinal neoplasms 1.08 0.74 0.70 1.66
Unspecified intracranial and intraspinal neoplasms 1.08 0.86 0.44 2.69
Most deprived 1.00
2 0.99 0.96 0.58 1.68
3 1.21 0.49 0.70 2.10
4 1.27 0.38 0.74 2.17
Most affluent 0.66 0.17 0.36 1.20
0.89 <0.01 0.85 0.92
Deprivation
Distance to nearest TCT centres (increase of 5km)
Gender 
Diagnostic group
Age at diagnosis
 
 
Due to the large number of CNS specialist centres it was not possible to perform mapping of 
patient distributions in the same way as seen with TCT centres. It was, however, possible to 
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examine the number of patients attending their closest CNS specialist centre according to road 
travel distance (Table 45).  
The proportion of patients admitted to the centre they resided closest to ranged from 10.0% 
(Imperial College Healthcare) to 100.0% (UCL). As several of the CNS centres are located in and 
around London there is likely to be significant patient cross over between trusts and this is 
demonstrated here (Table 45). Few patients had no admissions to a CNS centre during 
treatment, with 13 trusts having one or fewer patients with no admissions to a CNS centre. In 
contrast 38.8% of those living closest to the University Hospitals Coventry and Warwickshire 
NHS Trust had no admissions to a CNS centre and only 20.9% were admitted there. Very few 
patients were admitted to a centre other than their closest one, with the exception of UCL 
which attracted patients from all other trusts, further demonstrating the significant cross flow 
of patients between NHS trusts.  
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Table 45: Numbers of CNS patients closest to each CNS centre, and the centre actually attended (part 1) 
n % n % n % n % n % n % n % n % n % n % n % n % n % n % n % n % n % n % n % n % n % n % n % n % n %
Barking, Havering and Redbridge 
University Hospitals NHS Trust
8 20.0 4 10.0 0 0.0 3 7.5 0 0.0 0 0.0 17 42.5 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 2.5 0 0.0 0 0.0 0 0.0 1 2.5 0 0.0 0 0.0 0 0.0 4 10.0 0 0.0 0 0.0 2 5.0 40
Barts and the London NHS Trust 0 0.0 6 66.7 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 2 22.2 0 0.0 0 0.0 1 11.1 9
Brighton and Sussex University 
Hospitals NHS Trust
0 0.0 0 0.0 7 53.8 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 7.7 1 7.7 0 0.0 0 0.0 4 30.8 0 0.0 0 0.0 0 0.0 13
Cambridge University Hospitals NHS 
Foundation Trust
2 4.8 0 0.0 0 0.0 34 81.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 2 4.8 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 3 7.1 0 0.0 0 0.0 1 2.4 42
Hull and East Yorkshire Hospitals 
NHS Trust
0 0.0 0 0.0 1 4.0 0 0.0 19 76.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 4.0 0 0.0 0 0.0 0 0.0 2 8.0 2 8.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 25
Imperial College Healthcare NHS 
Trust
0 0.0 1 10.0 0 0.0 0 0.0 0 0.0 1 10.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 2 20.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 10.0 0 0.0 0 0.0 4 40.0 0 0.0 0 0.0 1 10.0 10
King's College Hospitals NHS 
Foundation Trust
0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 12 46.2 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 8 30.8 0 0.0 0 0.0 4 15.4 0 0.0 0 0.0 2 7.7 26
Lancashir Teaching Hospitals NHS 
Foundation trust
0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 16 51.6 1 3.2 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 5 16.1 0 0.0 0 0.0 0 0.0 0 0.0 3 9.7 1 3.2 0 0.0 0 0.0 0 0.0 5 16.1 31
Leeds Teaching Hospitals NHS Trust 0 0.0 0 0.0 0 0.0 0 0.0 3 7.5 0 0.0 0 0.0 0 0.0 33 82.5 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 2.5 1 2.5 1 2.5 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 2.5 40
North Bristol NHS Trust 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 1.6 0 0.0 0 0.0 0 0.0 60 95.2 1 1.6 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 1.6 63
Nottingham University Hospitals NHS 
Trust
0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 27 84.4 0 0.0 0 0.0 0 0.0 0 0.0 4 12.5 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 3.1 32
Oxford Radcliffe Hospitals NHS Trust 0 0.0 0 0.0 0 0.0 1 2.1 0 0.0 2 4.3 0 0.0 0 0.0 0 0.0 2 4.3 0 0.0 38 80.9 1 2.1 0 0.0 0 0.0 0 0.0 0 0.0 1 2.1 0 0.0 0 0.0 1 2.1 0 0.0 0 0.0 0 0.0 1 2.1 47
Plymouth Hospitals NHS Trust 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 11 26.8 0 0.0 0 0.0 25 61.0 0 0.0 0 0.0 0 0.0 0 0.0 1 2.4 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 4 9.8 41
Royal Free Hampstead NHS Trust 0 0.0 1 2.4 2 4.8 0 0.0 0 0.0 6 14.3 1 2.4 0 0.0 0 0.0 0 0.0 0 0.0 3 7.1 0 0.0 17 40.5 0 0.0 0 0.0 0 0.0 0 0.0 1 2.4 0 0.0 0 0.0 9 21.4 0 0.0 0 0.0 2 4.8 42
Salford Royal NHS Foundation Trust 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 41 70.7 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 4 6.9 0 0.0 1 1.7 0 0.0 12 20.7 58
Sheffield Teaching Hospitals NHS 
Foundation Trust
0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 12 75.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 6.3 0 0.0 0 0.0 3 18.8 16
South Tees Hospitals NHS 
Foundation Trust
0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 15 24.6 0 0.0 0 0.0 45 73.8 0 0.0 0 0.0 0 0.0 0 0.0 1 1.6 61
Southampton University Hospitals 
NHS Trust
0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 2 3.4 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 53 91.4 0 0.0 0 0.0 0 0.0 2 3.4 0 0.0 0 0.0 1 1.7 58
St George's Healthcare NHS Trust 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 4 8.7 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 2 4.3 0 0.0 1 2.2 0 0.0 0 0.0 0 0.0 0 0.0 34 73.9 0 0.0 0 0.0 3 6.5 0 0.0 0 0.0 2 4.3 46
The Newcastle upon Tyne Hospitals 
NHS Foundation Trust
0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 25.0 0 0.0 0 0.0 2 50.0 0 0.0 0 0.0 0 0.0 0 0.0 1 25.0 4
The Walton Centre NHS Foundtion 
Trust
0 0.0 1 3.4 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 3.4 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 25 86.2 0 0.0 0 0.0 0 0.0 2 6.9 29
University College London Hospitals 
NHS Foundation Trust
0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 4 100.0 0 0.0 0 0.0 0 0.0 4
University Hospital of North 
Satffordshire NHS Trust
0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 3.4 0 0.0 0 0.0 0 0.0 3 10.3 0 0.0 0 0.0 0 0.0 0 0.0 1 3.4 2 6.9 0 0.0 19 65.5 0 0.0 3 10.3 29
University Hospitals Coventry and 
Warwickshire NHS Trust
0 0.0 1 1.5 0 0.0 0 0.0 0 0.0 0 0.0 1 1.5 0 0.0 0 0.0 2 3.0 10 14.9 11 16.4 0 0.0 1 1.5 0 0.0 0 0.0 0 0.0 0 0.0 1 1.5 0 0.0 0 0.0 0 0.0 0 0.0 14 20.9 26 38.8 67
Total 833
NHS Trust to which the patient was admitted (CNS specialist centres)
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Barking, Havering and Redbridge 
University Hospitals NHS Trust
8 20.0 4 10.0 0 0.0 3 7.5 0 0.0 0 0.0 17 42.5 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 .5 0 0.0 0 0.0 0 0.0 1 2.5 . 0 0.0 . 4 10.0 . . 2 5. 40
Barts and the London NHS Trust 0 0.0 6 66.7 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0.0 . . . 2 22.2 . . 1 11.1 9
Brighton and Sussex University 
Hospitals NHS Trust
0 0.0 0 0.0 7 53.8 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 7.7 1 7.7 . . 4 30.8 . . . 13
Cambridge University Hospitals NHS 
Foundation Trust
2 4.8 0 0.0 0 0.0 34 81.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 2 4.8 0 0.0 0 0.0 0 0.0 0.0 . . . 3 7 1 . . 1 2.4 42
Hull and East Yorkshire Hospitals 
NHS Trust
0 0.0 0 0.0 1 4.0 0 0.0 19 76.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 4.0 0 0.0 0 0.0 0 0.0 2 8.0 2 8.0 0 0.0 0 0.0 . . . . 0 0. . 25
Imperial College Healthcare NHS 
Trust
0 0.0 1 10.0 0 0.0 0 0.0 0 0.0 1 10.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 2 20.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0.0 . . . 4 40.0 . . 1 1 . 10
King's College Hospitals NHS 
Foundation Trust
0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 12 46.2 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0.0 8 3 8 0 0.0 . 4 15.4 . . 2 7.7 26
Lancashir Teaching Hospitals NHS 
Foundation trust
0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 16 51.6 1 3.2 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 5 16 1 0 0.0 0 0.0 0.0 . 3 9.7 3.2 0 0 0 . . 5 16.1 31
Leeds Teaching Hospitals NHS Trust 0 0.0 0 0.0 0 0.0 0 0.0 3 7.5 0 0.0 0 0.0 0 0.0 33 82.5 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 2.5 1 2.5 1 2.5 . . . 0 0.0 . . 1 2.5 40
North Bristol NHS Trust 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 1.6 0 0.0 0 0.0 0 0.0 60 95.2 1 1.6 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0.0 0 0.0 . . 0.0 0 0.0 1 1.6 63
Nottingham University Hospitals NHS 
Trust
0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 27 84.4 0 0.0 0 0.0 0 0.0 0 0.0 4 12 5 0 0.0 0.0 . . . . 0 0.0 1 3.1 32
Oxford Radcliffe Hospitals NHS Trust 0 0.0 0 0.0 0 0.0 1 2.1 0 0.0 2 4.3 0 0.0 0 0.0 0 0.0 2 4.3 0 0.0 38 80.9 1 2.1 0 0.0 0 0.0 0 0.0 0 0.0 1 2.1 0 0.0 . 1 2.1 0 0.0 . 1 2 1 47
Plymouth Hospitals NHS Trust 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 11 26.8 0 0.0 0 0.0 25 61.0 0 0.0 0 0.0 0 0.0 0 0.0 1 2.4 . . . 0 0.0 . 4 9.8 41
Royal Free Hampstead NHS Trust 0 0.0 1 2.4 2 4.8 0 0.0 0 0.0 6 14.3 1 2.4 0 0.0 0 0.0 0 0.0 0 0.0 3 7.1 0 0.0 17 4 5 0 0.0 0 0.0 0 0.0 0.0 1 2.4 0 0.0 . 9 21.4 . . 2 4.8 42
Salford Royal NHS Foundation Trust 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 41 7 7 0 0.0 0 0.0 0.0 . . 4 6.9 1 1.7 . 12 20.7 58
Sheffield Teaching Hospitals NHS 
Foundation Trust
0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 12 75 0 0.0 0.0 . . . 1 6 3 . . 3 18.8 16
South Tees Hospitals NHS 
Foundation Trust
0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 15 24 6 0.0 . 45 73.8 . . . 1 1.6 61
Southampton University Hospitals 
NHS Trust
0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 2 3.4 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 53 91 4 . 0 0.0 . 2 3 4 . . 1 1.7 58
St George's Healthcare NHS Trust 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 4 8.7 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 2 4.3 0 0.0 1 2.2 0 0.0 0 0.0 0 0.0 0.0 3 73 9 . . 3 6 5 . . . 46
The Newcastle upon Tyne Hospitals 
NHS Foundation Trust
0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 25 0.0 . 2 5 . . . . 1 25.0 4
The Walton Centre NHS Foundtion 
Trust
0 0.0 1 3.4 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 3.4 0 0.0 0 0.0 0.0 . . 25 86.2 . . 2 6.9 29
University College London Hospitals 
NHS Foundation Trust
0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0.0 . . . 4 1 0.0 . . . 4
University Hospital of North 
Satffordshire NHS Trust
0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 3.4 0 0.0 0 0.0 0 0.0 3 1 3 0 0.0 0 0.0 0.0 . 1 3.4 2 6.9 19 65.5 0 0.0 3 10.3 29
University Hospitals Coventry and 
Warwickshire NHS Trust
0 0.0 1 1.5 0 0.0 0 0.0 0 0.0 0 0.0 1 1.5 0 0.0 0 0.0 2 3.0 10 14.9 11 16.4 0 0.0 1 1.5 0 0.0 0 0.0 0 0.0 0.0 1 1.5 0 0.0 . 0 0. 4 20. 26 38.8 67
Total 833
NHS Trust to which the patient was admitted (CNS specialist centres)
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Table 46: Numbers of CNS patients closest to each CNS centre, and the centre actually attended 
(part 2) 
n % n % n % n % n % n % n % n % n % n % n % n % n % n % n % n % n % n % n % n % n % n % n % n % n %
Barking, Havering and Redbridge 
University Hospitals NHS Trust
8 20.0 4 10.0 0 0.0 3 7.5 0 0.0 0 0.0 17 42.5 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 2.5 0 0.0 0 0.0 0 0.0 1 2.5 0 0.0 0 0.0 0 0.0 4 10.0 0 0.0 0 0.0 2 5.0 40
Barts and the London NHS Trust 0 0.0 6 66.7 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 2 22.2 0 0.0 0 0.0 1 11.1 9
Brighton and Sussex University 
Hospitals NHS Trust
0 0.0 0 0.0 7 53.8 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 7.7 1 7.7 0 0.0 0 0.0 4 30.8 0 0.0 0 0.0 0 0.0 13
Cambridge University Hospitals NHS 
Foundation Trust
2 4.8 0 0.0 0 0.0 34 81.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 2 4.8 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 3 7.1 0 0.0 0 0.0 1 2.4 42
Hull and East Yorkshire Hospitals 
NHS Trust
0 0.0 0 0.0 1 4.0 0 0.0 19 76.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 4.0 0 0.0 0 0.0 0 0.0 2 8.0 2 8.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 25
Imperial College Healthcare NHS 
Trust
0 0.0 1 10.0 0 0.0 0 0.0 0 0.0 1 10.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 2 20.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 10.0 0 0.0 0 0.0 4 40.0 0 0.0 0 0.0 1 10.0 10
King's College Hospitals NHS 
Foundation Trust
0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 12 46.2 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 8 30.8 0 0.0 0 0.0 4 15.4 0 0.0 0 0.0 2 7.7 26
Lancashir Teaching Hospitals NHS 
Foundation trust
0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 16 51.6 1 3.2 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 5 16.1 0 0.0 0 0.0 0 0.0 0 0.0 3 9.7 1 3.2 0 0.0 0 0.0 0 0.0 5 16.1 31
Leeds Teaching Hospitals NHS Trust 0 0.0 0 0.0 0 0.0 0 0.0 3 7.5 0 0.0 0 0.0 0 0.0 33 82.5 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 2.5 1 2.5 1 2.5 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 2.5 40
North Bristol NHS Trust 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 1.6 0 0.0 0 0.0 0 0.0 60 95.2 1 1.6 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 1.6 63
Nottingham University Hospitals NHS 
Trust
0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 27 84.4 0 0.0 0 0.0 0 0.0 0 0.0 4 12.5 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 3.1 32
Oxford Radcliffe Hospitals NHS Trust 0 0.0 0 0.0 0 0.0 1 2.1 0 0.0 2 4.3 0 0.0 0 0.0 0 0.0 2 4.3 0 0.0 38 80.9 1 2.1 0 0.0 0 0.0 0 0.0 0 0.0 1 2.1 0 0.0 0 0.0 1 2.1 0 0.0 0 0.0 0 0.0 1 2.1 47
Plymouth Hospitals NHS Trust 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 11 26.8 0 0.0 0 0.0 25 61.0 0 0.0 0 0.0 0 0.0 0 0.0 1 2.4 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 4 9.8 41
Royal Free Hampstead NHS Trust 0 0.0 1 2.4 2 4.8 0 0.0 0 0.0 6 14.3 1 2.4 0 0.0 0 0.0 0 0.0 0 0.0 3 7.1 0 0.0 17 40.5 0 0.0 0 0.0 0 0.0 0 0.0 1 2.4 0 0.0 0 0.0 9 21.4 0 0.0 0 0.0 2 4.8 42
Salford Royal NHS Foundation Trust 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 41 70.7 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 4 6.9 0 0.0 1 1.7 0 0.0 12 20.7 58
Sheffield Teaching Hospitals NHS 
Foundation Trust
0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 12 75.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 6.3 0 0.0 0 0.0 3 18.8 16
South Tees Hospitals NHS 
Foundation Trust
0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 15 24.6 0 0.0 0 0.0 45 73.8 0 0.0 0 0.0 0 0.0 0 0.0 1 1.6 61
Southampton University Hospitals 
NHS Trust
0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 2 3.4 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 53 91.4 0 0.0 0 0.0 0 0.0 2 3.4 0 0.0 0 0.0 1 1.7 58
St George's Healthcare NHS Trust 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 4 8.7 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 2 4.3 0 0.0 1 2.2 0 0.0 0 0.0 0 0.0 0 0.0 34 73.9 0 0.0 0 0.0 3 6.5 0 0.0 0 0.0 2 4.3 46
The Newcastle upon Tyne Hospitals 
NHS Foundation Trust
0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 25.0 0 0.0 0 0.0 2 50.0 0 0.0 0 0.0 0 0.0 0 0.0 1 25.0 4
The Walton Centre NHS Foundtion 
Trust
0 0.0 1 3.4 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 3.4 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 25 86.2 0 0.0 0 0.0 0 0.0 2 6.9 29
University College London Hospitals 
NHS Foundation Trust
0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 4 100.0 0 0.0 0 0.0 0 0.0 4
University Hospital of North 
Satffordshire NHS Trust
0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 3.4 0 0.0 0 0.0 0 0.0 3 10.3 0 0.0 0 0.0 0 0.0 0 0.0 1 3.4 2 6.9 0 0.0 19 65.5 0 0.0 3 10.3 29
University Hospitals Coventry and 
Warwickshire NHS Trust
0 0.0 1 1.5 0 0.0 0 0.0 0 0.0 0 0.0 1 1.5 0 0.0 0 0.0 2 3.0 10 14.9 11 16.4 0 0.0 1 1.5 0 0.0 0 0.0 0 0.0 0 0.0 1 1.5 0 0.0 0 0.0 0 0.0 0 0.0 14 20.9 26 38.8 67
Total 833
NHS Trust to which the patient was admitted (CNS specialist centres)
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n % n % n % n % n % n % n % n % n % n % n % n % n % n % n % n % n % n % n % n % n % n % n % n %
Barking, Havering and Redbridge 
University Hospitals NHS Trust
8 20.0 4 10.0 0 0.0 3 7.5 0 0.0 0 0.0 17 42.5 0 0.0 0 0.0 0 0.0 0 0.0 0 0 .0 1 2.5 0 0.0 0 0.0 0 0.0 1 2.5 0 0.0 0 0.0 0. 4 10.0 0 0.0 0.0 2 5.0 40
Barts and the London NHS Trust 0 0.0 6 66.7 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0.0 0 0.0 0 .0 0 .0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0. 2 22.2 0 0.0 .0 1 11.1 9
Brighton and Sussex University 
Hospitals NHS Trust
0 0.0 0 0.0 7 53.8 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0.0 0 0.0 0 0.0 0 .0 0 0.0 0 0.0 1 7.7 1 7.7 0 0.0 0. 4 30.8 0 0.0 .0 .0 13
Cambridge University Hospitals NHS 
Foundation Trust
2 4.8 0 0.0 0 0.0 34 81.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 2 4.8 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0.0 3 7.1 0 0.0 0.0 1 2.4 42
Hull and East Yorkshire Hospitals 
NHS Trust
0 0.0 0 0.0 1 4.0 0 0.0 19 76.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 4.0 0 0.0 0 0.0 0 0.0 2 8.0 2 8.0 0 0.0 0 0.0 0 0.0 0 0.0 0.0 0 0.0 0 0.0 0.0 0.0 25
Imperial College Healthcare NHS 
Trust
0 0.0 1 10.0 0 0.0 0 0.0 0 0.0 1 10.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 2 20.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 10.0 0 0.0 0 0.0 4 40.0 0 0.0 0 0.0 1 10.0 10
King's College Hospitals NHS 
Foundation Trust
0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 12 46.2 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 8 30.8 0 0.0 0 0.0 4 15.4 0 0.0 0 0.0 2 7.7 26
Lancashir Teaching Hospitals NHS 
Foundation trust
0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 16 51.6 1 3.2 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 5 16.1 0 0.0 0 0.0 0 0.0 0 0.0 3 9.7 1 3.2 0 0.0 0 0.0 0 0.0 5 16.1 31
Leeds Teaching Hospitals NHS Trust 0 0.0 0 0.0 0 0.0 0 0.0 3 7.5 0 0.0 0 0.0 0 0.0 33 82.5 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 2.5 1 2.5 1 2.5 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 2.5 40
North Bristol NHS Trust 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 1.6 0 0.0 0 0.0 0 0.0 60 95.2 1 1.6 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 1.6 63
Nottingham University Hospitals NHS 
Trust
0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 27 84.4 0 0.0 0 0.0 0 0.0 0 0.0 4 12.5 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 3.1 32
Oxford Radcliffe Hospitals NHS Trust 0 0.0 0 0.0 0 0.0 1 2.1 0 0.0 2 4.3 0 0.0 0 0.0 0 0.0 2 4.3 0 0.0 38 80.9 1 2.1 0 0.0 0 0.0 0 0.0 0 0.0 1 2.1 0 0.0 0 0.0 1 2.1 0 0.0 0 0.0 0 0.0 1 2.1 47
Plymouth Hospitals NHS Trust 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 11 26.8 0 0.0 0 0.0 25 61.0 0 0.0 0 0.0 0 0.0 0 0.0 1 2.4 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 4 9.8 41
Royal Free Hampstead NHS Trust 0 0.0 1 2.4 2 4.8 0 0.0 0 0.0 6 14.3 1 2.4 0 0.0 0 0.0 0 0.0 0 0.0 3 7.1 0 0.0 17 40.5 0 0.0 0 0.0 0 0.0 0 0.0 1 2.4 0 0.0 0 0.0 9 21.4 0 0.0 0 0.0 2 4.8 42
Salford Royal NHS Foundation Trust 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 41 70.7 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 4 6.9 0 0.0 1 1.7 0 0.0 12 20.7 58
Sheffield Teaching Hospitals NHS 
Foundation Trust
0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 12 75.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 6.3 0 0.0 0 0.0 3 18.8 16
South Tees Hospitals NHS 
Foundation Trust
0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 15 24.6 0 0.0 0 0.0 45 73.8 0 0.0 0 0.0 0 0.0 0 0.0 1 1.6 61
Southampton University Hospitals 
NHS Trust
0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 2 3.4 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 53 91.4 0 0.0 0 0.0 0 0.0 2 3.4 0 0.0 0 0.0 1 1.7 58
St George's Healthcare NHS Trust 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 4 8.7 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 2 4.3 0 0.0 1 2.2 0 0.0 0 0.0 0 0.0 0 0.0 34 73.9 0 0.0 0 0.0 3 6.5 0 0.0 0 0.0 2 4.3 46
The Newcastle upon Tyne Hospitals 
NHS Foundation Trust
0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 25.0 0 0.0 0 0.0 2 50.0 0 0.0 0 0.0 0 0.0 0 0.0 1 25.0 4
The Walton Centre NHS Foundtion 
Trust
0 0.0 1 3.4 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 3.4 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 25 86.2 0 0.0 0 0.0 0 0.0 2 6.9 29
University College London Hospitals 
NHS Foundation Trust
0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 4 100.0 0 0.0 0 0.0 0 0.0 4
University Hospital of North 
Satffordshire NHS Trust
0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 3.4 0 0.0 0 0.0 0 0.0 3 10.3 0 0.0 0 0.0 0 0.0 0 0.0 1 3.4 2 6.9 0 0.0 19 65.5 0 0.0 3 10.3 29
University Hospitals Coventry and 
Warwickshire NHS Trust
0 0.0 1 1.5 0 0.0 0 0.0 0 0.0 0 0.0 1 1.5 0 0.0 0 0.0 2 3.0 10 14.9 11 16.4 0 0.0 1 1.5 0 0.0 0 0.0 0 0.0 0 0.0 1 1.5 0 0.0 0 0.0 0 0.0 0 0.0 14 20.9 26 38.8 67
Total 833
NHS Trust to which the patient was admitted (CNS specialist centres)
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Table 47: Likelihood of admission to a CNS centre 
Odds 
ratio p value
Lower 
95%
Upper 
95%
Male 1.00
Female 1.12 0.50 0.81 1.55
1.09 <0.01 1.03 1.15
Astrocytoma 1.00
Other gliomas 0.77 0.32 0.45 1.29
Ependymoma 1.15 0.74 0.50 2.65
Medulloblastoma & other PNET 1.99 0.09 0.89 4.42
Other specified intracranial and intraspinal neoplasms 0.79 0.23 0.54 1.16
Unspecified intracranial and intraspinal neoplasms 0.34 <0.01 0.17 0.72
Most deprived 1.00
2 1.24 0.42 0.74 2.07
3 0.75 0.25 0.46 1.22
4 1.21 0.46 0.73 2.02
Most affluent 1.69 0.07 0.97 2.96
0.94 <0.01 0.92 0.99
Gender 
Age at diagnosis
Diagnostic group
Deprivation
Distance to nearest CNS centre (increase of 5km)  
Increasing age at diagnosis significantly increased the likelihood of admission to a CNS 
specialist centre by 9% for each year (OR 1.09 95%CI 1.03-1.15) (Table 47). In contrast a 
diagnosis of unspecified intracranial and intraspinal neoplasm (OR 0.34 95%CI 0.17-0.72) and 
increasing distance from residence to the closest CNS specialist centre decreased the 
likelihood of admission to a CNS unit during treatment (OR 0.94 95%CI 0.92-0.99). A diagnosis 
of unspecified intracranial and intraspinal neoplasm significantly decreased the likelihood of 
admission to the closest CNS centre by 66.0% when compared with astrocytoma (OR 0.34 
95%CI 0.17-0.72). Every 5km increase in distance from the patient’s place of residence to their 
closest CNS centre decreased the likelihood of admission to the centre by 6.0%. 
8.2.2 Geographical distribution of patients 
Unlike either of the haematological malignancies the majority of patients diagnosed with a 
CNS tumour spent the greatest proportion of their time as an inpatient in a specialist centre of 
some form, with the majority of patients receiving mostly specialist care in 27 of the 31 cancer 
networks (Table 48). The vast majority of this time was spent at a CNS specialist centre, with 
only the Pan Birmingham network having the majority of patients seen at a TCT centre and 
Yorkshire, North Trent and West London being the only networks where the majority of 
patients were treated as inpatients at both TCT and CNS centres (Table 49). 
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Table 48: Cancer network of residence at diagnosis and level of specialist inpatient care for CNS patients, 
by the amount of specialist care received (highlighted sections represent the highest proportion of 
patients for each cancer network) 
n % n % n %
Lancashire & South Cumbria 7 23.3 4 13.3 19 63.3 30
Greater Manchester & Cheshire 18 26.1 6 8.7 45 65.2 69
Merseyside & Cheshire 4 10.5 6 15.8 28 73.7 38
Yorkshire 2 5.1 1 2.6 36 92.3 39
Humber & Yorskhire Coast 0 0.0 3 14.3 18 85.7 21
North Trent 4 23.5 4 23.5 9 52.9 17
Pan Birmingham 7 25.9 0 0.0 20 74.1 27
Arden 7 33.3 2 9.5 12 57.1 21
Mid Trent 2 10.5 1 5.3 16 84.2 19
Derby/ Burton 1 14.3 0 0.0 6 85.7 7
Leicestershire, Northants & Rutland 3 9.1 6 18.2 24 72.7 33
Mount Vernon 6 66.7 0 0.0 3 33.3 9
West London 2 9.5 0 0.0 19 90.5 21
North London 9 47.4 0 0.0 10 52.6 19
North East London 1 9.1 1 9.1 9 81.8 11
South East London 4 20.0 2 10.0 14 70.0 20
South West London 6 20.7 2 6.9 21 72.4 29
Peninsula 14 36.8 6 15.8 18 47.4 38
Dorset 2 11.1 2 11.1 14 77.8 18
Avon, Somerest & Wiltshire 40 90.9 1 2.3 3 6.8 44
3 Counties 10 76.9 0 0.0 3 23.1 13
Thames Valley 6 12.8 3 6.4 38 80.9 47
Central South Coast 3 7.3 3 7.3 35 85.4 41
Surrey, West Sussex & Hampshire 3 17.6 2 11.8 12 70.6 17
Sussex 1 16.7 0 0.0 5 83.3 6
Kent & Medway 4 17.4 6 26.1 13 56.5 23
Greater Midlands 3 11.5 4 15.4 19 73.1 26
North of England 2 3.0 0 0.0 64 97.0 66
Anglia 6 15.8 1 2.6 31 81.6 38
Essex 2 11.1 3 16.7 13 72.2 18
Wales 2 100.0 0 0.0 0 0.0 2
Unknown 0 0.0 1 16.7 5 83.3 6
Total 181 21.7 70 8.4 582 69.9 833
Mostly Number of 
patients
Neither Some
 
 
Table 49: Cancer network of residence at diagnosis and type of specialist inpatient care for CNS patients, 
by type of specialist care received (highlighted sections represent the highest proportion of patients for 
each cancer network) 
n % n % n % n %
Lancashire & South Cumbria 7 23.3 4 13.3 16 53.3 3 10.0 30
Greater Manchester & Cheshire 18 26.1 14 20.3 35 50.7 2 2.9 69
Merseyside & Cheshire 4 10.5 3 7.9 31 81.6 0 0.0 38
Yorkshire 2 5.1 1 2.6 4 10.3 32 82.1 39
Humber & Yorskhire Coast 0 0.0 0 0.0 21 100.0 0 0.0 21
North Trent 4 23.5 0 0.0 2 11.8 11 64.7 17
Pan Birmingham 7 25.9 20 74.1 0 0.0 0 0.0 27
Arden 7 33.3 1 4.8 12 57.1 1 4.8 21
Mid Trent 2 10.5 0 0.0 15 78.9 2 10.5 19
Derby/ Burton 1 14.3 0 0.0 5 71.4 1 14.3 7
Leicestershire, Northants & Rutland 3 9.1 0 0.0 29 87.9 1 3.0 33
Mount Vernon 6 66.7 0 0.0 2 22.2 1 11.1 9
West London 2 9.5 0 0.0 8 38.1 11 52.4 21
North London 9 47.4 0 0.0 5 26.3 5 26.3 19
North East London 1 9.1 0 0.0 8 72.7 2 18.2 11
South East London 4 20.0 0 0.0 12 60.0 4 20.0 20
South West London 6 20.7 0 0.0 21 72.4 2 6.9 29
Peninsula 14 36.8 0 0.0 24 63.2 0 0.0 38
Dorset 2 11.1 0 0.0 16 88.9 0 0.0 18
Avon, Somerest & Wiltshire 40 90.9 0 0.0 4 9.1 0 0.0 44
3 Counties 10 76.9 1 7.7 2 15.4 0 0.0 13
Thames Valley 6 12.8 0 0.0 41 87.2 0 0.0 47
Central South Coast 3 7.3 0 0.0 35 85.4 3 7.3 41
Surrey, West Sussex & Hampshire 3 17.6 0 0.0 12 70.6 2 11.8 17
Sussex 1 16.7 0 0.0 4 66.7 1 16.7 6
Kent & Medway 4 17.4 0 0.0 18 78.3 1 4.3 23
Greater Midlands 3 11.5 8 30.8 15 57.7 0 0.0 26
North of England 2 3.0 0 0.0 64 97.0 0 0.0 66
Anglia 6 15.8 0 0.0 30 78.9 2 5.3 38
Essex 2 11.1 0 0.0 14 77.8 2 11.1 18
Wales 2 100.0 0 0.0 0 0.0 0 0.0 2
Unknown 0 0.0 0 0.0 6 100.0 0 0.0 6
Total 181 21.7 52 6.2 511 61.3 89 10.7 833
Number of 
patients
CNS & TCTNeither TCT CNS
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8.2.3 High volume centres 
All but one of the NHS trusts ranked in the top 15 in terms of number of CNS patients seen 
contained a specialist centre of some description (Table 50). Four trusts were recorded as both 
TCT and CNS specialists, two were recorded as TCT specialists and the remainder were 
reported to be CNS specialist centres. The Central Manchester University Hospitals NHS Trust 
accounted for 3.5% of all cases (29 patients). The Christie NHS Foundation Trust ranked 6th in 
terms of numbers of patients but accounted for the majority of admissions (Table 51). Of the 
16 trusts ranked in the top 15 according to number of admissions three were neither TYA nor 
CNS specialist, The Royal Marsden NHS Trust ranked 4th and accounted for 4.1% of admissions 
while the University Hospitals Bristol NHS Foundation Trust and Royal Devon & Exeter NHS 
Foundation Trust ranked 12th and 15th respectively (Table 51). 
Table 50: Number of CNS patients admitted to each NHS trust during the treatment period (top 15 only) 
Rank NHS Trust n %
1 North Bristol NHS Trust 68 8.2
2 University Hospital Southampton NHS Foundation Trust 58 7.0
3 Oxford Radcliffe Hospitals NHS Trust 52 6.2
4 Salford Royal Hospital NHS Trust 51 6.1
4 The Newcastle upon Tyne Hospitals NHS Foundation Trust 51 6.1
6 St George's Healthcare NHS Trust 44 5.3
6 The Christie NHS Foundation Trust 44 5.3
8 Nottingham University Hospitals NHS Trust 41 4.9
9 University College London Hospitals NHS Foundation Trust 40 4.8
10 Cambridge University Hospitals NHS Foundation Trust 38 4.6
11 The Walton Centre NHS Foundation Trust 36 4.3
12 Leeds Teaching Hospitals NHS Trust 34 4.1 CNS centre
12 University Hospitals Birmingham NHS Foundation Trust 34 4.1 TCT centre
14 King's College Hospital NHS Foundation Trust 33 4.0 Both
15 Central Manchester University Hospitals NHS Trust 29 3.5
833
Number of patients
Total number of patients
 
 
Table 51: Number of admissions to each NHS trust during the treatment period, CNS tumour patients 
Rank NHS Trust n %
1 The Christie NHS Foundation Trust 907 17.9
2 University Hospital Southampton NHS Foundation Trust 319 6.3
3 The Newcastle upon Tyne Hospitals NHS Foundation Trust 220 4.3
4 The Royal Marsden NHS Foundation Trust 209 4.1
5 University College London Hospitals NHS Foundation Trust 194 3.8
6 Lancashire Teaching Hospitals NHS Foundation Trust 185 3.6
7 Oxford Radcliffe Hospitals NHS Trust 172 3.4
8 Nottingham University Hospitals NHS Trust 169 3.3
9 Cambridge University Hospitals NHS Foundation Trust 161 3.2
10 Leeds Teaching Hospitals NHS Trust 136 2.7
11 North Bristol NHS Trust 120 2.4
12 University Hospitals Birmingham NHS Foundation Trust 92 1.8 CNS centre
12 University Hospitals Bristol NHS Foundation Trust 92 1.8 TCT centre
14 Sheffield Teaching Hospitals NHS Foundation Trust 90 1.8 Both
15 Royal Devon & Exeter NHS Foundation Trust 89 1.8
5076
Number of admissions
Total number of admissions
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8.3 Variation in the uptake of specialist care 
Variation was observed in the characteristics of the brain tumour and CNS patients seen across 
the specialist care groups (Table 52 &Table 53). Differences were seen when examining the 
data both by amount and type of specialist care received.  
Just over half of all patients receiving limited specialist input were in the younger age group 
(15 to 19 at diagnosis). In contrast the majority of patients receiving some and mostly 
specialist care were from the older age group (20 to 24 at diagnosis) following the overall 
pattern for this tumour group (Table 52). Very little variation was seen by type of specialist 
care, with the majority of patients from each specialist care group being aged 20 to 24 at 
diagnosis (Table 53).  
Patients were predominantly male; this was seen across all amounts of specialist care (Table 
52). The same pattern was seen for all types of specialist care, with the exception of patients 
receiving CNS and TCT specialist inpatient care, where the majority of patients were female 
(55.1%) (Table 53). 
The most commonly diagnosed tumour was astrocytoma, this was seen in all specialist groups 
with the exception of those receiving limited specialist input (Table 52) and those with CNS 
and TCT specialist inpatient care (Table 53), where other specified intracranial and intraspinal 
neoplasms formed the main part of the group. The proportion of patients with some specialist 
input diagnosed with other gliomas was lower than seen in any other group, and the 
proportion with medulloblastoma was higher. This same pattern was seen in patients with 
both CNS and TCT input (Table 53). 
A greater proportion of patients with both CNS and TCT input were alive at the end of the 
treatment period than any other group (Table 53). A higher proportion of patients receiving 
some specialist input had been diagnosed with a high grade tumour than those receiving 
either limited or mostly specialist input (Table 52).  
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Table 52: CNS patient details by amount of specialist inpatient care 
n % n % n % p value
15-19 94 51.9 27 38.6 247 42.4 368
20-24 87 48.1 43 61.4 335 57.6 465 0.40
Male 95 52.5 44 62.9 305 52.4 444
Female 86 47.5 26 37.1 277 47.6 389 0.25
Astrocytoma 59 32.6 34 48.6 222 38.1 315
Other gliomas 23 12.7 4 5.7 76 13.1 103
Ependymoma 11 6.1 6 8.6 23 4.0 40
Medulloblastoma & other PNET 9 5.0 12 17.1 35 6.0 56
Other specified intracranial & intraspinal neoplasms 66 36.5 14 20.0 203 34.9 283
Unspecified intracranial & intraspinal neoplasms 13 7.2 0 0.0 23 4.0 36 <0.01
Most affluent 28 15.5 11 15.7 113 19.4 152
4 39 21.5 13 18.6 122 21.0 174
3 46 25.4 12 17.1 100 17.2 158
2 36 19.9 19 27.1 105 18.0 160
Most deprived 30 16.6 14 20.0 137 23.5 181
Unknown 2 1.1 1 1.4 5 0.9 8 0.12
Yes 152 84.0 52 74.3 513 88.1 717
No 29 16.0 18 25.7 69 11.9 116 <0.01
I 53 29.3 15 21.4 146 25.1 214
II 51 28.2 20 28.6 187 32.1 258
III 9 5.0 4 5.7 47 8.1 60
IV 22 12.2 24 34.3 84 14.4 130
Unknown 46 25.4 7 10.0 118 20.3 171 0.01
Surgery 83 45.9 26 37.1 313 53.8 422
Surgery & additonal therapy 23 12.7 23 32.9 107 18.4 153
Chemoradiotherapy 13 7.2 5 7.1 42 7.2 60
None 62 34.3 16 22.9 120 20.6 198 <0.01
181 70 582 833
WHO tumour 
grade
Treatment 
received
Total (number of patients)
Gender
Diagnostic group
Deprivation
Alive at end of 
treatment period
Total
Age at diagnosis
Limited Some Mostly
 
Table 53: CNS patient details by type of specialist inpatient care 
n % n % n % n % p value
15-19 94 51.9 214 41.9 24 46.2 36 40.4 368
20-24 87 48.1 297 58.1 28 53.8 53 59.6 465 0.11
Male 95 52.5 280 54.8 29 55.8 40 44.9 444
Female 86 47.5 231 45.2 23 44.2 49 55.1 389 0.37
Astrocytoma 59 32.6 203 39.7 24 46.2 29 32.6 315
Other gliomas 23 12.7 67 13.1 7 13.5 6 6.7 103
Ependymoma 11 6.1 22 4.3 2 3.8 5 5.6 40
Medulloblastoma & other PNET 9 5.0 33 6.5 4 7.7 10 11.2 56
Other specified intracranial & intraspinal neoplasms 66 36.5 169 33.1 10 19.2 38 42.7 283
Unspecified intracranial & intraspinal neoplasms 13 7.2 17 3.3 5 9.6 1 1.1 36 0.03
Most affluent 28 15.5 107 20.9 7 13.5 10 11.2 152
4 39 21.5 105 20.5 8 15.4 22 24.7 174
3 46 25.4 83 16.2 9 17.3 20 22.5 158
2 36 19.9 97 19.0 6 11.5 21 23.6 160
Most deprived 30 16.6 113 22.1 22 42.3 16 18.0 181
Unknown 2 1.1 6 1.2 0 0.0 0 0.0 8 <0.01
Yes 152 84.0 444 86.9 38 73.1 83 93.3 717
No 29 16.0 67 13.1 14 26.9 6 6.7 116 0.01
I 53 29.3 131 25.6 9 17.3 21 23.6 214
II 51 28.2 168 32.9 14 26.9 25 28.1 258
III 9 5.0 43 8.4 5 9.6 3 3.4 60
IV 22 12.2 77 15.1 12 23.1 19 21.3 130
Unknown 46 25.4 92 18.0 12 23.1 21 23.6 171 0.11
Surgery 83 45.9 278 54.4 17 32.7 44 49.4 422
Surgery & additonal therapy 23 12.7 94 18.4 13 25.0 23 25.8 153
Chemoradiotherapy 13 7.2 33 6.5 9 17.3 5 5.6 60
None 62 34.3 106 20.7 13 25.0 17 19.1 198 <0.01
181 511 52 89 833
Treatment 
received
Total (number of patients)
Gender
Diagnostic group
Deprivation
Alive at end of 
treatment period
Total
WHO tumour 
grade
CNS TCT CNS & TCT
Age at diagnosis
Limited
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8.4 Patient outcomes 
8.4.1 Treatment received 
The treatment received by brain and CNS patients was similar across all three groups (Figure 
40), with the main difference being seen in those receiving some specialist care that had a 
greater proportion of patients undergoing surgery with additional therapy than the other two 
groups. A bigger difference was seen when the patients were grouped according to the type of 
specialist care they had received (Figure 41). Less than 60% of patients who had TCT specialist 
care had major surgery, a similar pattern was seen in those with limited specialist input, in 
contrast over 70% of patients with CNS input, either with or without additional TCT input had a 
major surgical resection of their tumour. Very few patients underwent chemoradiotherapy 
without a surgical resection although this was the case for approximately 20% of those with 
TCT care alone. 
Figure 40: Treatment received, by amount of specialist care 
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Figure 41: Treatment received, by type of specialist care 
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The time from diagnosis to first admission was similar across all the specialist care groups, 
ranging from a week before diagnosis to the week of diagnosis (Table 54 & Table 55). The 
biggest variation by specialist group was seen for the timing of the first chemotherapy. This 
was longest for patients with limited specialist input and shortest for those with some 
specialist care and those with TCT input. However it is important to remember that this is 
inpatient chemotherapy only and patients may have had outpatient treatment before this. 
Table 54: Time from diagnosis to first admission and first treatment, by amount of specialist treatment 
(a negative value represents an event prior to diagnosis) 
Median Median Median Median
0 -4 - 77 16.5 0 - 77 - - - - 0 -1 - 34
-0.5 -4 - 18 5 0 - 58 7.5 5 - 10 0 -1 - 77
0 -4 - 68 8.5 -1 - 69 3 -1 - 10 0 -3 - 289
Range Range
Weeks from diagnosis to 
first surgery
Weeks from diagnosis to 
first radiotherapy
Weeks from diagnosis to 
first chemotherapy
Range
Mostly specialist care
Some specialist input
Limited specialist input
Range
Weeks from diagnosis to 
first admission
 
 
Table 55: Time from diagnosis to first admission and first treatment, by type of specialist treatment (a 
negative value represents an event prior to diagnosis) 
Median Median Median Median
0 -4 - 77 16.5 0 - 77 - - - - 0 -1 - 77
0 -4 - 52 8 1 - 69 6 -1 - 10 0 -3 - 289
-1 -4 29 6.5 1 33 0 0 - 0 0 0 - 52
0 0 - 68 13 0 - 65 - - - - 0 0 - 245
Limited specialist input
CNS specialist care
CNS & TCT specialist care
TCT specialist care
Range Range Range Range
Weeks from diagnosis to 
first admission
Weeks from diagnosis to 
first chemotherapy
Weeks from diagnosis to 
first radiotherapy
Weeks from diagnosis to 
first surgery
 
8.4.2 Survival 
Survival to three years was assessed for multiple factors in brain and CNS tumour patients. 
There were differences in survival by diagnostic group (Figure 42), with patients with other 
specified CNS tumours and astrocytoma having the best survival to three years. 
Medulloblastoma and other PNET tumours and other gliomas had the worst. 
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Figure 42: Survival to three years from diagnosis, by diagnostic subtype of CNS tumour 
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Analysis by the grade of tumour showed the pattern which was expected, with higher grade 
tumours (III and IV) doing worse than those diagnosed with lower grade (I and II) tumours 
(Figure 43). Those patients with an unknown WHO grade or unclassified tumour had a broadly 
similar curve to those with a grade II tumour.  
Figure 43: Survival to three years from diagnosis, by grade of CNS tumour 
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Survival also differed when patients were grouped according to the amount of specialist care 
received. Patients with limited specialist care had the highest proportion surviving to three 
133 | P a g e  
 
years, whilst patients with some specialist input had the lowest (Figure 44). Those with mostly 
specialist care were seen to fall in the middle of the two other curves. 
When patients were grouped according to the type of specialist care they received differences 
in survival were again seen (Figure 44). Patients receiving limited specialist care and CNS 
specialist care only had very similar survival, whilst patients for whom the majority of care was 
at a TCT unit had the lowest survival to three years. Patients with a combination of CNS and 
TCT specialist care had the best survival, suggesting that there may be different patient and 
tumour characteristics between the two groups, supported by previous findings (Table 53). 
Figure 44: Survival to three years by amount to specialist care received, CNS patients 
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Figure 45: Survival to three years from diagnosis by type of specialist inpatient care, CNS tumours 
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In order to assess additional factors influencing survival a Cox regression model was produced 
to include patient characteristics, tumour details and care groupings. As the WHO tumour 
grades were based upon the tumour morphology and topology (diagnostic sub group), there 
was likely to be high correlation between these explanatory factors which would make a Cox 
regression model containing both variables unstable. The pair wise correlation coefficient for 
WHO tumour grade and diagnostic group was statistically significant showing a strong 
correlation (p=<0.01). A test of interaction between the WHO grade and the diagnostic group 
further demonstrated the association between tumour grade and diagnostic group (p=<0.01). 
The tumour grade was chosen for inclusion in the model rather than diagnostic subgroup as 
grade explained more of the variation in survival. The improvement in model fit was checked 
by comparing models after the addition of each variable individually to a baseline model 
containing neither. 
The proportional hazards assumption was tested and the results from this (Table 56) showed 
that overall this assumption held (p=0.25); this was also the case for each individual covariate 
(Table 33). When the effect of age at diagnosis was assessed there was no evidence to suggest 
that including age as a categorical variable produced a better fit (p=0.54) and so age was 
modelled as a continuous variable. 
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Table 56: Results of the proportional hazards test (stphtest) 
rho χ2 Prob> χ2
-0.04 0.24 0.62
Male 1.00
Female 0.03 0.20 0.66
0.04 0.28 0.60
1 (Most deprived) 1.00
2 0.01 0.04 0.85
3 -0.11 2.46 0.12
4 0.06 0.62 0.43
5 (Most affluent) 0.01 0.02 0.88
Low 1.00
2 -0.07 0.78 0.38
3 0.10 1.75 0.19
High 0.07 0.83 0.36
Unknown 0.02 0.10 0.75
Limited 1.00
Some 0.17 4.86 0.06
Mostly 0.15 4.63 0.08
Limited 1.00
CNS -0.15 4.39 0.06
TCT -0.13 3.44 0.06
CNS & TCT
18.19 0.25
Age at diagnosis
Gender
Year of diagnosis
Deprivation
Global test
WHO 
tumour 
grade
Amount of 
specialist 
care
Type of 
specialist 
care
 
Tumour grade and amount of specialist care received were found to have a statistically 
significant effect on survival (Table 57). Higher grade tumours had significantly worse survival 
than those with a low grade tumour. Those diagnosed with grade II, III and IV tumours had a 
3.3-, 11- and 11.5- fold increased risk of death compared to those with grade I tumours (HR 
3.32 95%CI 1.80-6.14, HR 10.99 95%CI 5.64-21.41 and HR 11.54 95%CI 6.32-21.06 
respectively). Increasing amounts of specialist care had a non-statistically significant beneficial 
effect on survival, an effect which became more pronounced as the amount of specialist care 
increased. Receiving both CNS and TCT specialist care combined was not associated with any 
difference in risk of death compared to those receiving limited specialist care. Receiving TCT 
care was associated with a 2.4 fold significantly increased risk of death compared to limited 
specialist care (HR 2.41 95%CI 1.21-4.83). CNS specialist care was also associated with a slightly 
increased risk of death, as was increasing deprivation and female gender; however these 
effects were not statistically significant.  
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Table 57: Cox regression model for CNS tumours 
Haz. Ratio p value Lower 95%Upper 95%
0.95 0.06 0.90 1.00
Male 1.00
Female 1.15 0.36 0.86 1.54
0.94 0.17 0.86 1.03
Most deprived 1.00
2 1.02 0.93 0.64 1.64
3 1.16 0.51 0.74 1.84
4 1.48 0.07 0.96 2.27
Most affluent 1.23 0.39 0.77 1.94
Low 1.00
2 3.32 <0.01 1.80 6.14
3 10.99 <0.01 5.64 21.41
High 11.54 <0.01 6.32 21.06
Unknown 2.97 <0.01 1.53 5.77
Limited 1.00
Some 0.95 0.90 0.49 1.88
Mostly 0.61 0.10 0.34 1.09
Limited 1.00
CNS 1.40 0.22 0.82 2.40
TCT 2.41 0.01 1.21 4.83
CNS & TCT 1.00 (omitted)
Confidence intervals
Age at diagnosis
Gender
Year of diagnosis
Deprivation
WHO tumour 
grade
Amount of 
specialist care
Type of 
specialist care
 
8.4.3 Health service usage 
The peaks in admissions to hospital were seen at the same time point from diagnosis across all 
specialist care groups, with the majority of admissions occurring a week before diagnosis to 
three months post diagnosis (Figure 46 & Figure 47). 
Figure 46: Number of admissions per week, by time from diagnosis and amount of specialist care 
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Figure 47: Number of admissions per week, by time from diagnosis and type of specialist care 
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Patients receiving some specialist care had the highest median number of admissions during 
treatment (Figure 48), the greatest proportion of unplanned admissions (Figure 49) and spent 
the largest proportion of their treatment period as an inpatient (Figure 50). Patients who had 
specialist CNS input had the highest number of admissions during treatment (Figure 48), whilst 
both those with CNS input and those with limited specialist input had high levels of unplanned 
admissions (Figure 49). In contrast it was those with TCT specialist care who spent the greatest 
proportion of their treatment period as an inpatient (Figure 50). 
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Figure 48: Median number of admissions per patient during treatment 
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Figure 49: Median proportion of admissions, per patient, during treatment which were unplanned 
 
Figure 50 : Median proportion of treatment period spent as an inpatient, per patient 
 
 
8.4.4 Health service costs 
Overall patients with some specialist input and those with TCT specialist input had the highest 
median total cost of admissions during treatment (Figure 51), this may be due to the fact that 
they had the highest median number of admissions per patient and spent the greatest 
proportion of the treatment period as an inpatient when compared to other specialist care 
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groups. In order to counteract this median cost per admissions was calculated (Figure 52); 
however this showed the same patterns. 
Figure 51: Median total cost of admissions during treatment, per patient 
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Figure 52: Median cost per admission 
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Chapter 9 Osseous and chondromatous neoplasms, Ewing’s sarcoma 
and other neoplasms of bone 
9.1 Specialist care  
As previously stated treatment for bone tumours was centralised at the time of this study with 
five centres treating the vast majority of cases and being the only centres permitted to 
operate. Alongside this patients may have also received parts of their treatment at TCT centres 
as well as other healthcare facilities. In order to assess the level of specialist care received the 
proportion of care received in a bone tumour centre was compared to that spent in a TCT 
centre. 
Figure 53: Assignment of bone tumour patients to a “level” of specialist care using the proportion of 
inpatient time spent in a specialist centre 
 
9.2 Access to specialist care 
9.2.1 Hospital catchment areas 
Due to the structure of services for TYA bone tumour patients, both bone tumour centres and 
TCT centres were assessed in the study. TCT centres were assessed first, followed by the access 
to bone tumour centres. 
TCT centres at UCL, the Christie, Leeds and Newcastle showed a larger distribution of patients 
in actuality (Map 12) when compared to their theoretical catchment area (Map 13). 
Southampton, Birmingham, Sheffield and Alder Hey all attracted patients from closer to the 
centre than predicted.  
Southampton, Birmingham, Sheffield and Alder Hey also had the greatest proportion of 
patients, for whom they were the closest centre, who were not admitted to a TCT centre 
during their treatment (Table 58). In contrast 97% who live the closest to Newcastle were 
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admitted to Newcastle, the remaining patient was admitted to Leeds during the course of their 
treatment. Leeds and the Christie had similarly low numbers of patients with no TCT 
admissions during treatment (14% and 17% respectively). 
Very few patients were admitted to a centre other than their closest one although the Christie 
admitted seven patients for whom Alder Hey was the closest unit and UCL who admitted seven 
patients for whom Southampton was the closest unit (Table 58). 
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Table 58: Numbers of bone tumour patients closest to each TCT centre, and the centre actually attended 
n % n % n % n % n % n % n % n % n %
Alder Hey Children's NHS Foundation 
Trust 6 19 0 0 0 0 0 0 7 22 0 0 2 0 0 0 17 53 32
Leeds Teaching Hospitals NHS Trust
0 0 28 80 0 0 0 0 0 0 1 2.9 0 8.2 1 2.9 5 14 35
Sheffield Teaching Hospitals NHS 
Foundation Trust 0 0 2 5.7 12 34 0 0 0 0 0 0 0 0 1 2.9 20 57 35
University Hospital Southampton NHS 
Foundation Trust 0 0 1 1.5 1 1.5 13 20 2 3 0 0 7 0 1 1.5 41 62 66
The Christie NHS Foundation Trust
0 0 0 0 0 0 0 0 21 72 0 0 0 0 3 10 5 17 29
The Newcastle upon Tyne Hospitals 
NHS Foundation Trust 0 0 1 2.7 0 0 0 0 0 0 36 97 0 263 0 0 0 0 37
University College London Hospitals 
NHS Foundation Trust 0 0 0 0 0 0 0 0 0 0 0 0 89 12 0 0 41 32 130
University Hospitals Birmingham NHS 
Foundation Trust 0 0 0 0 0 0 0 0 0 0 0 0 3 0 35 45 39 51 77
Total 44137 101
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Both increasing road travel distance from home to the closest unit and a diagnosis of “other” 
bone tumour decreased the odds of admission to a TCT unit. Each increment of 5km distance 
was associated with a 9% decrease in likelihood of admission to the closest TCT centre (OR 
0.91 95%CI 0.88-0.94). Those diagnosed with “other” bone tumours were 75% less likely to be 
admitted to their closest TCT centre than those with osteosarcoma (95% CI 0.13-0.48). Females 
also had lower odds of being admitted to a TCT unit (OR 0.74 95%CI 0.96-1.14) but the trend 
was not statistically significant.  In contrast, increasing age at diagnosis increased the odds of 
admission (OR 1.05 95%CI 0.96-1.14), but, again, the effect was not statistically significant 
(Table 59). 
Table 59: Likelihood of admission to a TCT centre for bone tumour patients 
Odds 
ratio p value
Lower 
95%
Upper 
95%
Male 1.00
Female 0.74 0.19 0.46 1.17
1.05 0.29 0.96 1.14
Osteosarcoma 1.00
Ewing's sarcoma 1.14 0.60 0.70 1.87
Other 0.25 <0.01 0.13 0.48
Most deprived 1.00
2 1.54 0.25 0.74 3.20
3 0.82 0.57 0.41 1.63
4 0.65 0.22 0.33 1.29
Most affluent 1.05 0.89 0.53 2.05
0.91 <0.01 0.88 0.94Distance to nearest TCT centres (increase of 5km)
Gender 
Diagnostic group
Deprivation
Age at diagnosis
 
 
The analysis of access to a bone tumour specialist centre demonstrated very different results 
from that seen when assessing access to TCT centres for the same patient group. 
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The predicted catchment area of the Royal National Orthopaedic Hospital (Map 15) mirrored 
almost exactly the actual catchment area of the hospital (Map 14). Of the remaining four bone 
tumour centres in England at the time of the study, Newcastle and Oxford were shown to 
attract patients from a smaller geographical area than predicted. The Royal Orthopaedic 
Hospital, Birmingham and the Robert Jones and Agnes Hunt Orthopaedic Hospital both had a 
larger catchment area than that which was predicted. 
The Robert Jones and Agnes Hunt Orthopaedic Hospital and the Royal National Orthopaedic 
Hospital had the greatest proportion of patients, for whom they were the closest centre, who 
were not admitted to a bone tumour centre during their treatment (Table 60). In contrast less 
than 35.0% of patients who lived the closest to Newcastle, Oxford or the Royal Orthopaedic 
Hospital had no admissions to a bone tumour centre during treatment. 
Unlike the distribution of patients attending a TCT centre (Table 58) there appears to be a large 
amount of patient mobility when examining admission to a bone tumour centre (Table 60). 
28.0% of patients for whom Newcastle was the closest centre, were instead admitted to the 
Royal Orthopaedic Hospital. 30.0% of those residing closest to the Nuffield Orthopaedic Centre 
were admitted to the Royal National Orthopaedic Hospital, and 44.0% of those closest to the 
Robert Jones and Agnes Hunt Orthopaedic Hospital were admitted to the Royal Orthopaedic 
Hospital.  
These results mirror policy and demonstrate the degree to which the centralisation of services 
for bone tumour patients has been implemented. It strongly suggests that the majority of 
patients in this group who go on to receive surgery are treated in line with current guidance. 
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Table 60: Numbers of patients closest to each bone tumour centre, and the centre actually attended 
n % n % n % n % n % n %
Freeman Hospital, Newcastle
37 58 0 0 0 0 1 1.6 18 28 8 13 64
Nuffield Orthopaedic Centre, Oxford
0 0 11 33 0 0 10 30 2 6.1 10 30 33
Robert Jones & Agnes Hunt Orthopaedic 
Hospital, Oswestry 0 0 0 0 3 4 1 1.3 33 44 38 51 75
Royal National Orthopaedic Hospital, 
Stanmore 0 0 4 2.9 0 0 67 49 4 2.9 62 45 137
Royal Orthopaedic Hospital, Birmingham
0 0 0 0 1 0.8 7 5.6 78 62 40 32 126
Total 441
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Increasing road travel distance from home to a bone tumour centre decreased the odds of 
admission to the centre by 3% for every 5km increase (OR 0.97 95%CI 0.94-0.99). This is a 
much smaller effect than that seen for admission to a TCT centre (Table 59) further supporting 
the argument that centralisation is being consistently employed. 
A diagnosis of Ewing’s sarcoma or “other” bone tumour when compared to osteosarcoma also 
decreased the likelihood of admission to a bone tumour centre (OR 0.29 95%CI 0.18-0.46 and 
OR 0.40 95%CI 0.21-0.75). Similarly, females had significantly decreased odds of admission to a 
bone centre, being 49.0% less likely than males to be admitted to a bone tumour centre (OR 
0.51 95%CI 0.33-0.79) (Table 61). 
Table 61: Likelihood of admission to a bone tumour specialist centre 
 
Odds 
ratio p value
Lower 
95%
Upper 
95%
Male 1.00
Female 0.51 0.00 0.33 0.79
0.96 0.27 0.88 1.03
Osteosarcoma 1.00
Ewing's sarcoma 0.29 <0.01 0.18 0.46
Other 0.40 0.01 0.21 0.75
Most deprived 1.00
2 1.12 0.73 0.59 2.14
3 1.03 0.92 0.55 1.96
4 1.19 0.61 0.62 2.28
Most affluent 1.93 0.05 1.01 3.68
0.97 <0.01 0.94 0.99
Deprivation
Distance to nearest bone centre (increase of 5km)
Gender 
Age at diagnosis
Diagnostic group
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9.2.2 Geographical distribution of patients 
In nine of the 31 cancer networks the majority of patients received only limited specialist care 
(Table 62).  Very few patients fell into the some specialist care category and this was not the 
most common group in any cancer network. 
Table 62: Cancer network of residence at diagnosis and level of specialist inpatient care, bone tumours 
(highlighted sections represent the highest proportion of patients for each cancer network) 
n % n % n %
Lancashire & South Cumbria 4 33.3 3 25.0 5 41.7 12
Greater Manchester & Cheshire 1 5.6 0 0.0 17 94.4 18
Merseyside & Cheshire 9 45.0 2 10.0 9 45.0 20
Yorkshire 1 3.7 1 3.7 25 92.6 27
Humber & Yorskhire Coast 4 28.6 0 0.0 10 71.4 14
North Trent 1 7.1 3 21.4 10 71.4 14
Pan Birmingham 3 20.0 0 0.0 12 80.0 15
Arden 0 0.0 1 11.1 8 88.9 9
Mid Trent 6 54.5 3 27.3 2 18.2 11
Derby/ Burton 2 25.0 1 12.5 5 62.5 8
Leicestershire, Northants & Rutland 13 81.3 0 0.0 3 18.8 16
Mount Vernon 0 0.0 2 28.6 5 71.4 7
West London 0 0.0 1 5.3 18 94.7 19
North London 1 7.1 1 7.1 12 85.7 14
North East London 1 10.0 1 10.0 8 80.0 10
South East London 0 0.0 4 33.3 8 66.7 12
South West London 4 66.7 0 0.0 2 33.3 6
Peninsula 19 95.0 1 5.0 0 0.0 20
Dorset 4 80.0 0 0.0 1 20.0 5
Avon, Somerest & Wiltshire 8 80.0 0 0.0 2 20.0 10
3 Counties 1 14.3 1 14.3 5 71.4 7
Thames Valley 5 29.4 5 29.4 7 41.2 17
Central South Coast 9 69.2 2 15.4 2 15.4 13
Surrey, West Sussex & Hampshire 0 0.0 1 25.0 3 75.0 4
Sussex 3 25.0 4 33.3 5 41.7 12
Kent & Medway 1 11.1 1 11.1 7 77.8 9
Greater Midlands 3 13.6 1 4.5 18 81.8 22
North of England 0 0.0 0 0.0 36 100.0 36
Anglia 15 78.9 2 10.5 2 10.5 19
Essex 0 0.0 2 15.4 11 84.6 13
Wales 0 0.0 0 0.0 14 100.0 14
Unknown 2 25.0 0 0.0 6 75.0 8
Total 120 27.2 43 9.8 278 63.0 441
Number of 
patients
Limited Some Mostly
 
 
The majority of patients receiving mostly specialist inpatient care received TCT input. Patients 
in only two networks   (Thames Valley and Wales) received bone specialist care as their 
majority specialist input. Five networks treated the majority of patients in bone and TCT 
specialist centres combined (Table 63). 
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Table 63: Cancer network of residence at diagnosis and type of specialist inpatient care, bone tumours 
(highlighted sections represent the highest proportion of patients for each cancer network) 
n % n % n % n %
Lancashire & South Cumbria 4 33.3 0 0.0 7 58.3 1 8.3 12
Greater Manchester & Cheshire 1 5.6 1 5.6 16 88.9 0 0.0 18
Merseyside & Cheshire 9 45.0 2 10.0 9 45.0 0 0.0 20
Yorkshire 1 3.7 0 0.0 26 96.3 0 0.0 27
Humber & Yorskhire Coast 4 28.6 0 0.0 10 71.4 0 0.0 14
North Trent 1 7.1 3 21.4 10 71.4 0 0.0 14
Pan Birmingham 3 20.0 2 13.3 1 6.7 9 60.0 15
Arden 0 0.0 2 22.2 4 44.4 3 33.3 9
Mid Trent 6 54.5 5 45.5 0 0.0 0 0.0 11
Derby/ Burton 2 25.0 2 25.0 1 12.5 3 37.5 8
Leicestershire, Northants & Rutland 13 81.3 0 0.0 3 18.8 0 0.0 16
Mount Vernon 0 0.0 0 0.0 6 85.7 1 14.3 7
West London 0 0.0 7 36.8 12 63.2 0 0.0 19
North London 1 7.1 2 14.3 11 78.6 0 0.0 14
North East London 1 10.0 0 0.0 9 90.0 0 0.0 10
South East London 0 0.0 0 0.0 11 91.7 1 8.3 12
South West London 4 66.7 0 0.0 2 33.3 0 0.0 6
Peninsula 19 95.0 1 5.0 0 0.0 0 0.0 20
Dorset 4 80.0 0 0.0 1 20.0 0 0.0 5
Avon, Somerest & Wiltshire 8 80.0 0 0.0 1 10.0 1 10.0 10
3 Counties 1 14.3 1 14.3 1 14.3 4 57.1 7
Thames Valley 5 29.4 7 41.2 5 29.4 0 0.0 17
Central South Coast 9 69.2 3 23.1 0 0.0 1 7.7 13
Surrey, West Sussex & Hampshire 0 0.0 0 0.0 4 100.0 0 0.0 4
Sussex 3 25.0 1 8.3 8 66.7 0 0.0 12
Kent & Medway 1 11.1 0 0.0 8 88.9 0 0.0 9
Greater Midlands 3 13.6 2 9.1 5 22.7 12 54.5 22
North of England 0 0.0 0 0.0 1 2.8 35 97.2 36
Anglia 15 78.9 0 0.0 4 21.1 0 0.0 19
Essex 0 0.0 0 0.0 13 100.0 0 0.0 13
Wales 0 0.0 13 92.9 1 7.1 0 0.0 14
Unknown 2 25.0 4 50.0 0 0.0 2 25 8
Total 120 27.2 58 13.2 190 43.1 73 16.6 441
Number of 
patients
Limited Bone TCT Bone & TCT
 
9.2.3 High volume centres 
Three of the trusts ranked in the top 15 in terms of  numbers of bone tumour patients were 
bone tumour specialist centres, one was both a bone and a TYA specialist centre (Newcastle), 
six were TYA specialist centres and the remainder were neither (Table 64). The Royal 
Orthopaedic Hospital and the Royal National Orthopaedic Hospital ranked 1st and 3rd in terms 
of patient numbers, but 4th and 15th in terms of admissions (Table 65). This would be expected 
as often surgery is undertaken at the bone tumour specialist centres but chemotherapy/ 
radiotherapy are performed elsewhere.  
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Table 64: Number of bone tumour patients admitted to each NHS trust during the treatment period (top 
15 only) 
Rank NHS Trust n %
1 The Royal Orthopaedic Hospital NHS Foundation Trust 138 31.3
2 University College London Hospitals 103 23.4
3 Royal National Orthopaedic Hospital NHS Trust 86 19.5
4 University Hospitals Birmingham NHS Foundation Trust 41 9.3
4 The Newcastle upon Tyne Hospitals NHS Foundation Trust 37 8.4
6 Leeds Teaching Hospitals NHS Trust 32 7.3
7 The Christie NHS Foundation Trust 30 6.8
8 Cambridge University Hospitals NHS Foundation Trust 19 4.3
9 University Hospitals Bristol NHS Foundation Trust 17 3.9
10 Clatterbridge Centre for Oncology NHS Trust 14 3.2
10 Oxford Radcliffe Hospitals NHS Trust 14 3.2
12 Nuffield Orthopaedic Centre NHS Trust 13 2.9
12 Sheffield Teaching Hospitals NHS Foundation Trust 13 2.9 Bone centre
12 University Hospital Southampton NHS Trust 13 2.9 TCT centre
15 University Hospitals of Leicester NHS Trust 12 2.7 Both
15 Nottingham University Hospitals NHS Trust 12 2.7
441
Number of patients
Total number of patients
 
 
Table 65: Number of admissions to each NHS trust during the treatment period, bone tumour patients 
Rank NHS Trust n %
1 University College London Hospitals 1,435 15.2
2 The Christie NHS Foundation Trust 1,074 11.3
3 The Newcastle upon Tyne Hospitals NHS Foundation Trust 821 8.7
4 The Royal Orthopaedic Hospital NHS Foundation Trust 741 7.8
5 Leeds Teaching Hospitals NHS Trust 734 7.8
6 University Hospitals Birmingham NHS Foundation Trust 568 6.0
7 Sheffield Teaching Hospitals NHS Foundation Trust 268 2.8
8 University Hospital Southampton NHS Trust 250 2.6
9 Cambridge University Hospitals NHS Foundation Trust 249 2.6
10 University Hospitals Bristol NHS Foundation Trust 248 2.6
11 University Hospitals of Leicester NHS Trust 243 2.6
12 Royal Devon & Exeter NHS Foundation Trust 188 2.0 Bone centre
13 Nottingham University Hospitals NHS Trust 186 2.0 TCT centre
14 Clatterbridge Centre for Oncology NHS Trust 182 1.9 Both
15 Royal National Orthopaedic Hospital NHS Trust 180 1.9
9,463
Number of admissions
Total number of admissions
 
9.3 Variation in the uptake of specialist care 
Age at diagnosis showed variation by both amount of specialist care received (Table 66) and by 
the type of specialist care (Table 67). In all groups, except for patients with both specialist 
bone and TCT input, patients were predominantly from the younger age group (15 to 19 at 
diagnosis). The reverse was seen in patients with specialist bone and TCT input, where the 
majority of patients (52.1%) were from the older group (20 to 24 at diagnosis) (Table 67). 
In keeping with the patterns of incidence of this tumour group, across all specialist care groups 
the majority of patients were male, with only 38.3% of patients being female. 
Variation was seen in the distribution of diagnostic sub-groups by specialist care group. 
Patients with limited specialist input had an equal division of osteosarcoma and Ewing’s 
sarcoma diagnoses, with only a small number of patients diagnosed with ‘other’ bone 
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tumours. A similar pattern was seen in patients receiving some specialist input (Table 66). 
However, half of all patients with mostly specialist care had been diagnosed with an 
osteosarcoma, which was higher than that seen in other groups. Patients with bone tumour 
specialist input (with or without TCT input) had more diagnoses of osteosarcoma than any 
other specialist care group (51.7% and 54.8% respectively). Patients with bone tumour input 
had lower incidence of Ewing’s sarcoma and higher incidence of ‘other’ bone tumours than 
other specialist care groups (Table 67). 
The lowest proportion of patients surviving to the end of the treatment period was seen in 
those receiving some specialist input (46.5%) (Table 66) and in patients with TCT specialist 
input (47.0%) (Table 67). The highest proportion of patients surviving to the end of treatment 
had bone tumour specialist input (87.9%) (Table 67). 
The majority of patients in all specialist care groups had undergone surgery, either with or 
without chemoradiotherapy. Very few patients had no treatment recorded; this was highest in 
patients with limited specialist input but accounted for only 1.7% of these patients. 
Table 66: Bone tumour patient details by amount of specialist inpatient care 
n % n % n % p value
15-19 79 65.8 23 53.5 149 53.6 251
20-24 41 34.2 20 46.5 129 46.4 190 0.07
Male 71 59.2 25 58.1 176 63.3 272
Female 49 40.8 18 41.9 102 36.7 169 0.65
Osteosarcona 50 41.7 20 46.5 139 50.0 209
Ewing's sarcoma 50 41.7 18 41.9 100 36.0 168
Other bone tumour 20 16.7 5 11.6 39 14.0 64 0.59
Most affluent 19 15.8 8 18.6 54 19.4 81
4 25 20.8 8 18.6 39 14.0 72
3 23 19.2 11 25.6 39 14.0 73
2 23 19.2 6 14.0 48 17.3 77
Most deprived 28 23.3 10 23.3 78 28.1 116
Unknown 2 1.7 0 0.0 20 7.2 22 0.47
Yes 64 53.3 20 46.5 160 57.6 224
No 56 46.7 23 53.5 118 42.4 197 0.35
Surgery 18 15.0 2 4.7 32 11.5 52
Surgery & additonal therapy 78 65.0 38 88.4 197 70.9 313
Chemoradiotherapy 22 18.3 2 4.7 49 17.6 74
None 2 1.7 0 0.0 0 0.0 2 0.06
120 43 278 441
Treatment 
received
Total (number of patients)
Gender
Diagnostic 
group
Deprivation
Alive at end of 
treatment 
Total
Age at 
diagnosis
Limited Some Mostly
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Table 67: Bone tumour patient details by type of specialist inpatient care 
n % n % n % n % p value
15-19 79 65.8 32 55.2 105 55.3 35 47.9 251
20-24 41 34.2 26 44.8 85 44.7 38 52.1 190 0.09
Male 71 59.2 37 63.8 115 60.5 49 67.1 272
Female 49 40.8 21 36.2 75 39.5 24 32.9 169 0.69
Osteosarcona 50 41.7 30 51.7 89 46.8 40 54.8 209
Ewing's sarcoma 50 41.7 5 8.6 88 46.3 25 34.2 168
Other bone tumour 20 16.7 23 39.7 13 6.8 8 11.0 64 <0.01
Most affluent 19 15.8 7 12.1 40 21.1 15 20.5 81
4 25 20.8 9 15.5 30 15.8 8 11.0 72
3 23 19.2 10 17.2 30 15.8 10 13.7 73
2 23 19.2 7 12.1 31 16.3 16 21.9 77
Most deprived 28 23.3 8 13.8 58 30.5 22 30.1 116
Unknown 2 1.7 17 29.3 1 0.5 2 2.7 22 0.59
Yes 64 53.3 51 87.9 90 47.4 39 53.4 244
No 56 46.7 7 12.1 100 52.6 34 46.6 197 <0.01
Surgery 18 15.0 24 41.4 6 3.2 4 5.5 52
Surgery & additonal therapy 78 65.0 33 56.9 141 74.2 61 83.6 313
Chemoradiotherapy 22 18.3 1 1.7 43 22.6 8 11.0 74
None 2 1.7 0 0.0 0 0.0 0 0.0 2 <0.01
120 58 190 73 441
Treatment 
received
Total (number of patients)
Gender
Diagnostic 
group
Deprivation
Alive at end of 
treatment 
Total
Age at 
diagnosis
Limited Bone TCT Bone & TCT
 
9.4 Patient outcomes 
9.4.1 Treatment received 
The proportion of patients undergoing surgery alone varied by the amount of specialist care 
received, the smallest proportion being seen in those with some specialist input. This group 
also had the largest proportion of patients having surgery with additional therapy (Figure 54). 
Overall very few patients received no treatment; in fact this was only seen in patients with 
limited specialist input. The type of specialist care received also appeared to affect the 
treatment (Figure 55). Close to 100% of patients with bone specialist care underwent surgery, 
with or without additional therapy. Very few of those who had TCT specialist input, with or 
without additional therapy had surgery alone. Chemoradiotherapy without surgery was seen 
mainly in those with limited specialist input or TCT input only. 
 
Figure 54: Treatment received, by amount of specialist care 
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Figure 55: Treatment received, by type of specialist care 
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Time from diagnosis to first admission varied by type of specialist care received, with those 
patients with bone tumour specialist care having earlier admissions than any other remaining 
groups (Table 69). The median time from diagnosis to major surgical resection of their tumour 
was also shorter than any of the other groups. Variation by amount of specialist care was 
minimal (Table 68). 
Table 68: Time from diagnosis to first treatment, by amount of specialist care (a negative value 
represents an event prior to diagnosis) 
Median Median Median Median
16 -4 - 75 4 -3 - 65 26 18 - 29 15 0 - 49
15 -4 - 59 3 -3 - 32 29.5 20 - 39 16 -1 - 31
18 -4 - 77 3 -3 - 58 31 1 - 36 14.5 -1 - 124
Range Range Range
Weeks from diagnosis 
to first admission
Weeks from diagnosis 
to first chemotherapy
Weeks from diagnosis 
to first radiotherapy
Weeks from diagnosis 
to first surgery
Limited specialist input
Some specialist input
Mostly specialist care
Range
 
 
Table 69: Time from diagnosis to first treatment, by type of specialist care (a negative value represents 
an event prior to diagnosis) 
Median Median Median Median
16 -4 - 75 4 -3 - 65 26 18 - 29 15 0 - 49
7 -4 - 75 9.5 2 - 32 - - - - 5 -1 - 84
19 -3 - 77 3 -3 - 58 30 1 - 39 16 -1 - 124
16 -4 - 76 3 0 - 57 31 31 - 31 15 0 - 77
Weeks from diagnosis 
to first admission
Weeks from diagnosis 
to first chemotherapy
Weeks from diagnosis 
to first radiotherapy
Weeks from diagnosis 
to first surgery
Range Range Range Range
Limited specialist input
Bone specialist care
TCT specialist care
Bone & TCT specialist care
 
9.4.2 Survival 
The three diagnostic groups assessed showed largely different survival curves with those being 
diagnosed with Ewing’s sarcoma of the bone fairing worst, with 50% surviving to three years. 
Osteosarcoma patients had better survival with 60% surviving to three years. ‘Other’ malignant 
bone tumours had the greatest overall survival (Figure 56). 
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Figure 56: Survival to three years from diagnosis, by diagnostic subtype of bone tumour 
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The poorest survival was seen in those who received some specialist input, with those with 
limited specialist care faring better and those who had mostly specialist care having the best 
survival to three years (Figure 57). 
Figure 57: Survival to three years by amount to specialist care received, bone tumour patients 
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Those who received bone tumour specialist care had the best survival to three years, patients 
who were admitted to a TCT unit, with or without the involvement of a bone tumour centre, 
showed poorer survival. This suggests that those who are admitted to a bone tumour centre 
only may have less aggressive, earlier stage disease which did not require systemic treatment 
and therefore did not require admission for chemo/radiotherapy (Figure 58).  
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Figure 58: Survival to three years from diagnosis by type of specialist inpatient care, bone tumours 
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The proportional hazards test for the proposed Cox proportional hazards model for bone 
tumours demonstrated that each variable was non-statistically significant, as was the global 
test (Table 70). Meaning that the proportional hazards assumption held and the model could 
be used. There was no evidence to suggest that the inclusion of age as a categorical variable 
resulted in a better fit than when age was modelled continuously (p=0.70) and so the latter 
method was chosen. 
Table 70: Results of the proportional hazards test (stphtest) 
rho χ2 Prob> χ2
0.06 0.57 0.45
Male 1.00
Female 0.04 0.27 0.61
-0.08 1.13 0.29
1 (Most deprived) 1.00
2 0.00 0.00 1.00
3 0.02 0.07 0.79
4 -0.03 0.16 0.69
5 (Most affluent) -0.01 0.04 0.85
Osteosarcoma 1.00
Ewing's sarcoma -0.06 0.55 0.46
Other malignant bone tumours -0.03 0.19 0.67
Limited 1.00
Some -0.01 0.01 0.94
Mostly 
Limited 1.00
Bone -0.03 0.18 0.67
TCT 0.00 0.00 0.97
Bone & TCT 0.12 2.31 0.13
6.83 0.92
Type of 
specialist 
care
Global test
Age at diagnosis
Gender
Year of diagnosis
Deprivation
Diagnostic 
subgroup
Amount of 
specialist 
care
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A diagnosis of ‘other malignant bone tumours’ had a statistically significant beneficial effect, 
with this diagnostic group having a 74% decreased risk of death compared to those diagnosed 
with osteosarcoma (HR 0.26 95%CI 0.11-0.61) . Receiving mostly specialist care had the same 
risk associated with it as receiving limited specialist care only, whereas having some specialist 
care led to a statistically significant increased risk of death (increase of 76%) (HR 1.76 95%CI 
1.05-2.96).  Receiving bone tumour specialist care was linked to a decrease in risk of death of 
91%, this was a statistically significant result (HR 0.09 95%CI 0.02-0.39). Both TCT and bone & 
TCT specialist care were also associated with a decreased risk of death but this was non-
significant (Table 71). 
Table 71: Cox regression model for bone tumours 
Haz. Ratio p value Lower 95% Upper 95%
1.03 0.35 0.97 1.09
Male 1.00
Female 1.02 0.89 0.74 1.41
0.95 0.23 0.86 1.04
Most deprived 1.00
2 1.00 1.00 0.64 1.58
3 0.80 0.36 0.49 1.30
4 0.65 0.11 0.38 1.10
Most affluent 1.19 0.44 0.77 1.83
Osteosarcoma 1.00
Ewing's sarcoma 1.29 0.12 0.94 1.77
Other malignant bone tumours 0.26 <0.01 0.11 0.61
Limited 1.00
Some 1.76 0.03 1.05 2.96
Mostly 1.00
Limited 1.00
Bone 0.09 <0.01 0.02 0.39
TCT 0.81 0.27 0.56 1.17
Bone & TCT 0.73 0.19 0.45 1.17
Confidence intervals
Diagnostic 
subgroup
Amount of 
specialist 
care
Type of 
specialist 
care
Age at diagnosis
Gender
Year of diagnosis
Deprivation
 
 
9.4.3 Health service usage 
The peak in admissions for bone tumour patients occurred at the same time from diagnosis 
regardless of the amount of specialist care (Figure 59). However when assessed by the type of 
specialist care the peak in admissions for patients with bone & TCT input showed a slower 
decline than that seen in any other age group (Figure 60). 
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Figure 59: Number of admissions per week, by time from diagnosis and amount of specialist care 
0
1
0
0
2
0
0
3
0
0
4
0
0
0
1
0
0
2
0
0
3
0
0
4
0
0
0 20 40 60 80
0 20 40 60 80
Limited specialist input Some specialist input
Mostly specialist care
N
u
m
b
e
r 
o
f 
a
d
m
is
s
io
n
s
Time from diagnosis to admission (weeks)
 
 
Figure 60: Number of admissions per week, by time from diagnosis and type of specialist care 
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The median number of admissions (Figure 61) showed little variation by amount of specialist 
care received, those with mostly specialist care had slightly fewer admissions. The same 
pattern was seen when examining the proportion of admissions which were unplanned (Figure 
62). Similarly there was little variation across groups for the proportion of the treatment 
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period (Figure 63), but those with limited specialist input spent less of this time period as an 
inpatient. 
Patients receiving only bone tumour specialist care had fewer admissions during treatment 
(Figure 61) and spent a smaller proportion of the treatment period as an inpatient (Figure 63), 
however a greater proportion of admissions for this group were unplanned than for any other 
type of specialist care (Figure 62). Patients receiving both bone and TCT specialist inpatient 
care spent the greatest proportion of the treatment period as an inpatient of any diagnostic 
group. 
Figure 61: Median number of admissions per patient during treatment 
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Figure 62: Median proportion of admissions per patient during treatment, which were unplanned 
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Figure 63: Median proportion of the treatment period spent as in inpatient, per patient 
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9.4.4 Health service costs 
Patients with limited specialist inpatient care had a lower total cost of admission during 
treatment than patients with any other amount of specialist input (Figure 64). This pattern was 
repeated for patients with bone tumour related specialist inpatient care; however this is 
reflective of the fact that they had the lowest median number of admissions during treatment 
of any type of specialist care. In order to address this, median cost per admission was 
calculated for each group (Figure 65). The patients receiving mostly specialist care had the 
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highest cost per admission and in the reverse of the pattern seen for total cost; patients with 
bone tumour specialist care had the highest cost per admission. 
Figure 64: Median cost of admissions during treatment, per patient 
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Figure 65: Median cost per admission 
0
500
1000
1500
2000
2500
Limited Some Mostly
M
e
d
ia
n
 c
o
st
 p
e
r 
a
d
m
is
si
o
n
 (
£
 s
te
rl
in
g
)
Amount of specialist care received
0
500
1000
1500
2000
2500
Limited Bone TCT Bone & TCT
Tyoe of specialist care received
 
159 | P a g e  
 
Chapter 10 Soft tissue sarcoma 
10.1 Specialist care 
Some forms of soft tissue sarcoma may be treated at specialist centres dependent on the  type 
and location of tumour. In order to incorporate such specialist care in the analysis both STS 
centres and TCT centres were deemed as specialist centres.   In order to determine what 
proportion of specialist care each patient received, therefore, the amount of care received in 
an STS centre was compared to the proportion spent in a TCT centre. 
 
Figure 66: Assignment of STS patients to a “level” of specialist care using the proportion of inpatient time 
spent in a specialist centre 
 
10.2 Access to specialist care 
10.2.1 Hospital catchment areas 
As previously mentioned STS patients may be treated at both STS and TCT centres. Firstly, 
therefore, access to TCT centres was assessed, followed by access to STS centres. 
Amongst the TCT centres Alder Hey, the Christie and Sheffield had larger catchment areas than 
anticipated (Map 16 and Map 17) whereas Southampton, Birmingham and Leeds had smaller.   
Newcastle and UCL had very similar actual and predicted catchment areas.  
Southampton, UCL and Sheffield had the greatest proportion of patients, for whom they were 
the closest centre, who were not admitted to a TCT centre during their treatment (Table 72). In 
contrast 96% (24 out of 25 patients) who live the closest to Leeds were admitted to Leeds. 
Newcastle had similarly low numbers of patients with no TCT admissions during treatment 
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(four out of 32 patients). Very few patients were admitted to a centre other than their closest 
one.  
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Table 72: Numbers of STS patients closest to each TCT centre, and the centre actually attended 
n % n % n % n % n % n % n % n % n %
Alder Hey Children's NHS Foundation 
Trust 5 19 0 0 1 3.7 0 0 5 19 1 3.7 0 14 0 0 15 56 27
Leeds Teaching Hospitals NHS Trust
0 0 24 96 0 0 0 0 0 0 0 0 0 0 0 0 1 4 25
Sheffield Teaching Hospitals NHS 
Foundation Trust 0 0 0 0 7 26 0 0 0 0 0 0 0 0 0 0 20 74 27
University Hospital Southampton NHS 
Foundation Trust 0 0 0 0 0 0 12 22 0 0 1 1.9 1 3.4 1 1.9 39 72 54
The Christie NHS Foundation Trust
0 0 0 0 0 0 0 0 16 53 0 0 0 0 1 3.3 13 43 30
The Newcastle upon Tyne Hospitals 
NHS Foundation Trust 0 0 0 0 0 0 0 0 0 0 28 88 0 273 0 0 4 13 32
University College London Hospitals 
NHS Foundation Trust 0 0 0 0 0 0 0 0 0 0 0 0 34 12 0 0 81 70 115
University Hospitals Birmingham NHS 
Foundation Trust 0 0 0 0 1 1.9 0 0 0 0 0 0 1 0 26 48 26 48 54
Total 36412 21 30 36
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Increasing road travel distance decreased the odds of admission to a TCT unit by 8% for every 
5km (OR 0.92 95%CI 0.89-0.96). A diagnosis of rhabdomyosarcoma or unspecified STS both 
significantly increased the odds of admission to a TCT centre (Table 73). Patients with 
rhabdomyosarcoma were 90% more likely to be admitted to a TCT centre than patients with 
fibrosarcoma (OR 1.90 95%CI 1.09-3.34), patients with unspecified STS were 28% more likely to 
be admitted than fibrosarcoma patients, however this was not statistically significant. Each 
single year increase in age at diagnosis was associated with an 11% increased likelihood of 
admission to a TCT centre (OR 1.11 95%CI 1.02-1.21). 
Table 73: Likelihood of admission to a TCT centre for STS patients 
Odds 
ratio p value
Lower 
95%
Upper 
95%
Male 1.00
Female 1.00 0.98 0.64 1.59
1.11 0.02 1.02 1.21
Fibrosarcoma 0.23 <0.01 0.10 0.54
Rhabdomyosarcoma 1.90 0.03 1.09 3.34
Other 1.00
Unspecified 1.28 0.42 0.70 2.36
Most deprived 1.00
2 0.69 0.26 0.36 1.31
3 1.03 0.93 0.54 1.95
4 0.64 0.22 0.31 1.31
Most affluent 0.59 0.15 0.28 1.22
0.92 <0.01 0.89 0.96
Gender 
Diagnostic group
Deprivation
Age at diagnosis
Distance to nearest TCT centres (increase of 5km)  
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When examining the distribution of patients around STS specialist centres mapping was not 
possible in the same way seen for TCT centres due to the large number of centres and small 
number of patients. However it was possible to examine the number of patients attending 
their closest STS specialist centre according to road travel distance (Table 74). In all cases the 
majority of patients were either admitted to their closest trust or were not admitted to a STS 
specialist centre during treatment. The proportion of patients admitted to each trust ranged 
from 93.3% (Newcastle) to 18.8% (The Royal National Orthopaedic Hospital). 
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Nottingham University Hospitals 
NHS Trust
The Newcastle upon Tyne 
Hospitals NHS Foundation Trust
University Hospitals of Leicester 
NHS Trust
Bristol Sarcoma Service
Plymouth Hospitals NHS Trust
Oxford University Hospitals NHS 
Trust
The Christie NHS Foundation 
Trust
Cambridge University Hospitals 
NHS Foundation Trust
Robert Jones and Agnes Hunt 
Orthopaedic Hospital NHS 
Foundation Trust
Total
Royal Liverpool and Broadgreen 
University Hospitals NHS Trust
Royal Devon and Exeter NHS 
Foundation Trust
The Royal Orthopaedic Hospital 
NHS Foundation Trust
Royal National Orthopaedic 
Hospital NHS Trust
None
Sheffield Teaching Hospitals NHS 
Foundation Trust
Leeds Teaching Hospitals NHS 
Trust
The Royal Marsden NHS Trust
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Table 75: Likelihood of admission to a STS specialist centre 
Odds 
ratio p value
Lower 
95%
Upper 
95%
Male 1.00
Female 0.78 0.25 0.51 1.20
1.03 0.52 0.95 1.11
Fibrosarcoma 0.47 0.01 0.25 0.85
Rhabdomyosarcoma 2.51 <0.01 1.40 4.49
Other 1.00
Unspecified 0.74 0.33 0.41 1.35
Most deprived 1.00
2 1.57 0.16 0.84 2.94
3 1.26 0.49 0.66 2.38
4 1.51 0.21 0.79 2.91
Most affluent 1.52 0.23 0.76 3.05
0.90 <0.01 0.87 0.93
Gender 
Age at diagnosis
Diagnostic group
Deprivation
Distance to nearest TCT centres (increase of 5km)  
 
As with admissions to a TCT centre, an increasing distance from the place of residence to the 
STS specialist centre decreased the odds of being admitted there (OR 0.90 95%CI 0.87-0.93) 
(Table 75).  Likewise, a diagnosis of fibrosarcoma or unspecified STS compared to ‘other’ STS 
decreased the odds of admission to a specialist STS centre. In contrast a diagnosis of 
rhabdomyosarcoma was associated with a greater than two fold increase of likelihood of 
admission to an STS specialist centre (OR 2.51 95%CI 1.40-4.49). 
10.2.2 Geographical distribution of patients 
In 13 of the 31 cancer networks the majority of patients received limited TCT and STS specialist 
inpatient care. In the Lancashire and South Cumbria network area the majority of patients 
received “some” specialist inpatient care. South West London showed an equal distribution 
between “limited input”, “some” and “mostly” specialist care, Kent and Medway showed an 
equal split between “some” and “mostly”. In the remaining 18 networks the majority of 
patients received mostly specialist inpatient care (Table 76). 
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Table 76: Cancer network of residence at diagnosis and level of specialist inpatient care, STS (highlighted 
sections represent the highest proportion of patients for each cancer network) 
n % n % n %
Lancashire & South Cumbria 2 28.6 3 42.9 2 28.6 7
Greater Manchester & Cheshire 9 39.1 1 4.3 13 56.5 23
Merseyside & Cheshire 9 47.4 1 5.3 9 47.4 19
Yorkshire 2 9.5 0 0.0 19 90.5 21
Humber & Yorskhire Coast 2 40.0 0 0.0 3 60.0 5
North Trent 8 57.1 1 7.1 5 35.7 14
Pan Birmingham 5 25.0 0 0.0 15 75.0 20
Arden 3 60.0 0 0.0 2 40.0 5
Mid Trent 1 9.1 0 0.0 10 90.9 11
Derby/ Burton 1 33.3 0 0.0 2 66.7 3
Leicestershire, Northants & Rutland 3 33.3 0 0.0 6 66.7 9
Mount Vernon 2 33.3 1 16.7 3 50.0 6
West London 7 53.8 0 0.0 6 46.2 13
North London 3 33.3 1 11.1 5 55.6 9
North East London 4 44.4 0 0.0 5 55.6 9
South East London 3 30.0 1 10.0 6 60.0 10
South West London 3 33.3 3 33.3 3 33.3 9
Peninsula 3 25.0 0 0.0 9 75.0 12
Dorset 3 75.0 1 25.0 0 0.0 4
Avon, Somerest & Wiltshire 8 61.5 1 7.7 4 30.8 13
3 Counties 3 42.9 0 0.0 4 57.1 7
Thames Valley 13 76.5 2 11.8 2 11.8 17
Central South Coast 16 94.1 0 0.0 1 5.9 17
Surrey, West Sussex & Hampshire 1 20.0 0 0.0 4 80.0 5
Sussex 5 62.5 1 12.5 2 25.0 8
Kent & Medway 2 25.0 3 37.5 3 37.5 8
Greater Midlands 6 50.0 1 8.3 5 41.7 12
North of England 35 100.0 0 0.0 0 0.0 35
Anglia 4 20.0 2 10.0 14 70.0 20
Essex 3 60.0 0 0.0 2 40.0 5
Wales 3 60.0 0 0.0 2 40.0 5
Unknown 1 33.3 0 0.0 2 66.7 3
Total 173 47.5 23 6.3 168 46.2 364
Number of 
patients
Limited Some Mostly
 
 
In seven networks the majority of patients received a combination of STS and TCT specialist 
inpatient care, in eight networks the bulk of the specialist input consisted of STS care and in 
four cases it was TCT alone. North London demonstrated an equal distribution between 
“limited” specialist input, TCT specialist care and STS specialist care (Table 77). 
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Table 77; Cancer network of residence at diagnosis and type of specialist inpatient care, STS (highlighted 
sections represent the highest proportion of patients for each cancer network) 
n % n % n % n %
Lancashire & South Cumbria 2 28.6 0 0.0 0 0.0 5 71.4 7
Greater Manchester & Cheshire 9 39.1 1 4.3 4 17.4 9 39.1 23
Merseyside & Cheshire 9 47.4 2 10.5 7 36.8 1 5.3 19
Yorkshire 2 9.5 0 0.0 1 4.8 18 85.7 21
Humber & Yorskhire Coast 2 40.0 0 0.0 0 0.0 3 60.0 5
North Trent 8 57.1 0 0.0 2 14.3 4 28.6 14
Pan Birmingham 5 25.0 0 0.0 0 0.0 15 75.0 20
Arden 3 60.0 0 0.0 0 0.0 2 40.0 5
Mid Trent 1 9.1 0 0.0 10 90.9 0 0.0 11
Derby/ Burton 1 33.3 0 0.0 2 66.7 0 0.0 3
Leicestershire, Northants & Rutland 3 33.3 1 11.1 5 55.6 0 0.0 9
Mount Vernon 2 33.3 3 50.0 1 16.7 0 0.0 6
West London 7 53.8 4 30.8 2 15.4 0 0.0 13
North London 3 33.3 3 33.3 3 33.3 0 0.0 9
North East London 4 44.4 4 44.4 1 11.1 0 0.0 9
South East London 3 30.0 1 10.0 6 60.0 0 0.0 10
South West London 3 33.3 2 22.2 4 44.4 0 0.0 9
Peninsula 3 25.0 0 0.0 9 75.0 0 0.0 12
Dorset 3 75.0 1 25.0 0 0.0 0 0.0 4
Avon, Somerest & Wiltshire 8 61.5 0 0.0 5 38.5 0 0.0 13
3 Counties 3 42.9 0 0.0 0 0.0 4 57.1 7
Thames Valley 13 76.5 4 23.5 0 0.0 0 0.0 17
Central South Coast 16 94.1 0 0.0 1 5.9 0 0.0 17
Surrey, West Sussex & Hampshire 1 20.0 0 0.0 4 80.0 0 0.0 5
Sussex 5 62.5 0 0.0 3 37.5 0 0.0 8
Kent & Medway 2 25.0 4 50.0 2 25.0 0 0.0 8
Greater Midlands 6 50.0 0 0.0 0 0.0 6 50.0 12
North of England 35 100.0 0 0.0 0 0.0 0 0.0 35
Anglia 4 20.0 2 10.0 13 65.0 1 5.0 20
Essex 3 60.0 1 20.0 1 20.0 0 0.0 5
Wales 3 60.0 0 0.0 0 0.0 2 40.0 5
Unknown 1 33.3 0 0.0 1 33.3 1 33.3 3
Total 173 47.5 33 9.1 87 23.9 71 19.5 364
Number of 
patients
Limited TCT STS STS & TCT
 
 
10.2.3 High volume centres 
Nine of the trusts ranked in the top 15 in terms of numbers of STS patients were STS specialist 
centres. Four of the centres were both STS and TYA specialist centres (Newcastle, Birmingham, 
Leeds and the Christie). Both UCL and Southampton were TYA specialist centres and the 
remainder were neither (Table 78).  
The Christie ranked 7th in terms of patient numbers but 1st in terms of admissions. St George’s 
Healthcare NHS Trust was ranked 11th in terms of patients, North Bristol was 13th as was the 
University of South Manchester NHS Trust. None of these ranked amongst the top 15 in terms 
of number of admissions. Alder Hey, Lancashire, Sheffield and James Paget NHS Trusts were 
seen in the top 15 for number of admissions, but did not appear in the top 15 for patient 
numbers. 
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Table 78: Number of STS patients admitted to each NHS trust during the treatment period (top 15 only) 
Rank NHS Trust n %
1 The Royal Marsden NHS Foundation Trust 34 9.1
1 The Royal Orthopaedic Hospital NHS Foundation Trust 34 9.1
3 University College London Hospitals NHS Trust 33 8.8
4 The Newcastle upon Tyne Hospitals NHS Foundation Trust 30 8.0
5 University Hospitals Birmingham NHS Foundation Trust 29 7.7
6 Leeds Teaching Hospitals NHS Trust 24 6.4
7 Royal National Orthopaedic Hospital NHS Foundation Trust 20 5.3
7 The Christie NHS Foundation Trust 20 5.3
9 Cambridge University Hospitals NHS Foundation Trust 14 3.7
10 Nottingham University Hospitals NHS Trust 13 3.5
11 University Hospital Southampton NHS Trust 12 3.2
11 St George's Healthcare NHS Trust 12 3.2
13 North Bristol NHS Trust 10 2.7
13 University Hospital of South Manchester NHS Trust 10 2.7 STS centre
15 Central Manchester University Hospitals NHS Foundation Trust 9 2.4 TCT centre
15 University Hospitals Bristol NHS Foundation Trust 9 2.4 Both
15 Royal Liverpool and Broadgreen University Hospitals NHS Trust 9 2.4
364
Number of patients
Total number of patients
 
 
Table 79: Number of admissions to each NHS trust during the treatment period, STS patients 
Rank NHS Trust n %
1 The Christie NHS Foundation Trust 470 10.7
2 The Royal Marsden NHS Foundation Trust 439 10.0
3 The Newcastle upon Tyne Hospitals NHS Foundation Trust 423 9.6
4 University College London Hospitals NHS Trust 320 7.3
5 Leeds Teaching Hospitals NHS Trust 268 6.1
6 University Hospitals Birmingham NHS Foundation Trust 254 5.8
7 Nottingham University Hospitals NHS Trust 187 4.2
8 University Hospital Southampton NHS Trust 181 4.1
9 University Hospitals Bristol NHS Foundation Trust 163 3.7
10 Cambridge University Hospitals NHS Foundation Trust 146 3.3
11 The Royal Orthopaedic Hospital NHS Foundation Trust 97 2.2
12 Alder Hey Children's Hospital NHS Foundation Trust 71 1.6 STS centre
13 Lancashire Teaching Hospitals NHS Foundation Trust 60 1.4 TCT centre
14 Sheffield Teaching Hospitals NHS Foundation Trust 58 1.3 Both
15 James Paget University Hospitals NHS Foundation Trust 53 1.2
4,402
Number of admissions
Total number of admissions
 
10.3 Variation in the uptake of specialist care 
Overall the majority of patients diagnosed with STS were aged 20 to 24 at diagnosis. This was 
reflected in patients with limited specialist input and those with mostly specialist care (Table 
80), the opposite was true for patients with some specialist input. Patients with STS specialist 
care followed the overall pattern whilst those with TCT input were predominantly from the 
younger age group (Table 81).  
The gender distribution was the same across all specialist care groups, with the majority of 
patients being male (Table 80 & Table 81).  
Surgery alone was more common in those with limited specialist input than any other 
specialist group. Surgery in combination with chemo/radiotherapy was more commonly seen 
in patients with either some specialist input (Table 80) or in those with TCT specialist inpatient 
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care (Table 81). The proportion of patients with no treatment recorded was lowest in those 
with both STS and TCT specialist inpatient care (Table 81). 
Table 80: STS patient details by amount of specialist inpatient care 
n % n % n % p value
15-19 74 42.8 14 60.9 74 44.0 162
20-24 99 57.2 9 39.1 94 56.0 202 0.26
Male 88 50.9 15 65.2 93 55.4 196
Female 85 49.1 8 34.8 75 44.6 168 0.37
Fibrosarcoma 45 26.0 0 0.0 23 13.7 68
Rhabdomyosarcoma 19 11.0 9 39.1 53 31.5 81
Other specified STS 81 46.8 11 47.8 61 36.3 153
Unspecified 28 16.2 3 13.0 31 18.5 62 <0.01
Most affluent 23 13.3 3 13.0 24 14.3 50
4 35 20.2 0 0.0 33 19.6 68
3 32 18.5 9 39.1 33 19.6 74
2 33 19.1 6 26.1 38 22.6 77
Most deprived 46 26.6 5 21.7 36 21.4 87
Unknown 4 2.3 0 0.0 4 2.4 8 0.23
Yes 144 83.2 13 56.5 122 72.6 269
No 29 16.8 10 43.5 56 33.3 95 <0.01
Surgery 88 50.9 0 0.0 48 28.6 136
Surgery & additonal therapy 49 28.3 13 56.5 73 43.5 135
Chemoradiotherapy 25 14.5 8 34.8 39 23.2 72
None 11 6.4 2 8.7 8 4.8 21 <0.01
173 23 168 364
Gender
Diagnostic 
group
Deprivation
Alive at 
censor date
Treatment 
received
Total (number of patients)
Total
Age at 
diagnosis
Limited Some Mostly
 
Table 81: STS patient details by type of specialist inpatient care 
n % n % n % n % p value
15-19 74 42.8 46 52.9 21 63.6 21 29.6 162
20-24 99 57.2 41 47.1 12 36.4 50 70.4 202 0.02
Male 88 50.9 51 58.6 19 57.6 38 53.5 196
Female 85 49.1 36 41.4 14 42.4 33 46.5 168 0.66
Fibrosarcoma 45 26.0 11 12.6 1 3.0 11 15.5 68
Rhabdomyosarcoma 19 11.0 30 34.5 12 36.4 20 28.2 81
Other specified STS 81 46.8 35 40.2 10 30.3 27 38.0 153
Unspecified 28 16.2 11 12.6 10 30.3 13 18.3 62 <0.01
Most affluent 23 13.3 16 18.4 2 6.1 9 12.7 50
4 35 20.2 16 18.4 3 9.1 14 19.7 68
3 32 18.5 16 18.4 10 30.3 16 22.5 74
2 33 19.1 24 27.6 9 27.3 11 15.5 77
Most deprived 46 26.6 14 16.1 9 27.3 18 25.4 87
Unknown 4 2.3 1 1.1 0 0.0 3 4.2 8 0.34
Yes 144 83.2 63 72.4 16 48.5 46 64.8 269
No 29 16.8 24 27.6 17 51.5 25 35.2 95 <0.01
Surgery 88 50.9 29 33.3 0 0.0 19 26.8 136
Surgery & additonal therapy 49 28.3 36 41.4 22 66.7 28 39.4 135
Chemoradiotherapy 25 14.5 16 18.4 9 27.3 22 31.0 72
None 11 6.4 6 6.9 2 6.1 2 2.8 21 <0.01
173 87 33 71 364
TCT STS & TCT
Treatment 
received
Total (number of patients)
Gender
Diagnostic 
group
Deprivation
Alive at 
censor date
Total
Age at 
diagnosis
Limited STS
 
10.4 Patient outcomes 
10.4.1 Treatment received 
The majority of patients diagnosed with a soft tissue sarcoma underwent surgery, either with 
or without additional therapy (Figure 67). No patient who had had some specialist care 
underwent surgery alone. This group also had the largest proportion of patients receiving 
chemoradiotherapy without surgery. Very few patients were recorded as having no treatment 
(>10%). This proportion was the smallest in patients who had mostly specialist care. When 
treatment was examined by the type of specialist care received from time of diagnosis to first 
admission, surgery, chemotherapy and radiotherapy varied very little by either the amount or 
type of specialist care received (Table 82 & Table 83). 
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Figure 67: Treatment received, by amount of specialist care 
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Figure 68: Treatment received, by type of specialist care 
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Table 82: Time from diagnosis to first admission and first treatment, by amount of specialist input (a 
negative value represents an episode prior to diagnosis) 
Median Median Median Median
Limited specialist input 0 -4 - 32 4 -1 - 57 20 20 - 20 3 -1 - 232
Some specialist input 0 -4 - 5 3 0 - 53 47 47 - 47 3 0 - 29
Mostly specialist care 0 -4 - 23 4 -4 - 70 14 3 - 39 5 0 - 82
Range Range
Weeks from diagnosis to 
first chemotherapy
Weeks from diagnosis to 
first admission
Weeks from diagnosis to 
first radiotherapy
Range
Weeks from diagnosis to 
first surgery
Range
 
 
Table 83: Time from diagnosis to first admission and first treatment, by type of specialist input (a 
negative value represents an episode prior to diagnosis) 
Median Median Median Median
Limited specialist input 0 -4 - 32 4 -1 - 57 20 20 - 20 3 -1 - 232
STS 0 -4 - 23 3 -1 - 69 - 4.5 0 - 82
TCT 0 -4 - 22 4.5 -4 - 27 21.5 4 - 39 4.5 0 - 25
STS & TCT 0 -4 - 18 4.5 -1 - 70 14 3 - 47 8 0 - 32
Weeks from diagnosis to Weeks from diagnosis to Weeks from diagnosis to Weeks from diagnosis to 
Range Range Range Range
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10.4.2 Survival 
Survival varied by diagnostic subtype for patients with a soft tissue sarcoma.  Close to 100% of 
patients diagnosed with a fibrosarcoma were alive three years post diagnosis. In contrast less 
than 35% of those with a rhabdomyosarcoma were alive at the same point.  Survival from 
other and unspecified STS was in between these two extremes (Figure 69). 
Figure 69: Survival to three years from diagnosis, by diagnostic subtype of STS 
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Those with limited specialist input had the best survival to three years with approximately 75% 
of patients alive at this point. Less than 50% of those with some specialist care were alive at 
the same point (Figure 70).  
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Figure 70: Survival to three years by amount to specialist care received, STS patients 
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Survival also varied by the type of specialist care received, those with limited specialist input 
fared the best with 75% surviving to three years. TCT specialist care without the involvement 
of an STS centre was associated with the poorest survival (under 50% surviving to three years). 
Patients admitted to an STS centre, with or without TCT involvement were seen between these 
two extremes of survival (Figure 71). 
Figure 71: Survival to three years from diagnosis by type of specialist inpatient care, STS tumours 
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The global results of the proportional hazards test showed no statistical significance and 
therefore the model was applied (Table 84). Age was assessed both categorically and 
continuously, there was no evidence to support that the inclusion of a non-linear term for age 
produced a better fitting model (p=0.72) and so a continuous scale was used. 
Table 84: Results of the proportional hazards test (stphtest) 
rho χ2 Prob> χ2
-0.06 0.43 0.51
Male 1.00
Female -0.12 2.18 0.14
0.07 0.69 0.41
1 (Most deprived) 1.00
2 -0.09 1.02 0.31
3 0.01 0.03 0.87
4 0.10 1.27 0.26
5 (Most affluent) 0.14 2.47 0.12
Other STS 1.00
Fibrosarcoma 0.01 0.01 0.93
Rhabdomyosarcoma 0.18 4.79 0.03
Unspecified STS 0.01 0.03 0.87
Limited 1.00
Some 0.04 0.28 0.59
Mostly 0.07 0.62 0.43
Limited 1.00
STS -0.11 1.53 0.22
TCT -0.17 4.28 0.04
STS & TCT
Global test 23.28 0.06
Diagnostic 
subgroup
Amount of 
specialist care
Type of 
specialist care
Age at diagnosis
Gender
Year of diagnosis
Deprivation
 
The Cox regression model (Table 85) demonstrated that increasing age at diagnosis was 
associated with an 8% increased risk of death (HR 1.08 95%CI 1.01-1.16). A diagnosis of 
rhabdomyosarcoma compared to other STS tumours was associated with a two-fold increased 
risk of death (HR 2.35 95%CI 1.51-3.64). Female gender and a diagnosis of fibrosarcoma were 
both factors linked to a statistically significant decrease in risk of death of 44% and 96% (HR 
0.56 95%CI 0.37-0.83 and HR 0.04 95%CI 0.01-0.28) respectively. Receiving some or mostly 
specialist care was associated with an increased risk of death compared to limited specialist 
care, as was receiving TCT care alone, although all were non-significant. Receiving limited 
specialist input and STS and TCT input was shown to have the same associated risk. 
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Table 85: Cox regression model for soft tissue sarcoma 
Haz. Ratio p value Lower 95% Upper 95%
1.08 0.03 1.01 1.16
Male 1.00
Female 0.56 <0.01 0.37 0.83
1.05 0.38 0.94 1.17
Most deprived 1.00
2 0.80 0.44 0.46 1.40
3 0.75 0.30 0.44 1.29
4 1.19 0.52 0.69 2.06
Most affluent 0.89 0.69 0.49 1.59
Other STS 1.00
Fibrosarcoma 0.04 <0.01 0.01 0.28
Rhabdomyosarcoma 2.35 <0.01 1.51 3.64
Unspecified STS 1.32 0.29 0.80 2.17
Limited 1.00
Some 2.00 0.07 0.95 4.17
Mostly 1.59 0.06 0.98 2.58
Limited 1.00
STS 0.80 0.37 0.49 1.31
TCT 1.19 0.58 0.64 2.21
STS & TCT 1.00
Diagnostic 
subgroup
Amount of 
specialist care
Type of 
specialist care
Confidence intervals
Age at diagnosis
Gender
Year of diagnosis
Deprivation
 
 
10.4.3 Health service usage 
The peak in admissions during treatment was seen at the same time point for all amounts of 
specialist care groups (Figure 72). The same was seen when the data were examined according 
to type of specialist input (Figure 73). 
Figure 72: Number of admissions per week, by time from diagnosis and amount of specialist care 
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Figure 73: Number of admissions per week, by time from diagnosis and type of specialist care 
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The graphs examining the data by the amount of specialist care received show a very similar 
pattern; patients with some specialist input had the greatest number of admissions during 
treatment (Figure 74), had the largest proportion of unplanned admissions (Figure 75) and 
spent the largest part of the treatment period as an inpatient (Figure 76). Patients with limited 
specialist input had the lowest score for each of these aforementioned variables. 
Patients with TCT specialist care had the greatest number of admissions during treatment 
(Figure 67), had the largest proportion of unplanned admissions (Figure 68) and spent the 
largest part of the treatment period as an inpatient (Figure 69) when compared to all other 
types of specialist care. 
 
Figure 74: Median number of admissions per patient during treatment 
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Figure 75: Median proportion of admissions, per patient, during treatment which were unplanned 
0
5
10
15
20
25
30
35
40
Limited Some Mostly
Amount of specialist care
M
e
d
ia
n
 p
ro
p
o
rt
io
n
 o
f 
a
d
m
is
s
io
n
s
 
w
h
ic
h
 w
e
re
 u
n
p
la
n
n
e
d
0
5
10
15
20
25
30
35
40
Limited STS TCT STS & TCT
Type of specialist care
 
Figure 76: Median proportion of the treatment period spent as an inpatient, per patient 
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10.4.4 Health service costs 
The total costs of admissions during treatment (Figure 77) are reflective of the fact that some 
groups had higher levels of admission than others. The cost per admission (Figure 78) mirrors 
the results seen when examining the total cost. 
Figure 77: Median total cost of admissions during treatment, per patient 
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Figure 78: Median cost per admission 
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Chapter 11 Germ cell and trophoblastic neoplasms 
11.1 Specialist care 
As there were no site-specific centres for the treatment of germ cell tumour at the time of this 
study the proportion of total inpatient time during treatment spent at a TCT centre was 
compared to the time spent at any other type of hospital for germ cell patients.  
Figure 79: Assignment of germ cell patients to a “level” of specialist care using the proportion of 
inpatient time spent in a specialist centre 
 
11.2 Access to specialist care 
11.2.1 Hospital catchment areas 
With the exception of the Christie, all TCT units showed a smaller actual catchment area (Map 
18) than theoretical one (Map 19). Leeds and Newcastle had the smallest proportion of 
patients, for whom they were the closest centre who were not admitted to a TCT centre during 
their treatment (Table 86). In contrast 90% (338 out of 374 patients) who lived the closest to 
UCL were not admitted to a TCT centre during treatment. Southampton and Alder Hey had 
similarly high numbers. 
Very few patients were admitted to a centre other than their closest one. With the exception 
of the Christie, who admitted 22 patients for whom Alder Hey was the closest unit (Table 86). 
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Table 86: Numbers of germ cell tumour patients closest to each TCT centre, and the centre actually 
attended 
n % n % n % n % n % n % n % n % n %
Alder Hey Children's NHS Foundation 
Trust 3 3.3 0 0 1 1.1 0 0 22 24 2 2.2 0 2.4 1 1.1 62 68 91
Leeds Teaching Hospitals NHS Trust
0 0 77 69 2 1.8 1 0.9 1 0.9 0 0 1 0 0 0 29 26 111
Sheffield Teaching Hospitals NHS 
Foundation Trust 0 0 1 1 31 32 0 0 0 0 0 0 0 0 1 1 63 66 96
University Hospital Southampton NHS 
Foundation Trust 1 0.5 0 0 0 0 46 24 1 0.5 0 0 0 0 4 2.1 142 73 194
The Christie NHS Foundation Trust
0 0 1 1 1 1 0 0 41 43 0 0 0 0 3 3.1 50 52 96
The Newcastle upon Tyne Hospitals 
NHS Foundation Trust 0 0 0 0 1 1.5 0 0 0 0 43 65 0 99 0 0 22 33 66
University College London Hospitals 
NHS Foundation Trust 0 0 1 0.3 0 0 5 1.3 0 0 1 0.3 28 12 1 0.3 338 90 374
University Hospitals Birmingham NHS 
Foundation Trust 0 0 0 0 1 0.6 0 0 0 0 0 0 0 0 61 34 116 65 178
Total 1206
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Increasing travel distance from home to a TCT centre decreased the odds of a TCT admission 
during treatment by 15% for each 5km increase in distance between home and the closest 
centre(OR 0.85 95%CI 0.82-0.88)(Table 87). A diagnosis of a non-gonadal germ cell tumour 
significantly increased the likelihood of a TCT admission (OR 2.52 95%CI 1.54-4.14).  
Table 87: Likelihood of admission to a TCT centre for germ cell tumour patients 
Odds 
ratio p value
Lower 
95%
Upper 
95%
Male 1.00
Female 0.90 0.68 0.56 1.47
0.95 0.07 0.89 1.01
Gonadal germ cell & trophoblastic neoplasm 1.00
Non-gonadal germ cell & trophoblastic neoplasm 2.52 <0.01 1.54 4.14
Most deprived 1.00
2 0.68 0.09 0.43 1.06
3 0.88 0.56 0.56 1.36
4 0.53 0.01 0.33 0.85
Most affluent 0.65 0.06 0.42 1.01
0.85 <0.01 0.82 0.88
Age at diagnosis
Diagnostic group
Deprivation
Distance to nearest TCT centres (increase of 5km)
Gender 
 
 
11.2.2 Geographical distribution of patients 
In four of the 31 cancer networks the majority of patients received mostly specialist TCT 
inpatient care (Table 88). All four networks either had a TCT centre in place during the study 
period or had pathways in place for patient transfer. The majority of patients received limited 
specialist input, several of the networks where this was the case had TCT centres at the time.  
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Table 88: Cancer network of residence at diagnosis and level of specialist inpatient care, germ cell 
tumours (highlighted sections represent the highest proportion of patients for each cancer network) 
n % n % n %
Lancashire & South Cumbria 30 65.2 1 2.2 15 32.6 46
Greater Manchester & Cheshire 34 45.3 5 6.7 36 48.0 75
Merseyside & Cheshire 49 90.7 1 1.9 4 7.4 54
Yorkshire 22 24.4 4 4.4 64 71.1 90
Humber & Yorskhire Coast 22 84.6 1 3.8 3 11.5 26
North Trent 18 41.9 1 2.3 24 55.8 43
Pan Birmingham 5 10.6 4 8.5 38 80.9 47
Arden 20 83.3 0 0.0 4 16.7 24
Mid Trent 38 97.4 0 0.0 1 2.6 39
Derby/ Burton 14 87.5 1 6.3 1 6.3 16
Leicestershire, Northants & Rutland 35 100.0 0 0.0 0 0.0 35
Mount Vernon 23 92.0 0 0.0 2 8.0 25
West London 23 100.0 0 0.0 0 0.0 23
North London 18 58.1 0 0.0 13 41.9 31
North East London 24 96.0 1 4.0 0 0.0 25
South East London 19 86.4 0 0.0 3 13.6 22
South West London 26 96.3 1 3.7 0 0.0 27
Peninsula 31 96.9 1 3.1 0 0.0 32
Dorset 14 100.0 0 0.0 0 0.0 14
Avon, Somerest & Wiltshire 48 100.0 0 0.0 0 0.0 48
3 Counties 27 96.4 0 0.0 1 3.6 28
Thames Valley 58 95.1 0 0.0 3 4.9 61
Central South Coast 61 100.0 0 0.0 0 0.0 61
Surrey, West Sussex & Hampshire 31 100.0 0 0.0 0 0.0 31
Sussex 26 100.0 0 0.0 0 0.0 26
Kent & Medway 39 97.5 0 0.0 1 2.5 40
Greater Midlands 33 70.2 0 0.0 14 29.8 47
North of England 69 98.6 1 1.4 0 0.0 70
Anglia 65 98.5 0 0.0 1 1.5 66
Essex 27 93.1 1 3.4 1 3.4 29
Wales 2 100.0 0 0.0 0 0.0 2
Unknown 2 66.7 0 0.0 1 33.3 3
Total 953 79.0 23 1.9 230 19.1 1,206
Mostly TCT Number of 
patients
Neither Some TCT
 
11.2.3 High volume centres 
Of the eight trusts with a TCT unit during the study period, seven were seen in the top 15 in 
terms of both patient numbers (Table 89) and admissions to hospital (Table 90).  These seven 
trusts admit 30.1% of all germ cell patients and account for 32.8% of all admissions during 
treatment for germ cell tumour patients. The remaining trusts seen in the top 15 are all large 
teaching hospital trusts or cancer centres, treating large volumes of patients annually. 
 
Table 89: Number of germ cell tumour patients admitted to each NHS trust during the treatment period 
(top 15 only) 
Rank NHS Trust n %
1 Leeds Teaching Hospitals NHS Trust 75 6.2
2 University Hospitals Birmingham NHS Foundation Trust 68 5.6
3 The Christie NHS Foundation Trust 62 5.1
4 University Hospitals Southampton NHS Trust 49 4.1
5 The Newcastle upon Tyne Hospitals NHS Foundation Trust 45 3.7
5 University Hospitals Bristol NHS Foundation Trust 45 3.7
7 The Royal Marsden NHS Foundation Trust 41 3.4
8 Nottingham University Hospitals NHS Trust 39 3.2
9 Sheffield Teaching Hospitals NHS Foundation Trust 37 3.1
10 Clatterbridge Centre for Oncology NHS Trust 31 2.6
10 Imperial College Healthcare NHS Trust 31 2.6
10 Oxford Radcliffe Hospitals NHS Trust 31 2.6
13 University College London Hospitals NHS Trust 28 2.3
14 Cambridge University Hospitals NHS Foundation Trust 27 2.2
15 Lancashire Teaching Hospitals NHS Foundation Trust 25 2.1 TCT centre
1,206
Number of patients
Total number of patients
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Table 90: Number of admissions to each NHS trust during the treatment period, germ cell tumour 
patients
Rank NHS Trust n %
1 The Christie NHS Foundation Trust 629 8.1
2 Leeds Teaching Hospitals NHS Trust 536 6.9
3 Sheffield Teaching Hospitals NHS Foundation Trust 368 4.8
4 The Newcastle upon Tyne Hospitals NHS Foundation Trust 338 4.4
5 The Royal Marsden NHS Foundation Trust 303 3.9
6 University Hospitals Birmingham NHS Foundation Trust 278 3.6
7 Nottingham University Hospitals NHS Trust 224 2.9
8 University Hospitals Bristol NHS Foundation Trust 209 2.7
9 University Hospitals Southampton NHS Trust 200 2.6
10 Imperial College Healthcare NHS Trust 196 2.5
11 Lancashire Teaching Hospitals NHS Foundation Trust 189 2.4
12 Cambridge University Hospitals NHS Foundation Trust 185 2.4
13 University College London Hospitals NHS Trust 185 2.4
14 Oxford Radcliffe Hospitals NHS Trust 177 2.3
15 Northampton General Hospital NHS Trust 164 2.1 TCT centre
7,729
Number of admissions
Total number of admissions
 
11.3 Variation in the uptake of specialist care 
The majority of patients diagnosed with a germ cell tumour were in the older age group (aged 
20 to 24 at diagnosis). This was the same across the three specialist care groups, however the 
ratio of older to younger patients was lower in the patients who received some specialist input 
(Table 91). Patients were predominantly male, but again the ratio of male to female was lower 
in the group of patients receiving some specialist input. The same was seen when examining 
diagnostic groups, with the majority of patients having been diagnosed with a gonadal germ 
cell tumour. The proportion of patients surviving to the end of treatment was high for all 
specialist care groups (98.8% to 89.6%). This was highest in patients with limited specialist 
input and lowest in those who had mostly specialist care. 
 
Table 91: Germ cell tumour patient details by amount of specialist inpatient care 
n % n % n % p value
15-19 249 26.1 11 47.8 75 32.6 335
20-24 704 73.9 12 52.2 155 67.4 871 0.01
Male 869 91.2 18 78.3 205 89.1 1,092
Female 84 8.8 5 21.7 25 10.9 114 0.16
Gonadal germ cell & trophoblastic neoplasms 894 93.8 17 73.9 203 88.3 1,114
Germ cell & trophoblastic neoplasms of non-gonadal sites 59 6.2 6 26.1 27 11.7 92 <0.01
Most affluent 207 21.7 3 13.0 44 19.1 254
4 200 21.0 2 8.7 32 13.9 234
3 170 17.8 6 26.1 46 20.0 222
2 204 21.4 2 8.7 41 17.8 247
Most deprived 168 17.6 10 43.5 66 28.7 244
Unknown 4 0.4 0 0.0 1 0.4 5 <0.01
Yes 942 98.8 22 95.7 206 89.6 1,170
No 11 1.2 1 4.3 24 10.4 36 <0.01
Surgery 311 32.6 0 0.0 10 4.3 321
Surgery & additonal therapy 598 62.7 19 82.6 191 83.0 808
Chemoradiotherapy 31 3.3 3 13.0 27 11.7 61
None 15 1.6 1 4.3 2 0.9 18 <0.01
953 23 230 1,206
Limited Some TCT
Total
Total (number of patients)
Deprivation
Alive at 
censor date
Treatment 
received
Age at 
diagnosis
Gender
Diagnostic 
group
Mostly TCT
 
11.4 Patient outcomes 
11.4.1 Treatment received 
The majority of patients diagnosed with a germ cell tumour were treated with a major surgical 
resection combined with additional therapy (Figure 80). This was seen across all the specialist 
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care groups, with the vast majority undergoing chemoradiotherapy additional to their surgical 
resection. No patients who had received some specialist input underwent surgery alone; 
however this was seen in the other two specialist care groups. Very few patients were 
recorded as having had no treatment but this proportion was largest in those with some 
specialist input. 
The time from diagnosis to surgery, first admission and first chemotherapy varied very little 
between groups (Table 92). 
Figure 80: Treatment received, by specialist group 
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Table 92: Time from diagnosis to first admission and first treatment, by specialist group (a negative value 
represents an episode prior to diagnosis) 
Median Median Median
Limited specialist input 0 -4 - 51 6 -4 - 53 0 -4 - 139
Some specialist input 0 -3 - 0 5 0 - 18 0 0 - 0
Mostly specialist care 0 -4 - 9 5 -4 - 51 0 -4 - 39
Weeks from diagnosis to 
first surgery
RangeRange Range
Weeks from diagnosis to 
first chemotherapy
Weeks from diagnosis to 
first admission
 
11.4.2 Survival 
Survival from germ cell and trophoblastic neoplasms was over 75% at three years for this 
group. Those diagnosed with non-gonadal tumours fared worse than those with gonadal 
tumours (Figure 81). Limited specialist input was associated with the best survival, those with 
mostly specialist care had the worst survival of the three specialist care groups (Figure 82). 
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Figure 81: Survival to three years from diagnosis, by diagnostic subtype of germ cell tumour 
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Figure 82: Survival to three years by amount to specialist care received, germ cell tumour patients 
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The global proportional hazards test was non-significant showing that overall the proportional 
hazards assumption held (Table 93), however, deprivation quintile was shown to be an area of 
concern. A likelihood ratio test demonstrated no benefit when including age as a categorical 
variable as opposed to a continuous one and so the latter was chosen (p=0.06). 
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Table 93: Results of the proportional hazards test (stphtest) 
rho χ2 Prob> χ2
0.12 0.88 0.35
Male 1.00
Female 0.09 0.41 0.52
-0.07 0.31 0.58
1 (Most deprived) 1.00
2 0.01 0.01 0.92
3 -0.03 0.03 0.86
4 0.29 4.18 0.04
5 (Most affluent) -0.01 0.01 0.93
Gonadal germ cell neoplasms 1.00
Non-gonadal germ cell neoplasms -0.01 0.01 0.94
Limited 1.00
Some 0.20 2.05 0.15
Mostly -0.08 0.30 0.58
Global test 11.72 0.30
Amount of 
specialist care
Gender
Year of diagnosis
Deprivation
Diagnostic 
subgroup
Age at diagnosis
 
Only diagnostic subgroup and amount of specialist care received were shown to have a 
statistically significant effect on survival (Table 94). Patients diagnosed with a non-gonadal 
tumour had a five-fold increased risk of death (HR 5.25 95%CI 2.81-9.81) while those receiving 
mostly specialist care had a similar 4.8 times increased risk of death (HR 4.83 95%CI 2.70- 
8.64). Receiving some specialist care also increased the risk but this was not statistically 
significant. 
 
Table 94: Cox regression model for germ cell and trophoblastic neoplasms 
Haz. Ratio p value Lower 95% Upper 95%
1.02 0.76 0.91 1.14
Male 1.00
Female 0.69 0.48 0.24 1.93
1.05 0.56 0.89 1.25
Most deprived 1.00
2 0.90 0.82 0.36 2.26
3 1.09 0.85 0.45 2.59
4 1.41 0.41 0.62 3.23
Most affluent 0.99 0.98 0.40 2.44
Gonadal germ cell neoplasms 1.00
Non-gonadal germ cell neoplasms 5.25 <0.01 2.81 9.81
Limited 1.00
Some 2.92 0.16 0.65 12.99
Mostly 4.83 <0.01 2.70 8.64
Amount of 
specialist care
Confidence intervals
Diagnostic 
subgroup
Age at diagnosis
Gender
Year of diagnosis
Deprivation
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11.4.3 Health service usage 
The peak of admissions was seen at the same point for all specialist care groups (Figure 83) 
however the peak in admissions during the week containing diagnosis was greater in patients 
with limited specialist input than seen in any other group. 
Figure 83: Number of admissions per week, by time from diagnosis and specialist group 
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Patients with some specialist care had the highest number of admissions during treatment 
(Figure 84), had the largest number of unplanned admissions (Figure 85) and spent the largest 
amount of the treatment period as an inpatient (Figure 86). 
Figure 84: Median number of admissions per patient during treatment, by specialist group 
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Figure 85: Median proportion of admissions, per patient, during treatment which were unplanned 
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Figure 86: Median proportion of the treatment period spent as an inpatient, per patient 
0
2
4
6
8
10
12
Limited Some Mostly
Type of specialist admission
M
e
d
ia
n
 p
ro
p
o
rt
io
n
 o
f 
s
u
rv
iv
a
l 
ti
m
e
 s
p
e
n
t 
a
s
 a
n
 
in
p
a
ti
e
n
t
 
11.4.4 Health service costs 
The total cost of admissions during treatment reflect the patterns seen in previous analyses, 
with patients receiving some specialist care having the highest overall cost, followed by 
patients with mostly specialist care and those with limited input having the lowest total cost 
(Figure 87). There is very little variation between the groups when examining the cost per 
admission (Figure 88). 
Figure 87: Median total cost of admissions per patient during treatment, by secialist group 
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Figure 88: Median cost per admission 
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Chapter 12 Melanoma and skin carcinoma 
12.1 Specialist care 
The proportion of total inpatient time during treatment spent at a specialist centre was 
compared to the time spent at any other type of hospital for melanoma patients. Due to the 
low level of admissions and the distribution of patients when comparing specialist to non-
specialist care it was decided that specialist care for melanoma and skin carcinoma patients 
was anything over 30%. 
 
Figure 89: Assignment of melanoma and skin carcinoma patients to a “level” of specialist care using the 
proportion of inpatient time spent in a specialist centre 
 
12.2 Access to specialist care 
12.2.1 Hospital catchment areas 
With the exception of Newcastle, all TCT units showed a smaller actual catchment area (Map 
20) than theoretical one (Map 21). Leeds and Newcastle had the smallest proportion of 
patients, for whom they were the closest centre and who were not admitted to a TCT centre 
during their treatment (Table 95). Overall, very few melanoma and skin carcinoma patients 
were admitted to a TCT centre during treatment and very few patients were admitted to a 
centre other than their closest one (Table 95).  
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Table 95: Numbers of melanoma and skin carcinoma patients closest to each TCT centre, and the centre 
actually attended 
n % n % n % n % n % n % n % n % n %
Alder Hey Children's NHS Foundation 
Trust 0 0 0 0 0 0 0 0 1 1 2 1.9 0 1.8 1 1 101 96 105
Leeds Teaching Hospitals NHS Trust
0 0 30 33 1 1.1 0 0 0 0 0 0 0 0 0 0 61 66 92
Sheffield Teaching Hospitals NHS 
Foundation Trust 0 0 0 0 35 28 0 0 2 1.6 0 0 0 0 0 0 86 70 123
University Hospital Southampton NHS 
Foundation Trust 0 0 0 0 3 1.3 13 5.6 0 0 0 0 0 0 1 0.4 215 93 232
The Christie NHS Foundation Trust
0 0 0 0 0 0 0 0 32 38 0 0 0 0 2 2.4 51 60 85
The Newcastle upon Tyne Hospitals 
NHS Foundation Trust 0 0 1 1.5 0 0 0 0 1 1.5 22 33 0 51 0 0 42 64 66
University College London Hospitals 
NHS Foundation Trust 0 0 0 0 1 0.4 0 0 0 0 0 0 1 12 0 0 271 99 273
University Hospitals Birmingham NHS 
Foundation Trust 0 0 0 0 1 0.7 0 0 0 0 0 0 0 0 39 27 103 72 143
Total 1119
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Both increasing travel distance and a diagnosis of skin carcinoma rather than melanoma 
decreased the odds of admission to a TCT centre during treatment, however only travel 
distance was statistically significant and each 5km increase was associated with an 11% 
decrease in the likelihood of admission(OR 0.89 95%CI 0.84-0.94)(Table 96). 
Table 96: Likelihood of admission to a TCT centre for melanoma and skin carcinoma patients 
Odds 
ratio p value
Lower 
95%
Upper 
95%
Male 1.00
Female 0.71 0.19 0.43 1.19
1.08 0.17 0.97 1.21
Melanoma 1.00
Skin carcinoma 0.45 0.02 0.23 0.90
Most deprived 1.00
2 1.11 0.81 0.48 2.56
3 1.20 0.67 0.52 2.77
4 1.17 0.71 0.51 2.66
Most affluent 1.35 0.45 0.62 2.95
0.89 <0.01 0.84 0.94
Deprivation
Distance to nearest TCT centres (increase of 5km)
Gender 
Diagnostic group
Age at diagnosis
 
 
12.2.2 Geographical distribution of patients 
In all 31 networks the majority of melanoma patients received limited specialist TCT inpatient 
care (Table 97). This may have more to do with the nature of the disease, however, than 
referral patterns and healthcare structure as many patients (particularly with early stage 
disease) are treated on an outpatient basis. Very few melanoma patients are admitted during 
the course of treatment and the majority of interventions are undertaken as outpatients.  
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Table 97: Cancer network of residence at diagnosis and level of specialist inpatient care, melanoma and 
skin carcinoma (highlighted sections represent the highest proportion of patients for each cancer 
network) 
n % n %
Lancashire & South Cumbria 51 98.1 1 1.9 52
Greater Manchester & Cheshire 76 83.5 15 16.5 91
Merseyside & Cheshire 50 100.0 0 0.0 50
Yorkshire 68 82.9 14 17.1 82
Humber & Yorskhire Coast 25 100.0 0 0.0 25
North Trent 68 87.2 10 12.8 78
Pan Birmingham 36 85.7 6 14.3 42
Arden 13 86.7 2 13.3 15
Mid Trent 54 98.2 1 1.8 55
Derby/ Burton 11 84.6 2 15.4 13
Leicestershire, Northants & Rutland 22 91.7 2 8.3 24
Mount Vernon 17 100.0 0 0.0 17
West London 11 100.0 0 0.0 11
North London 12 100.0 0 0.0 12
North East London 19 100.0 0 0.0 19
South East London 9 100.0 0 0.0 9
South West London 35 100.0 0 0.0 35
Peninsula 70 100.0 0 0.0 70
Dorset 20 100.0 0 0.0 20
Avon, Somerest & Wiltshire 46 97.9 1 2.1 47
3 Counties 8 88.9 1 11.1 9
Thames Valley 32 100.0 0 0.0 32
Central South Coast 37 100.0 0 0.0 37
Surrey, West Sussex & Hampshire 21 100.0 0 0.0 21
Sussex 28 100.0 0 0.0 28
Kent & Medway 14 100.0 0 0.0 14
Greater Midlands 38 88.4 5 11.6 43
North of England 93 97.9 2 2.1 95
Anglia 44 97.8 1 2.2 45
Essex 18 100.0 0 0.0 18
Wales 3 100.0 0 0.0 3
Unknown 6 85.7 1 14.3 7
Total 1,055 94.3 64 5.7 1,119
Mostly TCT Number of 
patients
Limited
 
 
12.2.3 High volume centres 
Few melanoma patients are admitted to hospital during the course of their treatment. A much 
wider number of trusts admitted patients from this diagnostic group during their treatment, 
with the Sheffield Teaching Hospitals NHS Trust (ranked 1st in terms of number of patients) 
admitting 39 (3.5%) of the total number (Table 98). As with all the other diagnostic groups the 
majority of TCT units are in the top 15 (5 out of 8).  
The trust with the greatest number of admissions was St Helens and Knowsley. This is a large 
teaching hospital and works as a specialist burns and plastic surgery centre for a population of 
four million. This specialisation may go some way to explain why admissions to this trust are so 
much higher than the next closest (6.1% versus 4.4%) (Table 99). Again five out of the eight 
TCT units are seen in the top 15. However the admission numbers are much lower in this 
diagnostic group than in any other, with the trust ranked 15th only having 37 admissions. 
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Table 98: Number of melanoma patients admitted to each NHS trust during the treatment period (top 15 
only) 
Rank NHS Trust n %
1 Sheffield Teaching Hospitals NHS Foundation Trust 39 3.5
2 St George's Healthcare NHS Trust 36 3.2
2 University Hospitals Birmingham NHS Foundation Trust 36 3.2
4 The Christie NHS Foundation Trust 34 3.0
5 Nottingham University Hospitals NHS Trust 33 2.9
6 St Helens and Knowsley Hospitals NHS Trust 31 2.8
7 Lancashire Teaching Hospitals NHS Foundation Trust 30 2.7
7 Leeds Teaching Hospitals NHS Trust 30 2.7
9 North Bristol NHS Trust 26 2.3
9 University Hospital of South Manchester NHS Trust 26 2.3
11 Oxford Radcliffe Hospitals NHS Trust 24 2.1
12 Plymouth Hospitals NHS Trust 22 2.0
12 South Tees Hospitals NHS Foundation Trust 22 2.0
12 The Newcastle upon Tyne Hospitals NHS Foundation Trust 22 2.0
15 Royal Devon & Exeter NHS Foundation Trust 19 1.7 TCT centre
1,119
Number of patients
Total number of patients
 
Table 99: Number of admissions to each NHS trust during the treatment period, melanoma patients 
Rank NHS Trust n %
1 St Helens and Knowsley Hospitals NHS Trust 113 6.1
2 The Christie NHS Foundation Trust 81 4.4
3 Sheffield Teaching Hospitals NHS Foundation Trust 68 3.7
4 Oxford Radcliffe Hospitals NHS Trust 61 3.3
4 University Hospitals Birmingham NHS Foundation Trust 61 3.3
6 Nottingham University Hospitals NHS Trust 60 3.2
7 Lancashire Teaching Hospitals NHS Foundation Trust 59 3.2
8 St George's Healthcare NHS Trust 54 2.9
9 Leeds Teaching Hospitals NHS Trust 53 2.9
10 Royal Devon & Exeter NHS Foundation Trust 41 2.2
11 North Bristol NHS Trust 39 2.1
11 Plymouth Hospitals NHS Trust 39 2.1
11 The Newcastle upon Tyne Hospitals NHS Foundation Trust 39 2.1
11 South Tees Hospitals NHS Foundation Trust 38 2.0
15 Royal Cornwall Hospitals NHS Trust 37 2.0 TCT centre
1,854
Number of admissions
Total number of admissions
 
12.3 Variation in the uptake of specialist care 
The distribution of patient characteristics between the specialist care groups for patients 
diagnosed with melanoma or skin carcinoma was similar (Table 100). A higher proportion of 
patients who received mostly specialist care had been diagnosed with malignant melanoma 
than those who received limited specialist input.  The distribution of age groups, gender, 
deprivation and treatment was broadly similar across the groups. 
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Table 100: Melanoma patient details by amount of specialist inpatient care 
n % n % p value
15-19 268 25.4 10 15.6 278
20-24 787 74.6 54 84.4 841 0.13
Male 366 34.7 24 37.5 390
Female 689 65.3 40 62.5 729 0.71
Melanoma 833 79.0 54 84.4 887
Skin carcinoma 222 21.0 10 15.6 232 0.02
Most affluent 214 20.3 17 26.6 231
4 219 20.8 12 18.8 231
3 208 19.7 10 15.6 218
2 219 20.8 12 18.8 231
Most deprived 186 17.6 12 18.8 198
Unknown 9 0.9 1 1.6 10 0.87
Yes 1,038 98.4 60 93.8 1,098
No 17 1.6 4 6.3 21 <0.01
Surgery 754 71.5 39 60.9 793
Surgery & additonal therapy 33 3.1 4 6.3 37
Chemoradiotherapy 3 0.3 2 3.1 5
None 265 25.1 19 29.7 284 <0.01
1,055 64 1,119Total (number of patients)
Deprivation
Alive at 
censor 
Treatment 
received
Limited
Total
Age at 
diagnosis
Gender
Diagnostic 
group
Mostly TCT
 
12.4 Patient outcomes 
12.4.1 Treatment received 
The treatment for melanoma and skin carcinoma patients was difficult to quantify as the 
majority of patients did not have any admissions during the treatment period. The protocols 
and guidelines in place for both melanoma and skin carcinoma mean that it is possible for the 
majority of therapy to be undertaken in an outpatient setting. A large number of patients have 
had an excision which leads to diagnosis, this is often a total excision meaning that no further 
treatment is required.  
This is reflected in the summary of the treatment received shown in Figure 90. Approximately 
half of all patients with limited specialist input were recorded as having no treatment, the 
remaining patients had surgery with or without chemo-radiotherapy. The proportion of 
patients who had received mainly specialist care who were recorded as having no treatment 
was much smaller (circa 30%), a greater proportion of these patients were reported as having 
had surgery with or without chemo-radiotherapy. 
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Figure 90: Treatment received, by specialist group 
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12.4.2 Survival 
Survival for patients diagnosed with a melanoma or skin carcinoma was approaching 100% at 
three years (Figure 91). Very few patients with limited specialist input had died whilst survival 
for those receiving mostly specialist care was over 80% at three years (Figure 92).  
Figure 91: Survival to three years from diagnosis, by diagnostic subtype of skin cancer 
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Figure 92: Survival to three years by amount to specialist care received, melanoma patients 
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The proportional hazards assumption was shown to hold for each variable included in the 
model individually and also for the model as a whole (Table 101). A likelihood ratio test 
showed that the inclusion of a non-linear term for age had no benefit when compared to age 
as a continuous variable (p=0.44). 
Table 101: Results of the proportional hazards test (stphtest) 
rho χ2 Prob> χ2
-0.17 1.30 0.25
Male 1.00
Female 0.14 1.10 0.30
0.07 0.24 0.63
1 (Most deprived) 1.00
2 -0.14 0.92 0.34
3 -0.14 0.97 0.32
4 -0.14 0.96 0.33
5 (Most affluent) 0.04 0.08 0.78
Melanoma 1.00
Skin carcinoma -0.14 0.99 0.32
Limited 1.00
Mostly -0.14 1.05 0.31
Global test 8.49 0.46
Age at diagnosis
Amount of 
specialist 
Gender
Year of diagnosis
Deprivation
Diagnostic 
subgroup
 
Several variables were shown to be statistically significantly associated with the risk of death. 
Female gender was associated with a sizable decreased risk of death (83%) compared to male 
patients (HR 0.17 95%CI 0.09-0.32). A diagnosis of skin carcinoma had a similar effect when 
compared to a diagnosis of melanoma with a decrease of 91% (HR 0.09 95%CI 0.02-0.37). 
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Receiving mostly specialist care was linked to a three-fold increased risk of death when 
compared to patients who received only limited specialist care (HR 3.65 95%CI 1.6308.19) 
(Table 102).  
 Table 102: Cox regression model for melanoma and skin carcinoma 
Haz. Ratio p value Lower 95% Upper 95%
0.97 0.57 0.86 1.08
Male 1.00
Female 0.17 <0.01 0.09 0.32
0.95 0.56 0.81 1.12
Most deprived 1.00
2 1.40 0.51 0.51 3.89
3 2.19 0.10 0.86 5.63
4 1.18 0.74 0.43 3.26
Most affluent 0.92 0.88 0.33 2.55
Melanoma 1.00
Skin carcinoma 0.09 <0.01 0.02 0.37
Limited 1.00
Mostly 3.65 <0.01 1.63 8.19
Deprivation
Diagnostic 
subgroup
Amount of 
specialist care
Confidence intervals
Age at diagnosis
Gender
Year of diagnosis
 
12.4.3 Health service usage 
The peak in admissions for melanoma and skin carcinoma patients was difficult to interpret 
(Figure 93) as there were, overall, so few admissions. There is a distinct peak in admissions 
during the week of diagnosis and up to a month after this, before the admissions tail off for 
patients with limited specialist input. Patients with mostly specialist care show a much smaller 
peak in admissions around the same time from diagnosis. 
Figure 93:  Number of admissions per week, by time from diagnosis 
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Table 103: Health service usage during treatment, by amount of specialist care 
Specialist group Median Lower 95% Upper 95%
Limited 1 1 1
Mostly 2 2 2
Limited 0 0 0
Mostly 0 0 0
Limited 0.0 0.0 0.0
Mostly 0.5 0.4 0.7
Number of admissions during treatment
Proportion of admissions during treatment 
which were unplanned
Proportion of treatment period spent as an 
inpatient
Confidence intervals
 
12.4.4 Health service costs 
Due to the low proportion of patients admitted during their treatment it was not possible to 
compare costs for this group. 
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Chapter 13 Carcinomas 
13.1 Specialist care 
The proportion of total inpatient time during treatment spent at a TCT centre was compared to 
the time spent at any other type of hospital for carcinoma patients. Due to the wide range of 
diagnoses in this group and the small number of patients in each sub-group it was not possible 
to assess site-specific specialist centres for these patients. This means that for carcinoma 
patients the proportion of treatment received at a TCT centre was compared to treatment at 
any other NHS facility. 
Figure 94: Assignment of carcinoma patients to a “level” of specialist care using the proportion of 
inpatient time spent in a specialist centre 
 
13.2 Access to specialist care 
13.2.1 Hospital catchment areas 
All TCT units showed a smaller actual catchment area of carcinoma patients (Map 22) than 
theoretical one (Map 23).  
Leeds, Newcastle and the Christie had the smallest proportion of patients, for whom they were 
the closest centre, who were not admitted to a TCT centre during their treatment (Table 95). 
Overall, very few carcinoma patients were admitted to a TCT centre during treatment and very 
few patients were admitted to a centre other than their closest one (Table 104).  
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Table 104: Numbers of carcinoma patients closest to each TCT centre, and the centre actually attended 
n % n % n % n % n % n % n % n % n %
Alder Hey Children's NHS Foundation 
Trust 0 0 0 0 0 0 0 0 10 13 0 0 0 0 0 0 66 87 76
Leeds Teaching Hospitals NHS Trust
0 0 62 63 2 2 0 0 1 1 0 0 0 0 0 0 34 34 99
Sheffield Teaching Hospitals NHS 
Foundation Trust 0 0 1 1 35 33 0 0 0 0 0 0 0 0 1 1 68 65 105
University Hospital Southampton NHS 
Foundation Trust 0 0 2 0.9 2 0.9 28 13 1 0.5 0 0 1 0 1 0.5 186 84 221
The Christie NHS Foundation Trust
0 0 0 0 1 0.8 0 0 61 50 0 0 0 0 2 1.7 57 47 121
The Newcastle upon Tyne Hospitals 
NHS Foundation Trust 0 0 1 1.2 0 0 0 0 0 0 34 40 0 47 0 0 50 59 85
University College London Hospitals 
NHS Foundation Trust 0 0 0 0 0 0 3 0.7 1 0.2 0 0 27 12 0 0 397 93 428
University Hospitals Birmingham NHS 
Foundation Trust 0 0 0 0 0 0 0 0 0 0 0 0 1 0 50 27 131 72 182
Total 131731 74 34 29
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As with all other cancer sites, increasing distance from home to a TCT centre was associated 
with decreasing odds of admission to a TCT centre, with each 5km increase in distance having a 
4% decreased likelihood of admission (OR 0.96 95%CI 0.95-0.97). A diagnosis of breast cancer 
significantly decreased the odds of a TCT centre admission by 52% (OR 0.48 95%CI 0.25-0.90) 
whilst a diagnosis of carcinoma of “other and ill-defined sites” significantly increased the odds 
of a TCT centre admission by 69% (OR 1.69 95%CI 1.10-2.60) (Table 105). 
 
Table 105: Likelihood of admission to a TCT centre for carcinoma patients 
Odds 
ratio p value
Lower 
95%
Upper 
95%
Male 1.00
Female 1.11 0.48 0.84 1.46
0.97 0.18 0.93 1.01
Thyroid 1.00
Head and neck 0.88 0.56 0.58 1.34
Trachea, bronchus, lung and pleura 0.63 0.21 0.31 1.30
Breast 0.48 0.02 0.25 0.90
GU tract 1.04 0.82 0.77 1.40
GI tract 0.84 0.32 0.60 1.18
Other & ill defined sites 1.69 0.02 1.10 2.60
Most deprived 1.00
2 0.72 0.05 0.52 1.00
3 1.13 0.47 0.81 1.57
4 0.83 0.29 0.59 1.18
Most affluent 0.95 0.76 0.67 1.34
0.96 <0.01 0.95 0.97Distance to nearest TCT centres (increase of 5km)
Gender 
Diagnostic group
Deprivation
Age at diagnosis
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13.2.2 Geographical distribution of patients 
The vast majority of networks see the bulk of their TYA carcinoma patients being treated with 
limited TCT specialist inpatient care, in fact only patients in the Yorkshire and North Trent 
Networks spent the majority of their inpatient time in a TCT centre (Table 106). 
Table 106: Cancer network of residence at diagnosis and level of specialist inpatient care, carcinomas 
(highlighted sections represent the highest proportion of patients for each cancer network) 
n % n % n %
Lancashire & South Cumbria 38 80.9 5 10.6 4 8.5 47
Greater Manchester & Cheshire 59 60.8 17 17.5 21 21.6 97
Merseyside & Cheshire 46 97.9 0 0.0 1 2.1 47
Yorkshire 25 30.9 17 21.0 39 48.1 81
Humber & Yorkshire Coast 26 89.7 1 3.4 2 6.9 29
North Trent 20 46.5 2 4.7 21 48.8 43
Pan Birmingham 28 49.1 10 17.5 19 33.3 57
Arden 26 89.7 1 3.4 2 6.9 29
Mid Trent 38 97.4 1 2.6 0 0.0 39
Derby/ Burton 21 95.5 0 0.0 1 4.5 22
Leicestershire, Northants & Rutland 29 96.7 1 3.3 0 0.0 30
Mount Vernon 26 92.9 1 3.6 1 3.6 28
West London 50 94.3 0 0.0 3 5.7 53
North London 22 78.6 0 0.0 6 21.4 28
North East London 40 95.2 1 2.4 1 2.4 42
South East London 34 97.1 0 0.0 1 2.9 35
South West London 46 93.9 0 0.0 3 6.1 49
Peninsula 42 100.0 0 0.0 0 0.0 42
Dorset 25 100.0 0 0.0 0 0.0 25
Avon, Somerset & Wiltshire 58 100.0 0 0.0 0 0.0 58
3 Counties 22 91.7 0 0.0 2 8.3 24
Thames Valley 54 100.0 0 0.0 0 0.0 54
Central South Coast 56 100.0 0 0.0 0 0.0 56
Surrey, West Sussex & Hampshire 24 96.0 1 4.0 0 0.0 25
Sussex 20 95.2 0 0.0 1 4.8 21
Kent & Medway 42 97.7 0 0.0 1 2.3 43
Greater Midlands 35 87.5 1 2.5 4 10.0 40
North of England 82 98.8 0 0.0 1 1.2 83
Anglia 52 98.1 0 0.0 1 1.9 53
Essex 30 96.8 0 0.0 1 3.2 31
Wales 1 50.0 0 0.0 1 50.0 2
Unknown 4 100.0 0 0.0 0 0.0 4
Total 1,121 59 137 1,317
Limited Some TCT Mostly TCT Number of 
patients
 
13.2.3 High volume centres 
Carcinoma patients have a much wider range of diagnoses than that which is seen in any of the 
previous groups. This would suggest that a similar pattern would be seen in this group as was 
seen in melanoma and skin carcinoma, a large number of trusts treating relatively few 
patients. All the trusts seen in the top 15, both in terms of patients and admissions, are large 
teaching hospitals and cancer centres (Table 107 & Table 108). In both cases seven out of eight 
TCT centres are seen in the top 15. 
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Table 107: Number of carcinoma patients admitted to each NHS trust during the treatment period (top 
15 only) 
Rank NHS Trust n %
1 The Christie NHS Foundation Trust 73 5.5
2 Leeds Teaching Hospitals NHS Trust 65 4.9
3 The Royal Marsden NHS Foundation Trust 63 4.8
4 University Hospital Birmingham NHS Foundation Trust 51 3.9
5 Barts and the London NHS Trust 44 3.3
6 Imperial College Healthcare NHS Trust 39 3.0
7 Sheffield Teaching Hospitals NHS Foundation Trust 38 2.9
8 Nottingham University Hospitals NHS Trust 34 2.6
9 The Newcastle upon Tyne Hospitals NHS Foundation Trust 33 2.5
10 Cambridge University Hospitals NHS Foundation Trust 30 2.3
10 University Hospitals Bristol NHS Foundation Trust 30 2.3
12 University College London Hospitals NHS Trust 29 2.2
13 Guy's and St Tomas' NHS Foundation Trust 28 2.1
14 King's College Hospital NHS Foundation Trust 27 2.1
14 Oxford Radcliffe Hospitals NHS Trust 27 2.1
14 University Hospitals of Southampton NHS Trust 27 2.1 TCT centre
15 Gloucestershire Hospitals NHS Foundation Trust 26 2.0
1,317
Number of patients
Total number of patients
 
 
Table 108: Number of admissions to each NHS trust during the treatment period, carcinoma patients 
Rank NHS Trust n %
1 Leeds Teaching Hospitals NHS Trust 496 5.2
2 The Christie NHS Foundation Trust 483 5.1
3 The Royal Marsden NHS Foundation Trust 362 3.8
4 Nottingham University Hospitals NHS Trust 299 3.2
5 Sheffield Teaching Hospitals NHS Foundation Trust 293 3.1
6 University Hospitals Bristol NHS Foundation Trust 262 2.8
7 Lancashire Teaching Hospitals NHS Foundation Trust 247 2.6
8 Imperial College Healthcare NHS Trust 231 2.4
9 Gloucestershire Hospitals NHS Foundation Trust 230 2.4
10 Barts and the London NHS Trust 223 2.4
11 University Hospital Birmingham NHS Foundation Trust 221 2.3
12 The Newcastle upon Tyne Hospitals NHS Foundation Trust 217 2.3
13 Royal Devon & Exeter NHS Foundation Trust 166 1.7
14 University Hospitals of Southampton NHS Trust 155 1.6
15 University College London Hospitals NHS Trust 154 1.6 TCT centre
9,486
Number of admissions
Total number of admissions
 
13.3 Variation in the uptake of specialist care 
The majority of carcinoma patients were aged 20 to 24 at diagnosis, this ranged from 75.6% of 
patients with limited specialist input, to 65.7% of patients with mostly specialist care (Table 
109). The gender distribution was similar across all three groups, although the proportion of 
male patients was slightly higher in the group with mostly specialist care.  
The vast majority of patients were diagnosed with a genito-urinary (GU) tract tumour; this is 
reflected in the distribution of diagnoses for patients with limited specialist input. In contrast, 
over half (57.6%) of all patients with some specialist input had a thyroid carcinoma, whilst only 
10.2% had a GU tract carcinoma. The distribution in patients with mostly specialist care was 
more reflective of the overall pattern. 
The majority of patients survived to the end of the treatment period (86.4% of patients with 
limited specialist input to 72.3% of patients with mostly specialist care). 
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Surgery, with or without chemo-radiotherapy, was the mainstay of treatment for this group, 
with well over half of all patients undergoing surgery. The major variation in treatment was 
seen in the use of chemo/radiotherapy without surgery, with was used in 38 cases (27.7%) in 
patients who have mainly specialist care, as opposed to 8.7% of cases with limited input and 
16.7% of cases with some specialist input. A greater proportion of those with limited input had 
no treatment recorded than in any other group.  
Table 109: Carcinoma patient details by amount of specialist inpatient care 
n % n % n % p value
15-19 273 24.4 20 33.9 47 34.3 340
20-24 848 75.6 39 66.1 90 65.7 977 0.01
Male 295 26.3 15 25.4 44 32.1 354
Female 826 73.7 44 74.6 93 67.9 963 0.21
Thyroid 271 24.2 34 57.6 38 27.7 379
Head and neck 115 10.3 2 3.4 22 16.1 160
Trachea, bronchus, lung & pleura 33 2.9 1 1.7 7 5.1 45
Breast 66 5.9 3 5.1 5 3.6 77
Genito-urinary tract 312 27.8 6 10.2 28 20.4 458
Gastrointestinal tract 250 22.3 10 16.9 27 19.7 347
Other 74 6.6 3 5.1 10 7.3 129 <0.01
Most affluent 190 16.9 8 13.6 17 12.4 215
4 202 18.0 10 16.9 20 14.6 232
3 200 17.8 8 13.6 26 19.0 234
2 262 23.4 10 16.9 26 19.0 298
Most deprived 262 23.4 23 39.0 47 34.3 332
Unknown 5 0.4 0 0.0 1 0.7 6 0.04
Yes 957 85.4 51 86.4 99 72.3 1,107
No 164 14.6 8 13.6 38 27.7 210 <0.01
Surgery 449 40.1 14 23.7 37 27.0 550
Surgery & additional therapy 451 40.2 34 57.6 58 42.3 543
Chemoradiotherapy 98 8.7 10 16.9 38 27.7 146
None 73 6.5 1 1.7 4 2.9 78 <0.01
1,121 100 59 100 137 100 1,317
Gender
Diagnostic group
Total (number of patients)
Deprivation
Alive at end of 
treatment period
Treatment 
received
Limited Some TCT Mostly TCT
Total
Age at diagnosis
 
13.4 Patient outcomes 
13.4.1 Treatment received 
The treatment received by patients diagnosed with a carcinoma varied by the amount of 
specialist inpatient treatment (Figure 95). Patients receiving some specialist input underwent 
surgery and chemo-radiotherapy as their modal treatment. Whilst those with limited input had 
a greater proportion undergoing surgery alone as an inpatient and a larger number of cases 
with no treatment reported as an inpatient. Of all the groups those with mostly specialist 
inpatient care had the greatest proportion of patients undergoing chemo-radiotherapy with no 
surgery recorded. This supports the previous findings which demonstrated a variation in both 
patient and tumour characteristics by specialist care group (Table 109). 
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Figure 95: Treatment received, by specialist group 
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13.4.2 Survival 
Survival for patients diagnosed with a carcinoma varied by diagnostic sub group (Figure 96) 
and amount of specialist care received (Figure 97). Patients diagnosed with a thyroid 
carcinoma had the highest survival whilst those diagnosed with a carcinoma of the 
gastrointestinal tract or ‘other’ carcinoma had similarly low survival to three years from 
diagnosis.  Those with mostly specialist inpatient care had the lowest survival with 
approximately 60% surviving to three years from diagnosis, in contrast over 80% of those with 
limited or some specialist input survived to the same time point. 
 
Figure 96: Survival to three years from diagnosis, by diagnostic subtype of carcinoma 
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Figure 97: Survival to three years by amount to specialist care received, carcinoma patients 
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The results of the global test of the model showed that the proportional hazards assumption 
held, however inclusion of gender may cause some issues (Table 110). This could have been 
due to the distribution of diagnostic groups by gender. The results of a likelihood ratio test, 
comparing models using both linear and non-linear scales for age showed that there was no 
benefit to the inclusion of age as a categorical variable and so a continuous scale was used 
(p=0.69). 
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 Table 110: Results of the proportional hazards test (stphtest) 
rho χ2 Prob> χ2
-0.11 3.34 0.07
Male 1.00
Female 0.12 5.13 0.02
0.02 0.16 0.69
1 (Most deprived) 1.00
2 0.06 0.88 0.35
3 0.00 0.00 0.99
4 0.06 0.90 0.34
5 (Most affluent) 0.00 0.00 0.97
Genitourinary tract 1.00
Thyroid 0.01 0.02 0.88
Head and neck 0.12 3.80 0.05
Trachea, bronchus, lung and pleura 0.02 0.11 0.74
Breast 0.01 0.05 0.82
Gastrointestinal tract 0.07 1.54 0.21
Other and ill defined sites -0.04 2.00 0.16
Limited 1.00
Some -0.04 0.58 0.45
Mostly 0.07 1.39 0.24
Global test 20.94 0.14
Age at diagnosis
Amount of 
specialist 
care
Gender
Year of diagnosis
Deprivation
Diagnostic 
subgroup
 
Female gender was associated with a statistically significant 66% decrease in the risk of death 
(HR 0.44 95%CI 0.33-0.59). A diagnosis of thyroid or head and neck carcinoma were associated 
with a decrease in risk of death of 96% and 42% respectively (HR 0.04 95%CI 0.01-0.11 and HR 
0.58 95%CI 0.35- 0.94) when compared to genitourinary tumours. Diagnosis of a tumour of the 
gastrointestinal tract or other ill-defined sites was associated with a close to two--fold 
significant increase (HR 1.72 95%CI 1.23-2.39 and HR 2.02 95%CI 1.37-2.96). Receiving some or 
mostly specialist care led to an increased risk, but this was only significant for patients having 
mostly specialist care (HR 2.78 95%CI 2.02-3.18). Increasing affluence was associated with a 
decreased risk of death when compared to the most deprived group. 
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Table 111: Cox regression model for carcinoma 
Haz. Ratio p value Lower 95% Upper 95%
1.05 0.06 1.00 1.10
Male 1.00
Female 0.44 <0.01 0.33 0.59
0.97 0.34 0.90 1.04
Most deprived 1.00
2 0.99 0.97 0.72 1.37
3 0.96 0.81 0.68 1.35
4 0.70 0.06 0.48 1.01
Most affluent 0.76 0.18 0.51 1.13
Genitourinary tract 1.00
Thyroid 0.04 <0.01 0.01 0.11
Head and neck 0.58 0.03 0.35 0.94
Trachea, bronchus, lung and pleura 1.04 0.91 0.54 2.01
Breast 0.82 0.54 0.43 1.55
Gastrointestinal tract 1.72 <0.01 1.23 2.39
Other and ill defined sites 2.02 <0.01 1.37 2.96
Limited 1.00
Some 1.55 0.20 0.79 3.05
Mostly 2.78 <0.01 2.02 3.81
Diagnostic 
subgroup
Amount of 
specialist care
Confidence intervals
Age at diagnosis
Gender
Year of diagnosis
Deprivation
 
13.4.3 Health service usage 
There is a clear peak in admissions for patients with limited specialist input at the week of 
diagnosis and a smaller peak five weeks post diagnosis (Figure 98). The pattern is more difficult 
to interpret for the other specialist care groups where the peak is less distinct. 
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Figure 98: Number of admissions per week, by time from diagnosis 
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Patients receiving mostly specialist care had the highest number of admissions during 
treatment (Figure 99) and spent the largest amount of the treatment period as an inpatient 
(Figure 101). The proportion of unplanned admissions (Figure 100) was similar for all groups.  
Figure 99: Median number of admissions per patient during treatment, by specialist group 
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Figure 100: Median proportion of admissions, per patient, during treatment which were unplanned 
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Figure 101: Median proportion of the treatment period spent as an inpatient, per patient 
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13.4.4 Health service costs 
Patients who received mostly specialist care had the highest overall cost of admissions during 
the treatment period, reflective of the fact that they had the highest median number of 
admissions (Figure 102). The median cost per admission for this group was the lowest, 
however, with patients receiving some specialist care having a higher cost per admission 
(Figure 103). 
Figure 102: Median total cost of admissions during treatment, per patient 
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Figure 103: Median cost per admission 
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Chapter 14 Summary of findings 
The following subsections summarise the key findings and then breaks down the results for 
each diagnostic group. The main findings are described here but are discussed in detail in 
Chapter 15 and Chapter 16. 
14.1 Key findings 
Distance between a patients home and their closest centre was a significant factor in the 
likelihood of admission to a TCT centre during treatment for all diagnostic groups, although the 
size of the effect varied between groups (Figure 104). A 5km increase in distance from the TCT 
centre had the greatest effect for patients diagnosed with germ cell tumours, decreasing the 
likelihood of admission by 15% (OR 0.85 95%CI 0.82-0.88). The smallest effect was seen in 
those diagnosed with lymphoma where each 5km increase reduced the likelihood of admission 
by 3% (OR 0.97 95%CI 0.96-0.98). The remaining diagnostic groups fell between these two 
extremes. 
 
Figure 104: Odds ratios of admission to a TCT centre, by diagnostic group (showing 95% confidence 
intervals) 
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The proportion of patients from each diagnostic group who had one or more admission to a 
TCT centre during treatment also varied between diagnostic groups, ranging from 61.9% of 
bone tumour patients to 16.9% of melanoma patients (Figure 105).  The proportion admitted 
to a site specialist centre also varied between diagnostic groups, although a greater proportion 
212 | P a g e  
 
of patients from each of the three groups were admitted once or more to a site specialist 
centre (Figure 106). 
 
Figure 105: Proportion of patients admitted to a TCT centre during treatment, by diagnostic group 
 
 
Figure 106: Proportion of patients admitted to a site specialist centre during treatment, by diagnostic 
group 
 
The three diagnostic groups for which there were site specialist units (CNS, bone and STS) 
spent a greater proportion of time as inpatients in specialist centres. Overall 69.9% of brain 
and CNS patients spent more than 60% of their time as inpatients in specialist centres. This 
proportion was 63.0% of bone tumour patients and 46.2% of STS patients. This is in contrast to 
213 | P a g e  
 
the high proportion (94.3%) of melanoma patients who spent less than 30% of their time as an 
inpatient at a specialist centre. Similarly 85.1% of those with carcinomas spent less than 30% 
of time at a specialist centre, as did 79.0% of germ cell tumour patients (Figure 107). 
 
Figure 107: Proportion of time spent at a specialist centre, by diagnostic group 
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The effect of specialist care on survival varied between groups. For leukaemia, lymphoma and 
brain tumours a greater proportion of time spent in a specialist centre appeared to reduce the 
risk of death. In contrast, STS, germ cell, melanoma and skin carcinoma, and carcinoma 
patients receiving the highest proportion of specialist care fared worse in terms of survival 
than those with limited input. Receiving some specialist care appeared to be related to a 
higher risk of death in the majority of diagnostic groups, the exceptions being non-Hodgkin’s 
lymphoma and brain tumours, where it had a positive effect, although this was non-significant 
(Table 112).  
The effect of the type of care was assessed for brain and bone tumours and STS. For patients 
diagnosed with a bone tumour age appropriate care, site specific  care and a combination of 
the two had a protective effect on the risk of death, although this was only statistically 
significant in the case of site-specialist care, where it reduced the risk of death by 91% (HR 0.09 
95%CI 0.02-0.39). Site specific care had a similarly beneficial effect on survival for patients 
diagnosed with an STS, although this was non-significant. Age-appropriate care for this group 
was associated with a non-significant increase in risk of death. Involvement of either age- or 
site- specific care alone was related to an increased risk of death for patients diagnosed with a 
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brain tumour, e.g. age-appropriate care alone increased the risk of death 2.4 fold (HR 2.41 
95%CI 1.21-4.83) (Table 112). 
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The following sections summarize the results for each diagnostic group in detail. 
14.2 Leukaemia 
14.2.1 Access to specialist care  
Eight TCT units were able to admit TYA patients during the study period, whilst over half of 
these patients were not admitted to a TCT unit during the study period (Table 24). Distance 
from home address to the closest unit was a significant factor affecting the likelihood of a TCT 
admission (Table 25). 
Admission to a TCT specialist centre varied by geography, with some units attracting patients 
from outside their catchment areas (Map 6 &Map 7), whilst others had large numbers of 
patients in their catchment area who were not admitted to a TCT centre during treatment 
(Table 24).  
In the majority of cancer networks, most patients received limited specialist inpatient input 
during the treatment period. Four cancer networks, however, either contained or were in close 
proximity to a TCT centre at the time of the study (Table 26). Six out of the 16 trusts admitting 
the greatest number of patients had a TCT centre, which accounted for 75% of all TCT centres 
open at the time. 
14.2.2 Specialist care uptake 
In total 21.1% of patients received more than limited specialist inpatient input during their 
treatment, 3.5% received some specialist care and 17.6% had mostly specialist inpatient care. 
Overall 79.9% received limited specialist input, so that less than 30% of their total inpatient 
stay was spent in an NHS trust with a TCT centre (Table 29). 
The distribution of age at diagnosis, diagnostic group and treatment received differed between 
the specialist care groups. More patients receiving limited specialist input were from the older 
age group (20-24). Acute lymphoblastic leukaemia was the most common diagnosis but this 
made up a larger proportion of all diagnoses in the group receiving some specialist input. The 
mainstay of treatment for patients with limited and mostly specialist care was chemotherapy, 
whilst for those with some specialist input it was chemoradiotherapy. All of these results 
demonstrate the case mix variations between the levels of care. 
14.2.3 Patient outcomes 
The highest proportion of patients with no treatment recorded was seen in those with limited 
specialist input (Figure 20). 
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Patients with a diagnosis of CML had the best three-year survival and those with AML had the 
poorest (Figure 21 & Table 32). Patients who received some specialist input had the poorest 
survival, whilst those with mostly specialist care had the best survival outcome (Figure 22 & 
Table 32). Those with some specialist input also had the highest health service usage during 
treatment, with the highest median number of admissions (Figure 24), the greatest proportion 
of unplanned admissions (Figure 25) and, on average, spent the largest proportion of the 
treatment period as an inpatient (Figure 26). This was reflected in the median cost of 
admissions during treatment, with those with some specialist input having the greatest total 
cost (Figure 27). 
14.3 Lymphoma 
14.3.1 Access to specialist care  
Only 31.5% of lymphoma patients (596 patients) were admitted to a TCT unit at any point 
during their treatment (Table 33), so that over two-thirds received no admission to a TCT 
centre during treatment. Once again increasing distance between residential address and the 
closest TCT unit was a significant factor in reducing the likelihood of admission to a specialist 
centre (Table 34).  
The proportion of patients admitted to a specialist centre varied by the geographical location 
of a patient’s home, with units such as Southampton and University College London Hospitals 
having large numbers of patients for whom they were the closest who were not admitted to 
any TCT unit (Table 33). The catchment area of units also varied, with several attracting 
patients from a larger area than predicted, whilst some had a tighter distribution of patients 
(Map 8 & Map 9). 
The majority of patients received limited specialist inpatient input in most cancer networks 
(Table 35). The majority of patients in eight networks received mostly specialist care, these 
networks either containing a TCT centre or having close links with one such unit at the time of 
admission. However this pattern was seen for several of the networks with limited specialist 
input suggesting that the presence of a TCT centre cannot be the sole explanatory factor. 
Six out of the eight TCT centres were seen in the top 15 highest ranking trusts in terms of 
patient numbers (Table 36) and five were in the top 15 in terms of admissions (Table 37). 
Southampton admitted 2.3% of all lymphoma patients but did not have enough admissions to 
appear in the top 15 in terms of admissions. The remaining trusts in both lists were 
predominantly high volume cancer centres or large trusts which covered a wide geographic 
area. 
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14.3.2 Specialist care uptake 
The demographics of the patients who received mostly specialist care were broadly similar to 
those who had limited specialist input. Those who had some specialist input were shown to be 
different (Table 38) from both other groups. These patients were predominantly from the 
younger age group (aged 15 to 19 at diagnosis) and were mostly female. Opposite patterns 
were seen in the other two specialist groups, where the majority of patients were older males, 
aged 20 to 24 at diagnosis.  
14.3.3 Patient outcomes 
The vast majority of patients were recorded as having had treatment of some description 
(Figure 29). Overall the patients who received mostly specialist care had the highest proportion 
with no recorded treatment, with 15.4% of all patients in this group having had no treatment 
recorded in either the HES or cancer registry data. 
Survival for patients diagnosed with lymphoma varied between diagnostic group and level of 
specialist care received. Overall, patients with a diagnosis of non-Hodgkin’s lymphoma had 
worse survival than those with Hodgkin’s lymphoma (Figure 30). The variation in survival by 
specialist care level differed between the two diagnostic groups: for non-Hodgkin’s lymphoma 
those with limited specialist input had the worst survival. Those receiving some and mostly 
specialist care had very similar survival curves (Figure 31). A different pattern was seen in 
patients with a Hodgkin’s lymphoma, such that those with some specialist input have the 
poorest survival and those with mostly specialist care had the highest chances of survival 
(Figure 32). Increasing age at diagnosis had a statistically significant detrimental effect on 
survival. Increasing year of diagnosis and receiving mostly specialist care significantly 
decreased the risk of death. 
Patients who received some specialist care had the highest number of admissions during 
treatment (Figure 34), the greatest proportion of unplanned admissions (Figure 35) and also 
spent the greatest proportion of the treatment period as an inpatient (Figure 36). This group 
also had the highest total cost for admissions during treatment (Figure 37), however those 
who received mostly specialist care had the highest median cost per admission (Figure 38). 
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14.4  Central nervous system and other intracranial and intraspinal 
neoplasms 
14.4.1 Access to specialist care  
In total 65.7% of brain and CNS tumour patients were not admitted to a TCT unit during 
treatment (Table 43), whilst in contrast only 8.7% had no admissions to a CNS specialist centre 
during treatment (Table 45).The number of patients admitted to specialist care varied by 
geography with some trusts admitting very few of the patients living closest to them and 
others attracting patients who lived closer to other centres. 
All TCT centres attracted CNS patients from a much smaller area than the expected catchment 
area mapped for each trust (Map 10 & Map 11). 
The distance from a patient’s home address to the closest specialist centre significantly 
affected the likelihood of admission to both TCT and CNS centres. Each 5km increase in 
distance from a TCT centre decreased the likelihood of admission by 11% (Table 44), and each 
5km increase in distance from a CNS centre decreased the likelihood of admission by 6% (Table 
47).  
In the majority of cancer networks most patients received mostly specialist care, whereas the 
majority of patients received limited specialist input in only four networks (Table 48). The 
specialist care received was predominantly CNS related, with only one network having the 
majority of those with mostly specialist care receiving care in a TCT centre (Table 49).  
All but one NHS trust which ranked in the top 15 in terms of patient numbers contained a 
specialist centre of some form (Table 50). Trusts which were seen in the top 15 in terms of 
number of admissions which were neither CNS nor TCT centres were high volume cancer 
centres or large teaching hospital trusts. 
14.4.2 Specialist care uptake 
In contrast to the other levels of specialist care, the majority of patients who received limited 
specialist care were from the younger age group (aged 15 to 19 at diagnosis) (Table 52 & Table 
53). In all groups with the exception of those receiving CNS & TCT specialist care, patients were 
predominantly male. A greater proportion of those with TCT input had been diagnosed with an 
astrocytoma. More patients who received CNS & TCT input were diagnosed with high grade 
tumours than in any other type of specialist care. 
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14.4.3 Patient outcomes 
Those patients receiving limited specialist input had the greatest proportion with no treatment 
recorded (Figure 40 & Figure 41). Over half of all patients were recorded as having undergone 
surgery, with or without chemo-radiotherapy. This proportion was higher in patients who had 
received mostly specialist care or CNS specialist care, with or without TCT input.  
Three year survival differed between diagnostic group, tumour grade, amount and type of 
specialist care received. Medulloblastoma and other PNET tumours had worse survival than 
any other diagnostic group (Figure 42). Patients with high grade tumours fared worse than 
those with low grade tumours (Figure 43). Those who received only limited specialist input had 
better survival than those with some or mostly specialist care, those with some specialist input 
had the worst survival, with less than 75% surviving to three years (Figure 44). Patients with 
TCT specialist input had the lowest survival, whilst patients with both CNS and TCT input had 
the best survival outcomes (Figure 45).  
Receiving TCT specialist care alone was associated with a negative effect on survival. Increasing 
amount of specialist care had a beneficial effect on survival (Table 57), however this was not 
statistically significant. 
Patients who received CNS or some specialist care had the highest number of admissions 
during treatment (Figure 48). Those with some specialist care also had the greatest proportion 
of unplanned admissions (Figure 49) and spent the largest proportion of the treatment period 
as an inpatient (Figure 50). Those receiving TCT specialist care spent the greatest proportion of 
the treatment period as an inpatient of any type of specialist care. 
Those who received some specialist care and those with TCT specialist care had the highest 
median cost of admissions during treatment (Figure 51) and also had the highest median cost 
per admission (Figure 52).  
14.5  Osseous and chondromatous neoplasms, Ewing’s sarcoma and 
other neoplasms of bone 
14.5.1 Access to specialist care 
Overall 38% of patients were not admitted to a TCT unit during the treatment period. This 
proportion varied between centres, with all of those living closest to the centre in Newcastle 
being admitted to a TCT centre. This was in contrast to only 38% of those who lived closest to 
the centre in Southampton (Table 58).   
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The centres at UCL, Leeds, the Christie and Newcastle admitted patients from a larger area 
than predicted, suggesting that patients were travelling beyond their closest centre for 
admission. In contrast the centres at Southampton, Birmingham, Sheffield and Alder Hey 
attracted patients from a smaller area than expected (Map 12 & Map 13). 
Every increase of 5km between a patient’s home address and the closest centre was 
associated with a statistically significant decrease in the likelihood of admission to the centre 
(Table 59). Those diagnosed with ‘other bone tumours’ were less likely to be admitted to a TCT 
centre than those with osteosarcoma. 
In total 64.2% of all bone tumour patients were admitted to a bone tumour centre at some 
point during treatment. The proportion of patients admitted varied between centres: the 
Freeman in Newcastle admitted 87% of patients for whom it was the closest centre. In contrast 
the Robert Jones and Agnes Hunt centre in Oswestry admitted only 49% of patients for whom 
it was the closest bone tumour diagnostic centre (Table 60). Most patients were admitted to 
bone tumour centres other than the one closest to their home address, for example patients 
closest to the centre in Newcastle travelled to the centre in Birmingham, patients from Oxford 
travelled to the centre at Stanmore and more patients who lived closest to the centre at 
Oswestry were admitted to Birmingham than Oswestry (Table 60).  
Centres at Birmingham and Oswestry attracted patients from a wider than predicted 
geographical area, whilst the centres in Newcastle and Oxford had a smaller catchment area 
than predicted (Map 14 & Map 15). 
As with admissions to a TCT centre, increasing distance from a bone tumour centre decreased 
the likelihood of admission to the centre. Both those diagnosed with Ewing’s sarcoma and 
those with ‘other bone tumours’ were less likely to be admitted to a specialist bone tumour 
centre than those diagnosed with osteosarcoma (Table 61). 
The majority of patients in 22 of the cancer networks received mostly specialist care, of these 
16 received the majority of their care in a TCT specialist centre. One cancer network in England 
(Thames) had the majority of patients treated in a bone cancer specialist centre, for the 
remaining five networks patients were mainly treated in bone and TCT centres combined 
(Table 62 & Table 63). 
Four of the five bone tumour specialist centres were seen in the top 15 high volume centres in 
terms of number of patients, the only exception being the Robert Jones and Agnes Hunt 
centre. In total 10 were specialist centres of some description (Table 64). Three of the five 
were in the top 15 in terms of number of admissions, both the Robert Jones and Agnes Hunt 
centre and the centre in Oxford fell outside this group (Table 65). 
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14.5.2 Specialist care uptake 
Bone tumour patients were more likely to be male and aged 15 to 19, except for patients who 
received bone and TCT specialist care who were predominantly from the older age group (20 
to 24) (Table 66 & Table 67). 
Half of all patients who received mostly specialist care had been diagnosed with an 
osteosarcoma; this proportion was greater than that seen in any of the other levels of 
specialist care (Table 66). The same predominance of osteosarcoma was seen in patients with 
bone tumour specialist input, with or without TCT input (Table 67).  
Those receiving some specialist input and those with TCT specialist care alone had the lowest 
proportion surviving to the end of the treatment period, whilst the highest proportion was 
seen in those with both bone and TCT specialist input (Table 67). 
The majority of patients in all groups had undergone major surgical resection of their tumour, 
with or without chemo/radiotherapy (Table 66 & Table 67). 
14.5.3 Patient outcomes 
Over 70% of patients in all specialist care groups had undergone surgery with or without 
additional therapy (Figure 54 & Figure 55). Those with TCT specialist input had the highest 
proportion who received chemo/radiotherapy and the lowest proportion who received surgery 
(Figure 55). Patients in all groups were recorded as having received treatment of some form. 
The only group where patients had no treatment recorded was those with limited specialist 
care. 
Patients diagnosed with ‘other bone tumours’ demonstrated the best three year survival and 
those with Ewing’s sarcoma had the worst, with 50% surviving to three years from diagnosis 
(Figure 56). The poorest survival was seen in those with some specialist input, the best was 
seen in those who received mostly specialist care (Figure 57). Treatment at a bone tumour 
specialist centre, without the involvement of a TCT centre, was associated with improved 
survival when compared with both limited specialist care and treatment at a TCT centre (Figure 
58). 
A diagnosis of ‘other bone tumour’ and treatment at a bone tumour specialist centre both had 
a statistically significant beneficial effect on survival (Table 71). Treatment at a TCT centre or at 
a combination of bone and TCT centres was also shown to reduce the risk of death, although 
this effect was not statistically significant. In contrast, receiving some specialist care had a 
statistically significant detrimental effect on survival.  
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There was little variation in the number of admissions during treatment by the amount of care 
received. However, those with bone tumour specialist care had fewer admissions than those 
with any other type of specialist care (Figure 61). In contrast those with bone tumour specialist 
care had a higher proportion of unplanned admissions than those with any other type of 
specialist care. Those with TCT input and mostly specialist care had the lowest levels of 
unplanned admissions (Figure 62). Despite the high levels of unplanned specialist admissions in 
those with bone tumour specialist input, they spent the smallest proportion of the treatment 
period in hospital, whilst those with bone and TCT input spent the greatest proportion of the 
treatment period as an inpatient (Figure 63). 
Those with limited specialist input and those with bone tumour specialist care had the lowest 
total cost of admissions during the treatment period, whereas those with bone and TCT 
specialist input had the highest (Figure 64). The same cost pattern was seen when examining 
the average cost per admission by the amount of care received. The opposite effect was seen 
when assessing the costs by the type of care received. Those with bone tumour specialist care 
had the highest average cost per admission, whilst those with bone and TCT specialist care had 
the lowest average cost per admission (Figure 65). 
14.6  Soft tissue sarcoma 
14.6.1 Access to specialist care 
In total 54.7% of those diagnosed with an STS were not admitted to a TCT centre during 
treatment. The proportion of patients who lived closest to each centre who were admitted 
ranged from 96% for those living closest to the TCT centre in Leeds to 26% for those living 
closest to the centre in Sheffield (Table 72). The centres at Alder Hey, Sheffield and the Christie 
attracted patients from outside the predicted area, inferring that they were travelling beyond 
their closest centre. The centres at Southampton, Birmingham and Leeds had smaller than 
predicted catchment areas (Map 16 & Map 17). 
A diagnosis of rhabdomyosarcoma or unspecified STS and increasing age at diagnosis increased 
the likelihood of admission to a TCT centre. Increasing road travel distance decreased the 
likelihood of admission to the closest centre (Table 73). 
In total 81.6% of STS patients were admitted to an STS specialist centre during treatment. The 
proportion of patients admitted to their closest centre varied between centres. The centre at 
Newcastle admitted 93.3% of the patients for whom it was the closest in contrast to the Royal 
National Orthopaedic Hospital at Stanmore which admitted 18.8% of those who lived closest 
to it (Table 74).  
224 | P a g e  
 
Increasing road travel time decreased the likelihood of admission to the closest STS centre.  In 
contrast to the results seen for TCT centres, a diagnosis of unspecified STS also decreased the 
likelihood of STS admission. Rhabdomyosarcoma was associated with an increased likelihood 
of an admission to an STS centre (Table 75). 
In 18 of 31 cancer networks the majority of patients received mostly specialist care; in three 
networks patients received some specialist care; in the remainder the majority of patients 
received limited specialist input (Table 76). In seven networks the majority of patients received 
STS and TCT specialist input. In eight, the majority of patients received STS specialist care and 
in four the majority received TCT specialist care (Table 77). 
Nine of the top 15 trusts in terms of the number of patients were STS specialist centres, four 
were both STS and TCT centres, whilst two were TCT centres (Table 78). Two trusts which 
ranked in the top 15 in terms of admissions were neither STS nor TCT specialist centres (Table 
79), two in the top 15 in terms of patient numbers were neither STS nor TCT specialist centres 
however these were not the same centres. 
14.6.2 Specialist care uptake 
Soft tissue sarcoma was predominantly diagnosed in older male patients (20-24) from more 
deprived groups (Table 80 & Table 81). A different pattern was seen in those receiving some 
specialist input, STS specialist care and those with TCT care where the patients were 
predominantly from the younger group (15-19). The most commonly diagnosed tumour type 
was “other specified STS”. Despite the relative rarity of the diagnosis itself, “unspecified” STS 
accounted for over 30% of diagnoses in those with TCT specialist input. Over 50% of all 
patients survived to the end of the treatment period, the exception being patients with TCT 
specialist input, with 48.5% surviving through to the end of treatment. 
14.6.3 Patient outcomes 
The majority of patients in all specialist groups underwent a major surgical resection of their 
tumour. Overall very few patients were recorded as having no treatment, the largest 
proportion of patients with no treatment were seen in those with limited specialist input 
(Figure 67 & Figure 68).  
Close to 100% of those diagnosed with a fibrosarcoma were alive three years post diagnosis, 
whereas less than 35% of those with a rhabdomyosarcoma were alive at the same point from 
diagnosis (Figure 69). Receiving limited specialist care was associated with better survival than 
either mostly or some specialist care (Figure 70). When examining survival by the type of 
specialist care those with limited specialist input again had the best survival. Patients admitted 
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to a TCT centre alone had the worst survival, whilst those with STS involvement fell between 
these two ranges (Figure 71). 
Increasing age at diagnosis and a diagnosis of rhabdomyosarcoma were associated with a 
statistically significant increased risk of death. Receiving some and mostly specialist care was 
also associated with an increased risk of death, however this was not statistically significant. 
Fibrosarcoma and being female were associated with a statistically significant decreased risk of 
death (Table 85). 
Those with some specialist input and those with TCT specialist care had the highest number of 
admissions during treatment, those with limited input had the lowest (Figure 74). The same 
groups had the highest and lowest proportions of unplanned admissions (Figure 75). Those 
with some specialist input and TCT specialist care also spent the greatest proportion of the 
treatment period as inpatients (Figure 76). 
The groups with the highest number of admissions and those which spent the greatest 
proportion of the treatment period in hospital also had the highest total cost of admissions 
during treatment (Figure 77), and they also had the highest average cost per admission (Figure 
78).  
14.7  Germ cell and trophoblastic neoplasms 
14.7.1 Access to specialist care 
In total 31.8% of those diagnosed with a germ cell tumour were admitted to a TCT centre 
during treatment. The range in the proportion of patients admitted to their closest centre 
varied between centres. 74% of those closest to the Leeds TCT centre were admitted to a TCT 
centre at some point during treatment, in contrast only 10% of those closest to the UCL centre 
were admitted to a TCT centre (Table 86). The Christie attracted patients from a larger 
geographical area than predicted, whereas the other centres had a smaller than predicted 
catchment area (Map 18 & Map 19). Increasing distance to a TCT centre significantly decreased 
the likelihood of admission whilst a diagnosis of a non-gonadal germ cell tumour increased the 
likelihood of admission (Table 87). 
The majority of patients in four of the 31 cancer networks received mostly specialist care. 
These networks all contained a TCT centre at the time of the study, however networks in 
which the majority of patients received limited specialist care also contained a TCT centre 
(Table 88). 
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Seven of the eight TCT centres were seen in the top 15 centres in terms of both patients and 
number of admissions, whilst the other centres were high volume hospitals covering large 
geographical areas (Table 89 & Table 90).   
14.7.2 Specialist care uptake 
The germ cell tumour patients were predominantly aged 20 to 24 at diagnosis, male and had 
been diagnosed with a gonadal germ cell tumour. This profile differed between the specialist 
care groups. There was a higher proportion of younger (15-19) and female patients seen in 
those with some specialist care. This group also had a higher proportion of those from more 
deprived areas. Survival for the duration of treatment was high across all groups, ranging from 
98.8% in those with limited specialist input to 89.6% in those with mostly specialist care. 
14.7.3 Patient outcomes 
The majority of germ cell tumour patients were treated with surgery and additional therapy. 
Very few patients were recorded as having no treatment, although this proportion was highest 
in those who had received some specialist input (Figure 80).  
Patients diagnosed with a gonadal germ cell tumour fared better than those with a non-
gonadal tumour with over 75% alive at three years from diagnosis (Figure 81). Limited 
specialist input was associated with the best survival whilst those who received mostly 
specialist care had the worst survival (Figure 82). A diagnosis of a non-gonadal germ cell 
tumour was associated with a statistically significant increased risk of death, as was receiving 
mostly specialist care (Table 94). 
Patients who received some specialist care had the highest number of admissions during 
treatment (Figure 84), had the largest number of unplanned admissions (Figure 85) and spent 
the largest proportion of the treatment period as an inpatient (Figure 86). This group also had 
the highest median total cost of admissions during the treatment period (Figure 87), however 
the median cost per admission was the same across all groups (Figure 88). 
14.8  Melanoma and skin carcinoma 
14.8.1 Access to specialist care 
In total 16.9% of patients diagnosed with a melanoma or skin carcinoma were admitted to a 
TCT centre during treatment. The number of patients admitted to their closest centre varied 
between TCT centres, for instance 1% of those living closest to the centre at UCL were 
admitted to a TCT centre. In contrast 40% of those living closest to the Christie were admitted 
to a TCT centre during treatment (Table 95). 
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The centre at Newcastle attracted patients from a larger geographical area than expected, 
whereas the remaining centres all had a smaller than expected catchment area (Map 20 & 
Map 21). 
Increasing road travel distance was associated with a statistically significant decrease in the 
likelihood of admission to a TCT centre (Table 96). A diagnosis of skin carcinoma was 
associated with a decreased likelihood of TCT admission, however this was non-significant. 
In all cancer networks the majority of patients received limited specialist care (Table 97). Five 
out of the eight TCT centres appeared in the top 15 trusts in terms of patient and admission 
numbers (Table 98 & Table 99). 
14.8.2 Specialist care uptake 
In both specialist care groups the patients were predominantly aged 20 to 24, female and 
diagnosed with a malignant melanoma. The proportion of patients diagnosed with a skin 
carcinoma was higher in the group that received limited specialist care. Although over 90% of 
patients in both specialist care groups survived to the end of the treatment period, this 
proportion was higher in those receiving limited specialist care (Table 100). 
14.8.3 Patient outcomes 
Approximately 50% of patients who had limited specialist care were recorded as having no 
treatment, whilst this proportion was lower in those with mostly specialist care (around 30%). 
The remaining patients were reported as having surgery with or without additional therapy 
(Figure 90). 
Survival for both melanoma and skin carcinoma was approaching 100% at three years, 
however those diagnosed with malignant melanoma had slightly worse survival than those 
with skin carcinoma (Figure 91). Patients who received mostly specialist care had worse 
survival than those with limited specialist input (Figure 92). Female gender and a diagnosis of 
skin carcinoma were both shown to  reduce the risk of death, whilst receiving mostly specialist 
care was associated with an increased risk of death (Table 102). 
14.9  Carcinomas 
14.9.1 Access to specialist care 
In total 24.9% of patients diagnosed with a carcinoma were admitted to a TCT centre during 
treatment. The proportion of patients not admitted to a TCT centre during treatment varied 
between centres. 34% of those who lived closest to the centre at Leeds were not admitted to a 
TCT centre, whilst in contrast 93% of those who lived closest to the centre at UCL were not 
228 | P a g e  
 
admitted to a TCT centre during treatment (Table 104). All the units showed a smaller than 
predicted catchment area (Map 22 & Map 23). 
Increasing distance from the place of residence to a TCT centre decreased the likelihood of 
admission to a TCT centre during treatment as did a diagnosis of a breast cancer. A diagnosis of 
carcinoma of other and ill-defined sites increased the odds of a TCT admission (Table 105). 
In the Yorkshire and North Trent cancer networks the majority of patients received mostly 
specialist care, in the remainder of networks, the majority of patients received limited 
specialist care (Table 106). All TCT centres with the exception of Alder Hey were seen in the 
top 15 in terms of both patient and admission numbers (Table 107 & Table 108).  
14.9.2 Specialist care uptake 
The majority of patients were aged 20 to 24 at diagnosis. The vast majority were also female 
and from more deprived groups. The greatest variation in demographics across the specialist 
care groups was seen in the distribution of diagnoses, with thyroid carcinoma accounting for 
over half of all those who received some specialist care. This was also the most common 
diagnosis in the group receiving mostly specialist care, closely followed by carcinoma of the 
genito-urinary tract. This was also the most common diagnosis in those with limited specialist 
input (Table 109). 
14.9.3 Patient outcomes 
The largest proportion of patients recorded as having no treatment was seen in the group who 
received limited specialist care. Overall the majority of patients received surgery with or 
without additional treatment. The proportion of patients receiving chemo-radiotherapy 
without surgery was highest in the group who had mostly specialist care (Figure 95). 
Patients diagnosed with thyroid carcinoma had the best survival, whilst those with carcinoma 
of the gastro-intestinal (GI) tract, or other carcinoma had the worst (Figure 96). Those with 
mostly specialist care had the lowest survival to three years, whereas those with limited or 
some input had similar survival (Figure 97). 
Female gender, a diagnosis of thyroid carcinoma, head and neck carcinoma and decreasing 
deprivation were associated with a decreased risk of death. A diagnosis of carcinoma of the GI 
tract and receiving some or mostly specialist care were both associated with an increased risk 
of death (Table 111). 
Patients who received mostly specialist care had the highest number of admissions during 
treatment (Figure 99). There was little variation between specialist groups in terms of the 
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proportion of unplanned admissions (Figure 100). Those with mostly specialist care spent the 
greatest proportion of the treatment period as an inpatient (Figure 101). 
Patients with mostly specialist care had the highest total cost of admissions during treatment 
(Figure 102), however those with some specialist input had the highest average cost per 
admission and those with mostly specialist care had the lowest cost (Figure 103).
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Chapter 15 Conclusions 
This study covered a wide range of diagnoses in a diverse and unique population. It is a novel 
piece of health services research evaluating variation in specialist care and its effects on 
patient outcomes and hospital burden. A summary of the findings are described in the 
following chapter.   
15.1 Attitudes towards specialist care 
The survey undertaken assessed the attitudes of healthcare professionals to what constituted 
the optimal specialist care TYA cancer patients should receive. Attitudes varied and the factors 
of care identified by the professionals as being key to ‘specialism’ varied widely falling into 
three clusters (Figure 18). The survey determined that many of the aspects of care deemed as 
important in the TYA IOG were assigned low importance by those professionals delivering care. 
There are a multitude of diagnoses, treatments, pathways and protocols for TYA cancer and 
evidence already exists demonstrating patterns of care vary36. But, prior to this study the 
extent of this variation was not well quantified and the proportion of TYA patients treated at 
TYA specialist units was not known. It was also not clear to what extent any differences were 
due to patient choice or to a lack of appropriate referral to specialist units.  This project was 
intended to provide evidence to help clarify these questions 
All the respondents to the survey were involved in the treatment of TYA patients but, by their 
responses, it was clear there were divergent attitudes towards what constitutes optimal care 
for this TYA group. This variation in attitudes may reflect the known variation in place of 
treatment for TYA and, at least partially, explain why there is variation in how and where many 
TYA patients are treated. The preference of the person referring the patient towards a type of 
specialist care, age, site or both, may increase the likelihood that a particular care setting 
would be used over other available services. 
This survey adds to what was already known about the variation in referral to specialist 
services for TYA cancer patients. The results were used to identify areas of interest for the 
main part of the project which were then examined using the routine data available, such as 
the importance of place of care. It was also used as a benchmark against which variation in 
care could be measured. Additionally the degree of disagreement with protocols seen in the 
survey was assessed against the extent to which patients were treated in line with protocol. 
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15.2 Access to specialist care 
The access to specialist care analyses undertaken in this project demonstrated more variation 
than was expected. Very few patients in any diagnostic group were admitted to a TCT unit 
other than their closest centre and TCT centres generally admitted patients from a smaller 
than predicted geographical area. This, and the fact that increasing road travel distance 
significantly decreased the likelihood of admission to a TCT centre, suggests that ease of access 
to specialist care is a key influence on its uptake. Unfortunately, however, the data available 
for this project meant that it wasn’t possible to determine whether this was influenced by 
patient choice, or lack of referral.  
In contrast, patients frequently travelled to a site-specific specialist centre other than their 
closest unit despite increasing road travel distance decreasing the likelihood of admission to a 
specialist centre. This was particularly striking in the case of bone tumours, which is likely to be 
due to the structure of services for this group123. Diagnosis and surgery for bone tumours is 
centralised and policy dictates it ought only to take place at one of five centres in England 
meaning that, unlike that seen with TCT centres, there is no alternative place of care for this 
patient group. Similar patterns were seen for both brain and STS patients. The findings of this 
study demonstrate that where centralisation has been implemented the policy is, for the most 
part, adhered to in practice. A far smaller proportion of bone tumour patients had no 
admission to a site- specialist centre than an age-appropriate centre. Where there is flexibility 
in the referral pathway the variation in place of care is significant and there appears to be less 
standardisation. Work undertaken examining the impact of specialist care on patient outcomes 
demonstrates that treatment at a specialised centre is, for some of the cancers, associated 
with improved outcomes. Patients were more likely to be admitted to a specialist centre the 
closer they lived to a unit. This finding was statistically significant for bone tumour patients, 
but overall very few patients diagnosed with a bone tumour were never admitted to a bone 
tumour centre. Where flexibility remained in the referral pathway a greater proportion of 
patients failed to be admitted to a specialist centre. It is important to acknowledge that whilst 
travel time significantly affects the likelihood of admission to a centre those with centralised 
services appeared to have a higher uptake of specialist care. 
The presence or absence of a TCT or site-specialist centre in a cancer network did not seem to 
consistently influence the level of care that the majority of patients received. Cancer networks 
where the majority of patients received mainly specialist care contained a TCT centre or site 
specialist centre. However there were networks with functioning centres in which the majority 
of patients received limited specialist care. The simple existence of a TCT centre did not ensure 
that the majority of patients were admitted to a specialist centre. This supports the findings of 
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the survey in suggesting that the uptake of specialist care is influenced, at least partly, by 
clinician attitudes. 
Seven of the eight TCT centres consistently appeared in the top 15 trusts in terms of the 
number of TYA patients admitted and the number of admissions during treatment. In the three 
tumour groups for which there were site-specialist centres the majority of the top 15 
contained a specialist centre. Those trusts which were neither site- nor age-specialist centres 
were high volume trusts which covered large urban populations.  
Geographical barriers seemed to have a greater effect with regards to admission to TCT 
centres, where there was an alternative place of care, often closer to a patient’s home 
address.  More work would be needed to determine to what extent this is affected by patients 
choosing to remain close to home and what information informs this decision, or whether it is 
associated with under referral.    
15.3 Uptake of specialist care 
One possible explanation for variation in outcomes and uptake between the groups could be 
due to case-mix rather than due to the influence of specialist care. In order to attempt to 
quantify the differences in case-mix between the specialist care groups the demographic 
profile of each was compared. 
This demonstrated clear variation between those receiving different levels of care. In all 
diagnostic groups the characteristics of the patients who received limited specialist care 
differed from those who received mostly specialist care. Staging information was not routinely 
available in the routine NHS data on which this study is based. This meant that, with the 
exception of brain and CNS tumours, where the predicted grade of the tumour was calculated 
from the tumour morphology, it was possible to establish whether those who received mostly 
specialist care had more advanced disease which would explain their need for specialist care. 
Staging was unlikely to completely explain the survival difference between the groups. The 
effect in melanoma and skin carcinoma patients is likely to have been significant as the 
majority of patients admitted were likely to be later stage, metastatic disease267 268. Several 
other measures were used as a proxy for stage, such as number of admissions, length of stay 
and treatment received. Variation in these factors was assessed across the specialist care 
groups. For the most part those receiving some specialist care had the highest number of 
admissions and spent the greatest proportion of the treatment period as an inpatient, this 
result is difficult to interpret as it could be caused by later stage disease, equally it may be the 
result of suboptimal or ineffective care. For bone tumour and carcinoma patients, the only 
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diagnostic groups where this was not the case, receiving some specialist care was associated 
with an increased risk of death (significant in the case of bone tumours). The patient 
demographics and treatment received varied little between the two groups, certainly there 
was not enough variation to suggest a significant difference in stage mix between those 
receiving some specialist care and others. 
15.4 Patient outcomes 
The level of care associated with the poorest outcomes varied between diagnostic groups and 
may, in part, be explained by the variation in tumour grade and morphology. However, a 
proportion of this variation in outcome can be directly linked to the amount of specialist care 
received. It has been demonstrated in this study that some patients do not require specialist 
care in order to alter their hard outcomes (such as those with skin carcinoma). It has also been 
demonstrated that receiving some specialist care is detrimental in most diagnostic groups, 
suggesting that these patients are not receiving optimal care. Some of this effect may be due 
to the case mix of the populations and the stage of disease at diagnosis. An attempt was made 
to assess this by examining the patient demographics in the different specialist care groups 
and comparing them across diagnostic groups. Whilst it was possible to assess the variation in 
demographics such as age at diagnosis, gender and tumour biology other factors which may 
have influence outcomes, such as stage of disease were not available. In groups such as non-
Hodgkin’s lymphoma and brain tumours, where the biology of the disease and outcomes are 
intrinsically linked and treatments vary, case mix may have had a greater impact than in cases 
such as bone tumours where there were relatively few diagnostic sub groups. In order to 
address this in future work more detailed tumour information would be required, alongside 
information on stage at presentation and treatment received. 
15.4.1 Treatment 
The modality of curative treatment differed between the diagnostic groups and, due to 
limitations in data availability, it was not possible to determine the dose or type of 
chemotherapy or radiotherapy received by patients. Nonetheless, it was possible to establish 
which patients had undergone a potentially curative operation. Binary treatment variables 
were compared (surgery Y/N, chemotherapy Y/N and radiotherapy Y/N) and the proportion of 
patients receiving gold standard treatment was shown to vary at each level of care, across all 
specialist care groups. Patients with limited specialist care were consistently less likely to 
receive what would be considered potentially curative treatment than those with mostly 
specialist care. Patients from diagnostic groups for which there were site-specialist centres, 
who were admitted to a site-specialist centre with or without TCT admissions, had a 
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potentially curative group of treatments more frequently than those who attended TCT 
centres alone or who had limited specialist care. This suggests that those who receive limited 
specialist input, or lack site-specialist input may have different predicted outcomes from the 
initiation of treatment. Staging information and details of the treatment intent, MDT 
outcomes, could be used in future work to quantify this. 
15.4.2 Survival 
The level of specialist care received and the impact on survival differed between groups.  
Patients diagnosed with leukaemia and HL who received mostly specialist care had the best 
survival outcomes when compared to those receiving some, or limited specialist input. In both 
cases those with some specialist input had the worst outcomes. This suggests that clinical 
guidelines for patients from these diagnostic groups should recommend that they receive most 
of their care in specialist centres. Hodgkin’s lymphoma differed from all other diagnostic 
groups in that patients with some specialist input had the best survival, whilst those with 
limited input had the worst. 
In contrast patients diagnosed with a germ cell tumour, melanoma or skin carcinoma or other 
carcinoma who received mostly specialist care had the worst survival outcomes whilst those 
with limited input had the best. This could be due to those who received limited input having a 
lower grade tumour requiring less inpatient care which would be available in a less specialised 
setting. Future work using more detailed data, including staging is important in order to 
establish what influence this is having. 
In all diagnostic groups for which there were site specialist centres (brain, bone and STS) those 
patients who received limited specialist care had the best outcomes; as for germ cell tumours, 
melanoma, skin carcinoma and other carcinomas this may be due to an increased likelihood of 
patients with less advanced disease being seen outside of specialist centres. However, patients 
with a brain or bone tumour or STS who received some specialist care had the worst 
outcomes. For this reason and due to the variation in patient demographics between the levels 
of care, patients who receive some specialist care ought to be receiving a higher proportion of 
their care in specialist centres. Those experiencing limited specialist care are likely to have 
different clinical needs so that they are more likely to be treated successfully away from the 
specialist setting. 
Patients receiving site specialist care, irrespective of involvement of a TCT unit, had improved 
survival when compared to those who were admitted to a TCT centre alone. This is likely to be 
due to differences in disease between the groups, with those admitted to a TCT centre alone 
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potentially being more likely to receive chemo/radiotherapy as a result of presenting with 
more extensive disease. 
15.4.3 Health service usage 
Health service usage was assessed as an outcome which may vary according to the level of 
specialist care received. In all groups, except for bone tumours and carcinoma, those patients 
with some specialist care had the highest number of admissions, the greatest proportion of 
unplanned admissions and spent the largest proportion of the treatment period as an 
inpatient. In a large number of diagnostic groups they also had the poorest outcomes. This 
may mean that this group either had more advanced disease or suggest that this group are 
potentially not receiving the most effective care. 
15.4.4 Health service costs 
Increased total cost of admissions during treatment was associated with those patients who 
had a higher number of admissions, an increased proportion of admissions which were 
unplanned and a greater proportion of the treatment period seen as an inpatient. However 
those specialist care groups with the highest total cost did not necessarily have the highest 
average cost per admission, suggesting that the number of admissions was masking the effect 
of the higher cost and less frequent admissions. 
 
236 | P a g e  
 
Chapter 16 Discussion 
This study is the first in the world to quantify specialist care for teenage and young adult 
patients across an entire nation. It is a novel piece of health services research which examined 
the variation in access to such care for those treated in NHS facilities between 2001 and 2009 
and the impact on survival and hospital burden. The relationship between the level of 
specialist care received and patient outcomes had not previously been assessed in such a wide 
group of tumours in this age group.  
The results from this address the aims which were set out in Chapter 1 
Aim i – to produce a definition of specialist care for TYA 
This study has successfully quantified the care received by TYA patients in England between 
2001 and 2009. It was possible to examine the proportion of care received by patients in each 
diagnostic group and demonstrate that not all patients had the same level of care, it was also 
shown that this could not entirely be explained by the case mix of the population in each 
diagnostic group. It also cannot be explained by geographical barriers as a large proportion of 
patients for whom there was a site specific specialist centre were admitted there, whilst a 
substantial number of patients were not admitted to a TCT centre. This variation emphasises 
the need for more structured referral and treatment pathways for TYA patients to enable a 
standardisation of care. However before this could be undertaken work would be needed to 
determine the exact reasons for the variation which was quantified in this study.  
Aim ii – to describe variation in care pathways nationally in England 
This project aimed to describe the variation in care for TYA patients in England over the study 
period and has, for the most part, entirely succeeded in achieving this aim. For each diagnostic 
group it has been possible to quantify and describe the variation in the level of care received, 
place of care, treatment undergone and health service usage for patients. As with the previous 
aim this variation cannot entirely be explained by the case mix of the population as there was 
little clinically significant variation between the groups. Whilst it is important to remember 
that the results of this study are not implying causation it can be demonstrated that care was 
not equal across the country and that this may mean some patients are not receiving optimal 
care and that inequities exist. The description of the variation in care pathways has been 
completed, meaning that work can now be undertaken to address this variation where 
possible. 
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Aim iii – to determine the effect of the level of specialist care received on 
survival and health service usage, during treatment 
After describing the variation present, this project then attempted to determine the effect of 
this variation and the level of care received on patient outcomes. In all diagnostic groups 
survival varied according to the level of care received, as did health service usage and the cost 
of admissions during treatment. The major outcome from this work was that it was possible to 
demonstrate not only that the level of care received by patients varied across the country but 
also that survival appeared to be influenced by the amount and type of specialist care 
received. These survival differences, in combination with the variation in care, further 
emphasise the need for standardisation of care to enable a greater proportion of patients to 
receive the optimal care pathway for their diagnostic group. This is the first study to quantify 
this effect in TYA cancer patients.  
This study showed that the amount of specialist care received by each patient varied both 
between and within diagnostic groups. The centralisation of services, such as that for bone 
tumours, positively influenced the likelihood of admission to a specialist centre. This is thought 
to be due to the rigid referral guidelines in place for these services. Travel distance between 
home and the closest centre affected the likelihood of admission, supporting the case for more 
TCT centres, or a greater number of shared care centres allowing greater access for the TYA 
cancer population as a whole. The level of specialist care received influenced survival and 
health service usage in all groups. Groups of patients were identified, such as those with skin 
carcinoma, for whom specialist care appeared to have little effect. However for the most part 
those who received some specialist care had the poorest outcomes, suggesting that these 
patients ought to have received mostly specialist care. This contrasts with those who received 
limited specialist care who seemed to display different characteristics to those in the other 
group and, for the most part, appeared to receive limited benefit from specialist input. This 
suggests that, for this group, specialist care was not required, emphasising the need to target 
specialist care appropriately, rather than assuming that all patients require the same level of 
care. Or indeed that failure to receive age specialist care was detrimental in all cases.  
As shown in the literature review and background (Chapter 2), the evidence base supporting 
treatment in specialist centres for TYA patients in the UK and elsewhere around the world is 
relatively weak. The findings from this work provide, therefore, important information on the 
delivery of care among 15-24 year olds and can act as a benchmark for the NHS.  
The data available to perform this work, whilst being of high quality in some areas, also had 
some well recognised weaknesses, such as incomplete staging and treatment data and lack of 
outpatient information. Certain methodologies had to be adapted to address these issues 
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where possible. The unique nature of this study also meant that there were few other high 
quality, population-based studies to compare the results to.   
The strengths and limitations of this study are discussed in this chapter, as are the key findings 
from the study and their implications for service development and structure. Finally, the 
additional questions raised by this study and future areas of research will be considered and 
discussed in the future.   
16.1 Strengths of the study 
This was a high quality population based study which utilised national data and had full 
coverage of England meaning that the study had the greatest possible statistical power. The 
data were cleaned using a novel algorithm designed specifically for use on cancer registration 
data regarding TYA patients, allowing for the production of the most accurate dataset possible. 
The cancer registration data were linked to HES data using validated methodologies240. 
Methodologies were adapted to fit the data available and the questions posed. 
16.2 Limitations of the study 
Certain limitations of the study mean that some of the results should be interpreted with a 
degree of caution. Limitations relate to issues around data quality, study design and certain 
aspects of the analysis.  
16.2.1 Data quality 
The design of the survey meant that there was likely to be bias in the sample selection, 
however this was unavoidable due to the nature of the data. The nature of the purposive 
sampling approach meant that generalisations across all healthcare professionals dealing with 
TYA patients are difficult to make. Nonetheless, this was the first survey of its kind to address 
attitudes towards specialist care for this group and there was little available evidence in which 
to compare the results. 
One of the most significant issues relating to this project was the quality of the available data. 
This project relied mainly upon routine healthcare data comprising cancer registration and 
electronically linked hospital admission records.  
There are acknowledged limitations with cancer registration and HES data. Firstly, the cancer 
registration records for a small proportion of individuals were not linked to a HES record. This 
may have been due to a lack of admissions for these patients, because these patients were not 
treated as an inpatient at any time. Alternatively this may have been caused by issues with the 
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patient identifiers, so that patients may have been admitted to secondary care but this was 
not identified from the data linkage. In order to avoid drawing any incorrect conclusions, these 
patients were excluded from the analyses presented in this thesis. The numbers excluded for 
each diagnostic group were small (range 3.6% to 31.6% for melanoma) and did not present a 
significant problem. 
Staging data were unavailable for 99% of cases, therefore it was not possible to use methods 
such as multiple imputation to overcome these missing data. Stage of disease is an important 
prognostic factor when assessing the case mix variation between specialist care groups. 
Although it wasn’t possible to adjust for stage, several other proxy variables were identified, 
such as length of stay, number of admissions and diagnostic group. These would not correlate 
perfectly with stage of disease but allowed an attempt at identifying patient groups which may 
have presented with more advanced disease. 
The HES data used in this study included only inpatient and day case episodes, thus it wasn’t 
possible to examine outpatient or A&E attendances. The majority of TYA patients with cancer 
would, as a minimum, be expected to have a day case admission during treatment, so that it 
was possible to draw conclusions regarding health service usage across the diagnostic groups. 
Standardised treatment pathways ought to imply that within diagnostic groups there should 
be little variation in the care setting, in terms of in or outpatient care, limiting the effect on this 
study. This was not the case for melanoma and skin carcinoma patients, where the majority of 
treatment is undertaken either in primary care or as an outpatient. Patients who were 
admitted frequently were undergoing different treatment from those with less frequent 
admissions and so the results for this group have been cautiously interpreted. 
A further limitation was the lack of detailed treatment information available. Surgery is well 
coded in HES data due to payment by results, however chemotherapy and radiotherapy coding 
is known to be variable. A combined treatment variable was produced to overcome this 
problem using a combination of HES and registry data. However, it was not possible to 
determine the dose or regimen patients received. HES data is also unlikely to give a complete 
picture of usage due to both coding issues and treatment undertaken in an outpatient setting . 
This problem is likely to be resolved in the future through developments in national cancer 
registration which will receive electronic data feeds from chemotherapy and radiotherapy 
episodes, supplementing the hospital episodes data already available269 270. 
There are several known issues with the data recorded in HES, such as incorrect admission and 
discharge dates and improper coding of place of care. The admission start and end dates were 
therefore recalculated and ought not to have affected the results of the study. To avoid 
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problems with the coding of place of care, the NHS trust to which a patient was admitted was 
used instead of the individual hospital site. This meant that it was impossible to infer whether 
a patient had been admitted to a specialist centre, although it was possible to specify whether 
the NHS trust to which a patient was admitted had a specialist centre. A necessary assumption 
was therefore made with regards to the involvement of specialists in the care of a patient 
based on where they were treated. This may have influenced the classification of level of care 
received by each patient. The comparison of time spent in a trust within a specialist centre to 
that spent elsewhere was used to assign each patient to a level of care. However the structure 
of specialist services means that admission to an NHS trust with a specialist centre would 
automatically result in the involvement of a specialist MDT, even if the patient was not 
admitted to the specialist ward itself. This means that the results regarding the level of care 
received can be relied upon. 
16.2.2 Study design and data analysis 
A major strength of this study is that it is the first of its kind in the area of TYA specialist care 
and applies recognised methodologies such as the linkage of multiple routine data sources 
Another strength is the number of cases used in comparison to other studies, particularly as 
TYA cancer is rare. This is one of the largest health services research studies in the area 
covering the whole of England over a diagnosis period of six years and treatment period up to 
the end of 2009.  
The problems related to power in this study were unavoidable as, despite the small numbers, 
the results refer to a national analysis and several steps were taken in order to reduce the 
effect of the small sample size, such as the analysis of groups of diagnoses rather than 
individual morphological groups. A number of the effects seen, such as the beneficial effect of 
mostly specialist care in some groups failed to reach statistical significance, despite their 
clinical plausibility. The small number of patients means that there was, in some cases, limited 
power in the analyses influencing the significance of the results. 
It was not possible to assess the levels of specialist care and type of specialist care in one 
analysis, they were assessed as separate variables due to the small number of patients in some 
of the groups. The analyses of these as separate variables allowed more detailed 
investigations. 
The small number of events (deaths) for certain diagnostic groups  may have led to a lack of 
power and under-reporting of some effects which were important clinically but may not have 
been statistically significant. All Cox regression models adhered to the proportional hazards 
assumption and were carefully tested for possible interactions and multicollinearity. 
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Multiple testing may also have led to the reporting of erroneous significant findings due to the 
number of comparisons carried out.  Nonetheless, the research questions were carefully 
formulated at the beginning of the study. These were listed explicitly in Chapter 1 to minimise 
the over-reporting of significant findings through chance alone.  
16.2.3 Interpretation 
Mindful of these limitations,  interpretation of the results should be done with some degree of 
caution. 
The assignment of patients to a level of care was based on the proportion of time spent in 
specialist centres compared to other places of care. Caution should be used when interpreting 
the results in terms of distinct proportions of specialist care as these relied upon such 
components of care derived from HES data, which refer to inpatient and day case admissions 
only. No conclusions could be drawn in terms of outpatient admissions or health service usage 
in its entirety. 
Missing data may also have influenced some of the conclusions drawn, in particular with 
regards to treatment. Missing staging information meant it was not possible to adjust for more 
advanced disease, this adjustment would have allowed more accurate inferences. Additionally 
the lack of HES data for some cases reduced the power of the analyses as these patients had to 
be excluded. 
 
16.2.4 Strengths and weaknesses in relation to other studies 
A major advantage of this study is that it is population based, whereas previous studies have 
tended to focus on a single region or centre. Also this study examined all diagnoses in TYA 
patients, the majority of studies examine a single cancer site, which appears counterintuitive 
as the service is designed for the age group as a whole.  
It is the first to assess the influence of specialist care on outcomes comprehensively in this 
patient group. Other studies investigating specialist care for TYA patients have tended to focus 
on patient experience, psychosocial impact and place of care. Many of the findings of this 
research support results from other studies37 129 271 272. 
This study has shown, in agreement with others36 114 192, that there is significant variation in the 
place of care for TYA patients. This was the first study to assess both age-specific and site-
specialist care and report analyses which combined these two components to assess the 
impact on clinical outcomes. Additionally, this study assessed the influence of access to 
specialist care on the likelihood of admission to a specialist centre and also examined 
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admissions centre by centre. This is the first study to combine these analyses across all 
diagnoses in this age range. 
A key finding was that specialist care influenced survival across all diagnostic groups. This 
supported the findings of several other studies35 119 273 274, however these focus on much older 
adult patients. The inclusion of multiple patient outcomes sets this work apart from other 
studies which focus on survival as the main outcome. 
16.3 Implications for teenage and young adult cancer care 
Admission to a TCT or site-specialist centre was shown to influence outcomes in all diagnostic 
groups. The involvement of a site-specialist centre was uniformly associated with a survival 
benefit and the increase in centralisation of services to these centres means that referral to 
these services was seen in the majority of cases. However, this was not the case for the TCT 
centres and there appeared to be significant barriers to referral into these units. Whilst 
findings from this work support the value and use of specialist services, it also highlights the 
disparity between diagnostic groups in terms of the proportion of patients who received 
specialist care. 
The results from this study, in particular the influence of the levels of specialist care on patient 
outcomes, will be used to inform analyses in a cohort study known as BRIGHTLIGHT275 led by 
an experienced multi-disciplinary research team from the University College London Hospitals, 
University of Manchester and University of Leeds to examine the influence of specialist care on 
the quality of life for TYA patients. The methodology used to assign a type and level of 
specialist care in this analysis will be applied to the BRIGHTLIGHT cohort and results used to 
inform the future organisation of cancer services for this age group. 
The work presented in this thesis encompasses a time period which includes the introduction 
of the IOG in 2005. Changes in the cancer registration process276 will facilitate more detailed 
and timely treatment information to be made available for analysis. Nonetheless, this study 
can be used to benchmark improvement in patient outcomes and specialist service usage over 
time from 2001 onwards. 
16.4 Unanswered questions and future work 
Future work, including more timely data, would allow for an assessment of patient outcomes 
after the IOG had been fully implemented. It would also be possible to include staging and 
treatment information in the analysis, rather than using proxies in an attempt to assess the 
influence of these on outcomes and therefore provide a more accurate assessment of the 
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effect of specialist care. As previously stated efforts were made to determine whether stage of 
disease was at least partly responsible for the outcome differences between those with some 
specialist care and other groups, new systems in place for cancer registration ought to increase 
the proportion of cases with a reported stage. This would allow a more in-depth analysis of the 
relationship between stage, specialist care and outcome. 
This project quantified the variation in uptake of specialist care across England but there 
remains the question as to why this occurs. Further work is needed to determine whether this 
is due to patient choice or  limitations in the way services operate for young people with 
cancer which may result in lack of referral to specialist centres. 
Also further studies may examine the influence of specialist care on late effects. This was not 
possible in this project due to the relatively short follow up period included in the analysis. 
However the results of such work will be vital for future service design regarding long term 
follow up of TYA cancer patients, especially whether certain patients are managed more 
effectively in primary or secondary care . 
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Appendix 
Appendix A – Classification of tumours according to the Birch classification 
scheme 
Table A 1: Classification of leukaemia according to the Birch classification scheme 
T code restrictions
1.1 Acute lymphoid leukaemia
1.2 Acute myeloid leukaemia
1.3 Chronic myeloid leukaemia
1.4
1.4.1
Other lymphoid leukaemia and lymphoid leukaemia 
NOS
1.4.2
Other myeloid leukaemia and myeloid leukaemia 
NOS
1.4.3 Other specified leukaemias
1.4.4 Unspecified leukaemias
Diagnostic Group
1. Leukaemias
Other and unspecified leukaemias
9733, 9742, 9805, 9830, 
9841, 9842, 9850, 9867, 
9800, 9801
9820, 9822, 9823, 9831
9860, 9862, 9864, 9865 
9826, 9827, 9831, 9832, 
9833, 9834, 9835, 9836, 
9840, 9861, 9866, 9871, 
9872, 9873, 9874, 9891, 
9863, 9875, 9876
Morphology code
 
Table A 2: Classification of lymphomas according to the Birch classification scheme 
T code restrictions
2.1. 
2.1.1 NHL,specified Subtype
2.1.2 Unspecified NHL
2.2. 
2.2.1 HL specified sub-type
2.2.2 HL  NOS
2. Lymphomas
Non-Hodgkins Lymphoma[NHL]:
Hodgkin lymphoma [HL]:
9651 - 9667
9650
Diagnostic Group Morphology code
9593-9649, 9670-9714, 
9716, 9717, 9718, 9719, 
9590, 9591, 9592
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Table A 3: Classification of central nervous system tumours according to the Birch classification scheme 
T code restrictions
3.1
 C72.3
None
3.1.2 Other specified low grade astrocytic tumours None
3.1.3 Glioblastoma and anaplastic astrocytoma None
3.1.4 Astrocytoma, NOS None
3.2
3.2.1 Oligodendroglioma None
3.2.2 Other specified glioma None
3.2.3 Glioma, NOS Except C72.3
3.3. Ependymoma None
3.4
3.4.1 Medulloblastoma C71.6
3.4.2  Supratentorial PNET
C70.0 to C72.9 Except 
C71.6
3.5
3.5.1 Craniopharyngioma None
3.5.2 Other Pituitary tumours C75.1, C75.2
3.5.3 Pineal tumours C75.3
3.5.4 Choroid plexus tumours None
3.5.5 Meningioma None
3.5.6 Nerve sheath tumours of CNS C70.0-C72.9
3.6. 
3.6.1
Unspecified malignant intracranial and  intraspinal 
neoplasms (behaviour code 3 only)
C70.0-C72.9, 
3.6.2
Unspecified benign and borderline intracranial and 
intraspinal neoplasms (behaviour code less than 3)
C70.0-C72.9, 
Astrocytoma
Other glioma
Medulloblastoma and other PNET
Other specified CNS, intracranial and intraspinal
Unspecified intracranial and  intraspinal neoplasms
3. Central Nervous System and Other Intracranial and Intraspinal Neoplasms
8000-8004, 8010, 9990
8000-8004,  8010, 9990
9530-9539
9540-9570, 9571
3.5.7 Other specified intracranial and intraspinal neoplasms
8140, 8270-8281, 8300, 
9161, 9480, 9505, 9493, 
9508
C70.0-C72.9 
9350, 9351, 9352
Except 9350, 9060-9102, 
9582
Except 9060-9102
9390
9381–9384, 9430 9444, 
9460
9380
9391-9394
+9260, 9364, 9365, 9470-
9473, 9474
+9260, 9364, 9365, 9470-
9473, 9474
9421
9410-9420, 9422-9424
9401, 9440, 9441, 9442
9400
9450, 9451
Diagnostic Group Morphology code
3.1.1 Pilocytic astrocytoma 
9380
 
 
261 | P a g e  
 
Table A 4: Classification of osseous neoplasms according to the Birch classification scheme 
T code restrictions
4.1 Osteosarcoma None
4.2 Chondrosarcoma None
4.3 Ewing sarcoma
Not C70.0 to C72.9 
None*
4.3.1 Ewing sarcoma of bone C40.0 to C41.9
4.3.2 Ewing sarcoma of specified site other than bone
Any except those in 
4.3.1 or 4.3.3,  3.4.1 or 
4.3.3 Ewing sarcoma of unspecified site
C76.0 to C76.9, C78.7, 
C80.0, C80.9
4.4
4.4.1 Other specified bone tumours None
4.4.2 Unspecified bone tumours C40.0 – C41.9
Other specified and unspecified bone tumours
4. Osseous and Chondromatous Neoplasms, Ewing Tumour and Other Neoplasms of Bone.
9180-9187, 9192, 9193, 
9194, 9195
9220-9240, 9242, 9243
9260, 9364+,   9365, 9470-
9473, 9474
C40.0 to C41.9
Any except those in 
4.3.1 or 4.3.3,  3.4.1 or 
C76.0 to C76.9, C78.7, 
C80.0, C80.9
8812, 9250, 9261, 9370, 
9371, 9372
8000-8004, 8800, 8801, 
8803, 8805, 8806
Diagnostic Group Morphology code
 
Table A 5: Classification of soft tissue sarcomas according to the Birch classification scheme 
T code restrictions
5.1
5.1.1 Fibrosarcoma None
5.1.2 +Malignant fibrous histiocytoma None
5.1.3 Dermatofibrosarcoma None
5.2 Rhabdomyosarcoma None
5.3
5.3.1 Liposarcoma None
5.3.2 Leiomyosarcoma None
5.3.3 Synovial sarcoma None
5.3.4 Clear cell sarcoma None
None
Except C70.0-C72.9
5.3.6 Nerve sheath tumours Except C70.0-C72.9
5.3.7 Alveolar soft part sarcoma None
None
5.4 Unspecified soft tissue sarcoma Except (C40.0 – C41.9)
5. Soft Tissue Sarcomas
Morphology code
Fibromatous neoplasms
Other specified soft tissue sarcoma
8800-8803, 8805, 8806
9044
9120-9160
9161
9540-9570, 9571
9581
8804, 8840, 8990, 9014, 
9015, 9170, 9251, 9252, 
9561, 9580
8810, 8811, 8813, 8814, 
8815
8830, 8835, 8836
8832, 8833
8900-8920,  8921, 8991
8850-8881
8890-8896
9040-9043
Diagnostic Group
5.3.5 Blood vessel tumours
5.3.8 Other Specified
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Table A 6: Classification of germ cell tumours according to the Birch classification scheme 
T code restrictions
 C56.9, C62.0-C62.9
C62.0-C62.9
6.2.
6.2.1  Intracranial*
C70.0-C72.9, C75.1, 
C75.2, C75.3
Any site except 
C56.9, C62.0-C62.9, 
C70.0-C72.9, C75.1, 
Germ cell and trophoblastic neoplasms of non-gonadal sites.
6. Germ cell and trophoblastic neoplasms
Diagnostic Group Morphology code
 9060-9102, 9103, 9104, 
9105
9060-9102, 9103, 9104, 
9105
6.1
6.2.2
Germ cell and  trophoblastic neoplasms of gonads.
Other non-gonadal sites
9060-9102, 9103, 9104, 
9105
†8010-8239, 8246-8580
 
Table A 7: Classification of melanoma and skin carcinoma according to the Birch classification scheme 
T code restrictions
7.1. Melanoma None
7.2. Skin carcinoma C44.0-C44.9
7. Melanoma and Skin Carcinoma
Diagnostic Group Morphology code
8720-8780
8010-8589
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Table A 8: Classification of carcinomas according to the Birch classification scheme 
T code restrictions
8.1. Thyroid carcinoma C73.9
8.2. 
8.2.1 Nasopharyngeal carcinoma C11.0-C11.9
C00.0 -C10.9, 
C12.0-C14.8
8.2.3. 
Nasal cavity, middle ear, sinuses, larynx and other and 
ill-defined head and neck
C30.0 - C32.9, C76.0
8.3. Carcinomas of trachea, bronchus and lung C33.0-C34.9
8.4. Carcinoma of breast C50.0-C50.9
8.5. 
8.5.1 Carcinoma of kidney C64.9
8.5.2 Carcinoma bladder C67.0-C67.9
8.5.3 Carcinoma of ovary C56.0
8.5.4 Carcinoma of cervix C53.0-C53.9 
8.6.  
8.6.1 Carcinoma of colon and rectum C18.0-C21.8
8.6.2 Carcinoma stomach C16.0-C16.9
8.6.3 Carcinoma of liver and intrahepatic bile ducts C22.0-C22.9
8.6.4 Carcinoma  pancreas C25.0-C25.9
8.7. 
8.7.1   Adrenocortical carcinoma C74.0-C74.9
8.7.2  Carcinoma of other and ill-defined sites, NEC
Any other C codes 
including C58.9 except 
Diagnostic Group Morphology code
8. Carcinomas
Carcinomas of other and ill-defined sites NEC
Carcinoma GI tract
Carcinoma GU tract:
C51.0-C52.9, C54.0-
55.9, C57.0-C57.9, C60.0-
C61.9, C63.0-C63.9, 
C65.9, C66.9, C68.0-
C15.0-C15.9, C17.0-
C17.9, C23.0-C24.9, 
C26.0-C26.9
8.5.5 Carcinoma of other and ill-defined sites in GU tract
8.6.5 Carcinoma of other and ill-defined sites in  GI tract
8.2.2 Other sites in lip, oral cavity and pharynx.
Other carcinoma of head and neck
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Table A 9: Classification of other and unspecified neoplasms according to the Birch classification scheme 
T code restrictions
9.1
9.1.1 Wilms tumours
9.1.2 Neuroblastoma
9.2. 
9.2.1 Paraganglioma and glomus
9.2.3 
Myeloma, mast cell tumours and miscellaneous 
lymphoreticular neoplasms NEC
T code restrictions
Any site except: 
C40.0-C41.9, 
C70.0-C72.9, C75.1, 
C75.3
Morphology code
Other paediatric and embryonal tumours NEC
Other specified neoplasms NEC:
10. Unspecified Malignant Neoplasms NEC
Diagnostic Group Morphology code
8000-8005, 9990
9731- 9754, 9756 - 9764
9.2.4 Other specified neoplasms NEC
8930-8951, 8980, 9020, 
9050-9053, 9110, 9270-
9330, 9342
10 Unspecifed malignant neoplasms NEC
8680 – 8710, 8711
9.2.2 Other specified gonadal tumours
8590 - 8650, 9000, 8670
*8240-8245
8959, 8960 - 8962
9490, 9500
9.1.3 Other paediatric and embryonal, NEC
8963, 8964, 
8970-8972, 8973 8981, 
9507, 9510-9523
9. Miscellaneous Specified Neoplasms NEC
Diagnostic Group
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Appendix B – Classification of procedures 
CHEMOTHERAPY CODES 
Table B 1: OPCS codes for chemotherapy related procedures recorded in HES data 
OPCS 
code Description 
A106 Insertion of carmustine wafers in neoplasm of tissue of brain 
A542 Injection of therapeutic substance into cerebrospinal fluid 
M494 Introduction of therapeutic substance into bladder 
T482 Introduction of cytotoxic substance into peritoneal cavity 
X281 Intermittent intravenous infusion of therapeutic substance 
X288 Intermittent infusion of therapeutic substance, other specified 
X292 Continuous infusion of therapeutic substance NEC 
X352 Intravenous chemotherapy 
X384 Subcutaneous chemotherapy 
X701 Procurement of drugs for chemotherapy for neoplasm for regimens in Band 1 
X702 Procurement of drugs for chemotherapy for neoplasm for regimens in Band 2 
X703 Procurement of drugs for chemotherapy for neoplasm for regimens in Band 3 
X704 Procurement of drugs for chemotherapy for neoplasm for regimens in Band 4 
X705 Procurement of drugs for chemotherapy for neoplasm for regimens in Band 5 
X708 Procurement of drugs for chemotherapy, other specified 
X709 Procurement of drugs for chemotherapy, unspecified 
X711 Procurement of drugs for chemotherapy for neoplasm for regimens in Band 6 
X712 Procurement of drugs for chemotherapy for neoplasm for regimens in Band 7 
X713 Procurement of drugs for chemotherapy for neoplasm for regimens in Band 8 
X714 Procurement of drugs for chemotherapy for neoplasm for regimens in Band 9 
X715 Procurement of drugs for chemotherapy for neoplasm for regimens in Band 10 
X718 Procurement of drugs for chemotherapy, other specified 
X719 Procurement of drugs for chemotherapy, unspecified 
X721 
Delivery of complex chemotherapy for neoplasm including prolonged infusional 
treatment at first attendance 
X722 Delivery of complex parenteral chemotherapy for neoplasm at first attendance 
X723 Delivery of simple parenteral chemotherapy for neoplasm at first attendance 
X723 Delivery of subsequent element of cycle of chemotherapy for neoplasm 
X728 Delivery of chemotherapy for neoplasm, other specified 
X729 Delivery of chemotherapy for neoplasm, unspecified 
X731 Delivery of exclusively oral chemotherapy for neoplasm 
X738 Delivery of oral chemotherapy for neoplasm, other specified 
X739 Delivery of oral chemotherapy for neoplasm, unspecified 
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RADIOTHERAPY CODES 
Table B 2: OPCS codes for chemotherapy related procedures recorded in HES data 
OPCS 
code Description 
B022 Implantation of radioactive substance into pituitary gland 
M712 Implantation of radioactive substance into prostate 
P205 Implantation of radioactive substance into vagina 
Q151 Introduction of radioactive substance into uterine cavity NEC 
X651 Delivery of a fraction of total body irradiation 
X652 Delivery of a fraction of intracavitary radiotherapy 
X653 Delivery of a fraction of interstitial radiotherapy 
X654 Delivery of a fraction of external beam radiotherapy NEC 
X655 Oral delivery of radiotherapy for thyroid ablation 
X656 Delivery of a fraction of intraluminal brachytherapy 
X658 Radiotherapy delivery, other specified 
X659 Radiotherapy delivery, unspecified 
Y352 Introduction of iridium wire into organ NOC 
Y353 Introduction of radium into organ NOC 
Y354 Introduction of radioactive substance into organ for brachytherapy NOC 
Y358 Introduction of removable radioactive material into organ, other specified 
Y359 Introduction of removable radioactive material into organ, unspecified 
Y361 Introduction of gold seeds into organ NOC 
Y363 Radioactive seed implantation NOC 
Y364 
Introduction of non-removable radioactive substance into organ for brachytherapy 
NOC 
Y911 Megavoltage treatment for complex radiotherapy 
Y912 Megavoltage treatment for simple radiotherapy 
Y913 Superficial or orthovoltage treatment for radiotherapy 
Y914 Megavoltage treatment for adaptive radiotherapy 
Y918 External beam radiotherapy, other specified 
Y919 External beam radiotherapy, unspecified 
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MAJOR SURGICAL RESECTION CODES 
Central nervous system and other intracranial and intraspinal neoplasms 
Table B 3: Major resection (OPCS) codes for brain and CNS tumours, reported in HES 
OPCS 
Code Description 
A01 Major excision of tissue of brain 
A02 Excision of lesion of tissue of brain 
A17 
Therapeutic endoscopic operations on ventricle of 
brain 
A29 Excision of lesion of cranial nerve 
A38 Extirpation of lesion of meninges of brain 
A43 Other extirpation of lesion of meninges of brain 
A44 Partial extirpation of spinal cord 
A51 Other operations on meninges of spinal cord 
A57 Operations on spinal nerve root 
A61 Extirpation of lesion of peripheral nerve 
 
Osseous and chondromatous neoplasms, Ewing’s sarcoma and other neoplasms of bone 
Table B 4: Major resection (OPCS) codes for bone tumours, reported in HES 
OPCS 
Code Description 
V06 Excision of maxilla 
V07 Excision of bone of face 
V14 Excision of mandible 
V43 Extirpation of lesion of spine 
W05 Prosthetic replacement of bone 
W06 Total excision of bone 
W08 Other excision of bone 
W09 Extirpation of lesion of bone 
X07 Amputation of arm 
X08 Amputation of hand 
X09 Amputation of leg 
X10 Amputation of foot 
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Soft tissue sarcoma 
Table B 5: Major resection (OPCS) codes for soft tissue sarcoma, reported in HES 
OPCS Code Description 
X07 Amputation of arm 
X08 Amputation of hand 
X09 Amputation of leg 
X10 Amputation of foot 
T011 Thoracoplasty 
T013 Excision of lesion of chest wall 
T018 Partial excision of chest wall, other specified 
T019 Partial excision of chest wall, unspecified 
G01 Excision of oesophagus and stomach 
G27 Total excision of stomach 
G281 Partial gastrectomy and anastomosis of stomach to duodenum 
G282 Partial gastrectomy and anastomosis of stomach to transposed jejunum 
G283 Partial gastrectomy and anastomosis of stomach to jejunum NEC 
G288 Partial excision of stomach, other specified 
G289 Partial excision of stomach, unspecified 
G49 Excision of duodenum 
G50 Open extirpation of lesion of duodenum 
G58 Excision of jejunum 
G59 Extirpation of lesion of jejunum 
G69 Excision of ileum 
G70 Open extirpation of lesion of ileum 
T312 
Excision of lesion of anterior abdominal wall and insert of prosthetic material into anterior 
abdominal wall 
T313 Excision of lesion of anterior abdominal wall NEC 
T33 Open extirpation of lesion of peritoneum 
T361 Omentectomy 
T362 Excision of lesion of omentum 
T371 Excision of lesion of mesentery of small intestine 
T53 Extirpation of lesion of fascia 
T65 Excision of tendon 
T71 Excision of sheath of tendon 
T77 Excision of muscle 
T831 Destruction of lesion of muscle 
T962 Excision of lesion of soft tissue NEC 
T072 Open excision of lesion of pleura 
T078 Open excision of pleura, other specified 
T079 Open excision of pleura, unspecified 
T312 
Excision of lesion of anterior abdominal wall and insert of prosthetic material into anterior 
abdominal wall 
T313 Excision of lesion of anterior abdominal wall NEC 
T33 Open extirpation of lesion of peritoneum 
X141 Total exenteration of pelvis 
X142 Anterior exenteration of pelvis 
X143 Posterior exenteration of pelvis 
K221 Excision of lesion of atrium 
K231 Excision of lesion of wall of heart NEC 
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Germ cell and trophoblastic neoplasms 
Table B 6: Major resection (OPCS) codes for germ cell tumours, reported in HES 
 
 
 
 
 
 
 
 
 
OPCS 
Code Description 
N05 Bilateral excision of testes 
N06 Other excision of testis 
N07 Extirpation of lesion of testis 
Q07 Abdominal excision of uterus 
Q08 Vaginal excision of uterus 
Q221 Bilateral salpingoophorectomy  
Q223 Bilateral oophorectomy 
Q231 Unilateral salpingoophorectomy NEC 
Q232 
Salpingoophorectomy of remaining solitary fallopian tube and 
ovary 
Q235 Unilateral oophorectomy 
Q236 Oophorectomy of remaining solitary ovary NEC 
Q241 Salpingoophorectomy NEC 
Q243 Oophorectomy NEC 
Q431 Excision of wedge of ovary 
Q432 Excision of lesion of ovary 
Q438 Partial excision of ovary, other specified 
Q433 Partial excision of ovary, unspecified 
Q491 Endoscopic extirpation of lesion of ovary NEC 
T361 Omentectomy 
X141 Total exenteration of pelvis 
X142 Anterior exenteration of pelvis 
X143 Posterior exenteration of pelvis 
A01 Major excision of tissue of brain 
A02 Excision of lesion of tissue of brain 
A29 Excision of lesion of cranial nerve 
A38 Extirpation of lesion of meninges of brain 
A43 Other extirpation of lesion of meninges of brain 
B06 Operations on pineal gland 
E61 Open operations on mediastinum 
T33 Open extirpation of lesion of peritoneum 
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Melanoma and skin carcinoma 
Table B 7: Major resection (OPCS) codes for melanoma and skin carcinoma, reported in HES 
Code Description 
B353 Extirpation of lesion of nipple 
C101 Excision of lesion of eyebrow 
C121 Excision of lesion of eyelid NEC 
C126 Wedge excision of lesion of eyelid 
E091 Excision of lesion of external nose 
N012 Excision of lesion of scrotum 
N271 Excision of lesion of penis 
P054 Excision of lesion of vulva NEC 
P111 Excision of lesion of female peritoneum 
T293 Extirpation of lesion of umbilicus 
S05 Microscopically controlled excision of lesion of skin 
S06 Other excision of lesion of skin 
F02 Extirpation of lesion of lip 
D02 Extirpation of lesion of external ear 
 
Carcinomas 
Table B 8: Major resection (OPCS) codes for thyroid carcinomas, reported in HES 
Code Description 
B08 Excision of thyroid gland 
B09 Operations on aberrant thyroid tissue 
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Table B 9: Major resection (OPCS) codes for head and neck carcinomas, reported in HES 
Site Code Description 
Nasopharyngeal 
carcinoma 
E19 Excision of pharynx 
E23 Other open operations on pharynx 
E24 Therapeutic endoscopic operations on pharynx 
Other sites in lip, 
oral cavity and 
pharynx 
E19 Excision of pharynx 
E23 Other open operations on pharynx 
E24 Therapeutic endoscopic operations on pharynx 
F22 Excision of tongue 
F23 Extirpation of lesion of tongue 
F28 Extirpation of lesion of palate 
F38 Extirpation of lesion of other part of mouth 
F44 Excision of salivary gland 
F45 Extirpation of lesion of salivary gland 
Nasal cavity, 
middle ear, 
sinuses, larynx 
and other ill-
defined sites in 
head and neck 
D19 Extirpation of lesion of middle ear 
E29 Excision of larynx 
E30 Open extirpation of lesion of larynx 
E082 Extirpation of lesion of internal nose NEC 
E132 Excision of lesion of maxillary antrum 
E171 Excision of nasal sinus NEC 
E172 Excision of lesion of nasal sinus NEC 
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Table B 10: Major resection (OPCS) codes for carcinomas of the trachea, bronchus, pleura and lung, 
reported in HES 
Code Description 
E39 Partial excision of trachea 
E441 Excision of carina 
E43 Open operations on trachea 
E54 Excision of lung 
E552 Open excision of lesion of lung 
E558 Open extirpation of lesion of lung, other specified 
E559 Open extirpation of lesion of lung, unspecified 
T013 Excision of lesion of chest wall 
E461 Sleeve resection of bronchus and anastomosis HFQ 
E463 Excision of lesion of bronchus NEC 
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Table B 11: Major resection (OPCS) codes for carcinomas of the breast, reported in HES 
Code Description 
B27 Total excision of breast 
B28 Other excision of breast 
B341 Subareolar excision of mammillary duct 
B342 Excision of mammillary duct NEC 
B343 Excision of lesion of mammillary duct 
B352 Excision of nipple 
B37 Other operations on breast 
B40 Destruction of lesion of breast 
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Table B 12: Major resection (OPCS) codes for carcinomas of the GU tract, reported in HES 
Site Code Description 
Kidney M02 Total excision of kidney 
M038 Partial excision of kidney, other specified 
M039 Partial excision of kidney, unspecified 
M042 Open excision of lesion of kidney NEC 
M104 Endoscopic cryoablation of lesion of kidney 
M181 Total ureterectomy 
M182 Excision of segment of ureter 
M183 Secondary ureterectomy 
M252 Open excision of lesion of ureter NEC 
Bladder M34 Total excision of bladder 
M358 Partial excision of bladder, other specified 
M359 Partial excision of bladder, unspecified 
M411 Open extirpation of lesion of bladder 
Ovary Q07 Abdominal excision of uterus 
Q08 Vaginal excision of uterus 
Q221 Bilateral salpingoophorectomy  
Q223 Bilateral oophorectomy 
Q231 Unilateral salpingoophorectomy NEC 
Q232 Salpingoophorectomy of remaining solitary fallopian tube and ovary 
Q235 Unilateral oophorectomy 
Q236 Oophorectomy of remaining solitary ovary NEC 
Q241 Salpingoophorectomy NEC 
Q243 Oophorectomy NEC 
Q431 Excision of wedge of ovary 
Q432 Excision of lesion of ovary 
Q438 Partial excision of ovary, other specified 
Q433 Partial excision of ovary, unspecified 
Q491 Endoscopic extirpation of lesion of ovary NEC 
T361 Omentectomy 
X141 Total exenteration of pelvis 
X142 Anterior exenteration of pelvis 
X143 Posterior exenteration of pelvis 
Cervix P171 Total colpectomy 
P172 Partial colpectomy 
Q01 Excision of cervix uteri 
Q07 Abdominal excision of uterus 
Q08 Vaginal excision of uterus 
X141 Total exenteration of pelvis 
X142 Anterior exenteration of pelvis 
X143 Posterior exenteration of pelvis 
Other 
and ill-
defined 
sites in 
GU tract 
M181 Total ureterectomy 
M182 Excision of segment of ureter 
M183 Secondary ureterectomy 
M61 Open excision of prostate 
M621 Open extirpation of lesion of prostate 
M623 Prostatotomy 
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M65 Endoscopic resection of outlet of male bladder 
M72 Excision of urethra 
N26 Amputation of penis 
P051 Total excision of vulva 
P052 Partial excision of vulva 
P054 Excision of lesion of vulva NEC 
P06 Extirpation of lesion of vulva 
P11 Extirpation of lesion of female peritoneum 
P17 Excision of vagina 
P20 Extirpation of lesion of vagina 
Q07 Abdominal excision of uterus 
Q08 Vaginal excision of uterus 
Q09 Other open operations on uterus 
Q22 Bilateral excision of adnexa of uterus 
Q23 Unilateral excision of adnexa of uterus 
Q24 Other excision of adnexa of uterus 
Q52 Operations on broad ligament of uterus 
X141 Total exenteration of pelvis 
X142 Anterior exenteration of pelvis 
X143 Posterior exenteration of pelvis 
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Table B 13: Major resection (OPCS) codes for carcinomas of the GI tract, reported in HES 
Site Code Description 
Colon and 
rectum 
H04 Total excision of colon and rectum 
H05 Total excision of colon 
H06 Extended excision of right colon 
H07 Other excision of right hemicolon 
H08 Excision of transverse colon 
H09 Excision of left hemicolon 
H10 Excision of sigmoid colon 
H11 Other excision of colon 
H29 Subtotal excision of colon 
H33 Excision of rectum 
H044 Trans-sphicteric anastomosis of colon to anus 
X141 Total exenteration of pelvis 
X142 Anterior exenteration of pelvis 
X143 Posterior exenteration of pelvis 
Stomach G01 Excision of oesophagus and stomach 
G27 Total excision of stomach 
G281 Partial gastrectomy and anastomosis of stomach to duodenum 
G282 
Partial gastrectomy and anastomosis of stomach to transposed 
jejunum 
G283 Partial gastrectomy and anastomosis of stomach to jejunum NEC 
G288 Partial excision of stomach, other specified 
G289 Partial excision of stomach, unspecified 
Liver and 
intrahepatic 
bile ducts 
J02 Partial excision of liver 
J03 Extirpation of lesion of liver 
J27 Excision of bile duct 
J28 Excision of lesion of bile duct 
Pancreas J55 Total excision on pancreas 
J56 Excision of head of pancreas 
J57 Other partial excision of pancreas 
J58 Extirpation of lesion of pancreas 
Other and 
ill-defined 
sites in the 
GI tract 
G01 Excision of oesophagus and stomach 
G02 Total excision of oesophagus 
G03 Partial excision of oesophagus 
G04 Open extirpation of lesion of oesophagus 
G49 Excision of duodenum 
G50 Open extirpation of lesion of duodenum 
G58 Excision of jejunum 
G59 Extirpation of lesion of jejunum 
G69 Excision of ileum 
G70 Open extirpation of lesion of ileum 
H47 Excision of anus 
H48 Excision of lesion of anus 
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Table B 14: Major resection (OPCS) codes for carcinomas of other & ill-defined sites not elsewhere 
classified (NEC), reported in HES 
Site Code Description 
Adrenocortical 
carcinoma 
B22 Excision of adrenal gland 
B23 Operations on aberrant adrenal tissue 
B251 Excision of lesion of adrenal gland 
Other 
carcinomas 
NEC 
B08 Excision of thyroid gland 
B09 Operations on aberrant thyroid tissue 
B27 Total excision of breast 
B28 Other excision of breast 
B14 Excision of parathyroid gland 
B18 Excision of thymus gland 
H04 Total excision of colon and rectum 
H05 Total excision of colon 
H06 Extended excision of right colon 
H07 Other excision of right hemicolon 
H08 Excision of transverse colon 
H09 Excision of left hemicolon 
H10 Excision of sigmoid colon 
H11 Other excision of colon 
H29 Subtotal excision of colon 
H33 Excision of rectum 
J02 Partial excision of liver 
J03 Extirpation of lesion of liver 
J18 Excision of gall bladder 
J27 Excision of bile duct 
J28 Excision of lesion of bile duct 
K221 Excision of lesion of atrium 
K231 Excision of lesion of wall of heart NEC 
Q01 Excision of cervix uteri 
Q07 Abdominal excision of uterus 
Q08 Vaginal excision of uterus 
Q22 Bilateral excision of adnexa of uterus 
Q23 Unilateral excision of adnexa of uterus 
Q24 Other excision of adnexa of uterus 
T072 Open excision of lesion of pleura 
T078 Open excision of pleura, other specified 
T079 Open excision of pleura, unspecified 
T312 
Excision of lesion of anterior abdominal wall and insert 
of prosthetic material into anterior abdominal wall 
T313 Excision of lesion of anterior abdominal wall NEC 
T33 Open extirpation of lesion of peritoneum 
X141 Total exenteration of pelvis 
X142 Anterior exenteration of pelvis 
X143 Posterior exenteration of pelvis 
 
 
